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Gluten-Induced Extra-Intestinal Manifestations in Potential Celiac Disease—Celiac Trait
Reprinted from: Nutrients 2019, 11, 320, doi:10.3390/nu11020320 . . . . . . . . . . . . . . . . . . . 233
Elizabeth S. Mearns, Aliki Taylor, Kelly J. Thomas Craig, Stefanie Puglielli, 
Allie B. Cichewicz, Daniel A. Leffler, David S. Sanders, Benjamin Lebwohl and 
Marios Hadjivassiliou
Neurological Manifestations of Neuropathy and Ataxia in Celiac Disease: A Systematic Review
Reprinted from: Nutrients 2019, 11, 380, doi:10.3390/nu11020380 . . . . . . . . . . . . . . . . . . . 245
vi
About the Special Issue Editors
Marios Hadjivassiliou is a Consultant Neurologist and the Academic Director of the Department of
Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK. His primary research interest
is in the neurological manifestations of gluten-related diseases and ataxias, areas that he initially
studied for his MD thesis and which subsequently became the focus of his research career over the
last 24 years. He has a particular interest in autoimmune neurological diseases and runs joint clinics
with rheumatologists, managing patients with neurological manifestations of connective tissue
diseases. He has published extensively in high-impact journals, including 3 first author papers in the
Lancet. He runs a weekly gluten sensitivity/neurology, vasculitis/autoimmunity, and ataxia clinics,
and receives referrals from all over the United Kingdom and internationally. He is the director of the
Sheffield Ataxia Centre, caring for over 2000 patients with ataxias, and is a founding member of the
Sheffield Institute of Gluten-Related Diseases (SIGReD).
David Sanders is a Professor of Gastroenterology and a Consultant Gastroenterologist at the Royal
Hallamshire Hospital and the University of Sheffield. He has published ¿400 peer-reviewed papers
(H-score > 60). He is internationally recognised for his work in coeliac disease, percutaneous
gastrostomy feeding (PEG), and small bowel endoscopy. His other research interests include
pancreatic exocrine insufficiency, irritable bowel syndrome and gastrointestinal bleeding. He has
received a number of research awards, including the European Rising Star Award (2010), Cuthbertson
Medal in 2011 and Silver Medal in 2017 (both awards from the UK Nutrition Society), Swedish
Gastroenterology Society Bengt Ihre Medal (2017) and, most recently, the BSG Hopkins prize for
Endoscopy (2019). His clinical work with patients who have coeliac disease has resulted in him
being awarded the Coeliac UK Healthcare Professional of the Year Award (2010) and the inaugural
Complete Nutrition Coeliac Health Care Professional Award (2013). He is fortunate to work as part of
the Sheffield Gastroenterology Team, which has been recognised for their standards of clinical care.
The Small Bowel Endoscopy Service won one of the inaugural British Society of Gastroenterology
National GI Care awards (2011) and the Medipex award (2013). In 2012, the PEG team won both
the Health Service Journal’s Primary Care and Integrated Clinical Care awards. In 2014, the Sheffield
Gastroenterology team won one of the SAGE (Shire Awards for Gastrointestinal Excellence) awards
for their primary care and GI bleed unit services. In 2017, because of his diverse clinical nutrition
interests, he was voted (by patients and healthcare professionals) as the Clinical Nutrition Healthcare
Professional of the Year. Professor Sanders has chaired both the British Society of Gastroenterology
(BSG) Small Bowel and Nutrition Section (2006–2012) and the BSG Audit Committee (2010–2013).
He is the current Chair of the Coeliac UK Health Advisory Council, BSG Council Member, and
President of the International Society for the Study of Coeliac Disease (ISSCD). The Sheffield Unit




Preface to ”Extraintestinal Manifestations of 
Coeliac Disease”
Gluten-related disorders (GRDs) is the term used to describe a spectrum of diverse 
immune-mediated manifestations triggered by the ingestion of gluten. Coeliac disease (CD), also 
known as gluten sensitive enteropathy, is perhaps the most well-recognized and characterized 
entity within this spectrum. Extraintestinal manifestations have, up until recent years, been largely 
neglected and often wrongly presumed to be secondary to nutrient deficiencies. This is despite 
the fact that the recognition of one of such manifestation affecting the skin, known as dermatitis 
herpetiformis, goes back to the early 1960s. Apart from isolated case reports, neurological 
manifestations have been the subject of intense study during the last 20 years. This has resulted in 
well-characterized conditions, such as gluten ataxia, gluten neuropathy and gluten encephalopathy. 
Furthermore, the realisation that gluten sensitivity may exist in the absence of enteropathy has gained 
credence amongst gastroenterologists. The diagnosis of the whole spectrum of GRDs no longer relies 
on tests that are specific to the presence of enteropathy (endomysium and tissue transglutaminase 2 
antibodies) but on additional serological testing with anti-gliadin antibodies. This means that GRDs 
account for much more than 1% of cases, which is the prevalence rate of CD in the population. Finally, 
although identification of tissue transglutaminase 2 (TG2) as the autoantigen in CD has led the way 
in clarifying the pathophysiology of this disease, TG3, an epidermal transglutaminase, and TG6, a 
neural transglutaminase, have been shown to be respectively implicated in dermatitis herpetiformis 
and neurological manifestations.This Special Issue of Nutrients has, as its focus, the extraintestinal 
manifestations of GRDs, covering the whole spectrum from skin to neurological manifestations to 
endocrine, bone, and also liver and pancreatic involvement. Included are original research and 
systematic reviews from a range of experts in the field.
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Abstract: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. Increased
bone fracture risk is known to associate with coeliac disease, but this has been only scantly studied in
DH. In this study, self-reported fractures and fracture-associated factors in DH were investigated and
compared to coeliac disease. Altogether, 222 DH patients and 129 coeliac disease-suffering controls
were enrolled in this study. The Disease Related Questionnaire and the Gastrointestinal Symptom
Rating Scale and Psychological General Well-Being questionnaires were mailed to participants; 45 out
of 222 (20%) DH patients and 35 out of 129 (27%) of the coeliac disease controls had experienced at
least one fracture (p = 0.140). The cumulative lifetime fracture incidence did not differ between DH
and coeliac disease patients, but the cumulative incidence of fractures after diagnosis was statistically
significantly higher in females with coeliac disease compared to females with DH. The DH patients
and the coeliac disease controls with fractures reported more severe reflux symptoms compared to
those without, and they also more frequently used proton-pump inhibitor medication. To conclude,
the self-reported lifetime bone fracture risk is equal for DH and coeliac disease. After diagnosis,
females with coeliac disease have a higher fracture risk than females with DH.
Keywords: dermatitis herpetiformis; coeliac disease; fracture; bone health; quality of life
1. Introduction
Coeliac disease is a systemic autoimmune disorder triggered by gluten and characterized by
small-bowel mucosal villous atrophy. It has a highly heterogeneous clinical picture including intestinal,
extraintestinal, and asymptomatic manifestations [1]. A number of comorbidities are associated with
coeliac disease, one of which is metabolic bone disease predisposing to bone fractures [2]. At the
time of diagnosis, coeliac disease patients frequently suffer from decreased bone mineral density
(BMD) [2,3], which in turn may be a risk factor for fractures. Decreased BMD is not limited to only
patients with severe gastrointestinal symptoms; it also occurs in subclinical and asymptomatic coeliac
disease patients [4–6]. Once diagnosed, coeliac disease is treated with a life-long gluten-free diet (GFD).
Strict adherence to a GFD typically improves bone health in coeliac disease, but full bone recovery is
often not reached in adult coeliac disease patients [7]. Fracture risk in coeliac disease has been studied
Nutrients 2018, 10, 351; doi:10.3390/nu10030351 www.mdpi.com/journal/nutrients1
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extensively, and based on a recent meta-analysis, it can be concluded that the risk of fractures in coeliac
disease is increased by 30% for any fractures and by 69% for hip fractures [8].
Dermatitis herpetiformis (DH) is one of the well-established extraintestinal manifestations of
coeliac disease [9]. In DH, dietary gluten induces an itchy, blistering rash, which responds to a GFD [10].
Since a GFD often alleviates the intensively itching rash fairly slowly, patients with severe symptoms
are additionally treated with dapsone medication at the beginning of the dietary treatment to alleviate
the skin symptoms more quickly [11]. At diagnosis, DH patients also suffer from coeliac disease-type
small-bowel mucosal villous atrophy or inflammation. Occasionally gastrointestinal symptoms also
occur, but they are often minor [9,12]. It seems presumable that the increased risk of bone fractures
would also be associated with DH, but bone complications in DH have been studied scantily and
the results are thus far conflicting [13–17]. The only study focusing on the fracture risk in DH found
no increase in risk [13]. The aim of the current study was to discover whether DH patients have an
increased bone fracture risk similar to the one known to exist in coeliac disease. A further objective
was to study the factors associated with increased bone fracture risk in DH, and to assess the burden
related to fractures.
2. Materials and Methods
2.1. Patients, Controls, and Study Design
All patients with DH within the catchment area of the city of Tampere are diagnosed and treated at
a special outpatient clinic at Tampere University Hospital’s Department of Dermatology. The diagnosis
of DH is based on clinical symptoms and the demonstration of granular immunoglobulin A deposits
in perilesional skin biopsies studied with direct immunofluorescence [18]. From 1970 onwards, data
have been prospectively collected from all patients diagnosed with DH. All adult DH patients alive in
December 2015 and diagnosed before December 2014 (n = 413) were recruited to the study. The control
group comprised 222 biopsy-proven coeliac disease patients diagnosed at Tampere University Hospital
over the same time period who were suffering from abdominal symptoms at the time of diagnosis.
Self-administered study questionnaires (see below for more detail) were mailed to the patients
and controls. A second round of questionnaires were sent to all non-respondent patients and controls
under 80 years old. For the DH patients, the total response rate was 56% (237 out of 413). Of these
responders, 15 patients were excluded for having a coeliac disease diagnosis made more than one
year prior to the DH diagnosis. The remaining 222 DH patients constituted the study cohort. For the
coeliac disease controls, the final response rate was 59% (130 out of 222), and one patient was excluded
because of a DH diagnosis. The patients’ medical records were reviewed and the clinical, serological,
and histological severity of the disease and the use of dapsone were recorded.
The DH patients and coeliac disease controls received a full written explanation of the aims of
the study and they gave their written informed consent. The Regional Ethics Committee of Tampere
University Hospital approved the study protocol.
2.2. Questionnaires
Three self-administrated questionnaires were used in this study: the Disease Related Questionnaire
(DRQ), which was specifically designed for this study, and the general Psychological General
Well-Being (PGWB) and Gastrointestinal Symptom Rating Scale (GSRS) questionnaires, which have
been widely used in coeliac disease studies. The DRQ includes both open questions and multiple-choice
questions. Patients were asked to report all experienced bone fractures during their lifetime, the year
of each fracture, and the type of trauma causing the fracture. The DRQ also includes questions about
the respondent’s sociodemographic and lifestyle characteristics, presence of comorbidities, use of
long-term medication, and current weight and height. In addition, the questionnaire also enquires
about previous and current clinical symptoms related to coeliac disease and DH and the strictness of
the respondent’s GFD.
2
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The PGWB is a 22-item questionnaire used to evaluate quality of life and well-being [19,20].
It covers six emotional states: anxiety, depressed mood, self-control, positive well-being, general health,
and vitality. All of the items use a six-grade Likert scale, where value one represents the poorest and
value six the best possible well-being. The total PGWB score thus ranges from 22 to 132 points, with a
higher score indicating a better quality of life.
The GSRS is a 15-item questionnaire used to assess the severity of five groups of gastrointestinal
symptoms: diarrhoea, indigestion, constipation, abdominal pain, and reflux [21]. The questionnaire
uses a seven-grade Likert scale for each item, one symbolizing no symptoms and seven indicating the
most severe symptoms. The final scores are calculated as a mean for each sub-dimension and the total
GSRS score as the mean of all 15 items. A higher score indicates more severe symptoms.
2.3. Fractures
The self-reported fractures were categorized based on whether they had occurred before or after
the DH or coeliac disease diagnosis. The traumas causing the fractures were evaluated, and if the
trauma was considered sufficient to cause a bone fracture in any person (traffic accidents, high-energy
sports fractures), the fracture was excluded from further analysis. Fractures diagnosed as stress
fractures were also excluded from all further analysis.
2.4. Statistical Analysis
Median values, minimum and maximum values, and interquartile ranges (IQR) were used to
describe the continuous variables. All testing was two-sided and p < 0.05 was considered statistically
significant. The chi-squared test was used in cross-tabulations and the Mann–Whitney U test was
used for assessing changes between groups. Kaplan–Meier survival analysis was used to compare
the cumulative incidence of fractures between the groups. The odds ratios (OR) and 95% confidence
intervals (CI) were calculated by using binary logistic regression analysis. For fracture incidence rates,
95% CI were calculated assuming the number of fractures to have a Poisson distribution. All of the
statistical analyses were performed with SPSS version 20 (IBM SPSS Statistics for Windows, Version 20.0.
IBM Corp., Armonk, NY, USA) in cooperation with a statistician.
3. Results
In total, 101 of the 222 DH patients (45%) and 104 of the 129 coeliac disease controls (81%) were
female. The DH patients were younger at the time of diagnosis than the coeliac disease controls
(Table 1). At the time of the study, there were no differences in age or body mass index between the
groups. The median follow-up time after diagnosis was 23 years (range 2–53) for the DH patients
and 20 years (range 1–43) for the coeliac disease controls. The DH patients and the coeliac disease
controls reported a total of 128 fractures, of which 9 excess-trauma fractures and 5 stress fractures were
excluded from further analysis. There were no statistical differences between the groups in terms of
the number of study participants who reported a fracture (Table 1).
The fracture incidence rate per 105 person-years for the first fracture was 317 (95% CI 228–431) for
the DH patients and 388 (95% CI 259–558) for the coeliac disease controls. For the first fracture after
DH or coeliac disease diagnosis, the fracture incidence rates per 105 person-years were 629 (95% CI
427–894) for the DH patients and 1083 (95% CI 707–1589) for the coeliac disease controls. In the
binary logistic regression analysis, the risk of fracture for the coeliac disease group did not statistically
significantly differ from the DH group before (OR 1.47, 95% CI 0.88–2.43, p = 0.141) or after adjustment
for gender and age at the time of the study (adjusted OR 1.04, 95% CI 0.60–1.79, p = 0.891). In the
Kaplan–Meier analysis, neither the cumulative lifetime fracture incidence (Figure 1A) nor the incidence
before diagnosis (p = 0.127) significantly differed between the groups. The cumulative incidence of
fractures after the diagnosis was statistically significantly higher in the coeliac disease group than in
the DH group (Figure 1B). When the genders were analysed separately the difference was observed
for female (p = 0.021) but not for male patients (p = 0.291).
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Figure 1. Kaplan–Meier cumulative incidence of the first fracture (A) and for first fracture after
diagnosis (B) for the dermatitis herpetiformis (DH) patients and the coeliac disease controls.
In both study groups, patients with fractures were more often female, had more often been
diagnosed with osteoporosis, and more often had multiple long-term illnesses (Table 2). At the time of
the study, those with fractures were more often using proton-pump inhibitors (PPI) and vitamin D
4
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and calcium supplementation than those with no reported fractures (Table 2). The current usage of
hormone replacement therapy and diuretics was more common among the DH patients with reported
fractures than those without, but this was not seen in the coeliac disease controls. There were no
differences in the smoking habits or current adherence to a GFD, the amount of weekly exercise,
or the use of glucocorticoids or bisphosphonates between those with and without fractures in either
groups (Table 2). Compared to coeliac disease controls with fractures, DH patients with fractures were
statistically significantly more often male, and they were younger at the time of the diagnosis (Table 2)
and at the time of the first fracture (median 48 years vs. 57 years, p = 0.048).
The DH patients with fractures more frequently had severe villous atrophy in the small bowel at
the time of the diagnosis than those without fractures, but the difference in the histological severity of
the disease did not reach statistical difference (Table 3). There were no differences in the duration of
skin symptoms before DH diagnosis, the severity of skin symptoms, or the presence of gastrointestinal
symptoms at diagnosis between DH patients with fractures and those without, but DH patients with
fractures had used dapsone medication statistically significantly longer after diagnosis than those
without fractures (Table 3).
The severity of the gastrointestinal symptoms as measured with the GSRS total score did not differ
between DH patients or coeliac disease controls with and without fractures (Table A1). However, DH
patients with fractures reported higher GSRS reflux subscores than those without fractures (median
1.5 vs. 1.0, p = 0.012). This was also seen in the coeliac disease controls, although without reaching
statistical significance (median 1.5 vs. 1.0, p = 0.083). The quality of life measured with the PGWB
questionnaire was decreased in DH patients with fractures compared to those without in total score
(median 106 vs. 112, p = 0.006) and in all other subscores except depression (Table A1). This same
phenomenon was not observed in the coeliac disease controls (Table A1).
Table 1. Demographic data and reported fractures among 222 dermatitis herpetiformis (DH) patients




Controls (n = 129) p-Value
n % n %
Female 101 45 104 81 <0.001
Age at diagnosis, median (range), years 37 (5–78) 42 (7–72) 0.027
Age at the time of the study, median (range), years 65 (18–96) 66 (35–86) 0.654
BMI 1 at the time of the study, median (range), kg/m2 26 (17–40) 26 (15–46) 0.714
Reported fractures 45 20 35 27 0.140
Before diagnosis 13 6 3 3 0.143
After diagnosis 31 14 26 22 0.080
Reported multiple fractures 15 7 12 9 0.388
1 BMI, Body mass index.
5
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Table 3. Disease-related characteristics presented as percentages, median values, and interquartile






Year of DH diagnosis, median (IQR) 1990 (1976–2000) 1991 (1982–2002) 0.076
Duration of skin symptoms prior to DH
diagnosis, median (IQR), months 12 (6–60) 10 (5–24) 0.183




Presence of gastrointestinal symptoms at the
time of diagnosis, % 47 49 0.886
Small-bowel histology at diagnosis, % 0.405
Normal 16 24
PVA 1 35 39
SVA/TVA 2 49 37
Use of dapsone after diagnosis, % 79 77 0.854
Duration of dapsone, median (IQR), months 60 (12–171) 24 (12–60) 0.031
1 PVA, Partial villous atrophy; 2 SVA/TVA, Subtotal or total villous atrophy.
4. Discussion
In the current study, the lifetime fracture risk in DH was found not to differ from that in coeliac
disease, which is well known to be linked to increased bone fracture risk [8]. However, it was found
that females with coeliac disease had more fractures after coeliac disease was diagnosed than females
with DH after DH diagnosis. The sole previous study addressing bone fracture risk in DH, with a
respectable 846 DH patients from the United Kingdom, found no increased fracture risk in DH
compared to the general population (hazard ratio 1.1) [13]. However, the study had limitations, as
their observation period was rather short (median 3.7 years, 3496 person-years) and the data collected
regarding adherence to GFD treatment was scanty. In the current study, the fracture incidence was
smaller than in the work by Lewis et al. but the results are not comparable, as different study methods
and follow-up times were used. In addition, our study groups had good adherence to a GFD, which is
likely to decrease the fracture incidence. Other than the study by Lewis et al., bone health in DH
has been investigated in four small studies focusing on the DH patients’ BMD. Two studies found
that DH patients have a decreased BMD compared to non-DH controls but better BMD than coeliac
disease controls [14,15], and two studies found that the BMD in DH patients did not differ from that
expected [16,17].
It is acknowledged that strict adherence to a GFD increases BMD in coeliac disease patients [2,7],
and thus probably decreases the risk of bone fractures in the long term. In the current study, there
were no differences in the strictness of GFD at the time of the study in the DH patients and the coeliac
disease controls with and without fractures (Table 2). Overall, the GFD in this study cohort was strict,
showing that bone fractures also tend to occur when the patients adhere to the diet well. However,
we do not have short-term data about the strictness of the diet after the diagnosis. The duration of
dapsone use after diagnosis was longer for DH patients reporting fractures compared to those who
did not (Table 3). Longer requirement of dapsone usage suggests more active and prolonged rash,
which might be a consequence of ongoing gluten consumption from dietary lapses on GFD. Less strict
GFD after diagnosis in turn would be a logical cause for increased risk of fractures.
Bone deterioration in coeliac disease is considered a consequence of autoimmune reaction.
The autoimmune reaction causes local and systemic chronic inflammation, which in turn causes
7
Nutrients 2018, 10, 351
micronutrient deficiency and activates a network of cytokines that have deleterious consequences for
bone remodeling [22]. As DH and coeliac disease principally share the same pathogenetic mechanisms,
it is accurate to assume that the same mechanisms explain the increased fracture risk also observed in
DH. However, our study showed that after diagnosis, the female coeliac disease controls experienced
more fractures than the female DH patients. This difference could be caused by the on-going
small-bowel inflammation that remains in coeliac disease even after the recovery of the mucosal
architecture [23]. In addition, the age at diagnosis was higher for the coeliac disease controls compared
to the DH patients. The higher age at diagnosis has been linked to less complete bone recovery
following GFD, and it seems that the ability to bone recovery is the least satisfactory for peri- and
post-menopausal women [3,24]. The higher age at diagnosis might also indicate that coeliac disease
patients have suffered from the untreated disease longer than DH patients, and untreated disease
particularly before puberty would have unfavorable effects on bone health.
The prevalence of gastrointestinal symptoms at the time of diagnosis was not linked to reported
fractures, nor was any symptom other than reflux in the GSRS questionnaire at the time of the study.
Consistently with more severe reflux symptoms detected, both the DH patients and the coeliac disease
controls with fractures reported using PPI as a long-term medication more often than those without
fractures. The usage of PPI medication has been reported to increase the risk of fractures at any site in
a recent meta-analysis [25]. Thus, caution with PPI medications should be advised, although based on
the experienced reflux symptoms, there is a clear need for PPI medication in certain individuals with
DH and coeliac disease.
This study showed that the DH patients who reported fractures had a decreased quality of life
compared to those with no fractures. Although we do not know if this decrease in life quality is caused
by the burden of fractures or simply explained by a higher rate of multiple long-term illnesses detected
in patients with fractures, we think that more attention should be directed to fractures in DH. In this
study cohort, very few of the DH patients with fractures had been diagnosed with osteoporosis, which
suggests that BMD measurements may not have been carried out systematically in the presence of
fractures. This limits the awareness and motivation to adequately treat patients suffering from low
BMD, and thus it also limits the prevention of additional fractures.
The strengths of this study are the large cohorts of patients with biopsy-proven DH and coeliac
disease with strict inclusion and exclusion criteria, and thus a minimal possibility for misclassification
bias. The cohorts were diagnosed and treated by specialists during the same time period, and they
included patients with different severities of the disease from the same geographic area. The limitations
of this study should be recognized, however. The fractures in this study were self-reported, which
is not ideal. Nevertheless, questionnaire studies have in fact proven to be rather reliable [26], and
although we know that the results are underestimations of the true occurrence due to recall bias [27],
the groups in this study are comparable because they were both studied in a similar manner. Another
limitation is that we have not taken the site of the fracture into account in our analysis, so we do not
know how this would have differed between the groups. The study also compared only the fractures
between DH and coeliac disease, and we did not enrol healthy controls. The gender distributions
between our cohorts were unequal, but they correspond to the true distributions in both diseases and
therefore the cohorts cannot be considered unrepresentative.
5. Conclusions
In conclusion, the fracture risk in DH is analogous to that in coeliac disease, which is a disease
widely documented to be associated with increased bone fracture risk. However, after the diagnosis,
the fracture risk was higher in coeliac disease than in DH for female patients. The severity of the
skin disease did not correlate with the fracture risk in DH, but the reflux symptom and usage of PPI
medication were linked to an increased fracture risk. The quality of life was shown to be decreased in
DH patients with a history of fractures, which indicates that more attention should be directed to the
fracture risk in DH, and BMD measurements should not be overlooked.
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Appendix A
Table A1. Median values and interquartile ranges for the Psychological General Well-Being (PGWB) and
Gastrointestinal Symptoms Rating Scale (GSRS) totals and subscores for the dermatitis herpetiformis
(DH) patients and the coeliac disease controls with and without fractures. In the PGWB, a higher score
indicates a better quality of life, and in the GSRS, a higher score indicates more severe symptoms.








Fracture (n = 94) p-Value
GSRS
Total 1.9 (1.3–2.3) 1.6 (1.3–2.1) 0.191 1.9 (1.5–2.5) 1.7 (1.4–2.5) 0.472
Diarrhoea 1.7 (1.0–2.3) 1.3 (1.0–2.0) 0.116 2.0 (1.0–2.7) 1.7 (1.0–2.5) 0.635
Indigestion 2.0 (1.3–2.5) * 1.8 (1.5–2.5) 0.630 2.4 (1.8–2.8) 2.0 (1.5–3.0) 0.343
Constipation 1.3 (1.0–2.3) 1.3 (1.0–2.3) 0.568 1.7 (1.3–2.5) 1.7 (1.0–2.7) 0.572
Pain 1.7 (1.2–2.3) 1.3 (1.0–2.0) 0.130 1.7 (1.3–2.3) 1.7 (1.3–2.3) 0.517
Reflux 1.5 (1.0–2.0) 1.0 (1.0–1.5) 0.012 1.5 (1.0–2.5) 1.0 (1.0–2.0) 0.083
PGWB
Total 106 (94–113) 112 (101–119) 0.006 110 (93–120) 106 (97–116) 0.629
Anxiety 25 (22–27) 26 (23–28) 0.020 27 (21–29) 25 (23–28) 0.757
Depression 17 (16–18) 18 (16–18) 0.311 17 (15–18) 17 (15–18) 0.948
Well-being 17 (15–19) 18 (16–20) 0.007 18 (15–19) 17 (16–20) 0.941
Self control 16 (15–17) 16 (15–17) 0.052 16 (13–17) 16 (14–17) 0.888
General health 13 (11–15) 15 (13–16 0.012 13 (11–16) 13 (11–15) 0.712
Vitality 18 (17–21) 20 (17–21) 0.029 19 (17–20) 18 (16–20) 0.665
* p < 0.05 when the DH patients with fractures were compared to the coeliac disease patients with fractures.
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Abstract: The Gilles de la Tourette syndrome (GTS) and Non-Coeliac Gluten Sensitivity (NCGS) may
be associated. We analyse the efficacy of a gluten-free diet (GFD) in 29 patients with GTS (23 children;
six adults) in a prospective pilot study. All of them followed a GFD for one year. The Yale Global
Tics Severity Scale (YGTSS), the Yale-Brown Obsessive-Compulsive Scale—Self Report (Y-BOCS) or
the Children’s Yale-Brown Obsessive-Compulsive Scale—Self Report (CY-BOCS), and the Cavanna’s
Quality of Life Questionnaire applied to GTS (GTS-QOL) were compared before and after the GFD;
74% of children and 50% of adults were males, not significant (NS). At the beginning of the study, 69%
of children and 100% of adults had associated obsessive-compulsive disorder (OCD) (NS). At baseline,
the YGTSS scores were 55.0 ± 17.5 (children) and 55.8 ± 19.8 (adults) (NS), the Y-BOCS/CY-BOCS
scores were 15.3, (standard deviation (SD) = 12.3) (children) and 26.8 (9.2) (adults) (p = 0.043), and the
GTS-QOL scores were 42.8 ± 18.5 (children) and 64 ± 7.9 (adults) (p = 0.000). NCGS was frequent in
both groups, with headaches reported by 47.0% of children and 83.6% of adults (p = 0.001). After one
year on a GFD there was a marked reduction in measures of tics (YGTSS) (p = 0.001), and the intensity
and frequency of OCD (Y-BOCS/CY-BOCS) (p = 0.001), along with improved generic quality of life
(p = 0.001) in children and adults. In conclusion, a GFD maintained for one year in GTS patients led
to a marked reduction in tics and OCD both in children and adults.
Keywords: Gilles de la Tourette syndrome (GTS); children and adults; motor and vocal/phonic
tics; obsessive-compulsive disorder (OCD); non-coeliac gluten sensitivity (NCGS); gluten-free diet;
one-year adherence
1. Introduction
The Gilles de la Tourette syndrome (GTS) is a chronic neuropsychiatric process of unknown cause.
It is characterised by the presence of multiple motor tics and at least one vocal or phonic tic. Both types
of tic are usually intermittent, although not necessarily concurrently. They are of variable frequency,
with periods of intensification and remission, persisting for more than a year, from the appearance of
the first tic [1].
This disorder begins in childhood or adolescence before the age of 18 years [1]. Tic severity
worsens throughout childhood and for most patients, the worst ever period of tics occurs between 8
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and 12 years of age [2,3]. Although up to 80% of patients with GTS have a significant tic decrease during
adolescence, and by age 18 years tic intensity and frequency have decreased to such an extent that the
person no longer experiences any impairment from their tics, objective ratings indicate that up to 90% of
adults continue to exhibit mild tics, although they may occasionally pass unnoticed [3,4]. Its prevalence
in school-age children worldwide is around 1%, with a clear predominance in males compared with
females on average (3:1). The GTS may be associated with other comorbidities in up to 90% of cases,
including obsessive-compulsive disorder (OCD) and those related with attention-deficit/hyperactivity
disorder (ADHD) [5]. When comorbid OCD debuts during childhood, it tends to remit in adulthood
in only about 40% of cases. It also can develop during adolescence or early adulthood [3,6].
Non-coeliac gluten sensitivity (NCGS) was first described in 1980 [7], but it was classified as part
of the spectrum of gluten-related disorders, which also includes coeliac disease (CD) and wheat allergy
(WA), until being recognised as a separate clinical entity in 2010. The NCGS is the most frequent of
these and is estimated to occur at a prevalence as high as 13% in the general population [8,9].
The clinical presentations of NCGS are varied and overlap with those of CD. It is diagnosed
through the prior exclusion of CD, because the serological and histological markers of gluten are
usually negative and show a positive response to the withdrawal of gluten from the diet [10,11].
The extra-intestinal symptoms may be the only manifestations of the NCGS, affecting the skin and the
musculoskeletal and nervous systems in general [12]. All the associated symptoms improve notably,
even disappearing with prolonged adherence to a gluten-free diet (GFD), in a similar manner to what
occurs in coeliac patients [13].
The spectrum of neurological processes associated with gluten has progressively broadened in
recent years [14–16]. We might expect that the neurological symptoms in certain patients with GTS
would maintain a certain relation with the presence of a previously unknown associated NCGS. For this
reason, the GFD could have a beneficial effect on their general symptomatology, including neurological
symptoms. At present, there is little evidence of its utility in these patients and only isolated cases
have provided evidence of the efficacy of a GFD, showing that it could be beneficial [17–19], as has
been reported in patients with autism; in these cases, milk casein was also eliminated from the diet of
many of them [20]. Its long-term efficacy has been described in one isolated case of GTS treated with
GFD for 3 years, whose neurological and general symptomatology completely recovered. Currently,
no controlled studies are available of series of patients. A recent systematic review of the literature on
the influence of different dietary interventions in patients with GTS found nine articles and one book
chapter, none of which included isolated comparative or inter-group studies [21].
The aim of the current study was to analyse and evaluate the efficacy of the GFD, followed for
a year by a series of child and adult patients with GTS. The evolution of the neurological and other
symptoms associated with NCGS, and the changes observed in their quality of life were evaluated,
enabling the comparison of existing clinical aspects before starting the GFD and after 1 year of
adherence to it.
2. Materials and Methods
We carried out a prospective pilot study at the national level in Spain of patients diagnosed with
GTS to evaluate the efficacy of following a GFD in children and adults. Participants were recruited as
voluntary in the study through the online invitation from the National Forum for Tourette’s Syndrome.
Adults or children’s parents gave their written informed consent before they participated in the study.
Children are considered to be those younger than 14 years before inclusion in the study. A fundamental
inclusion criterion for all patients was that they exhibited motor tics and at least one vocal/phonic tic
that had lasted for more than one year.
Thirty-four consecutive patients with GTS began the study, comprising 26 children and eight
adults diagnosed, evaluated and followed up various specialists (paediatricians, neurologists, general
practitioners, psychiatrists and psychologists). Five patients (three children and two adults) were
withdrawn, three due to prolonged interruptions of the diet (one child and two adults) and two
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children due to voluntary abandonment of the diet. The final sample therefore comprised 29 patients
(23 children and six adults).
The children’s parents and the adults voluntarily agreed to take part in the study, having been
provided with detailed information about the characteristics of the GFD and control criteria. The study
was carried out in accordance with Good Clinical Practice, in accordance with the Personal Data
Protection and Confidentiality Law, thereby maintaining the anonymity of patients at all times.
This study received the ethical approval for the Committee of the Hospital Universitario Central
de Asturias (HUCA) with the ethical code number 6265481/16.
Patients were recommended to follow a strict and permanent GFD, as was explained in detail to
the parents and adults, and to avoid all types of contamination, for a minimum period of adherence of
one year. The observed differences in clinical evolution were compared, and the findings and data
collected during the period before starting the GFD and at the end of the year adhering to the diet.
Upon joining the study, patients were asked to undergo a wide range of blood tests, including a
complete blood count, general biochemistry, levels of serum anti-tissue transglutaminase antibodies
(TGt), the CD genetic markers Human Leukocyte Antigen-DQ2 and Human Leukocyte Antigen-DQ8
(HLA-DQ2 and HLA-DQ8), and serum levels of thyroid hormone and of 25(OH)-Vit. D.
Four questionnaires were administered upon commencement and after 1 year on the GFD. Two of
these covered different aspects of GTS, with respect to tics and to OCD. The other two addressed
quality of life: a generic one and another one specific to GTS. All the questionnaires were supervised
by the parents of the children or filled in by the adults themselves. Information was collected about the
principal symptoms related to the patients’ neurological characteristics and the signs and symptoms
associated with the presence of NCGS.
Our team reviewed all the questionnaires received to ensure that they were complete and
contained no contradictory responses. Contact by regular e-mails, telephone calls and/or face-to-face
meetings was maintained throughout the study with the parents of the children and with the adults
themselves to resolve queries and check the data.
2.1. Questionnaires Used in the Study
2.1.1. Questionnaire to Assess the Severity of Tics Using the Yale Global Tics Severity Scale (YGTSS)
The YGTSS is a widely used instrument for evaluating the intensity and clinical severity of tics
in patients with GTS. A variety of tics are enumerated and scored to derive three subscales: motor
tics, vocal/phonic tics, and the impairment caused by the tics. For each tics scale, the mean number,
total frequency, intensity, complexity and interference are scored between 0 (no affectation) and 5
(maximum affectation). The highest possible overall score for motor tics is 25 and for phonic tics is 25.
The score for the impairment arising varies between 0 (none) and 50 (maximum). The total score for
the YGTSS is obtained by summing the results obtained from the three subscales and has a maximum
value of 100. We used the validated Spanish version of the YGTSS [22,23].
2.1.2. Questionnaires for Evaluating OCD Using the Yale-Brown Obsessive-Compulsive Scale—Self
Report (Y-BOCS) and the Children’s Yale-Brown Obsessive-Compulsive Scale—Self Report (CY-BOCS)
The Y-BOCS and the CY-BOCS are used to evaluate obsessions and compulsions in children and
adults, respectively. They comprise ten items, scored from 0 (no symptoms) to 4 (severe symptoms),
to evaluate three components: (a) Obsessions: obtained as the sum of the first five items: Time occupied
by the main obsession, its interference in daily life, the distress caused, the resistance against them,
and the control over them; (b) Compulsions: comprising the latter five items, which likewise evaluate
the time, interference, distress, resistance and control of the principal compulsion presented by the
individual; (c) Overall evaluation of obsessions and compulsions: obtained as the sum of the two
previous measures. The overall score varies between 0 (minimum) and 40 (maximum). We used the
validated Spanish version [24,25].
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2.1.3. EuroQol-5D (EQ-5D) Generic Quality of Life Questionnaire
The EQ-5D is a generic instrument for evaluating a person’s state of general health. It analyses
five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each scored
on a scale of 1–3, representing best and worst health. The final evaluation includes a summary index,
whose maximum value is 1 (indicating a state of full health). It also includes a visual analogue scale
(VAS) from 0 to 100, where a value of 100 represents the best imaginable health state. We used the
validated Spanish version [26].
2.1.4. Cavanna’s Quality of Life Questionnaire Applied to GTS (GTS-QOL)
This is a specific instrument for evaluating the quality of life of patients with GTS. It comprises
27 items covering six dimensions, each scored from 0 (minimum possible value) to four (maximum
possible value): cognitive (eight items); psychological (six items); obsessive-compulsive (four items);
physical (three items); coprophenomena (three items); activities of daily living (three items). The results
from the six dimensions are evaluated by summing the scores of all the items and, for ease of
interpretation, transforming the total to give a value between 0 and 108. It also includes a VAS,
scored from 0 to 100, for which the maximum value represents the best possible health. The validated
scale in English was administered in Spanish [27].
2.2. Evaluation of Other Neurological Characteristics
Other data of GTS were collected at the time of inclusion, including age of onset and duration of
the different symptoms of the disease, number of family members affected, and types of medication
consumed. The changes that had occurred with respect to the various aspects under investigation by
the end of the year on the GFD were analysed.
2.3. Evaluation of NCGS Symptoms
The signs and symptoms related to the NCGS were evaluated with a questionnaire comprising
several items with a variable number of possible responses. Clinical characteristics of NCGS were
collected at the time of inclusion, along with information about family background, analytical results
and complementary tests and their evolution after the GFD. A group of questions designed to evaluate
the different symptoms distributed by organs and apparatus, each with a variable number of possible
responses, and a general score between 0 (absence of symptoms) and 3 (maximum possible intensity)
was included.
2.4. Evaluation of GFD Compliance
The evaluation and follow up of the diet compliance were carried out through questionnaires
filled in by the patients (in the case of adults) or their parents (in the case of children) and regular
contact by telephone, e-mail or, in some cases, face-to-face consultation.
2.5. Audio-Visual Monitoring Evaluation
For the assessment of tics and following the recommendations of the European clinical guidelines
for Tourette Syndrome and other tic disorders, we ask our patients for some audiovisual recordings,
reflecting spontaneous situations of everyday life [3]. The parents of one of our patients gave their
written informed consent to attach a demonstration video of their child’s evolution for scientific
purposes in this study, whose details are specified in the Supplementary Material Section.
2.6. Statistical Methods
Data were analysed with SPSS (v15.0 for Windows; SPSS Inc., Chicago, IL, USA). Descriptive
analyses were used to characterize the study population. Categorical variables were expressed as
absolute frequencies and percentages. Quantitative variables were expressed as the mean or median,
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if normally or non-normally distributed, respectively, and were compared within and between groups
using Student’s two-tailed independent samples t-test. To compare the proportions (frequencies)
of qualitative variables between the groups, contingency test methods (chi-squared (χ2) or Fisher’s
exact tests) were used, as appropriate. Student’s t-test and Mann-Whitney were used for independent
(unpaired) samples (children vs. adults). When the number of observations of any of the groups
compared was small, always the parametric tests (Student) were used; otherwise, the tests used were
Mann-Whitney and Wilcoxon. When the data were quantitative of low rank (for example, scores from
1 to 5) nonparametric tests were always used. For samples of repeated measurements, the McNemar
test has been used. The paired Wilcoxon signed-rank test was used to compare differences in the
medians of continuous non-parametric variables. The tests used and the variables of the groups in
which they have been applied are specified at the beginning of the foot of each table. In all cases,
a value of p < 0.05 was considered to indicate a statistically significant difference.
3. Results
3.1. Baseline Demographic Characteristics of Children and Adults
Comparing the baseline characteristics of child and adult patients included in the study, showed
that 74% of the children and 50% of the adults were male (NS). 69% of children and 100% of adults
presented an associated OCD (NS). ADHD was present in 52.2% of children and 66.2% of adults (NS).
The total tic score, as measured by the YGTSS questionnaire, was similar in the two groups (NS).
Conversely, the total OCD score assessed with the Y-BOCS/CY-BOCS questionnaires, was lower in
the children 15.3 (12.3) than in the adults 26.8 (9.2) (p = 0.043). The generic quality of life score at
the beginning of the study was similar in the two groups. However, GTS-specific quality of life was
lower in the children 42.8 (18.5) than in the adults 64.0 (7.9) (p = 0.000). There was no difference in
the consumption of medication between the groups, either overall or with respect to Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs). However, many fewer children than adults took psychotropics
(34.8% vs. 100%) (p = 0.006) (Table 1).
Table 1. Baseline demographic characteristics of children and adults.
Parameters Children (n = 23) Adults (n = 6) p
Males, n (%) 17 (74) 3 (50) NS
Mean age, years, (X ± SD) 8.3 ± 2.7 32.2 ± 11.9 NA
Age at commencement, years, (X ± SD) 3.8 ± 2.0 7.7 ± 3.4 NA
Duration of symptoms of GTS, years, (X ± SD) 4.5 ± 2.4 24.5 ± 10.9 NA
Associated OCD, n (%) 16 (69) 6 (100) NS
Associated ADHD, n (%) 11 (52.2) 4 (66.2) NS
Total YGTSS score, (X ± SD) 55.0 ± 17.5 55.8 ± 19.8 NS
Total Y-BOCS score, (X ± SD) 15.3 ± 12.3 26.8 ± 9.2 =0.043
Total EQ-5D score, (X ± SD) 0.6 ± 0.2 0.5 ± 0.2 NS
Total GTS-QOL score, (X ± SD) 42.8 ± 18.5 64.0 ± 7.9 =0.000
Drug consumption, n (%) 21 (91.3) 6 (100) NS
-NSAIDs, n (%) 21 (91.3) 6 (100) NS
-Psychotropics, n (%) 8 (34.8) 6 (100) =0.006
The Mann Whitney or Fisher tests were used when the variances were different and when they were similar,
the Student test was employed. X = Mean; SD = Standard Deviation; OCD = Obsessive Compulsive Disorder;
ADHD = Attention-Deficit/Hyperactivity Disorder; YGTSS = Yale Global Tics Severity Scale; Y-BOCS = Yale-Brown
Obsessive-Compulsive Scale; EQ-5D = EuroQol-5D; GTS-QOL = Gilles de la Tourette Syndrome-Quality of Life
Scale; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; NS = Non-Significant; NA = Not Applicable.
3.2. Baseline Characteristics of the Symptoms and Signs of Gluten Sensitivity in Children and Adults
Upon entering the study, a series of symptoms and signs related to the presence of NCGS, which
were present in the individual participants, were compared between the two groups. No significant
differences were found for any characteristics, except for the presence of headaches and/or migraines,
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which were more common in the adults than the children (83.3% vs. 47.8%) (p = 0.1), and of behavioural
disorders, which were also more common in adults (100% vs. 95.6%) (p = 0.001) (Table 2).
Table 2. Baseline characteristics of the symptoms and signs of NCGS in children and adults.
Parameters Children (n = 23) Adults (n = 6) p
Upper respiratory tract infections, n (%) 20 (86.9) 4 (66.7) NS
Lower respiratory tract infections, n (%) 15 (65.2) 2 (33.3) NS
Associated allergies, n (%) 12 (52.2) 2 (33.3) NS
Headaches and/or migraines, n (%) 11 (47.8) 5 (83.3) NS *
Infectious oral processes, n (%) 20 (86.9) 4 (66.7) NS
Other dental changes, n (%) 18 (78.3) 6 (100.0) NS
Musculoskeletal affectation, n (%) 21 (91.3) 5 (83.3) NS
Dermatitis, n (%) 20 (86.9) 5 (83.3) NS
Anaemia and/or ferropaenia, n (%) 17 (73.9) 5 (83.3) NS
Sleep disorders, n (%) 21 (91.3) 6 (100.0) NS
Behavioural disorders, n (%) 22 (95.6) 6 (100.0) NS **
Urinary disorders, n (%) 13 (56.5) 4 (66.7) NS
Dietary disorders, n (%) 20 (86.9) 6 (100.0) NS
Change in intestinal habit, n (%) 22 (95.6) 6 (100.0) NS
Change in stool consistency, n (%) 11 (47.8) 1 (16.7) NS
The Mann Whitney or Fisher tests were used when the variances were different and when they were similar, the
Student test was employed. * Comparing intensity, Mann-Whitney U, p = 0.1; ** Comparing intensity, Mann-Whitney,
p = 0.001 NCGS = Non-Coeliac Gluten Sensitivity; n = number; NS = Non-Significant.
3.3. Evolution of Neurological Symptoms and Quality of Life after 1 Year of a GFD
After one year of following a GFD, the improvement in neurological symptoms was very striking,
with a significant reduction in tics and OCD in both children and adults (p = 0.001). The same occurred
with the improvement found in the generic and specific quality of life (p = 0.001), whereby there was
no difference between the children and adults. This translated into a reduction in the consumption of
medication in both groups, the effect being very pronounced in children (p = 0.001) but more moderate
in adults (p = 0.072); the reduction among the adults was mainly a consequence of a decrease in the
consumption of psychotropics (p = 0.071) (Table 3).
Table 3. Evolution of neurological symptoms and quality of life after 1 year of a GFD.
Parameters Pre-GFD Post-GFD p
Total YGTSS score, (X ± SD), (Maximum 100)
-Children 55.0 ± 17.5 27.3 ± 22.3 =0.000
-Adults 55.8 ± 19.8 20.7 ± 13.5 =0.001
Total Y-BOCS/CY-BOCS score, (X ± SD), (Maximum 40)
-Children 15.3 ± 12.3 5.4 ± 8.6 =0.000
-Adults 26.8 ± 9.2 8.0 ± 8.9 =0.001
Total EQ-5D score, (X ± SD), (Maximum 1)
-Children 0.62 ± 0.23 0.88 ± 0.17 =0.000
-Adults 0.50 ± 0.22 0.87 ± 015 =0.004
Total GTS-QOL score, (X ± SD), (Maximum 108)
-Children 42.8 ± 18.5 22.4 ± 19.9 =0.000
-Adults 64.0 ± 7.9 20.5 ± 12.2 =0.001
Drug consumption *
-Children: -Total consumption, n (%) 21 (91.3) 16 (69.6) =0.001
-NSAIDs, n (%) 21 (91.3) 12 (52.2) =0.002
-Psychotropics, n (%) 8 (34.8) 7 (30.4) =0.190
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Table 3. Cont.
Parameters Pre-GFD Post-GFD p
-Adults: -Total consumption, n (%) 6 (100) 6 (100) =0.072
-NSAIDs, n (%) 6 (100) 5 (83.3) =0.100
-Psychotropics, n (%) 6 (100) 4 (66.7) =0.071
The tests used were the Wilcoxon signed-rank test for adults, the Student paired test for children and the
McNemar test for drugs consumption. * Comparing intensity, Wilcoxon test, GFD = Gluten-free diet; X = Mean;
SD = Standard Deviation; YGTSS = Yale Global Tics Severity Scale; Y-BOCS = Yale-Brown Obsessive-Compulsive
Scale; EQ-5D = EuroQol-5D; GTS-QOL = Gilles de la Tourette Syndrome-Quality of Life Scale; NSAIDs =
Non-Steroidal Anti-Inflammatory Drugs.
3.4. Evolution after 1 Year of a GFD of the Various Components of Motor and Phonic Tics, Obsessions
and Compulsions
The evolution of the different components of the motor and vocal/phonic tics, and of OCD,
was assessed, comparing the results obtained before beginning and a year after following the GFD.
With respect to the evolution of the characteristics of the motor tics, we found a notable decrease in
their various components (number, intensity, frequency, complexity and interference), that was more
significant in children (p = 0.000) than in adults (p = 0.027). The evaluation of the vocal/phonic tics
revealed a reduction in their principal characteristics in both groups, again being more pronounced
in children (p = 0.001) than in adults (p = 0.028). This was maintained with an identical significance
when jointly evaluating the motor and vocal/phonic tics, this improvement being somewhat smaller
in the adults than in the children. The evolution of the disability associated to the motor tics was
significantly reduced in the children (p = 0.000), but less so in the adults (p = 0.059). Likewise, a clear
improvement in the evolution of the disability related to the vocal/phonic tics was confirmed, the effect
being more significant in the children (p = 0.001) than in the adults (p = 0.041). The decrease in the
overall degree of disability along with the motor and vocal/phonic tics was significant in both groups,
though slightly higher in the children (p = 0.000) than in the adults (p = 0.027). Equally, after one
year on the GFD the various components of the obsessions (time, interference, distress, resistance and
control) were significantly reduced, which was somewhat more marked in children (p = 0.001) than
in adults (p = 0.028). The same components of the compulsions after a year on a GFD confirmed a
significant improvement in both groups, again being slightly greater in children (p = 0.008) than in
adults (p = 0.027) (Table 4).
Table 4. Evolution after 1 year of a GFD of the various components of motor and phonic tics, obsessions
and compulsions.
Parameters Pre-GFD Post-GFD p
Evaluation of motor tics (number, frequency, intensity, complexity and
interference), (X ± SD), (Maximum 25)
-Children 18.7 ± 4.3 10.1 ± 6.3 =0.000
-Adults 17.3 ± 7.1 9.0 ± 4.7 =0.027
Evaluation of phonic tics (number, frequency, intensity, complexity and
interference), (X ± SD), (Maximum 25)
-Children 14.4 ± 5.6 7.4 ± 7.1 =0.001
-Adults 15.2 ± 5.8 5.8 ± 3.9 =0.028
Overall evaluation of motor and phonic tics (number, frequency,
intensity, complexity and interference), (X ± SD), (Maximum 50)
-Children 33.1 ± 8.3 17.5 ± 12.1 =0.000
-Adults 32.5 ± 9.5 14.8 ± 7.7 =0.028
Overall disability of motor tics, (X ± SD), (Maximum 5)
-Children 2.3 ± 1.1 1.0 ± 1.1 =0.000
-Adults 2.5 ± 1.6 0.7 ± 0.8 =0.059
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Table 4. Cont.
Parameters Pre-GFD Post-GFD p
Overall disability of phonic tics, (X ± SD), (Maximum 5)
-Children 2.0 ± 1.2 1.0 ± 1.2 =0.001
-Adults 2.2 ± 1.3 0.5 ± 0.8 =0.041
Overall disability of motor and phonic tics, (X ± SD), (Maximum 10)
-Children 4.4 ± 2.0 1.9 ± 2.1 =0.000
-Adults 4.7 ± 2.2 1.2 ± 1.6 =0.027
Evaluation of obsessions (time, interference, discomfort, resistance and
control), (X ± SD), (Maximum 20)
-Children 8.7 ± 6.6 3.0 ± 4.7 =0.001
-Adults 13.5 ± 4.4 4.0 ± 4.5 =0.028
Evaluation of compulsions (time, interference, discomfort, resistance
and control), (X ± SD), (Maximum 20)
-Children 6.6 ± 6.3 2.4 ± 4.5 =0.008
-Adults 13.3 ± 4.9 4.0 ± 4.3 =0.027
The tests used were the Wilcoxon signed-rank test for adults and the Student paired test for children.
GFD = Gluten-free diet; X = Mean; SD = Standard Deviation.
3.5. Evolution of Symptoms of Non-Coeliac Gluten Sensitivity after 1 Year of a GFD
The evolution of the symptoms associated with NCGS after one year on a GFD was also very
favourable. The number and intensity of upper airway infections were significantly reduced in both
groups, though more notably in the children (p = 0.000) than in the adults (p = 0.068). The same
pattern was found for the lower airway, with children showing a more significant reduction (p = 0.001)
than the adults (p = 0.180). Conversely, no significant differences were found in the number of
associated allergies. Fewer episodes of headaches/migraines were observed, the effect being slightly
more significant in children (p = 0.013) than in adults (p = 0.068). Infectious or inflammatory oral
processes were notably reduced in children (p = 0.000) but were unchanged in adults (p = 0.104).
Musculoskeletal affectation decreased significantly in children (p = 0.002) and slightly less significantly
in adults (p = 0.042). Associated dermatitis also decreased strikingly in children (p = 0.002), more
significantly than in the adults (p = 0.058). Anaemia and iron deficiency improved notably in
children (p = 0.004) but was unchanged in adults (p = 0.131). Likewise, sleep disorders reduced
significantly in the children (p = 0.000) and in a smaller proportion of adults (p = 0.046). No significant
changes in urinary disorders were noted in children (p = 0.082) or adults (p = 0.109). Behavioural
disorders decreased significantly in children (p = 0.000) and to a lesser degree in adults (p = 0.028).
The improvement achieved in the dietary disorders was more evident in children (p = 0.000) than
in adults (p = 0.027), as was the case for the improvement in intestinal habit, which was greater in
children (p = 0.001) than in adults (p = 0.075) (Table 5).
Table 5. Evolution of symptoms of non-coeliac gluten sensitivity after 1 year of a GFD.
Parameters Pre-GFD Post-GFD p
Upper respiratory tract infections, (X ± SD), (Maximum 18)
-Children 3.2 ± 2.1 0.6 ± 0.9 =0.000
-Adults 4.5 ± 4.9 0.2 ± 0.4 =0.680
Lower respiratory tract infections, (X ± SD), (Maximum 9)
-Children 2.1 ± 2.2 0.1 ± 0.4 =0.001
-Adults 1.3 ± 2.1 0.3 ± 0.8 =0.180
Associated allergies, (X ± SD), (Maximum 27)
-Children 1.8 ± 3.4 1.7 ± 2.4 =0.782
-Adults 1.3 ± 2.8 2.2 ± 3.7 =0.285
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Table 5. Cont.
Parameters Pre-GFD Post-GFD p
Headaches and/or migraines, (X ± SD), (Maximum 18)
-Children 1.7 ± 2.7 0.4 ± 0.6 =0.013
-Adults 4.8 ± 4.9 0.8 ± 1.2 =0.068
Infectious oral processes, (X ± SD), (Maximum 15)
-Children 3.0 ± 2.3 1.0 ± 1.3 =0.000
-Adults 3.8 ± 4.2 0.5 ± 0.8 =0.104
Other dental changes, (X ± SD), (Maximum 15)
-Children 2.1 ± 1.6 1.6 ± 1.3 =0.105
-Adults 2.8 ± 2.1 1.8 ± 1.0 =0.276
Musculoskeletal affectation, (X ± SD), (Maximum 36)
-Children 5.0 ± 5.7 1.4 ± 2.5 =0.002
-Adults 9.0 ± 12.7 1.3 ± 2.0 =0.042
Dermatitis, (X ± SD), (Maximum 45)
-Children 4.8 ± 6.3 1.4 ± 1.9 =0.002
-Adults 6.3 ± 4.9 2.0 ± 2.1 =0.058
Anaemia and/or ferropaenia, (X ± SD), (Maximum 24)
-Children 2.8 ± 3.1 0.8 ± 1.4 =0.004
-Adults 4.0 ± 3.6 1.2 ± 1.5 =0.131
Sleep disorders, (X ± SD), (Maximum 27)
-Children 6.2 ± 6.4 1.6 ± 2.0 =0.000
-Adults 8.7 ± 5.3 2.0 ± 1.3 =0.046
Behavioural disorders, (X ± SD), (Maximum 24)
-Children 7.2 ± 5.6 2.6 ± 4.1 =0.002
-Adults 16.0 ± 3.0 3.0 ± 4.5 =0.028
Urinary disorders, (X ± SD), (Maximum 21)
-Children 1.8 ± 2.7 0.7 ± 1.3 =0.082
-Adults 3.3 ± 5.3 0.5 ± 0.8 =0.109
Dietary disorders, (X ± SD), (Maximum 45)
-Children 9.5 ± 9.5 1.3 ± 1.9 =0.000
-Adults 10.5 ± 9.4 1.8 ± 1.2 =0.027
Change in intestinal habit, (X ± SD), (Maximum 33)
-Children 9.1 ± 6.8 3.7 ± 4.8 =0.001
-Adults 7.7 ± 5.2 2.3 ± 2.1 =0.075
The tests used were the Wilcoxon signed-rank test for adults, the Student paired test for children and the McNemar
test for drugs consumption. GFD = Gluten-free diet; X = Mean; SD = Standard Deviation.
4. Discussion
At the beginning of the study, the presence of motor and vocal/phonic tics was similar in children
and adults. The generic quality of life was similar in the two groups; however, specifically GTS-related
quality of life was worse in children than in adults. Nevertheless, the adults were taking a higher
proportion of psychotropics than the children, with significant differences. Our results coincide with
those of other authors, in the sense that during childhood the intensity and frequency of tics are
usually higher in children than in adults, while OCD usually predominates in adults compared with
children, which accounts for the more widespread consumption of psychotropics among adults than
children [2,28,29].
People with NCGS usually exhibit a variety of associated symptoms such as headaches
or migraines, “brain fog”, fatigue, fibromyalgia, joint and muscle pain, leg or arm numbness,
tingling of the extremities, dermatitis (eczema or skin rash), allergies, atopic disorders, depression,
anxiety, anaemia, iron-deficiency anaemia, folate deficiency, asthma, rhinitis, eating disorders,
or autoimmune diseases. Among the extra-intestinal manifestations, NCGS has been implicated
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in some neuropsychiatric disorders, such as schizophrenia, autism, peripheral neuropathy, ataxia,
ADHD, mood swings, sensory symptoms, disturbed sleep patterns, and hallucinations (“gluten
psychosis”) [9,16,30–35].
Many coeliac patients or those with undiagnosed NCGS underestimate their multiple and frequent
discomfort from digestive and more general causes because they have grown accustomed to living
with a state of chronic poor health as though it were normal. They are only able to recognise that
they really did have symptoms related to the consumption of gluten when they start the GFD and the
improvement becomes obvious [36,37].
The disproportionately common occurrence in patients with GTS of immunologically determined
illnesses, such as allergic processes, rhinitis, asthma, dermatitis and conjunctivitis, frequently with
raised IgE and a positive family history of autoimmune diseases has been reported. Likewise,
the presence of migraines, autistic spectrum disorders, anxiety, depression, sleep disorders, behavioural
problems and hallucinations have frequently been noted [38–40].
At the beginning of our study, various symptoms and signs associated with NCGS were present
in similar proportions in both groups, with a slight predominance of headaches and/or migraines and
behavioural disorders in adults. After a year on the GFD a significant improvement was observed in
most of these symptoms and signs, both in children and adults, similar to what generally occurs in
patients with NCGS without associated GTS [8,34,41].
We found a significant improvement in the neurological signs of GTS after one year on the GFD,
with a notable reduction in motor and vocal/phonic tics and OCD symptoms, both in children and
adults. A probable explanation lies in the presence of an increase in intestinal permeability of patients
with NCGS, as happens in coeliac patients. This enables the passage of gluten peptides and other
related peptides to the bloodstream, crossing the blood-brain barrier and reaching different areas of the
brain, provoking the appearance of inflammatory processes localised in various structures within the
brain, which might explain the presence of the symptoms and signs related to the GTS [34]. This would
explain why the withdrawal of gluten from the diet produces a reduction in such deposits and thereby
gives rise to significant clinical improvement in the evolution of motor and vocal/phonic tics and
OCD symptoms. As Hadjivassiliou stated more than 15 years ago, “Gluten sensitivity can be primarily
and at times exclusively a neurological disease. The absence of an enteropathy should not preclude
patients from treatment with a gluten-free diet. Early diagnosis and removal of the trigger factor
by the introduction of gluten-free diet is a promising therapeutic intervention” and consequently
the fact “that gluten sensitivity is regarded as principally a disease of the small bowel is a historical
misconception” [42–44].
The GFD produced a clear improvement in generic and specific quality of life in both groups,
accompanied by a reduction in the overall consumption of drugs, this being more pronounced in
adults than children, largely due to the notable reduction in the consumption of psychotropics in the
former group, but not significant.
The improvement found with respect to the presence of tics was maintained upon evaluating the
degree of disability generated for the motor and vocal/phonic tics, although it was somewhat higher
in the children than the adults.
As confirmed by a systematic review, the risk of developing neurological complications in coeliac
patients is lower in children than in adults and their response to a GFD is generally quicker and
stronger, probably because they have spent less of their life eating gluten [45,46].
Likewise, an improvement was observed in the disability related to the presence of OCD, which is
also more striking in children than in adults. We have only found two previous reports in the literature,
one of a patient with OCD associated with GTS, and another of an isolated case, both of which showed
an improvement in symptoms along with a reduction in their previous disability [17,18].
The patients with GTS, as well as presenting motor and phonic tics, may develop multiple
behavioural problems in response to the impact of the symptoms that affect their relationships with
family members, friends, class-mates and teachers. Furthermore, it has been estimated that around
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90% present other comorbidities, including, amongst others, OCD and those related to ADHD, which
exacerbate the disorders of character and behaviour they already had that arose from the presence of
tics [47,48].
We can conclude that the improvement of the patients cannot be justified solely by the passage of
time because the children were in the stage of worse evolution of the GTS and the adults belong to the
subgroup of people whose disorder does not ameliorate or even get worse. In addition, the follow-up
period was only a year and the majority of patients had associated comorbidities. In the evaluation and
follow-up of diet compliance, 22 of the 29 patients indicated that they had suffered clearly identified
occasional contaminations due to errors in their diet. The tics reappeared or worsened in all cases
(16 cases with phonic and motor tics, 4 cases with only motor tics, 2 cases with only phonic tics);
all of the cases who previously had comorbid OCD experienced its reappearance or intensification.
The exacerbation was resolved after days or even weeks of resetting the gluten-free diet. It is interesting
to note that since these are inadvertent and involuntary contaminations verified a posteriori, mainly
associated with misinterpretations of labelling, eating out at restaurants or in family homes, the nocebo
effect can also be ruled out, especially in the case of children because they do not know the detailed
information about the diet. These data indicate a clear relationship between the improvement of GTS
symptoms and the withdrawal of gluten from the diet that is not conditioned by the passage of time or
hypothetical spontaneous remission.
We evaluated the symptoms related to the tics and the OCD using questionnaires that are widely
validated and accepted internationally. However, we did not evaluate the symptoms related to ADHD,
although we also found that they improved while on the GFD, as has been confirmed in a recent
systematic review of this subject [49].
This paper presents the results of a prospective uncontrolled cohort study, designed as a pilot,
and is the first of its kind, as far as we know. It has certain limitations, since the sample size of the
study was small, especially in the group of adults, and we have not been able to include a control
group. Our initial intention was to include it, but this was not possible. The patients who contacted
us presented significant affectation of their quality of life and all of them wanted to try the diet.
This prevents us from drawing definitive conclusions, added the fact that we cannot be sure that either
the children or the adults followed the GFD fully. Gluten is ubiquitous and removing it strictly from
the diet is difficult, especially when eating outside the home [50]. Ensuring fulfilment of the GFD is
complicated, as other authors have found [20,50–53] and we cannot be certain that it was achieved in
this study. Current studies show that compliance with the diet in patients with gluten sensitivity is
much worse than was formerly considered, demonstrating that approximately 79% of them continue to
present intestinal lesions, despite maintaining treatment with the GFD [52]. None of the methods used
to evaluate the strict compliance of the GFD has proved to be sufficiently accurate: questionnaires filled
in by patients; evaluation of symptoms; determination of gluten-specific antibodies; and findings in
duodenal biopsies [51,54]. Frequently, people with a poor educational level and a poor understanding
of how to follow a GFD believe that they are strictly following the diet, when in fact they are frequently
making mistakes [50,52]. This leads patients to overestimate their compliance when they fill in the
questionnaire, making their results unreliable. Neither the absence of digestive symptoms nor the
negativity of the antibodies guarantees that the intestinal mucosa recovers, which is complicated to
determine with biopsies because the intestinal lesions usually consist of minimal changes without
villous atrophy, and that are frequently patched and difficult to identify [51,54,55]. Recently, new
methods have been developed to monitor strict adherence to the diet, based on the determination
of the presence of gluten peptides in faeces or urine, which seem to offer a realistic alternative, but
have not yet been validated or become available for use in daily clinical practice [55]. We gave
detailed information to the patients about how to comply fully with the GFD. Although in the case
of the children we always recommend to parents that the whole family adopt a GFD, avoiding the
consumption of foodstuffs containing gluten at home, in school canteens and elsewhere cannot always
be fully achieved. We used questionnaires filled in by the patients (in the case of adults) or their parents
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(in the case of children) and had regular contact by telephone, e-mail or, in some cases, face-to-face
consultation, to monitor compliance and clarify doubts. However, for all the reasons stated above, we
conclude that we cannot guarantee that compliance with the gluten-free diet was entirely strict.
5. Conclusions
In conclusion, we have shown that following a GFD opens up a new line of therapy for patients
with GTS. It is entirely innocuous but requires a strict and prolonged adherence. It seems to be useful
for reducing the frequency and intensity of motor and vocal/phonic tics, and OCD symptoms. It is
also accompanied by an improved quality of life, both generally and specifically, and a reduction in
the consumption of NSAID drugs by children and of antipsychotics by adults.
Subsequent controlled and/or multi-centre studies including more patients and with a prolonged
period on the GFD will enable the efficacy of the diet to be determined more exactly.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/5/573/s1,
Video S1: A 7 years old child with GTS and OCD-evolution after 1 year of GFD. We include one video of the
evolution of an seven-year-old child, recorded before and after 1 year on the GFD, and the scores he obtained.
A clear improvement in his symptomatology can be seen. The child was not taking any medication.
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Abstract: Dermatitis herpetiformis (DH) is a common extraintestinal manifestation of coeliac disease
presenting with itchy papules and vesicles on the elbows, knees, and buttocks. Overt gastrointestinal
symptoms are rare. Diagnosis of DH is easily confirmed by immunofluorescence biopsy showing
pathognomonic granular immunoglobulin A (IgA) deposits in the papillary dermis. A valid
hypothesis for the immunopathogenesis of DH is that it starts from latent or manifest coeliac
disease in the gut and evolves into an immune complex deposition of high avidity IgA epidermal
transglutaminase (TG3) antibodies, together with the TG3 enzyme, in the papillary dermis. The mean
age at DH diagnosis has increased significantly in recent decades and presently is 40–50 years. The DH
to coeliac disease prevalence ratio is 1:8 in Finland and the United Kingdom (U.K.). The annual DH
incidence rate, currently 2.7 per 100,000 in Finland and 0.8 per 100,000 in the U.K., is decreasing,
whereas the reverse is true for coeliac disease. The long-term prognosis of DH patients on a gluten-free
diet is excellent, with the mortality rate being even lower than for the general population.
Keywords: dermatitis herpetiformis; coeliac disease; prevalence; epidermal transglutaminase;
gluten-free diet; long-term prognosis
1. Introduction
Dermatitis herpetiformis (DH) was described as a clinical entity by Louis Duhring in 1884,
four years before Samuel Gee published the symptoms of coeliac disease [1,2]. The hallmark of DH is the
symmetrical distribution of small vesicles and papules typically on the elbows, knees, and buttocks [3].
An intense itch is common, meaning that patients often scratch the vesicles. A breakthrough in the
accurate diagnosis of DH was the discovery of granular immunoglobulin A (IgA) deposits in the skin in
1969 [4]. Though patients with DH rarely presented with overt gastro-intestinal symptoms, small bowel
biopsies taken in the 1960s showed villous atrophy identical to that found in coeliac disease [5].
However, a quarter of the patients had normal small bowel villous architecture. Subsequently, it became
evident that these patients also had coeliac-type minor enteropathy, i.e., an increased density of
gamma/delta intraepithelial lymphocytes [6].
The rash in DH responds to a strict a gluten-free diet (GFD), albeit slowly, and the symptoms recur
on gluten challenge [7–9]. Therefore, a life-long GFD is the treatment of choice for all patients with
DH. Additionally, most patients initially receive dapsone (4,4-diaminodiphenylsulfone) medication,
which can be tapered off after a mean of two years’ strict adherence to a GFD [10].
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Genetic and family studies tie DH and coeliac disease closely together. Almost every patient with
DH and coeliac disease has the alleles contributing to the HLA-DQ2 or HLA-DQ8 haplotype [11].
These diseases segregate in the same families [12] and even monozygotic twin pairs can be affected by
DH and coeliac disease [13].
Clinical presentation of DH is not easy to recognize correctly by general practitioners and delay
of diagnosis for over two years occur in one third of the Finnish patients [14]. The presence of the
blistering rash with IgA deposits is the major difference between DH and coeliac disease. However,
other differences exist such as gender, age at onset, incidence, and long-term prognosis on a GFD.
These points will be discussed in more detail along with the immunopathogenesis of DH.
2. Clinical Presentation and Diagnosis of Dermatitis Herpetiformis
The typical sites of predilection of DH are the extensor surfaces of elbows and knees, and the
buttocks (Figure 1A,B). In addition, the upper back, abdomen, scalp and face can be affected, but oral
lesions are rare [3]. The rash is polymorphic with small blisters (Figure 1C). These are, however,
often eroded and crusted because of intense itch and scratching. Purpuric lesions may also appear on
the hands and feet, however, this is rare [3]. The presentation and activity of the rash varies greatly
from patient to patient, but complete remission is infrequent on a normal, gluten-containing diet.
Figure 1. Dermatitis herpetiformis. Typical scratched papules and macules on the elbows (A), and on
the knees (B). Fresh small blisters on the elbow (C). Direct immunofluorescence showing granular IgA
deposits in the basal membrane zone between epidermis and dermis (D).
The clinical picture is often highly suggestive of DH, although, linear IgA bullous disease is
always a diagnostic problem [15]. Itchy skin disorders such as urticaria, atopic or nummular dermatitis,
and scabies infestation should be considered as a differential diagnosis [3]. The localization and
burning itch experienced during the development of blisters is, however, usually severe enough to
raise suspicion of DH. The typical histopathological findings in the lesional skin of patients with DH
consists of subepidermal vesicles associated with an accumulation of neutrophils at the papillary tips.
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The histopathology of a DH skin lesion is not diagnostic since other bullous diseases, such as linear
IgA bullous disease and epidermolysis bullosa acquisita, may show similar findings [16]. Moreover,
the histopathologic picture of DH is often unspecific revealing only perivascular lymphocytic infiltrate
and minimal inflammation in dermal papillae.
The ideal method for diagnosis of DH is a direct immunofluorescence biopsy of unaffected skin
in close proximity to an active lesion [17]. This reveals pathognomonic granular IgA deposits at the
dermo-epidermal junction (Figure 1D), and the diagnosis of DH should not be made without this
finding [16].
3. Gender and Age at Onset
Earlier studies in adults with DH have shown male to female ratios ranging up to 2:1 [3] with
two recent large DH studies finding the ratio to be close to 1:1 [18,19]. This is in sharp contrast to
coeliac disease, in which females outnumber males [20] (Table 1). This gender imbalance may reduce
with increasing age, and it has also been absent in some coeliac disease screening studies [21,22].
These findings suggest that gender differences between DH and coeliac disease are perhaps not as
profound as was earlier thought.
Coeliac disease can be diagnosed at any age with the peak incidences being in early childhood
and between 40 and 60 years of age [20,23]. Clinical series in adults with DH from Europe and North
America have shown that the mean age at diagnosis is between 40 and 50 years [14,24]. Like coeliac
disease, the oldest DH patients have been over 80 years of age at diagnosis. In contrast to coeliac
disease, DH in childhood seems to be rare; it was found in only 4% of 476 Finnish patients [25].
However, differences may exist. In an Italian series comprising 159 DH patients, 36% were below the
age of 20 years [26], and a large series of 127 Hungarian children with DH has been published [27].
A study of 477 patients collected from 1970 onwards in Finland showed a significant increase in
the mean age at diagnosis [18]. The increase was from 35 to 51 years in men and from 36 to 46 years
in women. A similar increasing trend in the mean age at diagnosis has also been observed in recent
decades in adult coeliac disease, both in Finland and elsewhere [28–30]. One explanation for this trend
may be changes in dietary habits, such as the consumption of wheat, which in Sweden has changed
the appearance of childhood coeliac disease [31]. In Finland, the annual consumption of wheat, rye,
and other cereals per person has decreased from 150 kg to 71 kg over the past 50 years [32]. A lower
lifetime gluten load might thus explain the increasing age at diagnosis and perhaps also the trend
towards less severe small bowel atrophy in DH and coeliac disease [33–35].
Table 1. Differences between dermatitis derpetiformis and coeliac disease.
Dermatitis Herpetiformis Coeliac Disease
Gender Slightly more males Females predominate
Age at onset Mainly adults Children and adults
IgA-TG3 deposits in the skin 100% 0%
Small bowel villous atrophy 75% 100% *
IgA-TG2 deposits in the small
bowel mucosa [36,37] 80% up to 100% **
Prevalence in Finland and
United Kingdom [18,19,38] 75 and 30 per 100,000 660 and 240 per 100,000
Incidence Decreasing Increasing
Response to a gluten-free
diet [7,8,20]
Slow; months, in the beginning most
patients need dapsone to control the rash
Rapid; days or weeks until gastro-intestinal
symptoms end whereas small bowel villous
atrophy may persist for many years
Long-term prognosis on
a gluten-free diet [39–41] Excellent
All-cause and lymphoma mortality may
be increased
TG3 = epidermal transglutaminase, TG2 = tissue transglutaminase; * Potential coeliac disease with normal small
bowel mucosa architecture, inflammation and positive TG2 serology also exist; ** Data still sparse.
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4. Prevalence and Incidence
Two recent large DH studies with a total of 477 and 809 patients found a prevalence of 75.3 per
100,000 in Finland and 30 per 100,000 in the U.K., respectively [18,19] (Table 1). In the U.K. study the
prevalence of coeliac disease was 240 per 100,000, i.e., eight times higher than that of DH. The same 8:1
ratio was calculated in the Finnish study, where the national prevalence of coeliac disease was 661 per
100,000 [38]. Nevertheless, DH is evidently the most common extraintestinal manifestation of coeliac
disease [42].
The Social Insurance Institution of Finland maintains a nationwide register of adults with coeliac
disease and DH. In 2003, it included a total of 18,538 patients, of whom 3121 (17%) had DH [28].
When we compared the annual numbers of new cases in five-year periods from 1980 to 2003, it was
evident that in the first period patients with coeliac disease only slightly outnumbered those with
DH (Figure 2). After the first period, the annual number of DH patients slowly decreased, whereas
the number of coeliac disease patients continuously increased. In the ten-year period of 2005–2014,
the proportion of newly diagnosed patients with DH had decreased to only 4% [43] (Figure 2).
Years























Figure 2. Incidence of dermatitis herpetiformis and coeliac disease in Finland, 1980–2014. The data
include 3671 adult patients with Dermatitis herpetiformis and 31,385 adult patients with coeliac disease
registered with the Social Insurance Institution of Finland [28,43].
Importantly, a Finnish cohort study [18] and a U.K. register study [19] covering time periods of 30
and 20 years, respectively, showed convincingly that the annual incidence rate of DH has decreased
significantly. This decrease was from 5.2 to 2.7 per 100,000 in the Finnish study and from 1.8 to 0.8 per
100,000 in the U.K. study. The opposite was true for coeliac disease; there was a maximum of a fourfold
increase in the incidence rate [19]. The reason for this seems to be an increasing awareness of mild
symptoms, the development of efficient serological screening tests, and the identification of special
29
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risk groups, such as family members [20,23]. Sero-epidemiological studies suggest that in addition to
the better recognition of coeliac disease, there has also been a true increase in the incidence in recent
decades [44,45].
The decreasing incidence rate of DH in Finland and the U.K., along with a simultaneous
rapid increase in coeliac disease, fits our hypothesis that subclinical, undiagnosed coeliac disease is
a prerequisite for the development of DH. In support of this hypothesis, we know of patients initially
diagnosed with coeliac disease who did not follow or only partially followed a GFD and subsequently
developed DH [46]. Moreover, adult patients with DH frequently have coeliac-type dental enamel
defects, which develop early in childhood as a result of malabsorption or immune alteration caused by
undiagnosed coeliac disease [47].
5. Pathogenesis of Dermatitis Herpetiformis: From Gut to Skin
In DH, pathognomonic granular IgA deposits in the papillary dermis have long been suspected
to derive from the gut. In 2002, Sárdy et al. [48] showed that the autoantigen for deposited cutaneous
IgA is epidermal transglutaminase (TG3). This is closely related, but not identical, to the tissue
transglutaminase (TG2) autoantigen specific for coeliac disease [49]. The TG2 enzyme is a target for
IgA class autoantibody deposition in the small bowel mucosa in classical and potential coeliac disease,
and in DH [36,37,50]. The TG3 protein has not been detected in the small bowel similarly to the TG2
enzyme, but epitope spreading is a possibility [51]. Recently, DH patients with the active disease have
been shown to secrete high levels of TG3 antibodies into the gut organ culture medium, and also have
TG3-antibody-positive cells in the small intestinal mucosa [52]. At present, a valid hypothesis is that
the immunopathogenesis of DH starts from hidden coeliac disease in the gut with a TG2, and possibly
also a TG3, autoantibody response and evolves into an immune complex deposition of high avidity
IgA TG3 antibodies together with the TG3 enzyme in the papillary dermis [48]. Further support for
this comes from GFD treatment results; TG3 and TG2 antibodies in the blood disappear with the
dietary treatment and, at the same time, the rash and small bowel heal [53]. In contrast, the IgA-TG3
aggregates in the skin disappear very slowly with GFD treatment [54]. This seems to be due to the
active TG3 enzyme in the aggregates resulting in covalent cross-linking of the complex to dermal
structures [55].
6. Long-Term Prognosis on a Gluten-Free Diet Treatment
A GFD is the treatment of choice for all patients with DH regardless of whether they have villous
atrophy in the small bowel [7,8,10]. It is important to know the long-term prognosis for DH because,
as in coeliac disease, the risk of non-Hodgkin’s lymphoma is significantly increased [56]. However,
a strict GFD for more than five years seems to protect against lymphoma [57]. In agreement with this,
our cohort of 476 patients with DH, where almost all patients adhered to a GFD, showed a significantly
increased lymphoma mortality rate during the first five years of follow-up, but not thereafter [39].
Unexpectedly, the same study showed that the standardized mortality rate (SMR 0.70) was statistically
significantly reduced in the GFD-treated DH patients compared to the general population. In a previous
study of 846 DH patients from the U.K. [40], the adherence to a GFD was only partly known, and the
mortality rate was slightly, but non-significantly, reduced (hazard ratio 0.93).
In contrast to the excellent long-term prognosis for DH, a meta-analysis of prospective studies on
coeliac disease found a significantly increased risk for all-cause (odds ratio 1.24) and non-Hodgkin’s
lymphoma (odds ratio 2.61) mortality [41]. A recent large register study from England could only
confirm the excess risk of deaths from non-Hodgkin’s lymphoma [58]. However, in coeliac disease
mortality studies, the adherence to a GFD has not been analyzed or was only partially known [41,59];
therefore, there is a particular need to examine the relationship between mortality rate and
dietary compliance.
There are studies suggesting that patients with coeliac disease on a GFD retain a reduced quality
of life compared to the general population [60,61]. Recently, we examined long-term GFD-treated
30
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patients with DH [62]. Their quality of life was comparable to that of the general population, whereas
it was reduced in the coeliac disease controls.
7. Concluding Remarks
DH is the most common extraintestinal clinical manifestation of coeliac disease; at present,
the prevalence ratio of the disorders is 1:8. The incidence of DH is decreasing, whereas the opposite is
true for coeliac disease. A valid current hypothesis is that subclinical coeliac disease is a prerequisite
for the development of DH. The reason why only some undiagnosed coeliac individuals develop
an itchy blistering rash with dermal IgA-TG3 deposits remains unknown. The markedly increased age
at diagnosis and less severe small bowel damage both in DH and coeliac disease suggests changes in
environmental factors, such as a lowered lifetime gluten load. The long-term prognosis of DH patients
on a GFD is excellent, which seems to be due to a strict adherence to the diet.
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Abstract: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. At diagnosis,
the majority of patients have villous atrophy in the small bowel mucosa. The objective of this
study was to investigate whether the presence or absence of villous atrophy at diagnosis affects the
long-term prognosis of DH. Data were gathered from the patient records of 352 DH and 248 coeliac
disease patients, and follow-up data via questionnaires from 181 DH and 128 coeliac disease patients
on a gluten-free diet (GFD). Of the DH patients, 72% had villous atrophy when DH was diagnosed,
and these patients were significantly younger at diagnosis compared to those with normal small
bowel mucosa (37 vs. 54 years, p < 0.001). Clinical recovery on a GFD did not differ significantly
between the DH groups, nor did current adherence to a GFD, the presence of long-term illnesses,
coeliac disease-related complications or gastrointestinal symptoms, or quality of life. By contrast,
the coeliac disease controls had more often osteopenia/osteoporosis, thyroid diseases, malignancies
and current gastrointestinal symptoms compared to the DH patients. In conclusion, villous atrophy
at the time of DH diagnosis does not have an impact on the clinical recovery or long-term general
health of DH patients.
Keywords: dermatitis herpetiformis; coeliac disease; gluten-free diet; small bowel; villous
atrophy; prognosis
1. Introduction
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of coeliac disease currently
affecting approximately 13% of coeliac disease patients [1,2]. DH induces intense pruritus and a
symmetrical papulovesicular rash typically on the elbows, knees, and buttocks [3]. Coeliac disease and
DH are genetically predisposed by the human leukocyte antigen (HLA) DQ2 or DQ8 haplotypes, and
exogenous gluten causes an immune response and small bowel mucosal injury in both [4,5]. Furthermore,
autoantibodies against endogenous enzyme tissue transglutaminase (TG2) are characteristically present
in the serum and the intestine in both conditions [6–9].
Diagnosis of DH is verified with the detection of pathognomonic granular immunoglobulin A
(IgA) deposits in the uninvolved skin by direct immunofluorescence (IF) examination [10]. This IgA is
known to target epidermal transglutaminase (TG3) [11], which is considered the autoantigen in DH,
while in coeliac disease it is TG2 [6]. In addition to the skin, TG3 antibody response is often present in
Nutrients 2018, 10, 641; doi:10.3390/nu10050641 www.mdpi.com/journal/nutrients35
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the sera of DH patients, although TG3 antibodies are occasionally also found in the serum of some
coeliac disease patients without DH [12–14].
At the time of the DH diagnosis, some degree of small bowel mucosal villous atrophy is known to
exist in approximately 75% of patients, but the remainder have normal villous architecture with only
coeliac-type inflammation [15,16]. Regardless of the small bowel mucosal alterations, DH patients only
rarely present with obvious gastrointestinal symptoms [17,18].
A strict life-long gluten-free diet (GFD) is the mainstay of treatment in both DH and coeliac
disease. However, resolution of DH rash can take months or even longer on the dietary treatment, and
therefore, DH patients with severe skin symptoms are additionally treated with dapsone medication
to control the rash more quickly [3,19]. Coeliac disease and DH both carry an increased risk of
concomitant autoimmune conditions such as thyroid diseases and type 1-diabetes; furthermore,
the risk of developing non-Hodgkin lymphoma is increased [20–22]. Mortality in coeliac disease,
but not in DH, has shown to be increased [23]. A GFD is known to have a preventive effect against
the development of lymphoma in DH [24], but other than that, previous research about the factors
influencing the prognosis of DH is lacking. Currently, it is not known whether DH patients with small
bowel villous atrophy at diagnosis have a worse outcome compared to those with normal small bowel
mucosa, and furthermore, whether the prognosis of DH patients with villous atrophy is corresponding
to that of classical coeliac disease patients. This issue is of importance when necessary investigations,
at the time of DH diagnosis, are assessed.
The aim of the current study was to assess whether the presence of villous atrophy at DH diagnosis
would affect clinical recovery on a GFD or the long-term prognosis of DH. In addition, DH patients
were compared to classical coeliac disease controls with abdominal symptoms at diagnosis and a
histologically confirmed diagnosis. The hypothesis of this study was that the presence or absence of
villous atrophy at diagnosis would not be an influential factor in the prognosis of DH.
2. Materials and Methods
Between 1970 and 2014, a total of 526 DH patients were diagnosed at the Department of
Dermatology, Tampere University Hospital. During the study period, all patients with DH living
in a defined area around Tampere were diagnosed at this dermatology unit since IF biopsies required
for the diagnosis were not performed elsewhere. Each DH patient’s diagnosis was based on the typical
clinical picture and the demonstration of granular IgA deposits in skin biopsies [10]. In addition,
all diagnosed patients were routinely suggested to undergo gastroscopy and small bowel biopsy
obtainment at the time of the diagnosis while on a gluten-containing diet. After diagnosis, a strict
GFD was advised to all patients and dapsone was instituted in those with severe skin symptoms.
According to routine treatment policies, all patients were followed up at a DH outpatient clinic
until the rash had cleared and the dapsone medication could be discontinued. In this study, all DH
patients without prior coeliac disease diagnosis (made ≥2 years earlier) diagnosed between 1970 and
2014 and having an available small bowel biopsy result and commencing on a GFD after diagnosis,
were included as study patients. Altogether, 352 DH patients fulfilled the inclusion criteria and
were included as DH study patients. Further, 248 classical coeliac disease patients with abdominal
symptoms at diagnosis and a histologically confirmed diagnosis at Tampere University Hospital
during the same time period served as controls.
Data on demographic characteristics, the severity of clinical symptoms and small bowel mucosal
histology, and the results of coeliac autoantibodies and hemoglobin values at the time of DH or coeliac
disease diagnosis were gathered from the patient records of Tampere University Hospital between
March and October 2016. The small bowel biopsy results were graded as subtotal villous atrophy (SVA),
partial villous atrophy (PVA), or normal mucosa according to the analysis of the routine pathologist
as previously described [16]. In DH patients, the skin symptoms at the time of the diagnosis were
graded as mild, moderate, or severe according to the presence of a few, several or many blisters,
36
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macular eruptions and erosions. The grading was performed by one dermatologist. In addition,
the commencement and duration of dapsone medication after diagnosis was recorded.
Follow-up data were collected using questionnaires (see below for more detail) mailed to all
294 living DH patients fulfilling the inclusion criteria of this study (on December 2015) and the 222 living
coeliac disease controls (on May 2016). The final response rate was 62% for the DH patients and 58% for
the coeliac disease patients; hence, the follow-up study included 181 DH and 128 coeliac disease patients.
The study protocol and usage of the register-based data were approved by the Regional Ethics
Committee of Tampere University Hospital (R15143), and furthermore, informed consent was obtained
from each patient participating in the follow-up study.
2.1. Questionnaires
The disease-specific questionnaire designed for this study, the Psychological General Well-Being
(PGWB) [25] and Gastrointestinal Symptom Rating Scale (GSRS) [26] questionnaires were mailed to the
DH and coeliac disease study patients. PGWB and GSRS questionnaires are validated questionnaires,
which have been widely applied in previous coeliac disease studies [27–31]. In addition, the DH
patients received the Dermatology Life Quality Index (DLQI) questionnaire [32].
The disease-specific questionnaire included both open and multiple-choice questions. The patients
were asked about the presence and duration of DH and coeliac disease-related symptoms before and
after the diagnosis, the strictness of the GFD, smoking and other lifestyle characteristics, the number of
children born, the family history of coeliac disease or DH, and the patient’s current height and weight.
Compliance with a GFD was reported as strict diet without dietary lapses, dietary lapses once per
month, dietary lapses one to five times per month, or dietary lapses once per week. In addition, the
questionnaire included questions about the presence of coeliac disease complications and associated
diseases, malignancies, other long-term illnesses, and the regular usage of physician-prescribed
medications and over-the-counter (OTC) medications. In the malignancy analysis, non-melanoma skin
cancers were excluded, as were excessive trauma fractures in bone fracture analyses.
As previously described, the validated 22-item PGWB questionnaire evaluates self-perceived
health-related well-being and distress and includes six dimensions: Anxiety, depressed mood, positive
well-being, self-control, vitality, and general health [25]. The total score ranges from 22 to 132,
with a higher score indicating better quality of life. The 15-item GSRS questionnaire assesses
the severity and existence of gastrointestinal symptoms in five categories: Diarrhea, indigestion,
constipation, abdominal pain, and reflux [26]. It uses a seven-point Likert scale for each question:
One indicates an absence of symptoms and seven indicates severe symptoms. The DLQI is a 10-item
dermatology-specific quality of life instrument. The questionnaire includes six different sections:
Symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment
unit. The scores of all ten questions are calculated together, and the total score varies from a minimum
of 0 to a maximum of 30, with a higher score indicating a more impaired life quality [32].
2.2. Statistical Analysis
A Two-sided chi-squared test was used to compare the categorical variables and a Kruskall–Wallis
test was performed to assess differences between the continuous variables. Logistic regression analysis
was used to standardize the study groups according to age at the time of the study. Statistical significance
was set at p < 0.05. The analyses were performed using IBM SPSS Statistics for Windows (Version 23.0.,
IBM Corp., Armonk, NY, USA).
3. Results
3.1. DH Patients with Normal Villous Architecture Compared to DH Patients with Villous Atrophy at Diagnosis
Of the 352 DH patients, 98 (28%) had normal villous architecture, and 254 (72%) had small bowel
mucosal villous atrophy (PVA or SVA) at the time of the DH diagnosis (Table 1). GFD was not initiated
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before the diagnosis in study participants. Mean time since the year of DH diagnosis, was 20 years in
the DH patients with normal villous architecture and 23 years in the DH patients with villous atrophy,
and the difference was not statistically significant. The median age at diagnosis was significantly
higher in the DH patients with normal villous architecture compared to the DH patients with villous
atrophy (p < 0.001, Table 1). At diagnosis, the DH patients with villous atrophy were significantly
more often serum coeliac autoantibody-positive compared to the DH patients with normal villous
architecture (73% vs. 39%, p < 0.001, Table 1). The severity of the DH rash at diagnosis did not differ
significantly between the DH groups (p = 0.862). Eighty percent of all DH patients used dapsone after
the diagnosis. The duration of dapsone usage was longer in the DH patients with normal villous
architecture compared to the DH patients with villous atrophy at diagnosis (median 36 vs. 24 months),
but the difference was not statistically significant (p = 0.097, Table 1).
Table 1. Demographic data and disease-related characteristics of 98 dermatitis herpetiformis (DH)
patients with normal small bowel villous architecture and 254 DH patients with villous atrophy at
diagnosis, and 248 coeliac disease (CD) control patients.
DH Patients
CD Controls







Females; n (%) 50 (51) 125 (49) 193 (78) <0.001
Age at diagnosis; median (range) 52 (3–84) 37 (4–78) 42 (7–75) <0.001 a
Coeliac autoantibodies 1 present in the serum at diagnosis; n (%) 28/72 (39) 139/191 (73) 124/148 (84) <0.001 a
Haemoglobin level at diagnosis 2, g/L; median (Q1–Q3) 3 138 (128–148) 136 (129–146) 130 (121–140) 0.057
Dapsone treatment used; n (%) 75/93 (81) 191/243 (79) - -
Duration of dapsone treatment, months; median (range) 36 (5–324) 24 (2–384) - -
* p-value measured across the three study groups; 1 Transglutaminase 2-, endomysium-, or antireticulin IgA
antibodies; 2 Statistical analysis was further performed for patients ≥16 years of age and for females and males
separately—there were no statistically significant differences between the three groups; 3 Interquartile range;
a Statistically significant difference (p < 0.001) between DH patients with normal villous architecture and DH
patients with villous atrophy.
Of the 181 DH patients with available follow-up data, 39 (22%) had normal villous architecture,
and 142 (78%) had villous atrophy at the time of DH diagnosis. The median follow-up time was
20 years in patients with normal villous architecture and 23 years in the DH patients with villous
atrophy at diagnosis (Table 2). The presence of gastrointestinal symptoms at diagnosis did not differ
between the DH study groups according to the follow-up study questionnaire (p = 0.170). At the time
of the follow-up study, DH patients with normal villous architecture were significantly older compared
to those DH patients who had villous atrophy at diagnosis (Table 2).
The strictness of the GFD and BMI did not differ between the DH study groups at the time of
the study (Table 2). Similarly, no significant differences were detected in smoking habits or physical
activity: 3% of DH patients without villous atrophy and 13% of patients with villous atrophy at
diagnosis were current smokers, and 49% and 69% exercised at least three times a week, respectively.
Table 2. Follow-up data of 39 dermatitis herpetiformis (DH) patients with normal villous architecture











Females; n (%) 18 (46) 67 (47) 104 (81) <0.001
Follow-up time, years; median (range) 20 (1–44) 23 (1–42) 18 (6–43) 0.003
Age; median (range) 68 (52–85) 61 (18–96) 65 (34–85) <0.001 a
BMI, kg/m2; median (range) 25 (19–37) 25 (16–38) 26 (15–46) 0.772
Strict adherence to GFD, no dietary lapses; n (%) 30 (77) 101 (71) 107 (84) 0.170 b
Number of long-term illnesses; median (range) 1 (0–7) 1 (0–14) 2 (0–9) <0.001
Number of prescription medications used; median (range) 2 (0–11) 1 (0–18) 3 (0–16) 0.078
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Uses statin medication; n (%) 14 (36) 21 (15) 15 (12) 0.001 c
Uses antihypertensive medication; n (%) 20 (51) 50 (35) 49 (38) 0.188
Uses proton pump inhibitor medication; n (%) 5 (13) 16 (11) 16 (13) 0.938
Number of over-the-counter medications used; median (range) 0 (0–5) 1 (0–7) 2 (0–7) <0.001
Number of children born; median (range) 2 (0–5) 2 (0–6) 2 (0–5) 0.497
First-degree relatives with DH or CD; n (%) 13 (33) 53 (37) 55 (43) 0.464
BMI: Body mass index; GFD: Gluten-free diet. * p-value measured across the three study groups; a Statistically
significant difference (p < 0.001) between DH patients with normal villous architecture and DH patients with villous
atrophy at diagnosis; b p-value was tested for categorical variables including categories: strict diet, dietary lapses
once per month, dietary lapses 1–5 times/month, dietary lapses once per week; c Statistically significant difference
(p = 0.003) between DH patients with normal villous architecture and DH patients with villous atrophy at diagnosis.
At the time of the follow-up study, coronary heart disease and hypertension were significantly
more common among the DH patients with normal villous architecture compared to the DH patients
with villous atrophy at diagnosis (Figure 1); however, after adjustment for the current age, significant
differences disappeared (p = 0.198, OR = 0.482 and p = 0.273, OR = 0.653, respectively). Significant
differences were not detected in the presence of type 1- or 2-diabetes, thyroid diseases, cerebrovascular
diseases, osteopenia or osteoporosis, or malignancies between the DH study groups (Figure 1). Patients
with self-reported bone fractures were slightly more numerous among the DH patients with villous
atrophy than among those with normal villous architecture at diagnosis, but the difference was not
statistically significant (p = 0.321, Figure 1).
Figure 1. Percentages of dermatitis herpetiformis (DH) patients with normal small bowel mucosal
villous architecture and with villous atrophy at diagnosis, and coeliac disease control patients with
long-term illnesses or complications at the time of the follow-up study. (a) Statistically significant
difference (p < 0.05) between the three study groups; (b) statistically significant difference (p < 0.05)
between DH patients with normal villous architecture and DH patients with villous atrophy at diagnosis.
Statistically significant differences were not detected in the use of physician-prescribed regular
medications between the DH study groups; even the significant difference in the use of statin
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medication disappeared after adjustment for the current age (OR = 0.479, p = 0.88, Table 2). Furthermore,
the total amount of used OTC medications was similar in the DH groups; only the usage of vitamin D
was more frequent among DH patients with villous atrophy at diagnosis compared to those without
villous atrophy (40% vs. 23%, p = 0.050).
The presence of gastrointestinal symptoms or the quality of life according to the total or the
subscores of the GSRS, PGWB (Table 3) and DLQI questionnaires at the time of the study did not differ
between the DH study groups
Table 3. The Psychological General Well-Being (PGWB) and Gastrointestinal Symptom Rating Scale
(GSRS) questionnaires’ median and interquartile range (Q1–Q3) results for the gluten-free diet-treated
dermatitis herpetiformis (DH) patients with normal villous architecture and with villous atrophy at






Architecture (n = 39)
With Villous Atrophy
(n = 142)
PGWB median (Q1–Q3) median (Q1–Q3) median (Q1–Q3)
Total 110 (99–116) 110 (101–117) 106 (96–117) 0.200
Anxiety 26 (23–27) 26 (23–27) 25 (23–28) 0.891
Depression 17 (16–18) 17 (16–18) 17 (15–18) 0.587
Well-being 18 (16–20) 18 (16–20) 18 (16–20) 0.279
Self-control 16 (15–17) 16 (15–17) 16 (14–17) 0.295
General health 13 (12–15) 14 (12–16) 13 (11–15) 0.022
Vitality 20 (17–21) 19 (17–21) 18 (16–20) 0.104
GSRS median (Q1–Q3) median (Q1–Q3) median (Q1–Q3)
Total 1.6 (1.3–2.0) 1.7 (1.3–2.3) 2.1 (1.5–4.2) <0.001
Diarrhoea 1.0 (1.0–1.7) 1.3 (1.0–2.3) 1.7 (1.0–2.7) 0.006
Indigestion 1.8 (1.5–2.5) 2.0 (1.5–2.5) 2.0 (1.5–3.0) 0.227
Constipation 1.7 (1.0–2.3) 1.7 (1.0–2.3) 1.7 (1.0–2.4) 0.482
Pain 1.3 (1.0–1.7) 1.7 (1.0–2.0) 1.7 (1.3–2.3) 0.007
Reflux 1.0 (1.0–1.5) 1.0 (1.0–2.0) 1.5 (1.0–2.0) 0.084
* p-value measured across the three study groups.
3.2. Comparisons between the DH Patients and the Classical Coeliac Disease Controls
Compared to the DH patients, the coeliac disease controls were more often female (Tables 1 and 2),
and their median diagnostic age was significantly lower compared to DH patients with normal villous
architecture at diagnosis (Table 1).
In the long-term follow-up data, there were no observed differences in current smoking habits
or physical activity between the DH patients and the coeliac disease controls. By contrast, the total
number of long-term illnesses was found to be higher among the coeliac disease controls compared
to the DH patients (Table 2). More specifically, after adjustment for the current age, thyroid diseases
(OR = 3.443, p = 0.019) and osteopenia or osteoporosis (OR = 14.132, p = 0.012) were more common
among the coeliac disease controls than among the DH patients (Figure 1). However, the presence of
self-reported bone fractures did not differ significantly between the DH study groups and the coeliac
disease controls. In the malignancy analysis, the coeliac disease controls outnumbered the DH patients
after adjustment for the current age (OR = 6.527, p = 0.016) (Figure 1).
In the analysis of regularly used physician-prescribed medications and after adjustment for the
current age, the coeliac disease controls were found to use less statin medication compared to the DH
patients with normal villous architecture (OR = 0.319, p = 0.01). In turn, the total number of regularly
used OTCs was higher among the coeliac disease patients compared to the DH patients (p = 0.003,
Table 2), and specifically the use of calcium (p = 0.011) and vitamin D (p < 0.001) was more common.
Quality of life measured with the PGWB did not differ between the coeliac disease controls and
the DH patients with normal villous architecture at diagnosis, but the coeliac disease controls had
significantly lower PGWB general health scores compared to the DH patients with villous atrophy at
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diagnosis (Table 3). In the GSRS questionnaire, the coeliac disease controls had significantly higher
total symptoms gastrointestinal pain and diarrhea scores compared to both DH groups.
4. Discussion
This study demonstrated that the disease severity and the clinical response to a GFD does not
differ between DH patients with normal villous architecture and those with villous atrophy at diagnosis.
Furthermore, the long-term general health and well-being of DH patients are not influenced by the
severity of small bowel mucosal damage at the time of DH diagnosis. The outcomes of the current
study were obtained from a large, prospectively collected series of DH patients, all of whom adhered
to a GFD treatment. Furthermore, in the present study, the proportions of DH patients with villous
atrophy and normal villous architecture were consistent with the findings in earlier DH studies [15,33].
In our previous study, the presence of villous atrophy at DH diagnosis was found to be associated
with a delayed diagnosis, i.e., the presence of the rash for two years or more before the diagnosis,
suggesting that prolonged diagnosis might enable the small bowel mucosal damage to progress [34].
In the current study, the occurrence of villous atrophy did not associate with the severity of the rash
or with the presence of gastrointestinal symptoms at diagnosis. The duration of dapsone medication
was considered the most reliable method of determining the active period of rash after adherence to
a GFD since the majority of patients used dapsone medication, and the medicine was discontinued
as early as possible without a relapse in skin symptoms. The median duration of dapsone usage in
DH study groups corresponded well with previous GFD treatment studies [35,36], and even though
the duration was longer in DH patients with normal small bowel mucosa than in those with villous
atrophy at diagnosis, the difference was not statistically significant. Therefore, presence or absence of
small bowel villous atrophy at diagnosis seems not to influence the clinical recovery of the DH rash.
The long-term follow-up performed in the present DH patients further demonstrated that small
bowel villous atrophy at diagnosis did not have any impact on the presence of long-term illnesses
and complications, or long-term quality of life or the presence of persistent gastrointestinal symptoms.
Additionally, our previous study showed that the mortality of DH patients with villous atrophy
at diagnosis does not differ from that of DH patients with normal villous architecture, and in fact,
the mortality of DH patients was shown to be lower than in the general population [37]. Therefore,
all these results show that DH patients with and without villous atrophy at diagnosis have a similar
good long-term prognosis when they adhere to a GFD.
In contrast to DH, the mortality rate of the patients with coeliac disease are known to be increased
compared to the general population [23,38]. Moreover, when the GFD-treated coeliac disease patients in
the current study were compared to the DH patient groups, they had significantly more malignancies
and long-term illnesses, especially thyroid diseases and osteopenia or osteoporosis. A previous
comparison between DH and coeliac disease also showed a higher frequency of diseases of autoimmune
origin in patients with coeliac disease [39], but then another study demonstrated that autoimmune
diseases were as common among DH patients without classical coeliac disease symptoms than in
those DH patients with preceding coeliac disease diagnosis [40]. In the present study, the coeliac
disease controls were further found to have worse self-reported general health, and they had more
gastrointestinal symptoms at the time of the study compared to the DH patients. These results fit
with our recent study that likewise found a better quality of life and fewer gastrointestinal symptoms
among long-term treated DH patients compared to treated coeliac disease patients [41].
The results of the present study thus suggest that the prognosis of different phenotypes of coeliac
disease diverge and villous atrophy is not the determinative factor in the outcome of DH. Different
adherence rates to GFD or varying lifestyle habits did not explain the outcome differences between
coeliac disease and DH study patients in this study. One explanation for the different prognosis
between coeliac disease and DH might be slightly diverse autoimmune reactions, but this remains to
be elucidated in future studies.
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In the current study, the median age at diagnosis in DH patients with normal villous architecture
was significantly higher compared to DH patients with villous atrophy. We were aware from our earlier
long-term DH studies that the age at diagnosis had increased significantly from 1970 onwards [1], and
further, that there was a significant trend towards milder villous atrophy [16]. However, in the present
study, the time period of DH diagnosis did not differ significantly between DH study groups. Therefore,
the divergence in diagnostic periods does not explain the difference in the diagnostic age between DH
patients with and without villous atrophy at diagnosis. One explanation might be, however, that older
patients are more prone to develop milder small bowel mucosal alterations, e.g., due to divergent
immune responses. Previous research shows that older coeliac disease patients are more likely to
remain seronegative and further, a trend toward less severe histopathology has been observed with
increasing age at the time of coeliac disease diagnosis [42,43]. Nonetheless, these age-related findings
detected in coeliac disease and DH should be examined in more detail in further studies.
As a possible limitation of the current study, it must be recognized that the follow-up data were
obtained from questionnaires, which might cause selection bias. Recall bias is always a possibility when
requiring data from several decades ago. The disease-specific questionnaire used in the study was
designed for this particular study and for comparing the results of the study groups, and it has not been
used in other disease studies, and it has not been validated. GSRS is not optimized for coeliac disease,
but it has been the most commonly used generic questionnaire in coeliac disease studies [28]. PGWB is
not a disease-specific instrument, and therefore, it is possible that it might not assess all of the issues
that are having an impact on life in DH and coeliac disease patients. GSRS and PGWB questionnaires
have not been validated specifically for coeliac disease. Furthermore, all study patients were recruited
from the same hospital, and in the future, results from a more comprehensive geographical distribution
would be of value. In turn, the major strengths of the study are: A well-defined, prospectively collected
DH cohort from a high prevalence area with excellent dietary adherence rates, and the long follow-up
time [1]. Moreover, similar large DH studies with knowledge about the diagnostic small bowel mucosal
findings and long-term follow-up data consisting of GFD adherence rates have not been performed
previously to our knowledge.
5. Conclusions
The major outcome of this study is that skin IgA-IF proven DH patients evincing coeliac-type
small bowel mucosal villous atrophy at diagnosis does not differ from DH patients with non-atrophic
small bowel mucosa with regard to GFD treatment response, long-term quality of life, or the presence
of chronic illnesses or coeliac disease-associated complications.
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Abstract: Background: Gluten neuropathy (GN) is defined as an otherwise idiopathic peripheral
neuropathy in the presence of serological evidence of gluten sensitivity (positive native gliadin
antibodies and/or transglutaminase or endomysium antibodies). We aimed to compare the quality
of life (QoL) of GN patients with that of control subjects and to investigate the effects of a gluten-free
diet (GFD) on the QoL. Methods: All consecutive patients with GN attending a specialist neuropathy
clinic were invited to participate. The Overall Neuropathy Limitations Scale (ONLS) was used to
assess the severity of the neuropathy. The 36-Item Short Form Survey (SF-36) questionnaire was
used to measure participants’ QoL. A strict GFD was defined as effectively being able to eliminate all
circulating gluten sensitivity-related antibodies. Results: Fifty-three patients with GN and 53 age- and
gender-matched controls were recruited. Compared to controls, GN patients showed significantly
worse scores in the physical functioning, role limitations due to physical health, energy/fatigue,
and general health subdomains of the SF-36. After adjusting for age, gender, and disease severity,
being on a strict GFD correlated with better SF-36 scores in the pain domain of the SF-36 (beta 0.317,
p = 0.019) and in the overall health change domain of the SF-36 (beta 0.306, p = 0.017). Conclusion:
In GN patients, physical dysfunctioning is the major determinant of poor QoL compared to controls.
Routine checking of the elimination of gluten sensitivity-related antibodies that results from a strict
GFD should be encouraged, as such elimination ameliorates the overall pain and health scores,
indicating a better QoL.
Keywords: gluten neuropathy; coeliac disease; gluten free diet; quality of life; male
1. Introduction
Gluten neuropathy (GN) is one of the commonest neurological manifestations of gluten
sensitivity [1] and it is defined as an otherwise idiopathic peripheral neuropathy (PN) [2] in the
presence of serological evidence of gluten sensitivity (positive native gliadin antibodies, and/or
transglutaminase or endomysium antibodies) [1,3]. Some patients with GN have evidence of
enteropathy revealed by duodenal biopsy and are diagnosed with coeliac disease (CD), whereas
the majority of patients with GN do not have enteropathy.
The main type of gluten neuropathy is symmetrical sensorimotor axonal peripheral neuropathy [1],
however sensory ganglionopathy (SG) and, rarely, mononeuritis multiplex (MMX) may also
occur [1,4,5]. A gluten-free diet (GFD) has been shown to be effective in treating GN, irrespective of
the presence or not of enteropathy [6].
As in all axonal neuropathies, symptoms can be divided into sensory and motor. Incoordination
and gait disturbance are symptoms usually attributed to damage of the sensory nerves (sensory
ataxia) [2]. Other sensory symptoms include tingling, pins and needles, numbness, tightness, burning,
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and pain. Motor symptoms include muscle cramps, stiffness, weakness, and wasting [2]. The clinical
diagnosis is confirmed with nerve conduction studies.
Robust epidemiological data on the prevalence of GN neuropathy are lacking, however it is
known that PN of any etiology can affect between 2.4% and 8% of the general population [2] and that
CD is associated with a 2.5-fold increased risk of later neuropathy [5].
As in all chronic diseases, patients with GN are expected to have an impaired quality of life
(QoL) for reasons that are either directly or indirectly related to the disease. It has been shown that
patients with advanced peripheral neuropathy, for example, show worse scores in questionnaires
measuring QoL when compared to less impaired patients [7]. Such impairment, refers not only to
motor symptoms (i.e., weakness) but also to sensory symptoms, in particular pain [8–13]. Indirectly,
however, GN might cause an additional burden by having to adhere to a strict GFD. It has been shown
that the degree of difficulty in adhering to a GFD is associated with reductions in patient wellbeing
and psychological distress that the dietician is critically placed to address [14].
The purpose of this study was twofold. We wanted to compare the QoL of GN patients with that
of controls (subjects without peripheral neuropathy or gluten sensitivity) and to investigate the effect
of being on a GFD on the QoL in these patients.
2. Methods
2.1. Procedure and Participants
This was a cross-sectional study conducted at the Sheffield Institute of Gluten-Related Diseases
(SIGReD). Patients were recruited during their regular visits to the gluten/neurology clinic based at
the Royal Hallamshire Hospital, Sheffield, UK. Individuals (i.e., carers or relatives) without a diagnosis
of PN or risk factors for developing PN participated as controls.
To be enrolled, the patients had to meet the following inclusion criteria: (1) diagnosis of PN,
as confirmed by nerve conduction studies, (2) serological evidence of gluten sensitivity (positive
for native gliadin IgG and/or IgA antibodies with or without positivity for endomysial and
transgultaminase antibodies) at diagnosis prior to commencing a gluten-free diet, (3) absence of
other risk factors for developing PN (i.e., diabetes, vitamin deficiencies, exposure to neurotoxic agents)
(4) age equal to or greater than 18 years, (5) able to provide a written informed consent.
The study protocol was approved by the local ethics committee.
2.2. Measures
The demographic characteristics included age and gender. All patients went through extensive
investigations for possible causes of PN [2]. Patients with a family history of neuropathy were excluded.
The type of neuropathy (sensorimotor length-dependent PN, sensory ganglionopathy [15,16],
mononeuritis multiplex) for all patients was determined on the basis of nerve conduction studies,
which were performed by the same clinician on the day of the recruitment.
All patients were referred for an endoscopy and duodenal biopsy to establish the presence of
enteropathy. All biopsies were histologically assessed by an experienced pathologist for evidence of
enteropathy (triad of villous atrophy, crypt hyperplasia, and increase in intraepithelial lymphocytes).
The severity of neuropathy was assessed by the Overall Neuropathy Limitations Scale (ONLS),
which is a validated scale that measures limitations in the everyday activities of the upper and lower
limbs [17].
Biagi score was used to document adherence to a gluten-free diet [18]. Patients with a Biagi score
of equal to or above 3 were considered as being on a gluten-free diet. Furthermore, patients with
negative serology at the time of recruitment were considered to be on a strict gluten-free diet.
The 36-Item Short Form Survey (SF-36), a self-reported measure of health status and quality of
life [19], was used to determine patient health-related quality of life. SF-36 covers nine health and QoL
domains. These domains include physical functioning, role limitations due to physical health, role
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limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain,
general health and health change. Each item is measured using a Likert-type scale. The scores were
converted and analysed according to the marking guidelines for the SF-36, such that higher scores (out
of a total of 100 for each domain) constitute better health-related quality of life in this domain.
2.3. Statistical Analyses
A database was developed using the Statistical Package for Social Science (version 23.0 for Mac;
SPSS). Frequencies and descriptive statistics were examined for each variable. Comparisons between
patients on a gluten-free diet and patients not on a gluten-free diet were made using Student’s t-tests
for normally distributed continuous data, Mann–Whitney’s U test for non-normally distributed,
and chi-square test or Fischer’s exact test for categorical data.
Where differences with a p value lower than 0.10 were found, these variables were entered into
linear regression models, with the QoL domain score being the dependent variable. All accuracy and
generalization assumptions for the model were checked.
The level of statistical significance was set at the 0.05 level.
3. Results
3.1. Study Population
Fifty-three patients with GN were recruited (73.6% male, mean age 68.2 ± 9.3 years) and were
age- and gender-matched with 53 control subjects without a history of peripheral neuropathy or gluten
sensitivity. Thirty-six patients (67.9%) had a symmetrical length-dependent sensorimotor axonal PN,
16 (30.2%) had a sensory ganglionopathy, and 1 patient had mononeuritis multiplex (1.9%). The mean
disease duration was 12.6 ± 9.5 years (ranging from 0 to 37 years), suggesting that the GN is a late
extra-intestinal manifestation of serologically confirmed gluten sensitivity (occurring usually in the
sixth decade of life). Overall ONLS scores ranged from 1 to 7 (mean 3.1 ± 1.8).
Not all of the patients agreed to a duodenal biopsy. Of 32 patients who underwent duodenal
biopsy, nine (28.1%) had enteropathy (eight coeliac disease—Marsh type 3, one increased intraepithelial
lymphocytes—Marsh type 2).
3.2. QoL Compared to Controls
Table 1 summarizes the scores in all SF-36 subdomains in patients with GN and in controls.
Patients with GN showed significantly worse scores compared to controls in the following quality
of life modalities: physical functioning (p < 0.001), role limitations due to physical health (p < 0.001),
energy/fatigue (p = 0.045), and general health (p = 0.029). A trend of statistical significance (p = 0.094)
was observed in the pain modality of the SF-36 questionnaire.
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Table 1. Demopgraphics and quality of life (QoL) parameters of patients with gluten neuropathy (GN).
GN (n = 53) Controls (n = 53) p Value
Demographics
Age, in years (SD) 68.2 (9.3) 66.8 (10.0) 0.440
Male gender (%) 39 (73.6) 38 (71.7) 0.828
Quality of life modalities
Physical functioning 50.8 (32.8) 78.0 (23.0) <0.001 *
Role limitations due to physical health 53.9 (34.0) 77.4 (25.8) <0.001 *
Role limitations due to emotional problems 76.7 (29.4) 83.3 (25.5) 0.219
Energy/Fatigue 48.0 (21.8) 56.3 (20.1) 0.045 **
Emotional well-being 75.5 (15.9) 74.2 (16.7) 0.677
Social functioning 70.2 (30.5) 79.2 (25.9) 0.104
Pain 59.4 (27.9) 68.5 (27.3) 0.094
General Health 54.8 (23.6) 64.3 (20.1) 0.029 **
Health change 42.9 (19.8) 49.1 (18.3) 0.101
* p < 0.001; ** p < 0.05.
3.3. The Role of GFD (Self-Reported) on QoL
On the basis of the self-reported adherence to GFD (Biagi score equal to or greater than 3), 31 patients
(58.5%) were on a GFD. Table 2 summarizes the demographic, clinical, and quality-of-life-related
characteristics of patients with GN reporting being on GFD versus patients with GN reporting being on
a gluten-containing diet. The two groups did not differ significantly in age, gender, disease duration,
neuropathy severity, or neuropathy type. A trend of statistical significance (p = 0.094) was observed on
the overall health change subdomain of the SF-36.
Table 2. Demographic, clinical, and quality-of-life-related characteristics of patients with gluten
neuropathy reporting being on a gluten-free diet (GFD) compared to patients with gluten neuropathy




(n = 22) p Value
Demographics
Age, in years (SD) 68.6 (8.3) 67.6 (10.8) 0.702
Male gender (%) 20 (64.5) 19 (86.4) 0.115
Clinical characteristics
Disease duration, in years (SD) 13.8 (8.0) 11.0 (10.2) 0.259
Type of neuropathy 0.690
Symmetrical length-dependent PN (%) 21 (67.8) 15 (68.2)
Sensory ganglionopathy (%) 9 (29.0) 7 (31.8)
Mononeuritis multiplex (%) 1 (3.2) 0 (0.0)
Neuropathy severity
Total ONLS score (SD) 3.1 (1.7) 3.2 (1.8) 0.814
Quality of life modalities
Physical functioning 53.5 (34.3) 47.0 (31.0) 0.482
Role limitations due to physical health 56.0 (32.6) 50.9 (36.5) 0.589
Role limitations due to emotional problems 79.6 (25.2) 72.7 (34.7) 0.409
Energy/Fatigue 49.2 (23.5) 46.3 (19.5) 0.640
Emotional well-being 76.5 (16.1) 74.1 (15.9) 0.599
Social functioning 70.4 (27.4) 69.9 (35.1) 0.951
Pain 63.6 (28.0) 53.5 (27.3) 0.197
General Health 56.5 (22.9) 52.7 (24.9) 0.576
Health change 46.8 (19.1) 37.5 (20.0) 0.094
PN: peripheral neuropathy; ONLS: overall neuropathy limitations scale; SD: standard deviation.
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After adjusting for age, gender, and disease severity, being on GFD (self-reported) was positively
correlated with better SF-36 scores on the overall health change domain of the SF-36 (beta 0.258,
p = 0.047).
3.4. The Role of Strict GFD on QoL
Twenty-two patients managed to eliminate antigliadin, endomysial, and transglutaminase
antibodies by adopting the GFD. This population, which accounted for 41.5% of the total GN study
group and 71% of those GN patients self-reporting as being on a GFD, was considered to be on a
strict GFD.
Table 3 summarizes the demographic, clinical, and quality-of-life-related characteristics of patients
with GN being on a strict GFD versus patients with GN not on a strict GFD. The two groups did not
differ significantly in age, gender, disease duration, neuropathy severity, or neuropathy type. Patients
on a strict GFD had significantly higher scores (indicating better QoL) on the pain sub-domain of the
SF-36 (p = 0.03). A trend of statistical significance (p = 0.066) was also observed on the overall health
change subdomain of the SF-36.
Table 3. Demographic, clinical, and quality-of-life-related characteristics of patients with gluten
neuropathy being on a strict gluten-free diet versus patients not being on a strict gluten-free diet
(serologically confirmed by the elimination of anti-gliadin antibodies).
On Strict GFD
(n = 22)
Not on Strict GFD
(n = 31) p Value
Demographics
Age, in years (SD) 69.7 (8.5) 67.2 (9.9) 0.329
Male gender (%) 14 (63.6) 25 (80.6) 0.166
Clinical characteristics
Disease duration, in years (SD) 13.9 (8.1) 11.7 (9.6) 0.385
Type of neuropathy 0.462
Symmetrical length-dependent PN (%) 14 (63.6) 22 (71.0)
Sensory ganglionopathy (%) 7 (31.8) 9 (29.0)
Mononeuritis multiplex (%) 1 (4.5) 0 (0.0)
Neuropathy severity
Total ONLS score (SD) 3.2 (1.8) 3.0 (1.7) 0.695
Quality of life modalities
Physical functioning 58.4 (35.7) 45.5 (30.0) 0.160
Role limitations due to physical health 58.5 (33.9) 50.6 (34.2) 0.409
Role limitations due to emotional problems 81.8 (23.7) 73.1 (32.8) 0.293
Energy/Fatigue 50.0 (26.1) 46.6 (18.5) 0.578
Emotional well-being 76.8 (18.2) 74.5 (14.2) 0.608
Social functioning 69.6 (28.4) 70.6 (32.4) 0.916
Pain 69.2 (26.6) 52.5 (27.1) 0.030*
General Health 56.4 (23.9) 53.9 (23.7) 0.708
Health change 48.9 (21.1) 38.7 (18.1) 0.066
GFD: gluten free diet; PN: peripheral neuropathy; ONLS: overall neuropathy limitations scale; SD:
standard deviation.
After adjusting for age, gender, and disease severity, being on a strict GFD (serologically proven)
was positive correlated with better SF-36 scores on the pain domain of the SF-36 (beta 0.317, p = 0.019)
and the overall health change domain of the SF-36 (beta 0.306, p = 0.017).
4. Discussion
This case-controlled study demonstrates that patients with GN have significantly worse QoL
compared to age- and gender-matched controls on the basis of the SF-36 modalities of physical
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functioning, role limitations due to physical health, energy/fatigue, and general health. This finding
adds to the existing literature that the main impact of peripheral neuropathy on patients’ QoL is on the
modalities affecting their dysfunctioning (i.e., impaired activities of daily living) [7]. To our knowledge,
this is the first study investigating the QoL of patients with GN.
Another novelty of the current study is the examination of the role of GFD on QoL. For this,
we conducted two separate analyses, one based on the patients' reports and the other based on the
evidence of the elimination of all gluten sensitivity-related antibodies.
In their study, Lee et al. found that patients with coeliac disease reported that GFD had a negative
impact on their quality of life, as it restricted their social activities such as travelling or dining out [20].
In our study, patients on a GFD had higher scores in the sub-domains of SF-36 (Table 2), though
not statistically significant. There was, however, a trend for a statistically significant difference in
the scores of the overall health change subdomain of the SF-36. There are possible explanations for
such disparity. Firstly, awareness of gluten sensitivity and coeliac disease has increased over the last
decade with improved availability and a better range of gluten-free products. Furthermore, dining
out or travelling is much easier, as many restaurants and hotels do have gluten-free menus. Secondly,
the heterogeneity of the study populations may have affected the results, as Lee et al. included
patients with different gender distribution (female predominance), different age (younger), and a
different clinical picture (coeliac disease with gastrointestinal symptoms), whereas our cohort of
patients presented a neuropathy.
When comparing patients who strictly adhered to the GFD (as evidenced by the elimination of
all circulating gluten sensitivity-related antibodies) with patients either not being on the GFD or not
being strictly on the GFD, we showed that the former had significantly better scores in the pain and
the overall health change domain. This is in keeping with the current literature, which shows that
patients with GN benefit from a GFD with evidence of improvement of the neuropathy usually after
one year on strict GFD, associated with the elimination of gluten sensitivity-related antibodies [6,20].
Moreover, this finding highlights the importance of serological monitoring in an attempt to improve
adherence to a GFD. Interestingly, in our cohort, 29% of patients on the GFD still had positive serology.
Our study population comprised predominantly males (male to female ratio 3:1). As we recruited
patients in succession, this might indicate that GN is commoner in males, which is in contrast with
what Thawani et al. reported in their epidemiological study where they assessed the risk of neuropathy
among patients with CD and found no difference in the risk of developing neuropathy between the two
genders [5]. This difference in findings might be due to the fact that the majority of patients with GN
do not have enteropathy and, therefore, the male predominance possibly reflects this. Our observation,
however, is important, as male patients perceive illness and quality of life differently, and adherence to
a GFD has a different emotional impact in males compared to females [21].
Our results should be interpreted with some caution, given the limitations of our design. This is
a cross-sectional study based on patients attending a specialized clinic, and the results may not be
generalizable to other settings. Furthermore, our cohort included patients with large fiber axonal
peripheral neuropathies only. Pure small fiber neuropathy associated with gluten sensitivity is another
area that merits further consideration, as it is a particularly painful condition and therefore can affect
patients’ QoL.
In conclusion, in patients with GN, physical dysfunctioning is the major determinant of QoL
compared to control subjects. Contrary to previous observations in patients with classical CD, being on
a GFD does not have a negative effect on social functioning in patients with GN. Clinicians are advised
to regularly monitor the adherence to the GFD diet by serological testing for gluten sensitivity-related
antibodies, because a strict GFD ameliorates the overall pain and health change scores, indicating
better QoL.
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1. Overview
Celiac disease (CD) is a complex autoimmune disease that is triggered by the ingestion of gluten
(the major storage protein in wheat, rye, and barley) in genetically predisposed individuals, leading to
elevated titers of celiac-specific autoantibodies and resulting in a variable degree of small intestinal
inflammation and a wide range of gastrointestinal and extra-intestinal manifestations.
The extra-intestinal manifestations of CD seen most often in the pediatric population
include, but are not limited to, short stature, delayed puberty, dental enamel hypoplasia,
osteopenia/osteoporosis, iron-deficiency anemia refractory to oral iron supplementation, recurrent
stomatitis, liver and biliary disease, dermatitis herpetaformis, arthralgia/arthritis, headaches, ataxia,
peripheral neuropathy, epilepsy, behavioral changes, and psychiatric disorders and alopecia.
While the prevalence of extra-intestinal manifestations of CD is similar between the pediatric and
adult populations (60% and 62%, respectively), specific extra-intestinal manifestations and rates of
improvement differ. While short stature is the most common extra-intestinal manifestation of CD in
children, iron deficiency anemia is most common in adults. The other more commonly encountered
extra-intestinal manifestations in both children and adults include fatigue and headaches. Additionally,
on average, children appear to have much greater and faster rates of improvement as compared to
adults [1,2].
It has been shown that children with extra-intestinal manifestations of CD as the main presenting
symptom have a more severe degree of villous atrophy than those that are presenting with
gastrointestinal manifestations or asymptomatic patients that were detected through screening [2].
The exact etiology for this finding is uncertain. It is not then surprising, though, that at 24 months after
starting a strict gluten free diet (GFD), both children and adults with CD show greater and faster rates
of improvements in gastrointestinal (90% and 86%, respectively) versus extra-intestinal manifestations
of CD (87% and 80%, respectively), which is possibly owing to the more severe histologic findings
and more complex mechanism involved with extra-intestinal manifestations. Overall children show
greater rates of extra-intestinal symptom resolution as compared to adults and males show greater
rates of improvement as compared to females. Factors that appear to predict better rates of symptom
resolution after the initiation of a strict GFD include a strong family history of CD, shorter durations of
symptoms prior to the diagnosis of CD (those with longer duration of symptoms have greater risk of
an altered gut-brain axis setting off a cycle of amplified pain [3]), and strict adherence to the GFD [4].
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2. Short Stature and Delayed Puberty
Short stature is the most commonly encountered extra-intestinal manifestation of CD in children,
being found in roughly one-third of all new pediatric celiac diagnoses. While it can be directly related
to malabsorption of nutrients, it should completely reverse once a child is strictly adherent to a GFD.
In fact, within 24 months of starting a strict GFD, celiac children should attain appropriate catch up
growth and return to their expected trajectory for height. However, if a child is diagnosed post-puberty,
their chances for catch up growth are much decreased as the child has likely missed their window.
Thus, for post-pubertal patients with short stature, a bone age determination is important to best
predict the child’s capacity for additional height growth [1]. If short stature in a prepuberal patient
persists beyond 24 months on a strict GFD, it is imperative that the physician start an additional
investigation for other missed comorbidities.
In the 2017 study by Jericho et al. [1], 28% of children with persistent short stature despite strict
adherence to the GFD had another missed comorbidity (inflammatory bowel disease, food aversion,
Turner Syndrome, or growth hormone deficiency) requiring alternate treatments. Therefore, one must
never continue to attribute ongoing short stature to CD, once it appears that the CD has been adequately
treated [1].
Delayed puberty is another common manifestation of CD affecting roughly 10% of new pediatric
celiac patients [1]. Delayed puberty is defined by a lack of physical or hormonal signs of puberty at
the age of usual onset. Visible secondary sexual development usually begins when girls achieve a
bone age of 11 years and boys achieve a bone age of 12 years. In girls, a lack of breast development by
13 years, or a lack of menarche within three years after breast development or by 16 years is considered
to be abnormal. For boys, no testicular enlargement by 14 years or a delay in development for five
years or more after onset of genitalia enlargement is considered abnormal. In the case of CD, this delay
in puberty is directly related to malabsorption and malnutrition, and should resolve on a GFD, which
should prevent any long-term complications and restore normal maturation. If the delay in puberty
fails to improve within 12–24 months of starting a GFD, it is imperative that the patient be referred to
endocrinology for further evaluation of other underlying defects within the reproductive system [5].
3. Dental Enamel Hypoplasia and Recurrent Stomatitis
Dental Enamel Hypoplasia can be seen in as many as 40–50% of new pediatric celiac patients as
compared to 6% of the healthy population and it leads to the appearance of white, yellow, or brown
spots on the teeth with a mottled or translucent-looking appearance [6]. While there is no consensus as
to the exact mechanism by which CD leads to dental enamel hypoplasia it is hypothesized that it is
secondary to malabsorption of calcium in addition to genetic and immunological factors disturbing the
normal process of amelogenesis [7]. Dental enamel hypoplasia occurring in deciduous teeth, within
a symmetrical and chronological manner, and detectable in all quadrants of the dentition is most
suggestive of an underlying chronic malabsorptive disease, such as CD, as opposed to non-symmetric
defects, which are considered to be non-specific [8]. When dental enamel hypoplasia occurs in a child’s
permanent teeth, this is most often permanent and will not improve after adopting a strict GFD [9].
Roughly 46% of children with CD also suffer from aphthous stomatitis as compared to 20% of the
healthy population. It is not yet established whether aphthous ulcers are a direct manifestation of CD
or if they occur due to the indirect effects of malabsorption [10]. It is speculated that systemic CD leads
to an imbalance in the oral ecosystem that impairs oral health conditions, leading to both dental enamel
hypoplasia and aphthous stomatitis. The impact of oral ecosystem alterations, including a change to
salivary flow rate and alterations of the hard and soft oral tissues, and its impact on the development
of dental enamel defects and aphthous ulcers are being closely evaluated. In a study by Mida et al.
in 2011, there did not appear to be significant differences in salivary factors between celiac patients
and healthy controls [11], but there were significant differences in the quantity of leukocytes that are
present in patients with infectious processes and/or other systemic diseases involving the immune
system as compared to healthy controls. They showed that 80% of celiac children who complied
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with a strict GFD had the complete resolution of leukocyte presence in oral smears as compared to
patients with poor adherence to the diet. These non-adherent patients continued to show elevated
leukocyte levels and it was hypothesized that these leukocytes in oral smears are what contribute to
the formation of the recurrent aphthous ulcers [12] when the appropriate genetic predisposition is
present [13]. Others speculate that the direct presence of gluten within the oral cavity may stimulate
lymphocyte activity directly into the oral mucosa [11]. Aphthous stomatitis in celiac patients show
high rates of resolution on a strict GFD [1].
4. Osteopenia/Osteoporosis
Osteopenia (reduced bone density) and osteoporosis (reduced bone density leading to weak and
brittle bones) are the most frequent bone related complications of CD, and can ultimately lead to bone
fragility and a high prevalence of bone fractures if CD is left untreated. Roughly 75% of pediatric celiac
patients at the time of diagnosis will have osteopenia, while only 30% have osteoporosis.
Osteoblasts, which are derived from mesenchymal stem cells, are responsible for new bone
formation, while osteoclasts, which are differentiated monocyte-derived cells, are involved in bone
matrix removal. Through complicated mechanisms, bones are constantly remodeled through the
process of resorption and formation, and in a balanced manner, to limit ultimate bone loss. Nutrition
plays a very important role in this bone homeostasis, with the main players being vitamin D, calcium,
and minerals, which are predominantly absorbed in the proximal small bowel [14]. While our bodies
strive to produce strong bones, the ultimate goal of the human body is to maintain adequate serum
calcium levels. When calcium levels are adequate the body favors bone formation. Reduced serum
calcium levels, though, leads to parathyroid gland stimulation, increased production of parathyroid
hormone (PTH), subsequent bone resorption, and the release of stored calcium to bring the serum
calcium levels back into equilibrium.
Untreated CD to leads to inflammation and villous atrophy in the proximal small bowel,
malabsorption of calcium, and low serum levels. This, in turn, leads to secondary hyperparathyroidism,
the release of calcium and phosphate from the bone matrix, and the thinning of bones [15]. There is also
now evidence to suggest that, in addition to low calcium levels leading to thinning of bones, the chronic
release of proinflammatory cytokines, hormonal components, and other misbalanced bone remodeling
factors can also predispose celiac patients, on or off the GFD, to mineral metabolism derangements.
Specifically, cytokines interleukin 1 beta (IL-1β), interleukin 6 (IL-6), tumor necrosis factor alpha
(TNF-α), and interferon gamma (IFN-γ) has been implicated in bone loss during CD [16–19]. Lastly,
there have also been recent advances in the identification of receptor activators of nuclear factor
kappa B/receptor activator of nuclear factor kappa B-ligand (RANK/RANKL) signaling system,
in addition to the discovery of osteoprotegerin (OPG), a protein that may protect from excessive bone
reabsorption. Bone homeostasis is maintained through the balance of the reabsorbing activity of
RANKL and the decoy receptor OPG. It has been shown that the OPG/RANKL ratio is significantly
lower in celiac patients with recovery of intestinal mucosa as compared to healthy controls that are
positively correlating with their lower bone mass density [20].
Strict adherence to the GFD is the first-choice therapy for the treatment of osteopenia and
osteoporosis in children as it leads to healing of the small bowel and the reversal of intestinal
malabsorption. By 12 months on a strict and balanced GFD, most children will have near complete
re-mineralization of the bones, even without additional vitamin D and calcium supplementation [21,22].
A greater improvement at 12 months is seen in pediatric celiac patients with GI symptoms as
compared to non-GI symptoms, which is likely explained by a delay in the diagnosis of patients
lacking GI symptoms leading to more extensive disturbances in bone metabolism at the time of celiac
diagnosis [23].
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5. Iron-Deficiency Anemia
While iron-deficiency anemia is one of the most common extra-intestinal manifestations at
diagnosis in adult CD patients (50%), and it is only found in roughly 10–15% of new pediatric
celiac patients [1,2,24]. This discrepancy can be attributed to delayed diagnoses of CD in adults
given the propensity for less typical gastrointestinal celiac symptoms than that seen in children.
Iron is predominantly absorbed in the first portion of the small bowel, the duodenum, which is
the main portion of the bowel affected by CD. CD induced duodenal inflammation subsequently
leads to the malabsorption of iron and resultant iron-deficiency anemia. This anemia will often
temporarily improve with iron supplementation only to recur when discontinued given the ongoing
iron malabsorption from the untreated CD. Eighty-four percent of celiac children receiving iron
supplementation and with strict adherence to a GFD had the complete recovery of their iron stores by
12–24 months [1].
6. Liver and Biliary Disease
Liver disease is seen in up to 50% of new pediatric celiac patients [25]. While is it possible
for celiac patients to have more severe liver disease, such as autoimmune hepatitis, primary biliary
cirrhosis, and sclerosing cholangitis, the majority develop a benign hypertransaminasemia or “celiac
hepatitis”. While it is not clear why damage to the liver occurs in CD, it is felt to be likely secondary
to damaged gut mucosa with resulting increased gut permeability allowing for endotoxins from gut
bacteria to reach the portal vein. Once in the liver, these endotoxins trigger a toll-like receptor-mediated
inflammatory response from immune cells, ultimately leading to inflammation and liver damage [26].
Patients with “celiac hepatitis” have excellent response rates to a strict GFD, with a 75–95% rate of
complete liver enzyme normalization by 12–24 months [1,27].
7. Dermatitis Herpetiformis
Dermatitis Herpetiformis (DH) is rather rare in pediatric celiac patients with rates of roughly 5%
or less. DH is a bilateral, itching, blistering skin disease that typically presents as a rash on the elbows,
knees, and buttocks. The diagnosis is confirmed by a skin biopsy with direct immunofluorescence
demonstrating granular immunoglobulin A (IgA) deposits in the papillary dermis. The majority
(but not all) of these patients will also have celiac specific enteropathy in the small intestine at diagnosis
as well. The rash responds well to a strict GFD with near 100% rates or resolution in children [1,28].
While some may receive additional medical therapy with diamino-diphenyl sulfone (dapsone) at
diagnosis, most celiac patients can be successfully weaned off the medication with time and remain
well controlled on a gluten free diet alone [28].
8. Arthralgia/Arthritis
Musculoskeletal manifestations, including arthralgia and arthritis, are seen in roughly 5–10%
of new celiac pediatric patients [1]. In a paper by Garg et al. in 2017, the authors investigated
the prevalence of early joint involvement in children with CD through the use of musculoskeletal
ultrasound, which is felt to be superior to conventional radiology in detecting a wide array of early
inflammatory and structural abnormalities in joints. They compared children aged 2–18 with newly
diagnosed CD on a strict GFD as compared to children with CD who had been on a GFD for at least
six months. Ultrasonographic assessment showed the presence of at least one abnormality in the
joints of 32% of newly diagnosed celiac patients as compared to only 3% of those on the diet for
at least six months. The most frequently involved joint was the knee with findings, including joint
effusion, synovial hypertrophy, and joint effusion with synovitis. Other joints, less often affected,
included the hip and ankle. Interestingly, the majority of patients with ultrasonographic evidence of
joint abnormalities were asymptomatic, suggesting a subclinical synovitis. The lower rates of joint
involvement found in children on a GFD for more than six months is suggestive that the GFD may lead
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to improvements in the joint abnormalities associated with CD [29]. Limitations of this study included
the small sample size and lack of healthy controls for comparison, though. To better understand the
rates of subclinical synovitis in the healthy population, Breton et al. in 2011 assessed 41 healthy control
pediatric patients, none of whom showed signs of subclinical synovitis evaluated by musculoskeletal
ultrasonography [30]. The children studied, however, were French with a mean age of nine years old
as compared to Indian children with a mean age of 6 in Garg, et al.’s study, thus making this healthy
control group not well suited for such a comparison.
9. Headaches, Peripheral Neuropathy, Ataxia and Epilepsy
While headaches can be seen in up to 20–30% of children with new CD, rates of peripheral
neuropathy and epilepsy are rarer. While these diseases may occur simultaneously by chance, there are
several reports demonstrating neurological improvement following the introduction of a strict gluten
free diet supporting a causative association.
Headaches are the most common neurological symptoms seen in pediatric CD. The exact
mechanism by which CD leads to headaches in is unclear, but it is speculated that it may be secondary
to a lack of vitamins, macro elements, such as magnesium [31], low levels of serotonin [32], which are
the direct result of the celiac associated malabsorption. An alternate hypothesis is that the impaired
immune response results in an imbalance of pro-inflammatory cytokines in response to ingested gluten,
leading to altered vascular tone, and subsequently, the onset of the headache [33]. Most pediatric
patients show excellent rates of headache improvement on a strict GFD, approaching 100% [1,34,35].
The most common neuropathy noted in CD is chronic, symmetric distal neuropathy,
but autonomic neuropathy, chronic inflammatory demyelinating neuropathy, acute inflammatory
demyelinating neuropathy (Guillain-Barre syndrome), and mononeuritis multiplex have also been
described [36]. Rates of peripheral neuropathy in pediatric CD range form 0.1–7.4% [37–39]. It is
speculated there may be an autoimmune cause for the neuropathy as many studies have located
anti-ganglioside antibodies in these patients [40]. It is also possible that the nutritional deficiencies
common to CD patients may account for the neuropathy. There has been great discrepancy as to
the effectiveness of the GFD on resolution of peripheral neuropathies in celiac disease, ranging from
findings of great symptom improvement [41], to only subjective improvements [42], to little to no
improvements at all [43]. Intravenous immunoglobulin, plasmapheresis and etanercept do not appear
to be effective in celiac related peripheral neuropathies [42].
While cerebellar ataxia is a well-recognized extra-intestinal manifestation of CD in adults
occurring in as many as 40% of adult CD patients, it is far less common in children with rates
that are closer to 0.068–1.79% [44–46]. The clinical presentation is indistinguishable from other forms
of cerebellar ataxia with progressive unsteadiness of the gait and limbs. Both sexes appear to be
affected equally, the mean age of onset is 53 years, and cerebellar atrophy can be detected by brain
magnetic resonance imaging (MRI) in a vast number of adult patients as well [47]. On the contrary
cerebellar atrophy appears to be exceptionally rare in children. While children are more prone to
developing unilateral or bilateral focal hyper-intense white matter lesions, actual cerebellar atrophy
is very uncommon [45,46]. The severity of cerebellar atrophy appears to correlate with the duration
of exposure to gluten likely explaining the decreased rates and severity of cerebellar atrophy seen in
children [48]. Similar to other neurologic manifestations in celiac patients, the effects of the GFD on
recovery are highly variable [49], and if there have been no improvements on the diet within a year
or the ataxia is rapidly progressive, the use of intravenous immunoglobulins has been reported to
provide possible benefits [50].
Most pediatric studies have failed to find and increase the prevalence of epilepsy in CD as
compared with the general population [37]. Epilepsy specifically associated with cerebral calcifications,
though, has been associated with CD. It was first reported in the pediatric literature in 1994 by Pascotto,
et al. who described four separate patients with epilepsy with cerebral calcifications refractory to
medical management, followed between 1980 and 1990 at the Clinic of Child Neuropsychiatry of
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Naples University. Despite extensive testing, an origin for the calcifications was not discovered.
These patients later underwent celiac testing, 1 for failure to thrive (FTT), while the other three had
no obvious gastrointestinal complaints. Two of the four patients, including the patient with FTT,
had elevated titers of immunoglobulin A (IgA) and Immunoglobulin G (IgG) antigliadin antibodies
and also demonstrated histologic findings of crypt hyperplasia, alterations of superficial epithelium
with picnotic, cubic cells, and remarkable lymphoplasmacellular infiltration, as is consistent with the
diagnosis of celiac disease. Following diagnosis, these two patients started a strict GFD with reverse of
the FTT and initial improvements in the seizure frequency, but worsened again roughly six months
later [51]. A subsequent, similar case report was published in 2012. In this case, the child was positive
for endomysial (EMA) immunoglobulin IgA, gliadin (DGP) IgA, and IgG and transglutaminase (tTG)
two IgA and IgG antibodies. Endoscopic biopsies showed subtotal villous atrophy in the duodenum
confirming the diagnosis. Additionally, high levels of antibodies to tTG six IgA and EMA (IgA)
were also found in the cerebrospinal fluid. The child was placed on a GFD and was seizure free for
18 months at the time of the publication of the paper [52].
10. Behavioral Changes and Psychiatric Disorders
A wide range of psychiatric symptoms and disorders have been associated with CD, including
anxiety disorders, depressive disorders, attention deficit hyperactivity disorders (ADHD), and autism
spectrum disorders (ASD). While psychiatric disorders that occur after the diagnosis of celiac disease
has been made are more often associated with an impaired quality of life and difficulty adapting
to the chronic nature of the disease [53], psychiatric disorders that occur prior to the diagnosis of
celiac disease have been hypothesized to be related to disease related cerebral hypoperfusion [54],
proinflammatory cytokines [55], and low folate levels [56]. We will focus on anxiety and depressive
disorders within this review as to date, no greater rates of ADHD and ASD have been found in the
celiac population as compared to the general population [57–59].
Rates of psychiatric disorders, including anxiety and depression, in pediatric celiac patients range
from 5–10% [1,60], substantially lower than those found in adults [61]. A recent study by Smith et al.
in 2018 examined maternal reports of their children’s psychological functioning over 3.5 years in celiac
children aged 2–3 years who were persistently positive for tTG IgA as compared to children with
normalized tTG IgA. These serology results were obtained in a retrospective manner by sampling of
stored blood. The mothers were blinded to the results of the serological testing. Mothers completed
the Achenbach Child Behavior Checklist, a well-validate questionnaire to measure behavioral and
emotional function in preschoolers aged 1.5–5 years old. There was a statistically significant difference
in the scores from mothers of celiac children with persistently elevated tTG IgA as compared to those
with normalized tTG IgA. Celiac children with persistently elevated tTG IgA scored significantly
higher for anxiety, depression, aggressive behaviors, and sleep problems. Initiation of the GFD did
not appear to have an impact on the psychological functioning of the patients in this study (though
very young children) [62]. Another study by Simsek et al. in 2015 assessed the rates of psychiatric
symptoms in newly diagnosed celiac pediatric patients aged 9 to 16 years old as compared to age
and sex matched healthy controls that had presented for routine checkup. On the contrary to the
previous study, this study showed no statistically significant differences between depression scores in
newly diagnosed CD patients and controls, though there were statistically lower scores on emotional
well within the CD patients as compared to the controls. Patients on a strict GFD showed significant
reductions in follow up depression scores as compared to patients that were non-compliant with the
diet [63]. There have been very mixed results, though, on improvements in depression once on a
GFD ranging from no change in depression [53], to moderate improvements in depression [1], to the
complete resolution of depression [64].
58
Nutrients 2018, 10, 755
11. Alopecia
While alopecia has an association with pediatric CD, it is one of the less common extra-intestinal
manifestations seen, occurring in roughly 1% of patients [1]. It is presumed to occur through
an autoimmune reaction involving T-cell dysregulation and can lead to patchy loss of skull hair
(alopecia areata), total loss of skull and facial hair (alopecia totalis), and total loss of full body hair
(alopecia universalis). It is speculated that there are autoantibodies directed against anagen-stage
hair follicle structures and a direct association with the human leukocyte antigen (HLA)-DQB1*0201
allele. A number of studies have assessed the involvement of alopecia areata in CD patients. Rates of
alopecia areata appear to be equally distributed between male and female celiac patients, roughly 40%
have a coinciding alternate autoimmune disorder, 70% had gastrointestinal symptoms in addition to
the alopecia, and 100% of patients had positive celiac serologies (tTG IgA or EMA IgA) with subtotal
or total villous atrophy on duodenal biopsies. Trials of oral zinc and other topical treatments were
attempted with minimal response. Of the patients who started a strict GFD, 26% had no regrowth,
22% had a partial regrowth, and 52% had the complete regrowth of hair by 12–24 months (most within
the first 2–3 months). All of the patients had a normalization of their celiac serologies and duodenal
biopsies by 24 months, despite the growth or lack of growth of hair. Younger patients and shorter
lag times between the onset of alopecia areata and initiation of the GFD led to a more favorable hair
growth response. Sex, lack of GI symptoms, and the severity of biopsy results did not appear to impact
whether a patient would or would not have regrowth of hair [65–71].
12. Treatment of the Extra-Intestinal Manifestations of CD
Strict, lifelong adherence to a GFD remains the only available treatment for patients that are
diagnosed with CD, and, as stated previously, should result in a complete return to health in the
majority of patients, especially pediatric. Other pharmacological therapies are being evaluated
for the treatment of CD, including enzymes, to inactivate immunogenic gluten peptides in the
human gastrointestinal tract [72], agents that sequester gluten in the lumen [73], modulators of
gut permeability [74], and of antigen presentation and immune responses, including those that block
tTG [75] and HLA [76], IL-15 inhibitors [77], and the development of vaccines that are able to induce
oral tolerance to gluten [78]. Of these treatment options, the only one that is currently on the market is
the gluten-specific enzyme, GliadinX (AN-PEP). Unfortunately, it is only capable of detoxifying 0.2 g
of gluten or roughly that of 1/8 of a slice of gluten-containing bread. For this reason, it should only be
used as an adjunct to the GFD when there are concerns for accidental gluten contamination and in an
effort to ameliorate symptoms, not as a replacement for the GFD.
While these pharmacological options are promising, it is still unclear how well they will work to
minimize gut inflammation and alleviate gastrointestinal, and, the even more complex extra-intestinal
manifestations of CD. While it is likely that some of the alternatives may come to fruition in the next
year or two, a true “cure”, although certainly possible, might take much longer [79].
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Abstract: Celiac disease (CD) is an immune-mediated, gluten-induced enteropathy that affects
predisposed individuals of all ages. Many patients with CD do not report gastrointestinal symptoms
making it difficult to reach an early diagnosis. On the other hand, CD is related to a wide spectrum
of extra-intestinal manifestations, with dermatitis herpetiformis (DH) being the best characterized.
These associated conditions may be the clue to reaching the diagnosis of CD. Over the last few years,
there have been multiple reports of the association between CD and several cutaneous manifestations
that may improve with a gluten-free diet (GFD). The presence of some of these skin diseases, even
in the absence of gastrointestinal symptoms, should give rise to an appropriate screening method
for CD. The aim of this paper is to describe the different cutaneous manifestations that have been
associated with CD and the possible mechanisms involved.
Keywords: celiac disease; dermatitis herpetiformis; urticaria; atopic dermatitis; psoriasis; recurrent
aphtous ulceration; rosacea; alopecia areata; cutaneous vasculitis; gluten-free diet
1. Introduction
Celiac disease (CD) is a chronic autoimmune systemic disease associated with an enteropathy
triggered by gluten intake which affects genetically predisposed individuals of both sexes and can
develop at any age. Gluten and its major protein fractions, gliadin and glutenin, are present in wheat,
rye, barley, oats, related species and hybrids, and processed foods [1]. Almost all patients with CD
present the human leukocyte antigen (HLA) DQ2 (>90%) or HLA DQ8 (5–10%); nevertheless, up to
40% of people in the Americas, Europe, and Southeast Asia also carry these alleles, indicating that these
genes are necessary but not sufficient for CD development [2]. The findings of inflammatory changes
in intestinal biopsies, ranging from lymphocytic enteritis to various degrees of villous atrophy, are the
gold standard for CD diagnosis, even in the presence of a negative serology for CD. IgA anti-tissue
transglutaminases are the most sensitive and cost-effective antibodies for the diagnosis of CD, although
deamidated gliadin peptide IgG antibodies might be useful in seronegative patients with innate IgA
deficiency. A life-long gluten-free diet (GFD) is mandatory, achieving clinical and histological recovery
in most patients [1].
In past decades, CD was considered to be an uncommon disease affecting mainly children and
limited to individuals of European ancestry. Currently, we know that this disorder may be detected at
any age and is regarded as one of the most common chronic diseases encountered worldwide with a
prevalence of about 1–2% [3]. The mean age of adult CD diagnosis is 45 years, although up to 20% of
Nutrients 2018, 10, 800; doi:10.3390/nu10070800 www.mdpi.com/journal/nutrients64
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patients are diagnosed at the age of 60 years or above. CD is probably an under-diagnosed entity in
adulthood partly because many patients in this age group lack the classical symptoms, such as diarrhea
or signs of malabsorption. In fact, in most adult patients, gastrointestinal symptoms are subtle or even
absent, and clinical suspicion arises from extra-intestinal manifestations (non-classic or atypical CD),
such as anemia, cutaneous disorders, neurological disease, osteoporosis, and abnormal liver function
tests [2,4]. We emphasize the importance of considering non-typical symptoms to diagnose adult CD
and actively searching extra-intestinal associated manifestations in order to start an early GFD and
prevent the onset of long-term complications.
CD patients are more frequently affected by other immune-mediated disorders (ID) compared
to the general population, as reported in previous studies, mainly thyroid and skin diseases and
type 1 diabetes mellitus [5,6]. This observation may be partially explained by a possible spread of
the adaptive immune response, initially triggered in the gastrointestinal tract, to other tissues [4,6].
Hashimoto’s thyroiditis is the most frequently associated ID, followed by several skin disorders, such
as psoriasis, atopic dermatitis (AD), vitiligo, systemic lupus erythematosus (SLE), alopecia areata (AA),
and oral lichen planus (OLP) [6]. Interestingly, 60% of CD patients with associated thyroid disease
that develop a third ID are skin related. These data suggest a relationship among the immunological
systems of the thyroid, skin, and small bowel, which seem to be more susceptible to developing
aberrant immunological responses against auto-antigens. [6–12].
Cutaneous manifestations associated with CD, other than dermatitis herpetiformis (DH), are
poorly known. It is currently recognized that DH is an undoubted extra-intestinal manifestation
of CD. In addition, there is growing evidence that supports the link between CD and several
skin disorders. In 2006, Humbert et al. proposed a classification of skin diseases associated with
CD, dividing them into four categories: autoimmune, allergic, inflammatory, and miscellaneous
(Table 1) [9–19]. Recently, Bonciolini et al. described 17 patients affected by non-celiac gluten sensitivity
with skin manifestations similar to eczema, psoriasis, and DH who did not show a specific histological
pattern [20]. The only common findings in most of these patients were severe itching, the presence
of C3 at the dermo–epidermal junction and rapid resolution after adopting a GFD. The authors
emphasized the importance of close collaboration between gastroenterologists and dermatologists due
to the multiple associations between gastrointestinal and skin disorders. In the present paper, we aim
to describe the multiple skin disorders associated with CD and the possible mechanisms involved.
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GFD: gluten-free diet; CD: celiac disease; HR: hazard ratio; OR: odds ratio; CI: 95% confidence interval; IgA:
immunoglobulin A.
2. Immunopathogenesis of Skin and Oral Lesions Associated with CD
The immune responses in CD are very wide. A probable explanation lies in the presence of an
increase in intestinal permeability in both groups of patients, in relation to the direct toxic effect of
gliadin on the surface of the intestinal epithelium [21,22]. This enables the passage of gluten peptides
and other related peptides to the bloodstream, provoking the appearance of different inflammatory
or autoimmune processes that may affect any organ or tissue, which can be the result of aberrant
immune responses [21,23,24]. As Hadjivassiliou stated more than 15 years ago, “that gluten sensitivity
is regarded as principally a disease of the small bowel is a historical misconception.” [22,25].
In the submucosa of the small intestine, starting with the the action of tissue transglutaminase
type 2 which unfolds gluten, a cascade of events occurs, causing a Th1 response that stimulates B
lymphocytes that release IgE and other immunoglobulins [26] which play a important roles in the
appearance of urticaria and AD, and a stimulation of Th2 mediated by T-lymphocytes which produces
the release of pro-inflammatory cytokines, such as TNF-α and interferon gamma (IFNγ), among
others [27], and that play important roles in several types of immune-mediated dermatitis, such as
psoriasis. In addition, these immunological responses can also cause the production of circulating
immunocomplexes due to antigen–antibody interactions which predominate in vasculitic lesions.
3. Dermatitis Herpetiformis
DH is a common extra-intestinal manifestation of CD. A special review article on this disease
was recently published in the May 2018 special issue in Nutrients [28]. In summary, DH presents
with itchy vesicles and papules, mainly on the elbows, knees, and buttocks. Overt gastrointestinal
symptoms are rare. Although in duodenal biopsies, up to 75% of patients with DH with varying
degrees of villous atrophy are observed, predominantly mild to moderate, it should be taking into
account that in the remaining 25%, only inflammatory changes of changes of lymphocytic enteritis
are observed, in the absence of villous atrophy. A diagnosis of DH is easily confirmed by biopsies
showing pathognomonic granular immunoglobulin A (IgA) deposits in the papillary dermis by direct
immunofluorescence. A valid hypothesis for the immune pathogenesis of DH is that it starts from
latent or manifested CD in the gut and evolves into an immune complex deposition of high avidity
IgA epidermal transglutaminase (TG3) antibodies, together with the TG3 enzyme, in the papillary
dermis. The DH to CD prevalence ratio is 1:8 in Finland and the United Kingdom (UK). The annual
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DH incidence rate, currently 2.7 per 100,000 in Finland and 0.8 per 100,000 in the UK, is decreasing,
whereas the reverse is true for CD. The long-term prognosis of DH patients on a GFD is excellent, with
the mortality rate being even lower than for the general population [28].
4. Urticaria
Urticaria is characterized by the onset of wheals, angioedema, or both (Figure 1) [29]. Urticaria is
a common disorder, occurring in 15–25% of individuals at some point in life [29,30]. Chronic urticaria
(CU) (duration ≥6 weeks) is seen in about 0.5–1% of the general population [31,32]. CU is associated
with a substantial decrease in quality of life [31]. The etiopathogenesis of CU is thought to be associated
with autoimmune mechanisms [33–36]. CU has been shown to have a genetic association with the
human leukocyte antigen HLA-DQ8 alleles [37]. Interestingly, HLADQ8 has an association with
CD [37,38].
 
Figure 1. Urticaria. Pale to red, well-demarcated, transient swellings, involving the dermis, mainly at
the thorax and the left arm.
In 1987, Hauteke et al. first described the association between CD and chronic urticaria [39],
although the relationship between these two diseases is not fully clear. Recently, Kolkhir et al.
stated that chronic spontaneous urticaria is strongly linked with various autoimmune diseases,
including Hashimoto’s thyroiditis, pernicious anemia, vitiligo, diabetes mellitus type 1, Grave’s
disease, rheumatoid arthritis, and CD [40]. In a large population study, 453 patients with CD and
no previous diagnosis of urticaria developed urticaria, and 79 of these 453 patients had chronic
urticaria [12]. The corresponding hazard ratios were 1.51 for any urticaria (95%CI = 1.36–1.68) and 1.92
for chronic urticaria (95%CI = 1.48–2.48). These data support an increased prevalence of urticaria and
chronic urticaria in patients with CD [12].
In some cases of CU, the adoption of a GFD has proven its effectiveness in controlling skin
flares [41,42], further sustaining that CU may be a cutaneous manifestation of CD and not only a
fortuitous association [11].
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5. Atopic Dermatitis
AD is a chronic inflammatory skin disease that is associated with a heterogeneous group of
symptoms and signs. The cutaneous signs of AD include erythema, lichenification, scaling, and prurigo
nodules (Figure 2). The symptoms of AD include cutaneous itch and pain [43], sleep disturbance and
fatigue [44,45], and mental health symptoms [46–48]. All of these manifestations contribute to diminish
the quality of life, limiting the ability to perform activities of daily life and causing psychosocial
distress and stigma [49]. AD affects 40 million individuals worldwide [50], and its prevalence is still
increasing. Notably, AD appears to be more prevalent among children under five years of age, and
its prevalence decreases with advancing age [51]. The onset of AD occurs primarily in childhood
and is thought to precede allergic disorders mediated by immunoglobulin E (IgE) sensitization to
environmental antigens, namely AD, asthma, and allergic rhino-conjunctivitis, the so-called atopic
triade [52–55]. Though extensive recent studies have shed light on the understanding of AD, the exact
pathogenesis of the disease is still unknown. The complex interaction between genetics, environmental
factors, microbiota, skin barrier deficiency, immunological derangement, and possibly autoimmunity
contributes to the development of the disease [56–59].
 
Figure 2. Atopic dermatitis. Excoriated bilateral erythematous scaling papules and plaques on the
right flexor elbow surface.
AD has also been linked with CD. Ress et al. analyzed the prevalence of CD in 351 children with
AD compared with a general pediatric population and showed a four-fold greater risk of developing
CD in patients with AD (OR, 4.18; 95% CI, 1.12–15.64) [60]. This study also emphasizes the need to
evaluate the cost-effectiveness of screening patients with AD for CD in time to prevent long-term
complications. Moreover, Ciacci et al. conducted a case control study involving 4114 adult patients,
with and without CD, and observed that AD was three-fold more frequent in patients with CD and
two-fold more frequent in their relatives than in their spouses (OR, 3.17; 95% CI, 1.02–9.82) [13].
6. Psoriasis
Psoriasis is an autoimmune chronic inflammatory skin disease with an estimated prevalence
of 2–4% in the adult population [61,62]. It affects over 7.5 million people in the United States and
approximately 125 million people worldwide [54]. Psoriasis is considered to be a multifactorial
disease, in which the genetic background interacts with environmental factors to define an individual’s
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risk [62–64]. The classical clinical manifestations of psoriasis consist of the presence of red, infiltrated
plaques, covered with a coarse, silvery scaling (Figures 3 and 4). Predilection sites include the elbows
and knees, scalp, and periumbilical and lumbar regions, although any anatomical site might be
affected [65]. The clinical course of psoriasis is marked by frequent relapses with fluctuating rates [62].
Figure 3. Extense plaque of psoriasis at the left elbow extensor side.
 
Figure 4. Psoriasis. Well demarcated, erythematous, scaly plaques that are relatively symmetrical on the back.
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Psoriasis is known to be associated with an increased risk of several comorbidities, including
inflammatory arthritis, metabolic syndrome, and atherosclerotic disease [63]. The association between
psoriasis and CD has been of recent interest, but its first recognition was in 1971 by Marks and
Shuster [66]. They described, for the first time, a “psoriatic enteropathy” in a small group of patients
with severe psoriasis. For many years, the relationship between psoriasis and CD has remained
controversial since the few available data were inconclusive. A recent meta-analysis demonstrated
a significantly higher risk of CD among patients with psoriasis compared with participants without
psoriasis with the OR of 3.09 (95%CI = 1.92–4.97) [16]. Furthermore, seven studies have reported a
positive association between psoriasis and CD markers [66–72]. In contrast, other studies did not
find evidence of an association between psoriasis and CD markers. However, these studies were
of smaller size and some did not employ control groups [73–77]. To resume the evidence for CD
antibody positivity in psoriasis, Bhatia et al. performed a meta-analysis of nine studies that reported
the frequency of IgA anti-gliadin antibody (IgA AGA) positivity in psoriasis cases and controls [17].
They found a statistically significant higher relative risk of having positive IgA AGA in patients
with psoriasis compared to controls (OR = 2.36, 95% CI 1.15–4.83). Other two studies suggested
that levels of CD antibodies correlate with psoriasis or psoriatic arthritis severity [78,79]. The use
of AGA determination for the diagnosis of CD has low sensitivity, and its use in clinical practice is
being abandoned, being replaced by other types of antibodies, such as anti-transglutaminase and
deaminated peptides of gliadin [6,21].
The pathophysiologic mechanisms behind the increased risk of CD among patients with psoriasis
are not known, but there are different hypotheses that try to explain them [16,80]. The association
between CD and several autoimmune diseases, such as type I diabetes mellitus and autoimmune
thyroid disease, is well-documented [81,82]. It is believed that shared genes (at-risk HLA haplotypes)
might be responsible for this association. The shared genes might play similar roles in the association
between psoriasis and CD. Genetic-wide association studies of these two conditions identified genetic
susceptibility loci at eight genes that regulate innate and adaptive immune responses: TNFAIP3,
RUNX3, ELMO1, ZMIZ1, ETS1, SH2B3, SOCS1 and UBE2L3 [80,83–85]. Another possible explanation
is that the increased proliferation rate of keratinocytes found in patients with psoriasis is known to
produce an excessive amount of interleukin (IL)-1 and IL-18, the essential signals for the induction
of Th1 response. Interestingly, mucosal inflammation in patients with CD is also caused by the
activation of Th1 in response to dietary gluten [86]. Therefore, it is possible that these ILs might
predispose patients to CD. On the other hand, it is possible that intestinal barrier dysfunction
associated with undiagnosed or untreated CD may allow the increased passage of immune triggers
resulting in an increased risk of autoimmune diseases, including psoriasis [86,87]. Finally, CD-related
malabsorption may affect psoriasis by causing a vitamin D deficiency status [9,88]. It is well known
that low levels of vitamin D predispose individuals to psoriasis and that exposure to sunlight
and topical administration of vitamin D analogues improves psoriatic lesions, probably due to its
immunoregulatory properties [88].
Although available data regarding the coexistence of CD and psoriasis are still inconclusive,
there is a considerable amount of evidence that suggests that psoriatic patients with concomitant CD
may benefit from a GFD [17,21,80,89]. Furthermore, the prevalence of the anti-gliadin IgA antibody
is significant higher among patients with psoriasis without a diagnosis of gluten-related disorders.
For this reason, anti-gliadin IgA testing can identify patients who are likely to benefit from GFDs [90].
To summarize, the relatively frequent coexistence of CD and psoriasis justifies monitoring of
patients with either condition for clinical evidence of the other. This is especially important in the
case of psoriasis, as it could be the only manifestation of an undiagnosed CD, even in the absence of
obvious digestive symptoms. It is advisable to perform the entire protocol to actively search for CD,
including duodenal biopsies, even when serological markers are negative. In the case of negative CD
findings, performing a trial with a GFD is currently the recognized diagnostic method [23].
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7. Aphthous Stomatitis
Numerous authors have described a wide variety of oral cavity disorders in patients with CD, and
some of these manifestations may be considered diagnostic clues in silent, atypical forms of CD [91].
Recurrent aphthous stomatitis (RAS) is a common clinical condition that produces painful
ulcerations in the oral cavity. RAS is characterized by multiple recurrent small, round, or ovoid
ulcers with circumscribed margins, erythematous haloes, and yellow or gray floors, typically first
presenting in childhood or adolescence [92,93] (Figure 5). RAS has been recognized for many years
as a symptom of CD (CD) [93–96]. A recent meta-analysis showed that celiac patients have greater
frequency of RAS (OR = 3.79, 95%CI = 2.67–5.39). When only the children were considered, the
OR was 4.31 (95%CI = 3.03–6.13), while in the adults, the OR of only one study was 47.90 (95%CI
6.29–364.57) [18]. RAS patients should be considered at-risk subjects, even in the absence of any
gastrointestinal symptoms and should therefore undergo a diagnostic procedure for CD [97]. RAS
may also be present in patients with DH [98]. A study reported non-specific mucosal ulcers in up to
40% of patients with DH [99]. The etiopathology of RAS is obscure; it is not known whether RAS
lesions are directly influenced by the gluten sensitivity disorder, or if these are related to hematinic
deficiency with low levels of serum iron, folic acid, and vitamin B12 or trace element deficiencies due
to malabsorption in patients with untreated CD [96].
 
Figure 5. Aphthous lesion on the tip of the tongue, on the upper side.
8. Rosacea
Rosacea is an inflammatory skin condition characterized primarily by persistent or recurrent
episodes of centrofacial erythema, with women being more affected than men [100] (Figure 6).
The pathophysiology is not completely understood, but dysregulation of the immune system as
well as changes in the nervous and vascular systems have been identified [101]. Rosacea can seriously
affect a patient’s quality of life, and this should prompt clinicians to diagnose it early and start
treatment [100]. Rosacea shares genetic risk loci with autoimmune diseases, such as type 1 diabetes
mellitus and CD [102]. One study showed that women with rosacea had a significantly increased risk of
CD (OR = 2.03, 95%CI 1.35–3.07) [103]. In a nationwide cohort study, the prevalence of CD was higher
among patients with rosacea when compared to control subjects (HR = 1.46, 95%CI = 1.11–1.93) [19].
In this study, rosacea was associated with an increased prevalence of Crohn’s disease, ulcerative colitis,
irritable bowel disease, small intestinal bacterial overgrowth, and Helicobacter pylori infection.
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Figure 6. Rosacea. Papule-pustular lesions on the face.
9. Alopecia Areata
AA is an autoimmune disease that presents as a non-scarring type of hair loss. AA affects
both sexes equally, affects patients of all ages, and is found in approximately 2% of the general
population [104]. Clinical presentation of AA is very heterogeneous, ranging from small and
well-circumscribed patches of hair loss to a complete absence of body and scalp hair (Figure 7).
Exclamation point hairs, dystrophic hairs, and yellow dots are features of AA that can be identified
with trichoscopy. Nail abnormalities, such as pitting, brittleness, or striations are seen in 10% to 20%
of patients. The main factors affecting prognosis include age at onset and disease extent; younger
age at initial presentation and severity at onset are the most important prognostic indicators [105].
The etiology of AA remains unclear, though it is believed to result from a loss of immune privilege in
the hair follicle, autoimmune-mediated hair follicle destruction, and the upregulation of inflammatory
pathways [105].
AA is associated with other autoimmune disorders, such as Addison’s disease, autoimmune
thyroiditis, atrophic gastritis, systemic lupus erythematous, rheumatoid arthritis, myasthenia gravis,
and vitiligo [106]. In 1995, Corazza et al. described, for the first time, the association between AA and
CD [107]. Since then, there have been other reports of this association. The estimated prevalence rate of
CD in patients with AA is from 1:85 to 1:116 [108,109], similar to that found in the general population,
so it could be considered to be a random association. However, due to the fact that alopecia improves
and even disappears with a GFD, its presence should indicate the possible existence of an undiagnosed
CD [11,108–110]. In addition, the prevalence of anti-gliadin antibodies in patients with AA was 18:100
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in a study conducted in 2011, occurring more often in severe variants of AA, in particular, alopecia
universalis [109]. An active search for CD using serological screening tests has been recommended
to diagnose the numerous cases of subclinical CD [9], but a recent study stated that the biological
tests to search for CD do not bring enough information and proof to disclose gluten intolerance in AA
patients [111].
 
Figure 7. Alopecia areata. Patchy head hair loss.
The positive effects of a GFD on the pattern of autoimmune conditions associated with CD, such
as AA, have been attributed to the normalization of the immune response [109]. Although remission
and recurrence may be observed during the clinical course of AA, many patients on a GFD have shown
complete regrowth of the scalp and other body hair and no further recurrence of AA at follow-up [112].
10. Cutaneous Vasculitis
Leukocytoclastic vasculitis, also known as “hypersensitivity vasculitis”, is a histopathologic
diagnosis given to cutaneous, small vessel vasculitis, characterized by the inflammation of the walls
of postcapillary venules [113]. The clinical features of leukocitoclastic vasculitis include palpable
purpura, nodules, hemorrhagic vesicles, bullae, and livedo reticularis, mainly distributed in the lower
extremities (Figure 8) [114]. Extracutaneous involvement is seen in approximately 30% of patients.
Systemic vasculitis shows a predilection for certain organs, such as the kidneys and lungs. In most
cases, leucocytoclastic vasculitis is mediated by immunocomplex deposition, with the antigen being
either exogenous or endogenous [115–118].
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Figure 8. Vasculitis. Palpable purpuric papules on the lower extremities.
When leukocytoclastic vasculitis is suspected, a biopsy should be performed, preferably in the
first 24 to 48 h of lesion onset. Additionally, direct immunofluorescence should be performed to
evaluate for the presence of immunoglobulins. If no systemic symptoms are present, laboratory testing,
including a complete blood count, measurement of the erythrocyte sedimentation rate, basic metabolic
panel, liver function tests, and urinalysis should be done as well. If there is concern for systemic
involvement, more extensive workup can be fulfilled. Around 90% of leukocytoclastic vasculitis cases
are self-limited, showing spontaneous resolution within weeks to months. The treatment depends on
the severity of the disease and can range from an oral corticosteroid course to various steroid-sparing
agents [113,114].
There are sporadic reports about the association between CD and cutaneous vasculitis
(CV) [115–119]. The coexistence of these two entities might be related to increased intestinal
permeability [120], and immune complexes, originating from exogenous or endogenous antigens,
might circulate because of the impaired phagocytic function of the reticular endothelium system and be
deposited in the skin. As seen in inflammatory bowel disease (IBD), exogenous antigens may permeate
the damaged CD mucous in larger quantities than normal. This is reflected by significant serum milk
and gluten fraction antibody titers. Moreover, autoimmune sensitization may result because of the
release of endogenous antigens from the damaged small bowel mucosa. Meyers et al. [118] described
a case of CV associated with CD and the remission of skin lesions after the treatment with a strict GFD.
Treatment with a GFD may improve CV lesions in cases associated with CD [9–11].
11. Other Skin Conditions Found in Patients with CD
As reported by Humbert et al. and Caproni et al., in addition to skin diseases with proven
association with CD and those improved by a GFD and/or with positivity of celiac serological markers,
there are also fortuitous associations with other skin conditions [9–11]. Some of these associations are
more common than others.
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Juvenile dermatomyositis and dermatomyositis have been reported in association with CD in
adult patients. In particular, when patients are newly diagnosed with these conditions, even in the
absence of gastrointestinal symptoms, screening for CD should be performed. Clinical manifestations
of dermatomyositis may respond to a GFD [121–124].
The possible association between CD and vitiligo is controversial. There are few cases that have
reported the improvement of vitiligo in patients that started a GFD. A common basic autoimmune
mechanism has been hypothesized [125,126].
Many similarities exist between the pathogeneses of CD and SLE, but it is still unknown whether
there is a true association or not [127–129].
Other reported and less frequent associations include lichen planus and lichen sclerosus [130–138],
linear IgA bullous dermatosis [139,140], prurigo nodularis [141], pityriasis rubra pilaris and
erythroderma [142], erythema elevatum diutinum [143–145], necrolytic migratory erythema [146–148],
pityriasis lichenoides [140], erythema nodosum [140,149–151], porphyria [152,153], cutaneous
amyloidosis [154], generalized acquired cutis laxa [155,156], acquired hypertrichosis lanuginosa [157],
ichthyosis [158], partial lipodystrophy [159], transverse leukonychia [160], atypical mole syndrome,
and congenital giant nevus [161]. Finally, we want to mention that earlier studies reported an increased
risk of malignant melanoma in patients with CD, but a recent study refuted this relation [162].
12. Other Oral Cavity Disorders
Other oral cavity manifestations among patients with CD have also been described
[18,97–99,110,163,164]. Rashid et al. described oral and dental manifestations of CD, consisting
of enamel defects, delayed eruption, recurrent aphthous ulcers, cheilitis, and atrophic glossitis [96].
Bramanti et al. found atrophic glossitis, angular cheilitis, and burning tongue to be more frequent in
CD patients than in control patients [165].
13. Conclusions
CD is a systemic process of autoimmune nature that affects genetically predisposed people in
relation to a permanent intolerance to gluten and related proteins. It has a worldwide distribution, a
slight female predominance, and can appear at any age, with a variable clinical course, ranging from
subclinical or asymptomatic cases to very severe ones. In the physical examination of these patients, it
is very important to recognize the presence of several types of dermatitis which are found in association
with CD, such as urticaria (HR: 1.51, CI: 1.36–1.68), chronic urticaria (HR: 1.92, CI: 1.48–2.48), atopic
dermatitis (OR: 3.17, CI: 1.02–9.82), psoriasis (HR: 1.72, CI = 1.54–1.92), aphthous stomatitis (OR: 3.79,
CI = 2.67–5.39) and rosacea (HR: 1.46, CI = 1.11–1.93), and other skin affectation processes that are
not so clearly related to CD. All of these diseases may occur in the form of outbreaks, accompanied
generally by pruritus, which negatively affects their quality of life. Their relationship with gluten is
through allergic, inflammatory, immunological, and mixed processes. The recognition of their probable
relationship facilitates the diagnosis of CD, and the establishment of a GFD improves the evolution of
cutaneous lesions and in some cases, full recovery is achieved.
It is very important to emphasize that the classic presentations of CD with associated
malabsorption syndrome are currently considered to be exceptional, especially from the age of two
years, and the predominant forms are those with mild, fluctuating, or even absent digestive symptoms
and a wide range of extra-intestinal manifestations [166–170]. Many undiagnosed celiac patients
underestimate their multiple and frequent discomfort from digestive and more general causes because
they have grown accustomed to living with a state of chronic poor health as though it is normal.
They are only able to recognize that they really did have symptoms related to the consumption of
gluten when they start the GFD and the improvement becomes obvious [171,172].
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Abstract: Celiac disease is a small intestinal inflammatory disease with autoimmune features that is
triggered and maintained by the ingestion of the storage proteins (gluten) of wheat, barley, and rye.
Prevalence of celiac disease is increased in patients with mono- and/or polyglandular autoimmunity
and their relatives. We have reviewed the current and pertinent literature that addresses the close
association between celiac disease and endocrine autoimmunity. The close relationship between
celiac disease and glandular autoimmunity can be largely explained by sharing of a common genetic
background. Further, between 10 and 30% of patients with celiac disease are thyroid and/or type 1
diabetes antibody positive, while around 5–7% of patients with autoimmune thyroid disease, type 1
diabetes, and/or polyglandular autoimmunity are IgA anti-tissue transglutaminase antibody positive.
While a gluten free diet does not reverse glandular autoimmunity, its early institution may delay or
even prevent its first manifestation. In conclusion, this brief review highlighting the close association
between celiac disease and both monoglandular and polyglandular autoimmunity, aims to underline
the need for prospective studies to establish whether an early diagnosis of celiac disease and a prompt
gluten-free diet may positively impact the evolution and manifestation of glandular autoimmunity.
Keywords: celiac disease; glandular autoimmunity; autoimmune thyroid disease; type 1 diabetes;
polyglandular autoimmune syndrome
1. Celiac Disease
Celiac disease (CeD) is defined as a life-long intolerance to dietary gluten that results in small
intestinal inflammation, villous atrophy, crypt hyperplasia, and often malabsorption. The ingestion of
gluten containing cereal grains, mainly wheat, rye, and barley, drives this T cell driven auto-destructive
process within the small intestinal mucosa which usually recovers when these cereals and gluten are
rigorously withdrawn from the diet [1–4].
At least 50% of CeD is diagnosed in adulthood, and in the majority of adolescents and
adults clinical features at diagnosis are subtle, with mild abdominal discomfort, fatigue, low bone
mineralisation and hypocalcaemia, and only rarely manifest anemia, weight loss, infertility, or recurrent
aphtous stomatitis. However, up to one third of adults suffer from one or more CeD-associated
autoimmune diseases, prominently with autoimmune thyroid disease (AITD) and type 1 diabetes
mellitus (T1D), but also rheumatoid diseases including systemic lupus erythematodes, Sjoegren’s
syndrome, autoimmune liver diseases, and others [5]. Severe complications, like refractory CeD type 2,
a premalignant condition, and overt enteropathy-associated T-cell lymphoma, occur in patients with
longstanding undetected and untreated CeD, but remain rare [6,7]. Iron, zinc, vitamin D, vitamin
B12, or folic acid deficiency, iron deficiency or overt anemia are the most common laboratory finding.
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Frequent episodes of hypoglycemia, a reduction of insulin requirements and brittle diabetes may
indicate the presence of CeD in patients with T1D [8]. CeD is considered sufficiently prevalent and the
benefits of diagnosis and treatment by gluten withdrawal are such that it is advocated to screen all
patients with T1D (and autoimmune thyroid disease) for this disorder.
Both endoscopic-histological diagnosis and the presence of circulating IgA antibodies (Ab) to
tissue transglutaminase (TG2) confirm the diagnosis. As shown in Table 1, anti-transglutaminase
antibodies may be of IgG isotype in the presence, but also in the absence of a selective IgA deficiency.
This suggests that the gluten-triggered autoantibody response shows mucosal IgA as its main
component, while systemic IgG may represent a long-term reaction probably related to the occurrence
of extra-intestinal manifestations. Consistently, it has been reported previously that the prevalence of
CeD in T1D increases dramatically when the detection of both IgA and IgG autoantibodies is used in
the screening. After a gluten-free diet the IgA-TG2-Ab disappear in most patients with CeD, usually
with a half-life between 30 and 60 days.
Table 1. Autoimmune disease specific antibodies.
Disease Autoantibodies











Genetic factors greatly determine susceptibility to CeD. All CeD patients carry HLA DR3/DQ2
(mainly DQA1*0501-DQB1*0201; 85–95%), or HLA DR4/DQ8 (DQA1*0301-DQB1*0302; 5–15%),
or both haplotypes [1–3]. Exceptions are certain Native American populations that mainly carry
DQ8 [9]. Since, e.g., the prevalence of HLA DQ2 in most populations is between 25 and 50%, only
a minority with this necessary but insufficient genetic predisposition will ever develop CeD. This
implies the involvement of additional, non-HLA linked genes, as well as environmental factors in CeD
manifestation, as discussed below.
The ubiquitous enzyme TG2, the CeD autoantigen, is central to the pathogenesis of CeD, since
it can deamidate specific glutamine residues in certain gluten peptides that remain undigested and
reach the subepithelial small intestinal lamina propria. This deamidation of the gluten peptides and
their haptenization by binding to TG2 itself (autocatalysis) thereby increases their affinity to DQ2 or
DQ8 on professional antigen presenting cells like macrophages, dendritic, and B cells, favoring the
subsequent gluten specific destructive T cell response [1,10–12].
2. Monoglandular and Polyglandular Autoimmunity
Patients with CeD show a high prevalence of glandular autoimmune disorders [13–16]. CeD
is associated with T1D, AITD i.e., Hashimoto’s thyroiditis (HT), Graves’ disease (GD), and the
polyglandular autoimmune syndrome (PAS) [17].
2.1. Type 1 Diabetes
T1D is a T-cell mediated glandular autoimmune disease that develops in genetically susceptible
individuals and results in destruction of the insulin-producing β cells. Of T1D patients, 15–30%
have AITD and 3–12% present with CeD [18]. The close relationship between CeD and glandular
autoimmunity can be widely explained by sharing of a common genetic background. However,
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some common pathogenic mechanisms have been further implicated, such as increased intestinal
permeability resulting from zonulin upregulation and dysfunction of tight junctions in both CeD
and T1D [19]. T1D is characterized by the infiltration of the pancreatic islets by lymphocytes and
macrophages, the presence of autoantibodies to islet cell antigens (ICA), tyrosine phosphatase (IA2),
glutamic acid decarboxylase-65 (GAD), insulin (IAA), and zinc transporter ZnT8 (Slc30A8), an increased
prevalence of organ-specific autoimmune disorders in T1D, a preferential occurrence of T1D in persons
carrying specific allelic combinations at immune response loci within the HLA gene complex. The
disease can be transferred by spleen or bone marrow cells and animal models of T1D show a defect in
immunoregulation contributing to the onset of disease [20].
2.2. Hashimoto’s Thyroiditis
HT is currently the most common autoimmune disease and frequently clusters with other
autoimmune endocrinopathies. It is defined by the presence of thyro-peroxidase (TPO) or thyroglobulin
(Tg) Ab and either normal or elevated serum thyroid stimulating hormone (TSH) concentrations.
The majority of patients with HT are hypothyroid; however there is a subgroup of thyroid
Ab-positive cases who are euthyroid. HT frequently occurs with T1D, with a prevalence of 13–20%
of subclinical hypothyroidism in T1D patients compared with 3–6% in a non-diabetic population.
Overt hypothyroidism is present in 4–18% of subjects with T1D. TPO-Ab are present in 15–30% of
adults and in 5–22% of children with T1D, compared with 2–10% and 1–4%, respectively, in healthy
controls. Up to 50% of TPO-Ab positive T1D patients progress to overt AITD. As many as 30% of
patients with T1D develop AITD. Age, duration of T1D, and female preponderance impact the link
between T1D and AITD [21,22]. In a prospective controlled study, celiac patients had an increased risk
of thyroid autoimmune disorders when compared to non-celiac controls on normal gluten-containing
diet [23]. However, in this Scandinavian trial, a gluten-free diet seemed not to prevent the progression
of autoimmune process during a follow-up of one year.
2.3. Graves’ Disease
GD is meanwhile less prevalent than HT; it affects approximately 1–1.5% of the general population
worldwide and is the underlying cause of 50–80% of cases of thyrotoxicosis. GD and HT share many
immunological features, including high serum concentrations of Ab against Tg and TPO. GD is caused
by TSH receptor stimulating Ab [24–26] that bind to and activate the TSH receptor on thyroid cells.
These Ab not only cause hypersecretion of thyroid hormone, but also promote hypertrophy and
hyperplasia of thyroid follicles, resulting in an enhanced vascularization of the gland and in a diffuse
goiter. Women are five to ten times more at risk of developing GD than men, due to the relevant
involvement of sex hormones. Also, stress and negative life events are regarded as risk factors for
GD and may trigger the disease. Subclinical endogeneous hyperthyroidism can be diagnosed in
6–10% of T1D patients, compared with 0.1–2% in the non-diabetic population. The incidence of overt
autoimmune hyperthyroidism in persons with a suppressed serum TSH is calculated at 2–4% per
year [27].
2.4. Polyglandular Autoimmune Syndrome
The association of two or more glandular autoimmune diseases is designated as PAS. Especially
in adults, the presence of one autoimmune endocrine disorder increases the risk of developing
other autoimmune diseases. CeD is a strong predictor not only of glandular but also polyglandular
autoimmunity. PAS shows a great heterogeneity of syndromes and usually manifests sequentially, with
a variable time interval between the occurrence of the first and second glandular autoimmune disease
component. It also clusters with several non-endocrine autoimmune diseases [28]. PAS is divided into
two major subtypes, which are distinguished according to age of presentation, characteristic patterns
of disease combinations and different modes of inheritance. Juvenile PAS I, also known as autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy, usually manifests in infancy or childhood
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at age three to five years, or in early adolescence, It is characterized by a persistent fungal infection
(chronic mucocutaneous candidiasis), the presence of acquired hypoparathyroidism and adrenal
failure. In most patients mucocutaneous candidiasis precedes the other immune disorders, usually
followed by hypoparathyroidism. The female-to-male ratio varies from 0.8:1 to 2.4:1. The highest
prevalence of PAS I has been found in populations characterized by a high degree of consanguinity or
descendants of small founder populations, particularly in Iranian Jews and Fins. PAS I is a monogenic
disease with autosomal recessive inheritance caused by mutations in the autoimmune regulatory
gene (AIRE) on chromosome 21. Adult PAS occurs mainly in the third or fourth decade. Adult PAS
subtype II encompasses adrenal failure or Addison’s disease (AD) with other autoimmune endocrine
disorders, i.e., AITD and/or T1D. AD may precede other endocrinopathies. In contrast to the juvenile
type, family members of adult PAS II patients are often affected. PAS II is believed to be polygenic,
characterized by autosomal dominant inheritance [29–34].
The adult PAS type III is the most frequent PAS type and is characterized by AITD and
T1D and the absence of AD. In contrast, the poorly defined PAS type IV is very heterogeneous
involving a large variety of glandular autoimmune diseases that are not considered within adult
PAS types 2 and 3. Being less well defined, it is often incorrectly described as a combination of
monoglandular autoimmune disease with one non-glandular autoimmune disease. In fact, PAS type
IV includes various combinations of autoimmune hypopituitarism, hypergonadotropic hypogonadism,
or hypoparathyroidism with T1D or an AITD. The adult form of PAS has a prevalence of 1:20,000,
and is far more prevalent than the juvenile type, with an annual incidence of 1–2:100,000. The gender
ratio of adult PAS types II–IV shows a female predominance of 75% [35,36]. The manifestation
peaks in the fourth and fifth decade depending on the combination of the various autoimmune
endocrinopathies [37].
Even if the time between the manifestations of CeD and other autoimmune endocrinopathies, as
well as the time until a PAS can be diagnosed, is highly variable, many patients with one autoimmune
disease already have Ab against other, often endocrine, tissues (Table 2). The reason is the tendency of
autoimmune diseases to associate with one another, especially when they share a genetic basis, of the
metachronous manifestations of the component diseases, and of the often subclinical initial course.
Mainly first but also second degree family members of patients are often at risk for developing related
autoimmunities and are already Ab positive.
Table 2. Prevalence of autoimmune thyroid disease auto-antibodies in patients with celiac disease.






Tg Ab, N = 12 11.2
[38]TMA, N = 16 15
70 TMA, N = 15 21 [39]
47 TPO, N = 14 29.7 [40]
34
TMA, N = 5 14.7
[41]Tg Ab, N = 11 32.4
TPO, N = 4 11.8
90 TPO, N = 13 14.4 [42]
36 TPO, N = 11 30.5 [43]
Modified according to reference [44]. CeD: celiac disease, Tg-Ab: thyroglobulin antibodies; TMA: thyroid
microsomal antibodies; TPO-Ab: thyro-peroxidase antibodies.
3. The Role of a Gluten Free Diet in Preventing Celiac Disease and Glandular Autoimmunity
A large prospective study demonstrated that in infants at genetic risk for CeD and T1D (i.e.,
from families with at least one affected parent and the DR3/DQ2 and/or DR4/DQ8 risk genes) a
careful early introduction of 100 mg gluten per day in the diet from month 5–6 did not prevent celiac
autoimmunity compared to placebo [45]. Moreover, the introduction of gluten at 12 instead of 6
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months of age only delayed the onset of CeD, with similar prevalences at age 5 years [46]. However,
a retrospective study indicated that patients on a long-term gluten free diet developed 50% fewer
autoimmune diseases in up to 15 years of follow up [47]. The (retrospective) studies that examined the
effect of a gluten free versus gluten containing diet on the development and severity of T1D and AITD
remain controversial (Tables 3 and 4). Interestingly, T1D appears to precede the development of CeD,
as determined by IgA-TG2 Ab positivity, which would assign a less important role to the gluten free
diet in the prevention of glandular autoimmunity [19].
Table 3. Gluten exposure and occurrence of type 1 diabetes.





90 2 NE Yes [42]
44 1.6 No Yes [48]
383 7.6 No NE [49]
1183 0.9 NE Yes [50]
19796 NE No NE [51]
4322 NE No NE [52]
150 3 NE Yes [53]
Table 4. Gluten exposure and occurrence of autoimmune thyroid disease (AITD).





909 >0.5 Yes NE [42]
44 1.6 No Yes [48]
66 1–5 Yes Yes [54]
343 0.25–16 NE No [55]
324 8 Yes No [56]
135 8.9 No No [57]
545 2 No No [58]
335 9 No No [59]
Dx: diagnosis; GFD: gluten free diet; NE: not evaluated.
Several mainly retrospective and correlative studies, often based on registries, have tried to
address the question, how far an early diagnosis of CeD and/or a gluten free diet may protect from
AITD or T1D. As shown in tables 3 and 4, in these studies early diagnosis of CeD did not appear to
protect from the development of T1D [42,48–53]; whereas some studies suggested such protection in
AITD [42,48,54–59]. In comparison, a gluten free diet (GFD) may positively impact the occurrence
of T1D rather than of AITD. These somewhat conflicting data need validation in large, prospective
studies with well-defined diagnosis and markers of CeD, T1D, and AITD. Such studies are currently
performed in children with an increased risk for the three diseases (being offspring of affected parents
and carrying the DQ2 and/or DQ8 genes. However, a beneficial effect of a gluten free diet may be
expected, since in general, in children as well as in adults, intestinal inflammation and the associated
dysbiosis, with or without underlying CeD, are known to promote extra intestinal autoimmune
diseases [60–62]. Therefore, any measure that would dampen gut inflammation in CeD patients will
likely positively impact the evolution and perhaps the manifestation of glandular autoimmunity.
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Abstract: Previously thought to be mainly a disorder of childhood and early adult life, coeliac
disease (CeD) is increasingly diagnosed in older adults. This may be important given the association
between CeD and osteoporosis. The primary aim of this study was to determine the seroprevalence of
undiagnosed CeD (‘at-risk serology’) in an older Australian community and relate this to a diagnosis
of osteoporosis and fractures during a follow-up period of 12 years. We included participants
from the Hunter Community Study (2004–2007) aged 55–85, who had anti-tissue transglutaminase
(tTG) titres, human leukocyte antigen (HLA) genotypes, and bone mineral density measurements
at baseline. Follow-up data included subsequent diagnosis of CeD and fractures using hospital
information. ‘At-risk’ serology was defined as both tTG and HLA positivity. Complete results were
obtained from 2122 patients. The prevalence of ‘at-risk’ serology was 5%. At baseline, 3.4% fulfilled
criteria for a diagnosis of osteoporosis. During a mean of 9.7 years of follow-up, 7.4% of the cohort
suffered at least one fracture and 0.7% were subsequently diagnosed with CeD. At-risk serology was
significantly associated with osteoporosis in a multivariate model (odds ratio 2.83, 95% confidence
interval 1.29–6.22); there was insufficient power to look at the outcome of fractures. The results
of this study demonstrate that at-risk CeD serology was significantly associated with concurrent
osteoporosis but not future fractures. Most individuals with a serological diagnosis of CeD were not
diagnosed with CeD during the follow-up period according to medical records. Coeliac disease likely
remains under-diagnosed.
Keywords: coeliac disease; osteoporosis; fractures
1. Introduction
Coeliac disease (CeD), once considered rare, is now estimated to affect 1–2% of the population
in Western countries [1,2]. It is an immune-mediated systemic condition, manifested by small
intestinal enteropathy triggered by exposure to gluten (a complex of water insoluble proteins in
wheat, rye, and barley) in the diet [1]. CeD occurs almost exclusively in those who are genetically
predisposed with the haplotypes human leukocyte antigen (HLA)-DQA1*05-DQB1*02 (DQ2) and/or
Nutrients 2018, 10, 849; doi:10.3390/nu10070849 www.mdpi.com/journal/nutrients93
Nutrients 2018, 10, 849
DQA1*03-DQB1*03:02 (DQ8) [1]. Previously thought to be a childhood disorder, CeD is increasingly
diagnosed in older patients with longstanding atypical symptoms in whom the diagnosis has not
previously been pursued [3,4]. The reported biopsy proven prevalence in older populations (over
55 years) has been reported to be 0.1–2.3% [5]. This may be important given the known association
between CeD and diseases such as cancer and osteoporosis [6]. A recent study on case finding in the
general community for individuals with undiagnosed CeD showed that these subjects were more
likely to develop osteoporosis [7].
Osteoporosis is characterized by low bone mineral density (BMD) and architectural distortion
of bone tissue that leads to bone fragility and an increased risk of fractures [8]. Age and gender are
the major risk factors for the condition, which predominantly affect post-menopausal females [9].
Osteoporosis is a major public health problem, and over 4.7 million Australians over the age of 50 have
low BMD [10]. This results in fractures, with over 140,000 fractures occurring in 2012 attributed to
osteoporosis [10]. This is estimated to cost the Australian health care system over AU$3 billion per
year [10].
Osteoporosis is common in CeD, and approximately 40% of patients with newly diagnosed CeD
demonstrate a low BMD [11]. Patients with CeD are at higher risk of osteoporotic fractures [12], a risk
which persists after diagnosis [13,14] for up to 20 years [15], although the absolute increase in fracture
risk is low [12,16]. Importantly, BMD improves with a gluten free diet [17–19], although recovery
is slow, taking up to 5 years to obtain complete recovery [20], in line with the slow rate of mucosal
recovery in CeD [21]. The degree of adherence to the gluten free diet [18], and degree of mucosal
damage at follow-up [22], has been shown to correlate with the degree of BMD recovery.
The aim of this study was to determine the seroprevalence of undiagnosed CeD in an older
Australian community and relate this to a diagnosis of osteoporosis and fractures during long-term
follow-up. Secondary aims included evaluation of the association between at-risk serology at baseline,




The research was approved by the Human Research Ethics Committees of the Hunter New
England Local Health District and the University of Newcastle, Australia.
2.2. Participants
Data for this study is from the Hunter Community Study, a prospective cohort of
community-dwelling older men and women (aged 55–96 years) from Newcastle, New South Wales,
Australia. The sample characteristics and recruitment strategy has been described previously in
detail [23]. Participants were randomly selected from the electoral roll between 2004 and 2007 and
recruited using a modified Dillman strategy which included two letters of invitation followed by a
phone call to non-responders. Invitation letters were sent to 9784 individuals, of whom 7575 responded
and 3877 agreed to participate. A total of 3253 eventually participated in the study (a response rate of
44.5%). The sample has been shown previously to be comparable to the general Australian population
in terms of gender and marital status, but is slightly younger in age [23].
2.3. Baseline Measures
Several self-report questionnaires were sent to participants at baseline, covering demographics,
self-reported diseases, and prescribed and over the counter medication use. Anthropometric
measurements including standing height (measured from the floor to the vertex of the head) and
weight (measured using Tanita digital scales, Tanita, IL, USA) were taken at an initial face-to-face
clinic visit. Bone mineral density was measured by heel ultrasound using the Sahara clinical bone
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sonometer (Holologic, Bedford, MA, USA) [24]. Osteoporosis was defined as a T score of less than
or equal to −2.5 [25]. A measurement of functional capacity was performed by a ‘timed up and go
test’ [26]. Physical activity was measured using a pedometer worn for seven consecutive days during
waking hours to record step count [23]. Samples of serum and plasma were taken for serological
measures (including anti-tissue transglutaminase (anti-tTG) antibodies, anti-nuclear antibodies (ANA),
and anti-thyroid peroxidase antibodies (TPO)). Samples of serum and plasma were cryopreserved in
1 mL aliquots at −80 degrees Celsius and subsequently thawed for serological measures (including
anti-tTG antibodies, anti-nuclear antibodies (ANA), and anti-thyroid peroxidase antibodies (TPO)), as
well as DNA isolation and genotyping. Hazardous alcohol intake was defined for males and females,
respectively, as greater than five or seven standard drinks per day or more than seven or eleven drinks
on any occasion based on national guidelines [27]. Current smoking status was self-reported.
2.4. Follow-Up Measures
Non-traumatic fractures during follow-up were determined using linkage with hospital inpatient
codes arising from contact with both public and private hospitals in the state of NSW from enrolment
until 2017; data were obtained from the Centre for Health Record Linkage (CHeReL). Fractures were
excluded if they were associated with a hospital code for trauma. A subsequent diagnosis of CeD
was determined by self-report at follow-up contact made at 5 and 10 years and using hospital
inpatient codes (ICD_10). Details regarding medications targeting low bone density (including
hormone replacement therapy, selective estrogen receptor modulators, bisphosphonates, denosumab,
or teriparatide) were available via linkages with the national Pharmaceutical Benefits Scheme (PBS)
as well as through self-reporting at baseline and follow-up. Date of death was obtained through the
National Death Index.
2.5. Coeliac Serology and Genotype
Anti-tissue transglutaminase antibody levels (anti-tTG) were measured by the hospital reference
laboratory on enrolment to the study, using the AESKULISA human recombinant combined
Immunoglobulin A (IgA) and IgG anti-tTG assay (Aesku.Diagnostics, Wendelsheim, Germany).
A cut-off of ≥25 IU/mL was considered positive in line with the local reference laboratory.
HLA genotyping was performed on thawed samples using an Affymetrix Kaiser Axiom array
(ThermoFisher scientific, Waltham, MA, USA). Single nucleotide polymorphisms (SNPs) on
chromosome 6 were used to locate HLA-DQ-2.5 and 8. Three SNPs were selected for tagging the
HLA-DQ2.2 haplotype, and haplotype phasing for the three DQ2.2 tag SNPs was performed using
SHAPEIT software [28]. Those HLA-DQ2- or DQ8-positive were considered to have a permissive
genotype for CeD. “At-risk serology” for CeD was defined as a combination of anti-tTG antibodies
greater than or equal to 25 IU/mL, and a permissive genotype for CeD (positive HLA-DQ2.2,
2.5 or DQ8).
2.6. Autoimmune Serology
ANA was assessed using HEp-2 ANA slides (Bio-Rad Laboratories, Hercules, CA, USA); ANA titre
of >1/160 was defined as positive. TPO-Abs were analysed by ELISA testing (Aesku.Diagnostics,
Wendelsheim, Germany).
2.7. Statistical Analysis
Statistical analysis was performed using STATA software (StataCorp, Texas, USA). Confidence
intervals were calculated using the binomial exact method. Two models examining the association
between “at-risk serology” and osteoporosis and fractures, respectively, were constructed; adjustment
for several other potential risk factors was based on pre-designed directed acyclic graphs [29]
(see Appendixs A and B). Given that there was no difference in the mean follow-up times or mortality
between at-risk serology groups, simple and multiple unconditional logistic regression was used.
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No multivariate analysis was conducted for the outcome of fractures according to the direct acyclic
graph in order to avoid over adjustment bias for the exposure of at-risk serology (see Appendix B).
3. Results
3.1. Sample Characteristics
Of the original sample, 2121 had serum available for serology and genotype analysis and were
included in the study. The included sample was slightly older (mean age 75.9 vs. 75.3 years, p < 0.0001)
and more likely to be female than the original cohort (58.2% vs. 50.0%, p < 0.0001). The mean follow-up
time was 9.7 years (range 0.2–12.4 years).
3.2. Prevalence of ‘At-Risk’ Serology, Osteoporosis, and Fracture during Follow-Up
Of the 2121 participants included in the analysis, 59.1% (95% confidence interval (CI) 56.7–61.2)
had a permissive genotype and 7.3% (95%% CI 6.2–8.4) were determined to have a positive anti-tTG,
with 0.8% having a high titre anti-tTG (>10 time the upper limit of normal) [21]. The mean anti-tTG
was 11.4 IU/mL (range 1–313). In the entire cohort, 22.3% (95% CI 20.5–24.1) possessed at least one
allele of HLA-DQ2.2, 27.2% (95% CI 25.3–29.1) possessed at least one HLA-DQ2.5 allele, and 18.9%
(95% CI 17.3–20.6) possessed at least one HLA-DQ8 allele. ‘At-risk serology’ was present in 5.0%
(95% CI 4.1–6.0), and 2.3% of participants who had positive anti-tTG but a non-permissive genotype
for CeD (see Figure 1). Of those with a high titre anti-tTG, 88% (15/17) had a permissive HLA. There
was no difference between those with and without at-risk serology in terms of mean follow-up time
(p = 0.50).
Figure 1. Overlap between participants with positive anti-tissue transglutaminase (anti-tTG) serology
and permissive human leukocyte antigen (HLA) genotype from the overall sample of 2121 subjects.
A diagnosis of osteoporosis was present in 3.4% (95% CI 2.6–4.2) of participants at baseline
(2.2% in males, 3.6% in females). At least one fracture (limb or other) occurred in 7.4% (95% CI 6.3–8.7)
of participants (n = 1883) during follow-up (see Figure 2). Of those with a baseline diagnosis of
osteoporosis, 10.2% received medication targeting bone density during the study period. Diagnosis
of CeD during follow-up was reported in only 0.7% (95% CI 0.4–1.1) of participants (n = 2081),
representing only 5.8% of the at-risk serology group. By the end of the follow-up period, 14.1% of
the cohort had died, with no significant difference between those with and without at-risk serology
(15.2% vs. 14.1%, p = 0.74).
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Figure 2. Overlap between participants with positive anti-tissue transglutaminase (tTG) serology,
permissive HLA genotype, and fractures during the follow-up period from the overall sample of
1883 subjects.
3.3. Association between Coeliac Serology and Other Autoimmune Markers
Positive anti-tTG antibodies were associated with positive TPO antibodies but not ANA. In those
with positive anti-tTG antibodies, 9.5% had a positive ANA compared with 6.8% of those without
(p = 0.07), and 17.5% had a positive TPO antibodies compared with 10.0% without (p = 0.003).
3.4. Osteoporosis
In a univariate analysis, at-risk serology was associated with a diagnosis of osteoporosis at
baseline (Odds Ratio [OR] 2.56, 95% CI 1.19–5.49) (see Table 1). Other factors significantly influencing
the presence of osteoporosis at baseline included positive anti-tTG, age, gender, body mass index
(BMI), and alcohol intake (see Table 1); no significant association was found for smoking or physical
activity. In the multivariate model, at-risk serology, BMI, gender, smoking status, and age, but not
alcohol intake, were all significantly associated with osteoporosis (see Table 2).
Table 1. Univariate analysis of risk factors associated with osteoporosis (OP). Risk factors are
expressed as percentages in the osteoporotic and non-osteoporotic groups unless otherwise specified.
CI—confidence interval. SD—standard deviation. BMI—body mass index.
OP—%(95% CI) No OP—%(95% CI) Odds Ratio (95% CI)
At-risk serology 11.3 (3.7–18.8) 4.7 (3.8–5.7) 2.56 (1.19–5.49)
Anti-tTG (IU/mL); mean (SD) 20.3 (50.4) 11.1 (31.0) 1.01 (1.00–1.01)
Positive anti-tTG 15.5 (6.9–24.1) 7.0 (5.9–8.1) 2.44 (1.26–4.75)
Positive HLA 63.4 (51.9–74.9) 59.0 (56.8–61.1) 1.20 (0.74–1.97)
Age (years); mean (SD) 80.2 (7.4) 75.8 (7.2) 1.08 (1.05–1.11)
BMI (kg/m2); mean (SD) 27.3 (5.3) 28.8 (4.9) 0.93 (0.88–0.98)
Gender (male) 36.6 (25.1–48.1) 50.4 (48.3–52.6) 0.57 (0.35–0.93)
Current smoker 6.1 (5.1–7.2) 9.9 (2.8–17.0) 1.67 (0.75–3.72)
Hazardous alcohol intake 1.4 (0.0–4.2) 9.7 (8.4–10.9) 0.13 (0.02–0.97)
Physical activity (step count per day); mean (SD) 6160 (5106–7216) 6700 (6530–6871) 1.00 (1.00–1.00)
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Table 2. Odds ratios from the multivariate analysis of factors associated with osteoporosis.
Odds Ratio 95% CI p Value
At-risk serology 3.09 1.32–7.23 0.009
BMI 0.94 0.89–1.00 0.04
Gender (male) 0.51 0.29–0.89 0.02
Current smoking 3.22 1.36–7.61 0.008
Hazardous alcohol intake 0.22 0.30–1.66 0.14
Age 1.08 1.04–1.12 <0.001
3.5. Fracture Risk
In those with osteoporosis, 21.2% sustained a fracture during the follow-up period, compared
with only 6.9% of the non-osteoporotic group (p < 0.001). There was no significant difference in the
rate of fractures in those with at-risk serology compared to those without (4.1% vs. 7.6%, p = 0.2)
(see Figure 2). None of the subjects with a high titre anti-tTG sustained a fracture during the follow-up
period. In the univariate analysis, fracture during follow-up was also significantly associated with age
and gender, but not BMI, smoking status, alcohol intake, physical activity, or the timed up and go test
(see Table 3). A multivariate analysis was not performed in order to avoid over adjustment bias in
accordance with the pre-constructed directed acyclic graph.
Table 3. Univariate analysis of factors associated with fractures during the follow-up period
(n = 1, 883). Risk factors are expressed as percentages in the fracture and no-fracture groups unless
otherwise specified.
Fracture—% (95% CI) No Fracture—% (95% CI) Odds Ratio (95% CI)
Osteoporosis (baseline) 10.0 (5.0–15.0) 3.0 (2.2–3.8) 3.6 (1.9–6.7)
At-risk serology 2.9 (0.1–5.7) 5.3 (4.3–6.4) 0.52 (0.19–1.44)
Anti-tTG (IU/mL); mean (SD) 8.0 (5.1–10.8) 11.6 (10.1–13.2) 0.99 (0.98–1.00)
Positive anti-tTG 5.0 (1.3–8.7) 7.5 (6.3–8.8) 0.64 (0.30–1.41)
Positive HLA 6.4 (5.6–7.2) 5.9 (5.7–6.2) 1.2 (0.9–1.8)
Positive tTG with non-permissive HLA 2.3 (−0.3–4.6) 2.2 (1.5–2.9) 0.98 (0.30–3.22)
Age (years); mean (SD) 80.4 (79.0–81.7) 76.0 (75.6–76.3) 1.08 (1.06–1.11)
BMI (kg/m2); mean (SD) 28.9 (27.9–29.9) 28.9 (28.6–29.1) 1.00 (0.97–1.04)
Gender (male) 33.6 (25.7–41.5) 51.7 (49.3–54.0) 0.47 (0.33–0.68)
Current smoker 5.0 (1.3–8.7) 6.0 (4.9–7.1) 0.83 (0.38–1.82)
Hazardous alcohol intake 7.1 (2.8–11.5) 9.8 (8.4–11.2) 0.71 (0.36–1.37)
Physical activity (step count per day); mean 6282 (5554–7101) 6615 (6433–6797) 1.00 (1.00–1.00)
Timed up and go test (seconds) 10.7 (10.0–11.4) 9.9 (8.8–11.1) 1.00 (1.00–1.01)
4. Discussion
We report a high prevalence of at-risk serology, with 5% of the sample having an elevated anti-tTG
and a permissive genotype for CeD. However, 2.3% of the cohort returned a positive anti-tTG in the
absence of permissive genotype, likely representing false positives. It follows that a proportion of
the ‘at-risk’ group would not have CeD if gastroscopy and duodenal biopsy were undertaken. This is
consistent with a previous seroprevalence study from Australia by Anderson et al. [30], which reported
anti-tTG IgA antibody positivity in 5.7% of a general population cohort (median age 54–56 years in
two combined cohorts), in whom approximately one-third had a non-permissive genotype for CeD.
The eventual prevalence of CeD in this cohort, estimated based on biopsy or extended serological
screening, was 1.2–1.9%. They suggested that in those who screen positive on anti-tTG, testing for
HLA-DQ status would reduce unnecessary gastroscopies due to false positive serology by 40% [30].
Our findings of similarly high rates of positive anti-tTG in the presence of non-permissive genotype
support these observations.
Second generation anti-tTG assays, employing human purified or human recombinant anti-tTG
antigen (as used in our assay) have been shown to be highly sensitive and specific, with a positive
predictive value of 85–100% [31,32]. These studies, however, are generally performed in cohorts
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with a high prevalence of disease and therefore high pre-test probabilities for an eventual diagnosis,
and their performance in general population screening cohorts is likely to be lower [33]. Furthermore,
there are no studies, to our knowledge, examining the performance of these assays specifically in older
adults. Reports regarding false positive anti-tTG results are not uncommon, and high rates of false
positivity have been demonstrated in cohorts with other autoimmune diseases [34], inflammatory
bowel disease [35,36], congestive heart failure [37], and liver disease [38,39]. The link between
osteoporosis and chronic diseases such as these is well established [40], and may partially explain
the link between positive serology and osteoporosis, although we did not evaluate these conditions
in this study. High rates of autoimmune markers have been previously reported in our own cohort,
with 8% of the overall cohort testing positive for anti-TPO antibodies, and 27% testing positive for ANA
antibodies [41]. We observed higher rates of both ANA and TPO antibodies in those testing positive
for anti-tTG antibodies, although this result was only statistically significant for TPO antibodies and
approached significance (p = 0.07) for ANA. There are two potential explanations for this. The first is
that autoantibody findings are common in an ageing population, explaining the association between
these autoantibodies and a positive anti-tTG. The second, specifically in regard to thyroid specific
antibodies, is that CeD and autoimmune thyroid disease are associated [21,42], and the association
between these antibodies in our cohort represents an underlying association between undiagnosed
CeD and thyroid disease. Although some have called for serological diagnosis of CeD in adults
(without biopsy) [43], the observations reported here do not support this diagnostic approach in
older adults.
Whilst the worldwide prevalence of CeD is thought to be 1–2% [42], this may be higher in older
cohorts. A study by Vilppula et al. [6] of 2815 subjects over 55 years of age in Finland screened
participants for CeD using serology, with positive cases going on to have duodenal biopsy to confirm
the presence of CeD. They reported positive serology in 2.5% of the group, but only 2.1% were
subsequently biopsy proven. A subset of this group was rescreened again 3 years later, of whom six
had undergone seroconversion and five had developed biopsy proven CeD, representing an increase
in seroprevalence to 2.7% and a biopsy proven prevalence to 2.3%, and suggesting an incidence rate of
0.08% per year [6].
The link between biopsy proven CeD and osteoporosis is well established, with a prevalence
of around 40% [11]. We report an association between positive serology (in the absence of biopsy
confirmation) and osteoporosis. This is consistent with previous literature which has also associated
anti-tTG seropositivity with low bone mineral density. Duerksen et al. [44] retrospectively evaluated
376 women who had both coeliac serology (anti-endomysial /tTG Ab) and bone mineral density tested
(with bone mineral density preceding coeliac serology by at least 6 months). They reported higher
rates of osteoporosis (68% vs. 45%, p < 0.05) in seropositive compared with seronegative women,
respectively. This has also been confirmed in a study from the USA in which undiagnosed CeD patients
were more likely to develop osteoporosis and autoimmune conditions, heralding CeD in older life
rather than classic malabsorption [7].
A gluten free diet improves bone mineral density in CeD patients, with complete resolution of
low BMD in younger patients after two years treatment with a gluten free diet [45]. The addition of
bisphosphonates, traditionally the first line pharmacologic therapy for osteoporosis, has been shown
to be no more effective than a gluten free diet alone [46]. Other traditional adjunctive therapies,
such as exercise, have also been shown to contribute little to BMD recovery in the context of gluten
withdrawal [19]. This suggests that the pathogenesis of osteoporosis is different in CeD, and related
to malabsorption of nutrients involved in bone mineralisation such as vitamin D [47], rather than
hormonal regulation of bone architecture.
If indeed a relationship exists between CeD serology and osteoporosis, this may be mediated by a
combination of factors, including a subset with undiagnosed CeD who develop osteoporosis secondary
to enteropathy, malabsorption, and low-grade inflammation, as well as a relationship between chronic
diseases that increase the likelihood of having both osteoporosis and false positive CeD serology.
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There was no significant association between at-risk serology and fractures sustained during the
follow-up period (20,181 person years). However, with only four participants with at-risk serology
sustaining a fracture during follow-up, it is likely that the analysis was underpowered to evaluate
this outcome. A systematic review by Olmos et al. [12] of case-control and cross sectional studies
examining fracture risk in CeD, which included eight studies of 20,995 CeD patients and 96,777 controls,
reported a fracture risk of 8.7% in CeD and 6.15% in controls (OR 1.43, 95% CI 1.15–1.78). A more recent
meta-analysis by Heikkila et al. [48] limited to six prospective studies reported a slightly increased
risk of bone fractures (random effects estimate: 1.30, 95% CI 1.14–1.50). Few prospective studies
have examined the association between undiagnosed CeD and osteoporosis or fracture risk [48].
Agardh et al. [49] reported a study of 6480 women aged 50–64 years old (mean age 56 years) in
whom both BMD (by wrist dual X-ray absorptiometry) and anti-tTG measurements were taken;
they found that those with elevated tTG (≥17 IU/mL), representing approximately 0.9% of the sample,
were significantly more likely to have osteoporosis (13.4% vs. 6.5%, p = 0.008) and fracture risk (32% vs.
19%, p = 0.009).
This study has a number of strengths, including the relatively unique demographic profile of
the cohort, the availability of both serological measures and bone mineral density measurements
at baseline, as well as long-term follow-up allowing us to estimate fractures over a 12-year period.
One significant limitation of this study is the lack of confirmatory biopsy for the diagnosis of CeD.
We defined a subsequent diagnosis of CeD based on hospital coding information and self-report
at follow-up as available tools of diagnosis. As mentioned, the high rate of false positivity of the
anti-tTG assay means that a significant proportion of the ‘at-risk’ group are likely not to have CeD
on confirmatory biopsy. Another limitation of this study is the measurement of bone mineral density,
which was performed by heel ultrasound as opposed to dual X-ray absorptiometry (DXA) which is
considered the gold standard [50]. Although quantitative heel ultrasound performs well against DXA
in predicting fracture risk [51,52], it generally underestimates bone mineral density when compared
with DXA, with lower sensitivity (21–45%) but high specificity (87–96%) at a cut-off of −2.5 for an
equivalent DXA score [52]. This reflects our relatively low prevalence figures when compared to other
local prevalence studies that have reported osteoporosis in 3–12% of males and 8–43% of females over
age 50 [10,53].
5. Conclusions
At-risk coeliac serology, defined by the presence of an elevated anti-tTG antibody and a permissive
genotype, is highly prevalent in older Australian adults and is significantly associated with low bone
mineral density as measured by quantitative heel ultrasound. Few with at-risk serology were diagnosed
with CeD during long-term follow-up. The issue of false positive serology should be addressed in
studies where biopsy is used to confirm disease, as high anti-tTG levels are documented in autoimmune
and liver disease. We did not find a significant relationship between at-risk serology and fractures
during the follow-up period, as our analysis was underpowered for this outcome. The findings in
this study would support considering the diagnosis of osteoporosis in older patients with newly
diagnosed CeD.
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Appendix A
Figure A1. Directed acyclic graph to determine relationship between at-risk serology and osteoporosis.
Appendix B
Figure A2. Directed acyclic graph to determine relationship between at-risk serology and fracture.
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Abstract: Gluten-related disorders are characterized by both intestinal and extraintestinal
manifestations. Previous studies have suggested an association between gluten-related disorder and
psychiatric comorbidities. The objective of our current review is to provide a comprehensive review
of this association in children and adults. A systematic literature search using MEDLINE, Embase and
PsycINFO from inception to 2018 using terms of ‘celiac disease’ or ‘gluten-sensitivity-related disorders’
combined with terms of ‘mental disorders’ was conducted. A total of 47 articles were included in our
review, of which 28 studies were conducted in adults, 11 studies in children and eight studies included
both children and adults. The majority of studies were conducted in celiac disease, two studies in
non-celiac gluten sensitivity and none in wheat allergy. Enough evidence is currently available
supporting the association of celiac disease with depression and, to a lesser extent, with eating
disorders. Further investigation is warranted to evaluate the association suggested with other
psychiatric disorders. In conclusion, routine surveillance of potential psychiatric manifestations in
children and adults with gluten-related disorders should be carried out by the attending physician.
Keywords: celiac disease; non-celiac gluten sensitivity; psychiatric disorders; depression;
anxiety disorders; eating disorders; ADHD; autism; psychosis
1. Introduction
Gluten-related disorders include three pathologies caused by the ingestion of gluten-containing
cereals grains, namely celiac disease (CD), non-celiac gluten sensitivity (NCGS) and wheat allergy
(WA) [1]. Although all of them are due to the toxicity of gluten proteins in the sensitive subject, their
respective pathogenetic mechanisms differ.
Celiac disease is a systemic autoimmune disease due to a permanent intolerance to gluten which
causes villous atrophy of the intestinal mucosa. It involves both innate and adaptive immune responses
that appear in genetically predisposed subjects exposed to gluten and, unlike food allergies, it is not
mediated by an immediate hypersensitivity reaction. It is a polygenic multifactorial disorder whose
development depends on the genetic constitution of the subject, on his/her exposure to gluten intake,
and on different environmental factors [2,3]. To date, the only effective treatment for the disease is to
observe a life-long strict gluten-free diet although other therapeutic approaches are being explored [4].
In relation to the genetic background of the disease, two HLA class II genes, the HLA-DQ2 and
the HLA-DQ8 heterodimers are present in almost all CD patients and their simultaneous absence
in a subject usually rules out a diagnosis of CD. However, these genes are also common in the
general population and the implication of other non-HLA genes is being investigated by genome
wide association studies [5]. Environmental factors that facilitate or, conversely, protect against the
development of CD are defectively known although they are considered important given that the
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genetic background is not enough to explain the increasing incidence and prevalence of CD [2].
Infant feeding practices such as the timing of the first gluten introduction in the diet and the presumed
protective role of maternal breastfeeding that were once considered important, have been recently
shown to be irrelevant in relation to the development of CD [6]. In contrast, gastrointestinal infections
and antibiotics use during the first year of life seem to be associated with a higher risk of developing
CD [7]; these latter factors could be related with the composition of gut microbiota that seems to be
different between children with and without CD [8].
As both the two most relevant genes associated with the development of CD as well as the
consumption gluten-containing foods are fairly prevalent in most of the world, it is not surprising
that there is high worldwide prevalence of CD [9]. The global worldwide prevalence of CD has been
shown to be higher when diagnosed only by serological tests, i.e., anti-tissue transglutaminase and/or
antiendomysial antibodies (1.4%, 95% confidence interval [CI] 1.1–1.7%) than when diagnosed with
intestinal biopsy (0.7%, 95% CI 0.5–0.9%) [10]. Some striking differences have been found among
different geographic areas; differences that are probably due to different genetic haplotypes, different
patterns of gluten-containing foods intake, and environmental differences. CD has been found to be
more frequent in females than in males and in children than in adults [10]. A fact worthy of mention
is that the CD prevalence has been increasing during the last decades [2,10]. This increase must be
partially attributed to an augmented awareness about the disease and more accurate diagnosis, but
environmental factors are also responsible for being the most relevant the increase to gluten exposure
in countries where nutrition traditionally relied on the intake of gluten-free grains such as rice or
corn [3].
The clinical manifestations of CD can be both gastrointestinal and extraintestinal. Gastrointestinal
symptoms include diarrhea, steatorrhea, abdominal pain, abdominal bloating, vomiting and failure to
thrive due to the malabsorption process. This kind of symptomatology is more frequent in children
and was formerly called “typical CD”, a term that has currently been replaced by “classic” CD [3].
Among the extraintestinal manifestations, some of them such as ferropenic anemia, osteopenia
and osteoporosis, short stature or dental enamel hypoplasia, are a consequence of the intestinal
malabsorption process. Others, however, seem to be due to the noxious effect of gluten in the affected
organs; dermatitis herpetiformis, gluten ataxia, gluten encephalopathy, epileptic seizures or elevation
of liver enzymes are examples of the latter. Extraintestinal symptoms, which are more frequently
found among adolescents and adults, were initially known as “atypical” CD, a term that has now been
replaced by “symptomatic” CD [3].
CD is frequently comorbid with mainly other autoimmune disorders, although non-exclusively,
type1 diabetes, Graves’ disease and inflammatory bowel diseases [11,12]. It has also been found to be
associated with a higher risk of non-Hodgkin lymphoma [13,14] and with Down [15,16] and Turner
syndromes [15,17].
Unlike CD, NCGS has not been shown to be associated with underlying autoimmune mechanisms.
Similar to patients with CD, subjects that experience NCGS may, after gluten intake, suffer a wide
variety of intestinal and/or extraintestinal symptoms that improve after following a gluten-free diet.
Contrarily to CD, the presence of anti-tissue transglutaminase and/or antiendomysial antibodies is
always negative, the HLA-DQ2/HLA-DQ8 combination in these patients is only slightly more frequent
than in the general population, and there is no atrophy of the small intestine mucosa although a rise in
intraepithelial intestinal lymphocytes has been observed [18]. Its prevalence is not yet well-known
although it does not seem to be an uncommon disease [19]. The pathogenetic mechanisms of NCGS
are, at present, poorly understood. Patients with NCGS benefit from a gluten-free diet but they have
been also shown to improve following a low FODMAPs (fermentable, oligo-, di-, monosaccharides
and polyols) diet, a fact that suggests that other constituents of grains may be responsible for the
symptoms of the disease [20].
Wheat allergy is an IgE-mediated reaction to the proteins contained in wheat and in particular,
although not exclusively, the omega-5-gliadin. WA can be developed by inhalation of wheat flour,
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the so-called baker’s asthma and baker’s rhinitis which are considered occupational diseases, or by
wheat ingestion [21]. The latter case, which is the most frequent, may cause urticaria, angioedema
and/or gastrointestinal symptoms such as nausea, vomiting, abdominal bloating, abdominal pain and
diarrhea; in the most severe cases it can induce systemic anaphylaxis [18]. WA is especially frequent in
children, being less commonly seen in adolescents and adults. The treatment is based on the avoidance
of wheat-containing foods, being less restrictive compared to gluten-free diet in CD, as it does not
require the restriction of rye and barley-containing foods [22].
Psychiatric disturbances have frequently been reported in patients with CD. Several narrative
reviews of the literature undertaken in the last five years indicate that CD could be associated with a
wide spectrum of psychiatric disorders, including anxiety disorders, dysthymia, major depression,
bipolar disorders, schizophrenia, eating disorders, autism spectrum disorders, and attention-deficit
hyperactive disorders [23–27]. However, these otherwise important reviews have several limitations.
Several of them were focused on specific psychiatric disorders such as anxiety and depression [24],
mood disorders and schizophrenia [25], or severe psychiatric disorders [27]. Some others, according to
their objectives comprised the whole spectrum of psychiatric disorders, but they do not specify their
search strategies and/or the biomedical literature database used for the review [23,26]. Finally, when
specified, literature searches were almost restricted to PubMed, thus providing a limited review of the
literature on this topic. Moreover, none of the previous have evaluated the association of psychiatric
disorders in children and adults with gluten-related disorders separately. The aim of this manuscript
is presenting a comprehensive review of the literature on the potential association of gluten-related
disorders with the whole spectrum of psychiatric disorders using the most common literature databases
for this kind of evaluation (namely, Medline, EMBASE and PyscINFO).
2. Methodology
2.1. Search Strategy
We searched the medical literature for published studies indexed in the Medline (1966 to January
2018), EMBASE (1947 to January 2018), and PsycINFO (1967 to January 2018). The search strategy
included terms of ‘celiac disease’ or ‘gluten-sensitivity related disorders’ combined with terms of
‘mental disorders’ as described in Supplementary Table S1. No limits or restrictions were applied.
Retrieved references were pooled and managed using EndNote X8 (Clarivate Analytics, Philadelphia,
PA, USA).
2.2. Inclusion Criteria
We included studies that investigated the prevalence, incidence or the likelihood of presenting
mental or psychiatric disorders in patients with CD or gluten-sensitivity related disorders. For that
purpose, comparative observational or interventional studies, including meta-analysis, assessing the
aforementioned objectives as part of their primary or secondary objectives were included. Only studies
published in English, Spanish, French, Portuguese, or Italian were included. Case-reports, case-series,
abstracts and editorials were excluded. The relationship between CD and psychiatric disorders
may be bidirectional. Our purpose was to assess the comorbidity between gluten-related disorders
and psychiatric manifestations; thus, those studies assessing the prevalence, incidence or likelihood
of presenting CD or gluten-related disorders in patients with diagnosed psychiatric disorders
were excluded.
Study eligibility was independently evaluated by the three investigators (MS, EPC, FRV).
Discrepancies in the evaluation were resolved by consensus among study investigators.
2.3. Data Extraction
Standardized data collection forms were used to extract data that included: (1) name of the first
author; (2) year of publication; (3) country where the study was conducted; (4) study objective(s);
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(5) study design; (6) assessment tools used in psychiatric comorbidities evaluation; (7) Disease
diagnostic criteria; (8) sample size and demographic characteristics; and (9) summary of outcomes.
Data extraction was independently completed by two investigators (MS and FRV). Discrepancies in
data extraction were solved by consensus.
3. Results
3.1. Study Selection
Our systematic search strategy identified 1375 potentially relevant articles (730 articles from
EMBASE, 453 articles from MEDLINE and 192 articles from PsycINFO). After removing 461 duplicate
articles, 914 articles underwent title and abstract screening. Seven hundred and eighty-eight articles
were excluded as they were case-reports, editorials, animal studies, basic science studies, did not
include comparator group, or were published in a language other than those specified in the inclusion
criteria, leaving 126 articles for a full-text screening. Two studies were excluded because we were
unable to obtain their full text [28,29]. A total of 77 were excluded following full-text review because
they were either published in abstract form, did not meet the specific objectives set for our current
review or did not report outcomes of interest, leaving a total of 47 articles that were included in our
review, of which 28 studies were conducted in the adult population, 11 studies were conducted in the
pediatric population and eight studies included both adults and children. Mixed studies (including
children and adults, n = 8) were classified under the corresponding population group with a larger
sample size (pediatrics (n = 4), adults (n = 4)) (Figure 1).
 
Figure 1. PRISMA flow chart.
3.2. Studies Conducted in Children with CD
We found 15 studies that evaluated psychiatric disorders in children or young adults with CD,
11 of which were conducted in clinical-based settings and four were conducted in community-based
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settings (Table 1). Studies were published between 1997 and 2018 [30–44]. Most studies (n = 12) were
cross-sectional, although one of them included a subsequent longitudinal phase [41]. Three studies
used a population-based cohort design and were conducted in Sweden using the same data source for
patients with CD [31,34,44]. Finally, one study used a cohort design [38]. With the exception of this
later study which was conducted in several countries [38], the remaining studies were conducted in
European countries or Turkey.
According to a population-based cohort study, children with CD have a 70% increased likelihood
of presenting a psychiatric disorder with intellectual disability being the most likely disorder (HR
1.7, 95% CI 1.4 to 2.1) [44]. A summary of results of studies evaluating the association between CD
and the occurrence or presence of psychiatric disorders is presented in Table 2. Regarding specific
conditions, cohort studies have shown that CD is associated with an increased likelihood of occurrence
of depression (HR = 1.8, 95% CI 1.6 to 2.2) [34] or mood disorders (HR 1.2, 95% CI 1.0–1.4) [44],
although this latter result did not reach statistical significance. In contrast, most cross-sectional studies
have found that the point prevalence of depression or the severity of depressive symptoms did not
differ in children with CD as compared with controls [33,35–37]. Pynnonen et al. [32], using a cross
sectional study, found no differences between patients with CD and controls in the point prevalence of
major depressive disorder, but the lifetime prevalence of major depressive disorder was significantly
increased in patients with CD (31% vs. 7%; OR = 6.06, 95% CI 1.18–31.23). Although a population-based
study found an increased likelihood of occurrence of anxiety disorder in patients with CD as compared
with controls (HR 1.2, 95% CI 1.0 to 1.4, p <0.05) [44], cross-sectional studies have not shown differences
between patients with CD and controls in the prevalence or severity of symptom of anxiety [32,35,36].
In children, no association has been found between CD and the occurrence of bipolar disorder [34].
The association of CD with psychotic disorders in children has been scarcely investigated, showing
no association with the occurrence of schizophrenia [31] or psychotic disorder [44]; an association
has been reported between CD and non-schizophrenic non-affective psychosis (HR 1.61, 95% CI
1.19–2.20) [31].
A population-based study found a significant association between CD and the occurrence of an
eating disorder (HR 1.4, 95% CI 1.1 to 1.8) [44], and the presence of the disorder seems to have a negative
impact on some dimensions of quality of life (namely, ill-being and joy-in-life) [39]. A population-based
cohort found an excess likelihood of occurrence of an autism spectrum disorder in patients with CD as
compared to controls [44]; however, a cross-sectional study did not find an association between both
disorders [30]. A slight, but significant, increase in the likelihood of occurrence of attention deficit and
hyperactive disorder (ADHD) in patients with CD has been reported [44].
Several factors have been suggested to contribute to depressive symptomatology in the pediatric
population including the presence of parental depressive disorders, low parental educational level,
divorce of the parents, presence of functional comorbid conditions and female gender [32,33,43].
Older age, higher body mass index and history of dietary restrictions were linked to higher risk of
eating disorders [39,40].
3.3. Studies Conducted in Adults with CD
We found 32 studies that evaluated psychiatric comorbidities in adult patients with CD or NCGS,
18 of which were conducted in clinical-based settings and nine were conducted in community-based
settings (Table 3). Studies were published between 1982 and 2018 [45–76]. More than half of these
studies were of cross-sectional design [45,48,51,53–57,59,60,63,67,68,71,72,74–76] and four of them
were representative of the general population [47,70,73,76].
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A summary of results of studies evaluating the association between CD and the occurrence or
presence of psychiatric disorders is presented in Table 4.
The prevalence rates of depression or depressive symptomatology were significantly higher
in patients with CD compared to controls in the majority of the published studies except for
two [56,60]. Nevertheless, significant variability in the point-prevalence of depression or depressive
symptomatology exists, ranging from 14% to 68.7% [53,56,57,59,60,63]. In a meta-analysis conducted
by Smith et al. [61], depression was shown to be more common and severe in CD than in healthy
adults, but not compared to patients with other medical conditions. Comorbid illnesses, including
type I diabetes mellitus or subclinical thyroid disease, and stress were associated with the presence
of depressive symptomatology in CD [57,60]. Increased severity of gastrointestinal symptoms in
CD was linked to worsened depressive symptoms [75] which, in turn, led to poorer QOL compared
to controls [63]. Although gluten-free diet (GFD) did not lead to any improvement in depressive
symptoms in two longitudinal studies [52,55], a meta-analysis conducted by Sainsbury et al. [66]
found a moderate association between poor adherence to GFD and greater depressive symptoms.
With respect to post-partum depression, it was assessed in a single study in which it turned out to be
significantly more prevalent in women with CD compared to controls (41% vs. 11%, p < 0.01) [65].
118
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In two studies conducted by the same research group, the prevalence of state anxiety in patients
with CD was substantially higher than in controls (62.5% vs. 31.3%, and 71.4% vs. 23.7%), although the
difference was statistically significant in only one study [53,55]. Generalized anxiety disorder diagnosis
in CD was not shown to be prevalent in CD compared to controls [57] and the overall prevalence of
anxiety was not significantly higher compared to healthy adults in the meta-analysis conducted by
Smith et al. [61]. The prevalence of social phobia in CD reached 70% in one cross-sectional study [59];
however, its lifetime prevalence in another study was only 8.3% [57]. Bipolar disorder and panic
disorders were significantly more prevalent in patients with CD [57,58,63].
Three studies assessed the prevalence and risk of eating disorders in CD. Their prevalence
was significantly higher in adults with CD compared to healthy controls as demonstrated via the
elevated scores on the different assessment scales employed in two cross-sectional studies [67,68].
Elevated Eating Attitudes Test scores were seen in around 16% of patients with CD in both studies,
whereas elevated Binge Eating Scale scores were only elevated in one study with 19.7% of adults
with CD reporting high scores [68]. Moreover, severe gastrointestinal symptoms were linked to
greater risk of eating disorders [75]. In the register-based cohort and case-control study conducted by
Marild et al. [69], the likelihood of developing anorexia nervosa was significantly higher in women
with CD (HR = 1.46, 95% CI: 1.08–1.98) and the likelihood was highest in women with normal mucosa
and positive serology (HR = 2.45, 95% CI: 1.1–5.45).
While patients with CD were less likely to experience alcohol-related disorders [72], their risk of
developing dementia was significantly higher as shown in a population-based cohort study [70,73].
The likelihood of developing poor sleep in CD based on the use of hypnotics was significantly
elevated compared to controls HR = 1.36, 95% CI: 1.3–1.41) in the population-based case-control study
conducted by Marild et al. [70]. On the other hand, sleep difficulty as measured with the Patient Health
Questionnaire did not differ significantly between adults with CD and controls (37.3% vs. 27.4%,
p = 0.15) in a population-based cross-sectional study [76].
While gender did not seem to affect the prevalence rates of ADHD in CD patients [45], males with
CD were less likely to experience poor sleep problems [70] or subsequent anorexia nervosa [69] and
they tended to score higher on the different Psychological General Well-being Index domains [71].
Conflicting results concerning the effect of the CD onset time on psychological symptomatology
were obtained; on one hand, earlier onset of CD symptoms was linked to higher prevalence of major
depressive disorder in one study [57] and on the other hand, depressive symptomatology scores did
not differentiate between childhood or adulthood diagnosis of CD [54]. Finally, severe gastrointestinal
symptomatology significantly correlated with increased psychological manifestations [68,75].
The risk of schizophrenia in patients with CD was assessed in three studies [47–49]. While one
population-based case-control study showed no increased risk of schizophrenia in CD (OR = 0.75,
95% CI: 0.4–1.4) [47], its risk was shown to be significantly elevated in a population-based cohort
study (Incidence rate ratio = 2.11, 95% CI: 1.1–3.6) and a cross-sectional study (adjusted incidence
rate = 3.6, 95% CI: 1.2–10.6) [48,49]. In a meta-analysis including four studies, an increased risk of
schizophrenia among patients with CD was found (OR = 2.03, 95% CI: 1.45–2.86) [50]. With respect
to autistic spectrum disorders, its risk in a population-based cohort of CD appeared to be increased
with the highest risk being present in patients with normal mucosa and positive serologic findings
(HR = 3.09, 95% CI: 1.99–4.8) [46].
ADHD was assessed in one cross-sectional study that reported an increased prevalence of this
disorder in adults with CD compared to controls (20.7% vs. 10.5%, p <0.01) [45]. The overall
psychological status in adults with CD was evaluated in one study whereby no difference in the
total Psychological General Well-Being Index was found between CD and controls [71].
In the two studies that evaluated the effects of gluten ingestion in adults with NCGS [62,64],
significant worsening of depressive symptomatology [64] and increase in the depression subscale
scores of Spielberger State Trait Personality Inventory [62] were reported.
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4. Discussion
Our current review of the literature revealed the existence of an association between CD
and other gluten-related disorders with psychiatric disorders across different age groups. CD is
primarily an autoimmune disorder that is characterized by villous atrophy of the intestinal mucosa
along with intraepithelial lymphocytosis and crypt hyperplasia [77]. Nevertheless, a major shift
in clinical presentation with extraintestinal manifestations becoming more prevalent than classical
gastrointestinal symptoms has been suggested [78]. The reviewed data demonstrate that a wide
range of psychiatric disorders have been investigated in CD and NCGS including autism spectrum
disorders, schizophrenia, attention-deficit disorder, depression and mood disorders, anxiety disorders,
bipolar disorder, feeding and eating disorders, sleep disorders, substance-related and addictive
disorders and neurocognitive disorders.
Most of the cross-sectional studies in the pediatric population did not find any significant
differences in the point prevalence of depression or anxiety disorders [32,33,35–37], however,
these studies had several methodological limitations which mainly included small sample size
(ranging between 29 and 42 children with CD), the lack of specialized psychiatric clinical assessment,
and the absence of adequate blinding measures to limit assessment bias. On the other hand,
two population-based cohort studies including >9000 children each provided evidence for an increased
likelihood of occurrence of depression and anxiety disorders in patients with CD [34,44]. In the cohort
study conducted by Ludvigsson et al. [34], it was shown that adults and children with CD are at
increased risk of being diagnosed with depression but not bipolar disorder later in life (i.e., during
adulthood for children diagnosed with CD), whereas in the study conducted by Butwicka et al. [44],
CD was identified as a risk factor for mood disorders, anxiety disorders, eating disorders, behavioral
disorders, ADHD, ASD, and intellectual disability diagnosed prior to 18 years of age. Although the
analyses in the two previous cohort studies were controlled for children’s age, stratified analyses
to identify the likelihood of occurrence of specific psychiatric disorders across the different age
groups are worth evaluation taking into consideration the variation in clinical presentation across the
developmental span between 0 and 15 years of age [79].
In adults, the point-prevalence of depression was significantly higher in patients with CD in
the majority of published studies. These findings were ascertained by a population-based cohort
study in which the HR of depression (in participants ≥16 years at diagnosis) was two folds higher
than controls [34] and by a meta-analysis in which depression was shown to be more common
and severe in CD than in healthy adults with an overall effect size of 0.97 [61]. A comprehensive
review, evaluating the comorbidity of depression and anxiety in CD, concluded that these disorders are
common disorders among patients with CD and contribute to a poorer quality of life [24]. Nevertheless,
the lack of differences in the prevalence of depression when compared to patients with other physical
disorders [61] raises a question about the existence of a specific underlying pathophysiological
mechanism in patients with CD or whether depression represents a non-specific disorder affected by
physical and psychosocial distress. The association between chronic medical diseases and depression
is well-known and many different causes, including both genetic predisposition and environmental
factors have been shown to be involved [80–82]. This association is frequently bidirectional, as the
presence of physical illness often worsens the affective disorder and vice versa [81]. The current
information relative to depression in patients with CD does not allow, at the present time, to
ascertain the exact relationship and the predisposing factors involved between CD or NCGS and
depressive symptomatology.
The association between CD and eating disorders has been investigated in a limited number of
studies. Current findings reveal an elevated prevalence of eating disorders in CD among both children
and adults with CD [39,40,44,67–69]. These disorders encompassed anorexia nervosa, bulimia nervosa
and binge eating. Poor dietary management can occur as a result of physical dissatisfaction, which is
not uncommon in patients with CD [83]. Moreover, evidence from the current literature suggests that
young adults with chronic illnesses that require dietary modification are at higher risk of developing
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pathological eating practices [39]. The elevated lifetime comorbidity between depression and eating
disorders [84] could be another explanatory mechanism of increased prevalence of eating disorders in
CD patients who are more prone to developing depressive symptomatology.
Concerning psychotic disorders, the current evidence provided by solely two population-based
cohort studies does not support the presence of an association between these disorders and CD in
children [31,44]. However, children and young adults (≥16 years of age) with CD were 1.8-fold more
likely to experience non-schizophrenic non-affective psychosis [31]. The authors of the latter cohort
study yet did not rule out the presence of a potential association between CD and schizophrenia as
the risk of the latter disorder was high despite the low number of individuals with schizophrenia.
These findings were similar to another population-based case-control study conducted in adults
in which no evidence of an increased risk of schizophrenia in CD was found [47]. In contrast,
Benros et al. [49] demonstrated an increased incidence of schizophrenia in patients with prior CD
in their population-based cohort study. Furthermore, Eaton et al. [48] showed also 3.8-fold increase
in incidence rates of prior CD diagnosis in subjects with schizophrenia. However, in the latter study,
data on parents’ celiac status were also included in their analysis which might have led to biased
findings. A meta-analysis including four studies demonstrated the presence of an increased risk of
schizophrenia among patients with CD [50]. We believe that the pooled-effect estimate in the previous
meta-analysis could be biased because their pooled analysis on one hand missed the negative findings
reported by West et al. [47] and on the other hand included the findings of a study in which the
prevalence of CD in patients with schizophrenia was investigated [85]. The objectives and outcome
measures of the latter study [85] did not match the principal objective of the meta-analysis whereby
the authors investigated the prevalence of autoimmune diseases (including CD) in patients with
schizophrenia and not the other way around [85]. The association between CD and gluten-related
disorders with schizophrenia has been under investigation for more than five decades but most
studies evaluated the prevalence or risk of gluten-related disorders in patients already diagnosed
with schizophrenia [86]. Current evidence suggests a two-fold increase in the prevalence of CD
in schizophrenia patients [87] and an association between gluten ingestion and exacerbation of
schizophrenia symptoms [88]; nonetheless, these findings are highly inconsistent across different
clinical, immunological, and epidemiological studies [86] and have not been replicated in patients
presenting with CD.
The underlying mechanisms behind the association between CD and psychiatric disorders are
not well-known. Nevertheless, several potential biological and psychosocial explanations have
been suggested: (i) Several psychiatric disorders such as depression, anxiety, and ADHD, among
others have been linked to certain nutritional and vitamin deficiencies [89] and it is well-known
that patients with CD often suffer from malnutrition prior to diagnosis or as a result of dietary
non-compliance [90]; (ii) The immune-mediated processes underlying CD have been postulated as
potential causative factors of the different psychiatric manifestations taking into consideration the
involvement of chronic immune system activation in the etiology of various psychiatric conditions [91];
(iii) The bidirectional communication between the gastrointestinal tract [92] and the brain may suggest
that alterations in the intestinal permeability, which is cardinal manifestation in CD [93], could be
eventually involved in the pathophysiology of psychiatric manifestations in patients with CD; (iv)
Finally, psychosocial aspects commonly seen in CD could place this population at an increased risk
of developing psychiatric disorders, for instance, the introduction of GFD is associated with radical
changes in daily life activities, eating habits and lifestyle which could be particularly stressful and
difficult to accept [43,94]. In addition, effective adherence to GFD entails greater burden manifested
via increased daily expenditure on more expensive products, social isolation and constant fear about
dietary mistakes [95].
The studies included in this review provided limited data on potential factors associated
with psychiatric comorbidity in patients with CD. Bearing in mind this limitation, none of the
demographic factors has been consistently associated with the presence or occurrence of psychiatric
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comorbidities and the role of ethnicity in this context has not been studied. Regarding clinical factors,
only severity of CD symptoms appears to be associated with the presence and/or severity of psychiatric
disorders [33,51,52,68,75]. In this regard, the significant positive association between increased severity
of gastrointestinal symptoms and worsening of psychiatric manifestations [75] and QOL [63] in
CD indirectly demonstrates the importance of adherence to GFD. Nevertheless, few studies have
documented the beneficial effects of GFD on psychiatric manifestations in patients with CD [27,66],
with the majority of these studies suffering from several methodological flaws limiting our capacity of
reaching definitive conclusions supporting the role of GFD in this context.
Only two studies in patients with NCGS supported the association between this relatively
new entity and depressive symptomology [62,64]. It has not been until recently that standardized
diagnostic criteria for NCGS were established [19], which might explain the limited number of studies
investigating psychiatric comorbidities in NCGS. In our current review search, we could not find any
study that investigated psychiatric comorbidities in patients with WA.
Limitations of our current review are essentially derived from the limited quality of the majority
of the studies that have investigated psychiatric disorders in CD. Most of these studies are of
cross-sectional design which does not allow establishing causal relationships and are of small sample
size, whereas very few population-based studies have been published.
Evaluating psychiatric comorbidities in different age groups adds strength to our current review
since up to the current date, none of the previous reviews had evaluated the evidence of psychiatric
disorders in children and adults with CD separately. Interestingly, according to our review, the presence
of CD in childhood seems to be associated with an increased risk of developing psychiatric disorders
later during adulthood, but not with an increased prevalence of these disorders during childhood.
5. Conclusions
Our current comprehensive review ascertains the presence of an association between CD and
psychiatric disorders with varying grades of evidence from one condition to another. In our view,
there is enough evidence supporting an association of CD with depression and, to a lesser extent,
with eating disorders. Some studies also point out to an association between CD and panic disorder,
autism and ADHD, but the evidence is limited, and these potential associations should be further
investigated. Finally, the data regarding the association of CD with schizophrenia or other anxiety
disorders is conflicting. Overall, psychiatric symptomatology which could be perceived as part of
the atypical manifestations of this chronic condition are linked to significant distortion in quality of
life and moderately increased risk of suicide [96] and thus warrants further attention. Therefore,
gastroenterologists and other healthcare professionals involved in the management of patients
with CD should be aware of the increased risk of psychiatric disorders in these patients. Thus,
routine surveillance of potential psychiatric manifestations, especially anxiety and/or depressive
symptomatology that seem to be the most common forms of disturbances, should be carried out by
the attending physician in order to refer the patient to the mental health services if necessary.
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Abstract: Immunologically mediated liver diseases belong to the common extraintestinal
manifestations of celiac disease. We have reviewed the current literature that addresses the association
between celiac disease and liver disorders. We searched relevant articles on MEDLINE/PubMed up
to 15 June 2018. The objective of the article is to provide a comprehensive and up-to-date review
on the latest hypotheses explaining the pathogenetic relationship between celiac disease and liver
injury. Besides the involvement of gut–liver axis, tissue transglutaminase antibodies, and impairment
of intestinal barrier, we integrate the latest achievements made in elucidation of the role of gut
microbiota in celiac disease and liver disorders, that has not yet been sufficiently discussed in the
literature in this context. The further objective is to provide a complete clinical overview on the
types of liver diseases frequently found in celiac disease. In conclusion, the review highlights the
clinical implication, recommend a rational approach for managing elevated transaminases in celiac
patients, and underscore the importance of screening for celiac disease in patients with associated
liver disease.
Keywords: autoimmunity; celiac hepatitis; gut–liver axis; liver immunity; non-alcoholic fatty liver
disease; tolerance; intestinal barrier
1. Introduction
The liver is an organ playing a regulatory role in innate and adaptive immunity. Constituents
in portal blood circulating from the intestine to the liver, such as food antigens (including peptides
derived from gluten and related cereals), bacterial components and products, can under specific
conditions (e.g., impaired intestinal barrier and/or dysregulation of gut–liver axis) trigger the hepatic
immune response, which is connected to liver inflammation and fibrosis.
During the past four decades a vast number of papers documented the clinical relationship
between celiac disease and liver disorders. Although immunologically mediated liver diseases are the
most common extraintestinal manifestations of celiac disease [1–8], there are still many scientific and
clinical question to be answered.
This narrative review attempts to summarize the current status of knowledge regarding (1) the
pathogenetic relationship between celiac disease and liver injury, (2) the types of liver diseases
frequently found in celiac disease, (3) recommendation for a rational approach for managing elevated
transaminases in celiac patients, and (4) vice versa for screening for celiac disease in patients with liver
diseases. A search for English written articles was performed using MEDLINE/PubMed (from 1977
Nutrients 2018, 10, 892; doi:10.3390/nu10070892 www.mdpi.com/journal/nutrients134
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up to 15 June 2018). We included scientific papers regarding liver immunology to emphasize liver as
an organ with unique immune function, and to summarize hypotheses explaining connection between
celiac diseases and liver disorders. Especially, we highlight the gut microbiota as further possible link
clarifying the relationship between liver injury and celiac disease. In addition, number of observational
studies and meta-analyses were used to document the current clinical approach to the liver disorders
in celiac patients.
2. Immune Reactivity in the Liver
The liver, traditionally viewed as the central organ engaged in metabolism, nutrient storage,
and detoxification, is also an immune organ, having an important regulatory role in innate and
adaptive immunity. From an immunological point of view, the liver is exposed to large numbers of
foreign molecules coming from the gastrointestinal tract via the portal vein. These non-self-antigens
are derived from food (including peptides derived from gluten and related cereals), and from the
microbiota (i.e., bacterial components and products) that have breached the intestinal barrier. The liver
must tolerate these gut–derived molecules, while still providing immunosurveillance for pathogenic
infections and malignant cells. The liver sinusoids and the sub-endothelial compartment (the space of
Disse) are populated with various resident immune cells (of the innate and adaptive immune system)
capable of dynamic interaction, antigen sensing, phagocytosis, antigen presentation, cytokine and
chemokine production, cytotoxicity, T cells programing, and communication with circulating immune
cells passing through the liver. The diversity of immune interplay determines the balance between
tolerance, protective immunity against infection, tissue damage, and metastases, and autoimmunity in
the liver. Variety of antigen-presenting cells (APCs), such as liver-resident macrophages, called Kupffer
cells, liver-resident dendritic cells, and liver sinusoidal endothelial cells, play a central role in creating
the tolerogenic environment of the liver. Kupffer cells act as the primary filter, constantly removing
antigens from the circulation. The liver is particularly enriched with populations of resident innate
lymphoid cells (natural killer (NK) cells, natural killer T (NKT) cells, mucosal-associated invariant
T cells, and γδ T cells), which recognize conserved antigens (expressed by microbial pathogens,
pathogen-infected cells, and tumor cells), and respond by killing target cells, or selectively activating
and regulating the diverse arms of both the innate and adaptive immune responses in the liver,
including T helper (Th)1, (Th)2, (Th)17, Treg cells, and antibody responses. Lymphoid cells of adaptive
immunity comprise the classic major histocompatibility complex (MHC)-restricted CD4+ and CD8+ T
cells, activated T cells, memory T cells, as well as B cells. Besides the above mentioned professional
APCs, parenchymal cells and hepatic stellate cells act as semi-professional APCs, which can work
as sensors or triggers of immune responses and assist in local or systemic immune regulation and
inflammation. All types of liver cells, including resident immune cells, hepatocytes, cholangiocytes,
sinusoidal endothelial cells, and hepatic stellate cells express a range of pattern recognition receptors
(PRRs), such as toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-like receptors, carbohydrate
receptors, and scavenger receptors, which bind to microbial-associated molecular patterns (MAMPs)
and damage-associated molecular patterns (DAMPs) that may be present in portal blood. Kupffer
cells, liver sinusoidal endothelial cells, and hepatocytes also express variable numbers of class II MHC
molecules and are capable of presenting antigens to classic T cells [9,10].
The liver is a highly immunotolerant organ with many mechanisms to actively prevent the
induction of immunity. While maintaining an overall tolerogenic setting, the hepatic immune system
must be capable of rapidly activating immune responses to “dangerous” antigens or to liver tissue
damage (of any origin). Immune tolerance to self-antigens in the liver can be impaired, which can
lead to autoimmune liver diseases, such as autoimmune hepatitis (AIH), primary biliary cholangitis
(PBC), and primary sclerosing cholangitis (PSC). The hepatic immune system plays an important role
in responding to hepatic injury, and in the initiation and progression of liver diseases. Thus, chronic
liver diseases of infectious, toxic, metabolic, cholestatic, and autoimmune origin are characterized by
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persistent activation of innate immune pathways, which are usually associated with cytopathic effects
on liver parenchymal cells [9,10].
About 1–2% of food antigens are translocated into the circulation in an immunogenic form [11].
The liver is able to suppress immunity to many antigens, including dietary antigens. Additionally,
various dietary constituents and metabolites can influence hepatic APCs and other liver cells (mainly by
activating specific receptors, leading to altered intracellular signaling, gene expression, and release of
cytokines) and therefore modulate physiological immune maintenance in the liver. Dietary constituents
and metabolites can also increase pathological activation of liver immune cells. Liver metabolic
processes are linked to hepatic inflammation through the inflammatory effects of metabolites such
as saturated fatty acids, cholesterol, or succinate, which promote TLRs signaling and inflammasome
activation on dendritic cells and macrophages [9,10]. Data sets published on the potential influence of
dietary components, such as branch-chain amino acids, arginine, tryptophan, vitamins, and various
types of lipids, on hepatic immunity show equivocal or conflicting results in terms of whether they
induce tolerance or initiate an immune response [10]. Similarly, the role of dietary gluten and other
immunogenic wheat proteins, in the modulation of hepatic immunity, has not been elucidated.
3. Gut–Liver Axis and Celiac Disease
Although the relationship between celiac disease (CD) and liver disorders have been clinically
evident for more than 40 years [1], its pathophysiology is far from being fully understood with many
explanations being hypothetical. In addition to a probable genetic relationship, the interplay of the
many aspects of the gut–liver axis may also contribute to the explanation of this link (Figure 1).
Figure 1. Putative pathogenesis of liver injury in celiac disease. Abbreviations: FGFR4, fibroblast
growth factor receptor 4; FXR, farnesoid X receptor; LPS, lipopolysacharide; NLRs, NOD like receptors;
PRRs, pattern-recognition receptors; SCFAs, short chain fatty acids; TGR5, Takeda G-protein receptor 5;
TLR-4, toll like receptor 4; TTG2, tissue transglutaminase 2.
The term gut–liver axis describes a close anatomical, metabolic, and immunologic connection
between the gut and liver. The liver and intestine are tightly linked via the portal circulation,
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which supplies the liver not only with nutrients but also with gut–derived food and bacterial antigens,
and bacterial metabolic products. The liver portal and liver arterial circulation are the afferent part
of the gut–liver axis, while the biliary tree is the efferent part of the gut–liver axis. Intestinal and
biliary epithelia share many properties, including expression of PRRs and tight junction (TJs) proteins,
as well as the ability to release secretory IgA. The secretion of bile (especially bile acids, and IgA)
affects the gut–liver axis and modulates the composition of the intestinal microbiota [12]. Moreover,
both organs are characterized by shared lymphocyte homing and recruitment pathways. Gut-derived
T-lymphocytes may also contribute to hepato-biliary inflammation [13].
The gut–liver axis is a complex system involving multiple components—the intestinal barrier,
gut microbiota, bile, shared lymphocyte homing, and several hepatic receptors, such as PRRs,
or farnesoid X receptor (FXR), Takeda G-protein receptor 5 (TGR5), fibroblast growth factor receptor
4 (FGFR4)—that connect metabolic pathways to inflammation. Dysregulation or impairment of the
gut–liver axis can activate the hepatic innate immune response leading to induction of liver injury,
or contribute to the progression of liver damage (of any origin) [12,14] (Table 1).
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When the intestinal barrier is impaired (i.e., during increased intestinal permeability or
dysregulated intestinal immunity), food antigens and bacterial antigens with strong immune-activating
properties (e.g., lipopolysaccharide (LPS), peptidoglycans, super-antigens, bacterial DNA, flagellin,
and heat shock proteins) can cross the intestinal epithelium in greater numbers than under healthy
conditions, which can stimulate gut–associated lymphatic tissue (GALT) to release pro-inflammatory
cytokines (TNF, IL-1, IL-6, etc.), chemokines, and eicosanoids. The load of antigens is not eliminated by
GALT and together with intestinal inflammatory cells, cytokines, chemokines, and bacterial metabolites
(such as ethanol, acetaldehyde, trimethylamine, short chain fatty acids (SCFAs), and free fatty acids) are
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transported to the liver via the portal vein. In the liver, the massive influx of these components activates
the hepatic immune response thus promoting liver damage, inflammation, and fibrogenesis. Increased
intestinal permeability as well as plasma levels of inflammatory cytokines has been demonstrated
in both the pathophysiology and progression of chronic liver diseases. Similarly, increased levels
of bacterial LPS have been documented in the portal and/or systemic circulation (endotoxemia) in
several chronic liver diseases [12,13,15,16].
Among the compounds that can disrupt the function of the intestinal barrier are known dietary
items or eating habits (e.g., alcohol use, high-fat, or high-carbohydrate diets), intestinal mucosal
inflammation (regardless of etiology), infections, toxins, medications (e.g., non-steroidal antirheumatic
drugs, proton-pump-inhibitors), and intestinal hypoperfusion [12]. It is also hypothesized that
industrial food additives (such as gluten, microbial transglutaminase, glucose, salt, emulsifiers, organic
solvents) that are commonly used in dough, may have a negative impact on the function of the
intestinal barrier [17]. Another leading factor influencing intestinal permeability is the microbiota [18].
In CD, increased intestinal permeability is thought to be an early feature in the pathogenesis.
Dietary gluten drives inflammation and impairs the function of the small intestinal barrier [19,20].
Using markers of epithelial apoptosis (cytokeratin 18 caspase-cleaved fragment) and enterocyte
damage (intestinal fatty acid-binding protein), we found an impairment of small intestinal mucosal
barrier integrity in patients with active celiac disease and also in patients with diabetes mellitus [21].
It has been demonstrated that patients having active CD with elevated serum transaminases have a
more severely compromised intestinal barrier and greater intestinal permeability than those having
active CD with normal liver tests; and both intestinal permeability and transaminases normalize when
patients follow a gluten-free diet (GFD) [20,22].
In CD, gliadin per se has been shown to increase intestinal permeability by releasing zonulin—a
modulator of small-intestinal TJs [13,23]. Luminal gliadin binds to the chemokine receptor, CXCR3,
expressed on intestinal epithelium, and induces an MyD88-dependent zonulin release, which leads
to an opening of enterocyte TJs. CXCR3 is over-expressed in CD patients, where it is co-localized
with gliadin. CXCR3 is predominantly expressed on immune cells, but its expression has also been
reported on non-immune cells, including hepatic parenchymal cells. Resident hepatic immune cells
and hepatocytes express CXCR3 in both the normal and injured liver. While the role of these receptors
in the homeostatic liver environment is not understood, during injury, they are engaged in cellular
survival, activation, proliferation, apoptosis, inflammatory cell infiltration, fibrogenesis, angiogenesis,
and expression of additional chemokines and growth factors [24]. Up-regulated production of
CXCR3 ligands under inflammatory gut–liver interactions was recently demonstrated using an
integrative multi-organ platform comprising human liver (hepatocytes and Kupffer cells) and intestinal
(enterocytes, goblet cells, and dendritic cells) models [25].
It is not known, if gluten can affect intestinal permeability and hepatic immunity in healthy
individuals. But, studies in murine monocytes/macrophages have demonstrated that gluten peptides
activate the arginase metabolic pathway and increase intestinal permeability in vitro (on Caco-2
epithelial monolayers) [26]. Gliadin activated monocytes/macrophages contribute to the innate
immune response in CD [27] by releasing inflammatory cytokines and nitric oxide (NO). Arginine
is an obligatory substrate of inducible NO synthase, an enzyme that produces large amounts of NO.
Moreover, it has been recently demonstrated that in both celiac subjects and healthy individuals, gluten
peptides exert the same level of activation of arginine metabolism and cell polarization in human
monocytes; therefore, ingested gluten might elicit innate activation of human monocytes even in
healthy people [28].
4. Involvement of Microbiota in Celiac Disease and Liver Disorders
Dysbiosis (i.e., a reduction in bacterial diversity of beneficial bacterial species, and an increase in
potentially pathogenic species relative to a healthy microbiome) is a feature of CD as well as both early
and advanced liver disease.
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CD is strongly associated with intestinal dysbiosis that is not completely restored by a GFD.
Although, no distinct celiac microbiota pattern has yet to be found, an altered composition of
fecal and duodenal microbiota has been identified in individuals with active celiac disease: e.g.,
an abundance of Firmicutes and Proteobacteria, or of Gram-negative bacteria (such as Bacteroides
and E. coli), or Staphylococcus and Clostridium. This is accompanied by a related reduction in
protective, anti-inflammatory bacteria (such as Bifidobacterium and Lactobacillus), and Gram-positive
bacteria [19,29]. Microbiota might contribute to the pathogenesis and manifestation of CD via
proteolytic activity that can modify the immunogenicity of gliadin peptides or by influencing intestinal
permeability and inflammation [30].
There is also growing evidence that perturbations in the microbiota composition (dysbiosis
or bacterial overgrowth) contribute to the pathogenesis (manifestation and/or maintenance and
progression) of certain liver diseases, such as non-alcoholic fatty liver disease (NAFLD) (and its
progressive variant, non-alcoholic steatohepatitis (NASH)), alcohol-related liver disease, primary
sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and even liver cirrhosis and its
complications including hepatocellular carcinoma [31,32]. The mechanism by which the microbiota
affects intestinal permeability and TJs function is unknown. Several studies have shown that dysbiosis
contributes to intestinal inflammation, bacterial translocation, and liver fibrosis [33].
The MAMPs are recognized by PRRs, such as TLRs or NLRs, which are expressed on intestinal
epithelial and antigen presenting cells, and on liver resident immune and parenchymal cells.
The CD14/TLR-4 complex (which is involved in the recognition and signal transduction of bacterial
LPS) plays a central role in the initiation or maintenance of innate immune responses in the small
intestine and in the liver and contributes to impairment of intestinal barrier [30].
In active celiac disease, increased TLR4 (and TLR2) expression in the duodenum has been
documented [34]. In addition, our group reported increased sCD14 protein seropositivity in active CD.
Soluble CD14 (sCD14) is considered to be an indicator of innate immunity activation in response to
mucosal translocation of LPS. So, in CD, circulating LPS might contribute to innate immune activation
of extraintestinal organs, including the liver [21].
In experimental models, the evaluation of specific bacteria isolated from celiac patients suggests
that some commensal bacteria might promote an adverse response to dietary gluten, whereas others
can be protective [35], and that gut microbiota can enhance or reduce celiac-disease-associated
immunopathology (such as modifying Treg induction, epithelial cell stress, and activation of
intraepithelial lymphocytes, maturation of dendritic cells, pro-inflammatory cytokine production,
intestinal permeability, and the induction of CD4+ T cell responses) [29]. Gut microbiota promotes
chronic liver inflammation and fibrogenesis through the activation of TLR4 (on Kupffer cells
and hepatic stellate cells). It has been demonstrated in mice, that bacterial LPS enhance TGF-β
signaling in hepatic stellate cells, via the TLR4-MyD88-NF-κB pathway, subsequently leading to liver
fibrogenesis [36]. Intestinal dysbiosis is associated with increased levels of LPS in the portal and/or
systemic blood (endotoxemia) and propagates liver injury in several types of chronic liver diseases [12].
In addition to TLR4, inflammasome activation contributes to the pathogenesis of most acute
and chronic liver disease. Inflammasomes are multiprotein complexes (involving NLRs) that can
recognize a diverse range of MAMPs and DAMPs. Inflammasome-mediated dysbiosis enhances liver
inflammation through activation of caspase-1 cascade and production of various proinflammatory
cytokines (such as IL-1, IL-18, IL-6, TNF-α), enhances hepatocyte dysfunction, necrosis, apoptosis,
and the generation of extracellular fibrosis [37].
Moreover, the activation of TLRs and inflammasome in hepatocytes seems to also be involved in
metabolic regulation, since dysbiosis may alter nutritional absorption and storage [38].
Dysbiosis may also influence bile acid signatures in the gut and in enterohepatic circulation.
Gut microbial enzymes (bile salt hydrolase, or bile acid-inducible enzymes) deconjugate and
dehydroxylate primary bile acids in the intestine into unconjugated secondary bile acids. Bile acids
(besides their well-known role in nutrient absorption and biliary secretion of lipids, toxic metabolites,
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and xenobiotics) are ligands for liver bile salt receptors, such as the nuclear FXR and membrane
TGR5 [14]. Hepatic FXR plays a key role not only in regulation of hepatic bile acids metabolism, but also
in the coordination of hepatic triglyceride, glucose, and energy homeostasis [39]. TGR5 is localized
on various non-parenchymal liver cells (sinusoidal endothelial cells, Kupffer cells, hepatic stellate
cells) and in cholangiocytes. Activation of TGR5 mediates choleretic, cell-protective, anti-inflammatory,
and proliferative effects in cholangiocytes. A disturbance in the bile acids signaling mechanisms can
contribute to the development or progression of biliary diseases, such as primary biliary cholangitis
(PBC) and primary sclerosing cholangitis (PSC) [40]. Moreover, bile acids also influence hepatic
inflammation and regeneration (via the intestinal bile acids-intestinal FXR-fibroblast growth factor
(FGF) 15/19 and liver FGF receptor 4 axis). The alteration in the bile acid profile might provide signals
that connect bile acid, lipid, and glucose metabolism in the liver to hepatic and biliary inflammation.
Bile acids also have antimicrobial properties and therefore can modulate gut microbiota composition,
intestinal immunity, and barrier integrity [14].
5. The Role of Tissue Tranglutaminase Antibodies and Vitamin D in a Pathogenetic Link
between Celiac Disease and Hepatic Disorders
Beside the contribution of the gut–liver axis to hepatic injury in CD, it has also been suggested
that tissue transglutaminase 2 (TTG2) (a key enzyme and part of target autoantigen involved in the
pathogenesis of celiac disease [19]) may play a role in celiac-associated liver damage. This hypothesis
is supported by observation that chronic unexplained hypertransaminasemia is frequently present
in active CD, but not in other small intestinal diseases associated with dysbiosis and an increased
inflammatory mucosal response, such as tropical sprue or diarrhea predominant-irritable bowel
syndrome [41].
TTG2 is a ubiquitous cellular and extracellular enzyme, participating in important biological
processes such as wound healing, tissue repair, fibrogenesis, apoptosis, inflammation, and cell-cycle
control. In the extracellular space, TTG2 is involved in cell-extracellular matrix interactions as well as in
remodeling and stabilization of the extracellular matrix [42]. It is also known to modulate inflammation
and fibrosis in chronic liver diseases, although the mechanism appears to be quite complex and is
not completely understood [43]. TTG2 is overexpressed in the liver (mainly in endothelial cells and
periportal hepatocytes) of patients suffering from chronic liver diseases. Our group documented that
overexpression of TTG2 is more pronounced in the liver tissue of patients suffering simultaneously
from both liver disease (such as toxic hepatitis, primary sclerosing cholangitis, or autoimmune hepatitis
type I) and active CD [44].
There is also evidence that enhanced TTG2 enzymatic activity seems to protect the liver from
acute and chronic injury [43]. In CD, the presence of celiac antibodies has been shown to inhibit TTG2
enzymatic activity, which can lead to a decrease in the availability of active transforming growth factor
(TGF)-β [45]. IgA antibodies targeted against TTG2 (IgA-TTG2 deposits), which have been found in
liver biopsy specimens from patients with active CD and elevated liver transaminase values, and also
in skeletal muscle, the appendix, and lymph nodes, suggest that alteration in TTG2 bioactivity (i.e.,
inhibition by anti-TTG2 antibodies) might play a role in celiac extra-intestinal manifestations, including
liver injury [46]. We described that also another autoantigen, calcium binding protein calreticulin,
could be involved in putative pathogenesis of liver injury and celiac disease [16,47].
Moreover, vitamin D deficiency, which is commonly found in active celiac disease [48], could also
contribute to a proinflammatory state in the liver. Vitamin D is known for its anti-inflammatory effects
on immune cells, which might be particularly relevant to the liver’s immune response. For instance,
vitamin D inhibits the inflammatory maturation of dendritic cells, influences the responsiveness of
macrophages to LPS and other MAMPs, and facilitates homing of activated T cells [10].
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6. Celiac Disease and Liver Disorders in the Clinical Context
Although CD is associated with a wide spectrum of liver disorders, two distinct
forms can be distinguished: (1) cryptogenic hypertransaminasaemia (celiac hepatitis), and (2)
associated autoimmune liver diseases (AILD), such as autoimmune hepatitis (AIH), autoimmune
cholangitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC). Cryptogenic
hypertransaminasaemia (celiac hepatitis), a common extraintestinal presentation of CD, is closely
related to gluten intake. Additionally, CD can simply coexist as a coincidental finding with several liver
diseases, such as non-alcoholic fatty liver disease (NAFLD) (and its subgroup termed non-alcoholic
steatohepatitis (NASH)), chronic viral hepatitis B or C, alcoholic liver disease, hemochromatosis,
Wilson’s disease, and other hereditary hepatic diseases [3,44,49–51]. Swedish epidemiological studies
have revealed that patients with CD have an increased risk of both prior and subsequent liver disease,
four-times and six-times, respectively [52], and an eight-times increased risk of mortality from liver
cirrhosis [53]; however, no increased risk of liver transplantation was found (HR, 1.07; 95% CI, 0.12–9.62;
p = 0.954) [52]. Similarly, in the large-scale screening study, we observed that seropositivity for IgA
anti-TTG antibodies in patients with various liver diseases is higher (3%) [44] then prevalence of celiac
disease in the general population [54].
6.1. Celiac Hepatitis
Isolated elevation of serum transaminases (alanine aminotransferase (ALT) and aspartate
aminotransferase (AST)) is often present in newly diagnosed, active CD. The liver injury in CD,
when other concomitant hepatic disease is absent, and that completely resolves after GFD, has been
termed “celiac hepatitis” [55]. The reported prevalence of elevated serum transaminase levels in active
celiac diseases varies from 10–50% [2–6].
Elevated transaminases do not correlate with sex, weight, height, or body mass index [4–6].
Some studies found no correlation with CD symptoms at diagnosis and found that patients were usually
asymptomatic [5,6,56]. While others have reported an association between hypertransaminasemia and
malabsorption and diarrhea, or poor growth in children [4,6]. In a study performed by Aarela et al.,
factors associated with increased ALT were poor growth and severe villous atrophy. There was
a moderate statistically significant correlation between ALT and endomysial antibodies (r = 0.334,
p < 0.001), TTG2 antibodies (r = 0.264, p = 0.002), and ferritin (r = −0.225, p = 0.03), but not with
other laboratory values [6]. Similarly, in adult celiac patients, one study found a correlation between
hypertransaminasemia and malabsorption (odds ratio (OR), 2.22; p = 0.004), diarrhea (OR, 1.72; p = 0.005),
and increasing severity of mucosal lesions (OR, 1.46; p = 0.001) [4]. By contrast, another study reported
that the severity of intestinal histological changes did not correlate with transaminases levels [57].
Hypertransaminasaemia has been shown to correlate with intestinal permeability. In active CD,
the intestinal permeability index (% lactulose/% mannitol in a 5 h urine collection) is statistically
significantly (p < 0.0001) higher in patients with elevated transaminases and is correlated with AST
(tau = 0.34; p < 0.0001) and ALT (tau = 0.32; p < 0.0001) [22].
Generally, hypertransaminasaemia is mild. Values greater than 5-time the ULN (upper limit of
normal) are seen in a minority of patients [4,5]. The clinical presentation of celiac hepatitis is often
asymptomatic but can vary up to advanced liver disease. Chronic untreated CD may also lead to chronic
hepatitis and consequent liver cirrhosis, including, although seldom, end-stage liver cirrhosis requiring
liver transplantation [58,59]. Acute cryptogenic liver failure, which resolved after a GFD without
the necessity for liver transplantation, has been, although rarely, described in untreated CD [58,60],
or CD that was diagnosed long after liver transplantation due to “cryptogenic” liver cirrhosis [61].
In childhood CD, six cases of severe liver disease (two of them needing liver transplantation) have been
reported [62].
No histologic findings are pathognomonic for celiac hepatitis. Non-specific reactive hepatitis is
the mostly described lesion, but the histologic picture varies from normal liver architecture, or minimal
lymphocytic infiltrates of portal tracts, to mild or moderate reactive hepatitis, steatosis, fibrosis, and
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rarely to late morphological changes, such as advanced fibrosis or cirrhosis. Inflammatory alterations
of the bile ducts have not been found [1,44,56,63].
Celiac hepatitis is characterized by the presence of liver injury that resolves after introduction of
a GFD. In the majority patients, a GFD leads to normalization of previously elevated transaminases
levels within 1 year [2–6,60]. This suggests that gluten intake (that is responsible for small intestinal
damage and the autoimmune reaction) drives the pathogenesis of celiac hepatitis.
Only a small percentage of patients with celiac hepatitis will need longer periods for complete
normalization of liver tests. The time needed probably reflects the time required for complete intestinal
mucosal recovery, which has been shown to take up to 3–5 years after the initiation of a GFD [64,65].
The relationship between hypertransaminasemia and gluten intake in celiac hepatitis has also
been documented in other observations: (1) liver transaminases remained elevated during GFD
non-compliance [66], (2) even normal transaminase levels decreased significantly on a GFD, and (3) a
gluten challenge can lead to mild but transient hypertransaminasemia [67]. Several other observations
have shown histologic improvement of liver injury (i.e., a decrease in steatosis, portal and lobular
inflammation, and fibrosis score) on a GFD [63].
6.2. Associated Autoimmune Liver Diseases
The association between CD and AILD is more uncommon than celiac hepatitis, although it has
been widely demonstrated. According to systematic reviews, the prevalence of CD in AIH is 6.3% in
children [2] and about 4% in adults [7]. The prevalence of CD in PBC varies from 3–7%, and in PSC
from 2–3% [8].
The pathophysiology of CD associated AILD is not driven directly by gluten, since good adherence
to a GFD alone usually does not lead to an improvement in liver tests or in the course of hepatic
disease [3,8,44,49,50]. Patients with AILD and CD require both specific immunosuppressive therapy
for the liver disorder as well as a GFD. GFD only improves symptoms related to CD while decreasing
the risk of long-term CD complications. It is unknown if the prognosis of patients with AILD associated
with CD is different from patients with AILD alone. The clinical impact of a GFD on the progression
of AILD, therefore, remains uncertain [68,69]. Although, studies carried out on a small number of
pediatric patients with AIH showed that children with AIH and CD on a GFD achieved treatment-free
sustained remission in a significantly higher proportion compared to those without CD [70,71]. Another
study reported that several children with CD and AIH developed relapses during a spontaneous gluten
challenge [72]. So, a GFD may prevent an early relapse of AIH in patients having AIH associated
with CD.
Moreover, in several patients with newly diagnosed CD and suffering simultaneously from
liver failure due to AILD, GFD was able to reverse hepatic dysfunction, even in cases where liver
transplantation was being considered [58,60]. The mechanisms underlying the association between CD
and AILD are poorly understood. The most important feature is likely a shared genetic predisposition
to autoimmunity [68,69]. Like other autoimmune diseases, CD is a polygenic disorder. In CD, genetic
susceptibility is largely associated with specific human leucocyte antigen (HLA) class II molecules
on antigen-presenting cells. About 90% of CD patients carry a particular HLA variant (HLA-DQ2.5)
that encodes the DQ2.5 molecule, the rest carry HLA-DQ8 or HLA-DQ2.2 [73]. The main genetic
marker of CD, HLA-DQ2.5, has a strong linkage disequilibrium with HLA-DR4, HLA-DR52, and
HLA-DR3, being the major HLA risk factor for autoimmune liver disease (AIH, PSC, PBC) [74].
Additionally, gene polymorphisms outside the HLA contribute to the genetic susceptibility to both CD
and AILD. There are 39 well-established non-HLA loci, including a greater number of independent
genetic variants that are associated with CD risk [73]. Many of these loci are related to immune
regulations, particularly to B cell and T cell function, and are also shared with other autoimmune
diseases, including AILD. The sharing of genetic loci between CD and AILD suggests that there are
also shared dysregulated immune responses contributing to the relationship between the two diseases.
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Moreover, epigenetics, microbiota, and intestinal barrier dysfunction are emerging as potent factors
modulating genetic susceptibility and affecting disease manifestation [32,73].
It remains an open question, whether recently described gluten/wheat-related disorders, such as
non-celiac gluten sensitivity and wheat-sensitive irritable bowel syndrome have any link to liver
diseases [75].
6.3. Non-Alcoholic Fatty Liver Disease and Celiac Disease
NAFLD is currently a major cause of chronic liver disease with an estimated global prevalence
of approximately 25% [76]. Its occurrence in CD patients is likely a coincidence rather than a true
relationship, due to the high frequency of both diseases in the general population [51].
Patients with NAFLD are at increased risk for a later diagnosis of CD [77]. The reported prevalence
of CD in patients with NAFLD is 2–14% [78]. Conversely, individuals with CD seem to be at increased
risk (4–6-times) of NAFLD compared to the general population [52,77]. The relative risk of NAFLD
development after a CD diagnosis is higher in the first five years (probably because of excessive weight
gain on a GFD) but remained statistically significant even 15 years after a CD diagnosis [77]. GFD could
be connected with some dietetic imbalances (such as slightly increased calories, lipid and cholesterol
intake, or decreased fiber intake) [79], so patients on GFD are prone to develop NAFLD.
Besides lipotoxicity of specific lipid classes that are stored in hepatocytes, the pathogenesis for
NAFLD/NASH may also involve changes in gut permeability, gut microbiota, and other components
of gut–liver axis [80]. It has been demonstrated (using the 51Cr-EDTA test, by immunohistochemical
analysis of zonula occludens protein-1 expression in duodenal biopsy specimens, by the
lactulose/mannitol ratio, and by increased levels of circulating zonulin) that NAFLD patients have
increased intestinal permeability [81,82]. Moreover, increased intestinal permeability and increased
levels of circulating zonulin correlate with the severity of steatosis [82].
NAFLD frequently occurs in type 2 diabetes mellitus and obesity. However, when metabolic
syndrome is absent, NAFLD may be related to concomitant CD. Therefore, in the absence of type 2
diabetes mellitus or obesity, and when other causes of liver disease are excluded, patients with NAFLD
should be screened for CD [50].
Conversely, NAFLD/NASH in patients with CD may also occur as a metabolic sequel of
malabsorption and long-standing malnutrition [51]. Malnutrition generates mitochondrial dysfunction
in hepatocytes and a reduction in mitochondrial fatty acid β-oxidation, which subsequently leads to
abnormal hepatic fat deposition [83]. A GFD usually leads to resolution of liver steatosis and even
steatofibrosis in these CD patients [84]. Beyond the mere improvement in nutritional status, a GFD
may contribute to restoration of innate immune liver function via harmonization of the gut–liver axis.
Luckily, CD disease presenting with severe malabsorption is now uncommon [85].
7. Clinical Implications: Hepatic Manifestation of Celiac Disease
Liver tests should be routinely checked in all patients with newly diagnosed CD. Hepatic
manifestation of CD (i.e., hypertransaminasemia in active CD) deserves specific clinical attention.
When a patient’s history and physical and/or ultrasonographic evaluation shows no signs of
concomitant hepatic disorder, there is a higher probability of celiac hepatitis than of associated
autoimmune liver disease or other coexisting liver disease. Asymptomatic hypertransaminasemia
(<5-time the ULN and an AST/ALT < 1) together with a normal physical and ultrasound examination
strongly suggests celiac hepatitis. Instead of initial extensive (and expensive) investigations for other
causes of liver injury, a “treat-first then re-evaluate” approach is recommended. Liver enzymes should
be re-checked after 6–12 months on a strict GFD. If the elevated transaminases return to normal after
gluten exclusion, a diagnosis of celiac hepatitis is confirmed, and only follow-ups are recommended,
which should optimally include a physical examination, abdominal ultrasound, and liver tests once
a year. Because of the nonspecific nature of the findings, liver biopsies are not useful in celiac
hepatitis [49,70].
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However, lack of normalization of liver enzymes within one year despite adherence to a GFD
increases the probability of another concomitant liver disease (of autoimmune, viral, metabolic, or toxic
origin). In such cases, a thorough hepatologic examination is necessary [49,70].
Furthermore, patients with elevated liver tests at the time of a CD diagnosis require an extended
search for other liver disease, i.e., when the clinical evaluation is not consistent with celiac hepatitis,
such as: (1) elevated transaminases levels >5-time the ULN and/or AST/ALT > 1, (2) laboratory signs
of cholestasis (i.e., elevated gamma glutamyl transferase, alkaline phosphatase of liver origin, and/or
bilirubin), (3) symptomatic liver disorder and/or (4) physical and ultrasonographic signs suggesting
a liver disorder. Additionally, abnormal liver tests during follow-up of CD patients who are strictly
adhering to a GFD should raise suspicion of other liver disease [49].
8. Clinical Implications: Screening of Celiac Disease in Liver Diseases
Screening for CD is recommended in groups of patients with associated AILD (AIH, PBC, PSC), as well
as in patients with chronic unexplained hypertransaminasemia, hepatitis or cirrhosis of unknown etiology,
and in patients with NAFLD (particularly in those without metabolic syndrome) [8,44,50,58,63,68].
Although the magnitude of the benefit from gluten avoidance relative to reversing autoimmune
liver disease in CD patients is controversial, a theoretical context (balance in gut–liver axis and
subsequent decline in liver innate immune response) and several of the above-mentioned clinical
observations suggest the importance of a GFD. Early detection and treatment of CD may mitigate
progression to end-stage liver disease and liver failure [8,58,69].
The first steps in CD screening should include serological testing of TTG2 IgA, together with
total serum IgA, followed by subsequent endomysial antibody (EMA) testing in questionable cases
(i.e., low titers, possibly false-positive result of TTG2 IgA, which can occur in other autoimmune
diseases, etc.). EMA has very high specificity (>99%) for CD. Serologic positivity needs to be confirm
with a distal duodenal biopsy [86]. Screening for CD in the context of liver disease deserves special
attention in terms of the interpretation of celiac serologic tests, since their accuracy is significantly lower
than in individuals without liver disease; especially the guinea pig based anti-TTG2 ELISA testing,
which has been shown to have higher rate of false positive results in patients with liver fibrosis. [49].
Thus, in patients with chronic liver disease, EMA evaluation is an important test that can increase
diagnostic accuracy. Moreover, immunosuppression (in AILD or after liver transplantation) in the
absence of gluten withdrawal can normalize both EMA and TTG2 antibodies. Therefore, in AILD or in
end-stage liver cirrhosis, screening for CD must be performed before the start of immunosuppressive
therapy or before liver transplantation [49,50].
9. Conclusions and Recommendation
The liver is a highly immunologically active organ that must simultaneously induce and maintain
tolerance while being able to trigger immune responses leading to both protective immunity as well as
liver inflammation and fibrosis. An impaired intestinal barrier, dysbiosis, and translocation of bacterial
antigens are characteristics of both CD and chronic liver diseases. Disturbances in the gut–liver axis,
inhibition of liver TTG2 enzymatic activity, and vitamin D deficiency probably all contribute to liver
injury associated with CD. The intestinal microbiome influences the composition of nutrients delivered
to the liver and affects metabolic liver functions connected with inflammation.
A simultaneous clinical presentation of CD with a wide spectrum of liver disorders is
well-documented and common. In celiac hepatitis, gluten intake drives liver injury, and a gluten-free
diet is the only widely used treatment. Patients with AILD associated with CD can (in addition to
specific immunosuppressive treatment) also benefit from a GFD. Overlooked CD can cause chronic
hepatitis and rarely liver cirrhosis. Screening for CD should be integrated into the diagnostic routine
not only in AIH, PSC, and PBD, but also in unexplained hypertransaminasaemia, chronic hepatitis or
cirrhosis of unknown origin, and NAFLD presenting without metabolic syndrome.
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A better understanding of the link between gluten-related immunity and liver injury
could contribute to prevention and offer new approaches to the treatment of liver diseases of
different etiologies.
Author Contributions: I.H. wrote the manuscript. D.S., L.T., and H.T.-H. had contributions to the manuscript
conception, and substantially revised the manuscript.
Funding: The work was supported by projects 13-14608S and 16-06326S of the Czech Science Foundation,
TH03010019 of Technology Agency of the Czech Republic, Institutional Research Concept RVO: 61388971,
and COST Action 1402, Programme Progres Q36/64 (Initial Stages of Diabetes Mellitus, Metabolic and Nutritional
Disorders) of Charles University, Czech Republic, and Strategy AV21-8 (The Czech Academy of Sciences).
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Abbreviations
AIH autoimmune hepatitis
AILD autoimmune liver disease
APCs antigen presenting cells
CD celiac disease
DAMPs damage-associated molecular patterns
DCs dendritic cells
DNA deoxyribonucleic acid
FGFR4 fibroblast growth factor receptor 4
FXR farnesoid X receptor
GALT gut–associated lymphatic tissue
GFD gluten free diet
GIT gastrointestinal tract




MAMPs microbial-associated molecular patterns
MDSC myeloid-derived suppressor cells
MHC major histocompatibility complex
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NK cells natural killer cells
NKT cells natural killer T cells NKT cells
NLRs NOD like receptors
PBC primary biliary cholantitis
PRRs pattern-recognition receptors
PSC primary sclerosing cholangitis
SCFAs short chain fatty acids
Treg cells regulatory T cells
TGF-β transforming growth factor β
TGR5 Takeda G-protein receptor 5
Th cells T helper cells
TJs tight junctions
TLRs toll like receptors
TNF tumor necrosis factor
TTG2 tissue transglutaminase 2
ULN upper limit of normal
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Abstract: Population-based screening studies have shown celiac disease to be one of the most common
chronic gastrointestinal diseases. Nevertheless, because of the diverse clinical presentation, the great
majority of patients remain unrecognized. Particularly difficult to identify are the multifaceted
extraintestinal symptoms that may appear at variable ages. Although the pathogenesis and
long-term outcome of these manifestations are still poorly established, there is some evidence that
unrecognized celiac disease predisposes to severe complications if not diagnosed and prevented with
an early-initiated gluten-free diet. Therefore, it is of utmost importance that physicians of different
disciplines learn to recognize celiac disease in individuals with non-gastrointestinal symptoms. In the
future, more studies are needed to clarify the factors affecting development and prognosis of the
extraintestinal manifestations.
Keywords: celiac disease; extraintestinal; recognition; diagnosis; clinical presentation; gluten-free
diet; prognosis
1. Introduction
During the past few decades, we have come to recognize that celiac disease is among the most
common gastrointestinal diseases, both in children and adults. The true prevalence of the disease in
many Western countries is estimated to be as high as 1–3% and is increasing [1]. At the same time,
modern sensitive and specific transglutaminase 2 (TG2) antibody based serological tests have made
non-invasive case finding and screening of celiac disease considerably easier. In theory, the simplified
diagnostics should have also increased the proportion of clinically detected cases, and this has indeed
been the case in some, particularly Northern European, countries [2,3]. However, even in these areas,
let alone globally, celiac disease remains seriously underdiagnosed. For example, it is estimated that
in the United States, more than 90% of all affected patients are unrecognized [4]. It must also be
emphasized that, instead of clinical case finding, a substantial proportion of patients in the aforesaid
countries are found by at-risk group screening [5].
The evident difficulty in identifying celiac disease may be explained by in part by the
heterogeneous and often vague clinical presentations. While the characteristic malabsorptive disease
and gastrointestinal symptoms are relatively well known, the majority of celiac disease patients
may in fact suffer from extraintestinal manifestations. These may affect almost every organ of the
body, including the nervous system, liver, skin, and reproductive and musculoskeletal system [6–9].
Furthermore, some of these manifestations appear in early childhood, while the rest are not seen
until adulthood, including in the elderly. Although evidence is limited, some extraintestinal
presentations may lead to permanent complications if not recognized and treated early enough.
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Therefore, extraintestinal celiac disease needs to be recognized by physicians of various specialities,
including gastroenterologists, internists, pediatricians, neurologists, dermatologists, gynecologists,
and particularly general practitioners and family doctors.
In this review, we will provide an overview about current understanding of the pathogenesis
and age-related clinical outcomes of the variable extraintestinal manifestations of celiac disease.
In particular, we aim to improve the early recognition and diagnostic yield of this multifaceted
condition, and subsequently reduce the risk of ill health and long-term complications.
2. Changes in Clinical Presentation
Celiac disease was long considered as a rare malabsorptive disease affecting mainly infants and
toddlers. Classical symptoms included failure to thrive, chronic diarrhea, and abdominal distention.
In the 1970s, the incidence of ‘typical’ celiac disease patients seemed to decrease and concurrently,
older patients with milder symptoms were identified. When screening for celiac disease with sensitive
and specific endomysium and transglutaminase antibodies from serum became possible in the 1980s
and 1990s, respectively, the high prevalence and wide clinical presentation of celiac disease started to
become evident [5,10].
Gastrointestinal related symptoms and signs such as anemia, impaired growth, decreased bone
mineral density, and micronutrient deficiencies were recognized from early on to be associated with
untreated celiac disease. Although these were initially thought to be present only in connection with
malabsorption, it was later understood that they could also be a sole manifestation [11–13]. Dermatitis
herpetiformis was among the first extra-intestinal symptoms of celiac disease recognized [14].
Later, other organ systems were found to be affected, when, for example, patients with earlier
unexplained neurological and articular symptoms were diagnosed. In addition, as a result of the
increased screening, the symptoms common in the general population, such as headache and tiredness,
were often recognized in celiac disease patients. However, their true association to the disease and
especially the response to the dietary treatment remains controversial [15]. Altogether, it is important
to remember the unspecificity and complexity of the above-mentioned symptoms, as they may be
present also in many other common disorders, such as irritable bowel syndrome (IBS), chronic fatigue
syndrome, and migraine.
3. Variable Definitions for Symptoms and Findings
Clinical features of celiac disease are often classified categorically as ‘typical’ and ‘atypical’.
However, the definition for these terms is heterogeneous, which likely reflects the above-described
historical background. Extra-intestinal manifestations are particularly difficult to classify, even though
they may actually be even more common than the ‘typical’ symptoms. Consequently, a few years
ago, a group of experts encouraged the alternate terminology of ‘classical’ and ‘non-classical’ celiac
disease [16].
Another challenge in celiac disease is to discriminate the symptoms from the complications and
from the independently associated diseases. Celiac disease symptoms should be reversible with the
gluten free diet, whereas complications may be permanent and irreversible, especially if the initiation
of treatment is delayed (Figure 1). Well-known associated conditions with an increased risk for celiac
disease are for example type 1 diabetes, autoimmune thyroidal disease, and Down’s syndrome [17].
Whether the early diagnosis and treatment of celiac disease could prevent some of these conditions has
been debated [18,19]. Again, these conditions should not be confused with totally unrelated disorders
with often overlapping symptoms, such as IBS.
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Figure 1. Extra-intestinal manifestations and complications of celiac disease classified based on their
response to early initiated gluten-free diet (GFD) and typical age of development.
4. Epidemiology and Pathogenesis of Extraintestinal Manifestations
Although the existence of extraintestinal manifestations in celiac disease has been known for
decades, their prevalence remains poorly established. This issue is complicated by the variable
definitions and considerable age-related variations in the appearance of these symptoms (Table 1).
For example, poor growth and delayed puberty are evidently exclusively pediatric presentations,
whereas osteoporosis, infertility, and dermatitis herpetiformis are typical adulthood findings. Anemia,
liver abnormalities, and joint problems are seen in both pediatric and adult patients (Table 1). Although
celiac disease is known to be more common in females, the gender distribution of the extraintestinal
symptoms is currently mostly obscure [20].
The pathogenesis of most extraintestinal manifestations is also obscure. There is some
evidence that their presence is associated with an overall more severe clinical and histological
presentation [20], but neither the appearance nor severity seems to be just a direct consequence
of intestinal damage [21–26]. Another intriguing question is the balance between genetic and
environmental factors, as even identical twins with celiac disease may have completely different
phenotype [27]. The at least partially different pathogenic background of the variable presentations
of celiac disease is further supported by the peculiar appearance of serological markers in some of
these conditions [6,22,24]. The clinical features and plausible pathophysiological mechanisms of the
best-characterized extraintestinal manifestations are further discussed below.
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Table 1. Prevalence of the best-characterized extraintestinal manifestations of untreated celiac disease
in children and adults.
Children Adults
% % References
Poor growth 1 11–70 - [20,28,29]
Short stature 1 4–33 3 [15,30–33]
Anemia 12–40 23–48 [12,15,20,28,30,32–34]
Neurological symptoms 4–52 24 [15,20,28,29,31]
Enamel defects 0–15 1–83 [20,29,32,33,35,36]
Liver abnormalities 1–57 2–5 [8,15,32]
Joint manifestations 1–10 2–9 [15,20,29,30,32,33]
Dermatitis herpetiformis 2–3 10–20 [20,30,32,37]
Osteoporosis 0 4–23 [15,32]
Infertility - 5 [9,15]
1 Definitions of poor growth and short stature have varied between the studies.
4.1. Poor Growth
Poor growth is likely one of the most common extraintestinal manifestations in pediatric celiac
disease, although defining its true prevalence is complicated by its variable definitions (Table 1).
We recently observed that impaired growth might be particularly common in children with a
younger age at diagnosis and a more severe overall presentation of the disease [11]. For example,
the malabsorption of nutrients and abnormalities in growth hormone-insulin-like growth factor axis
and/or in thyroid function have been suggested as pathogenic mechanisms [26,38,39], but further
studies are needed to confirm these findings.
4.2. Anemia
Anemia is a common extraintestinal manifestation of untreated celiac disease in all age groups
(Table 1). Like poor growth, the presence of anemia seems to be associated with a more severe
disease presentation [12,34]. Its prevalence could be expected to decrease over time as a result
of an earlier diagnosis and the generally improved nutritional status of children. Regardless,
celiac disease is still increasingly found in subjects with unexplained anemia [5]. With regards to
pathogenesis, malabsorption/deficiencies of iron, vitamin B12, and folic acid may be implicated [40].
However, the etiology of anemia in celiac disease might be more complex, as it may be present in
autoantibody positive individuals even before the development of enteropathy [41].
4.3. Neurologic Manifestations
Approximately one-fifth of celiac disease patients suffer from neurological manifestations
(Table 1). The most common of these are gluten ataxia and peripheral neuropathy [42], which often
present without accompanying gastrointestinal symptoms [43]. The pathogenesis of neurological
manifestations is still somewhat obscure. In gluten ataxia, gluten-dependent transglutaminase 6 (TG6)
autoantibodies targeted against the cerebellar cells may play a role and might be useful in the
diagnostics of this condition [6,22]. However, TG6 antibodies have also been detected in children with
celiac disease without association to neurological symptoms [23]. It remains to be proven whether this
could predict the later adult onset of neurological symptoms.
4.4. Dental Enamel Defects
Disturbances in the amelogenesis of permanent teeth is a well-defined finding in celiac disease,
but there are considerable variations in its reported prevalence (Table 1). Enamel defects have been
particularly common in older studies together with severe infant celiac disease and lower general
health [36]. It is possible that this manifestation is disappearing as, for example, is rickets related
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to celiac disease. However, for an accurate diagnosis the dental enamel should be evaluated by an
expert dentist. Malnutrition, hypocalcemia, and immunologic disturbances have been suggested as
causative factors of enamel defects [35], and the severity seems to be associated with the duration of
gluten-exposure [44].
4.5. Liver Abnormalities
Prevalence of hypertransaminasemia has been reported in older studies up to 57%, while more
recent studies report only 9–14% (Table 1), possibly again reflecting earlier diagnosis and milder
presentation of celiac disease. Usually the hepatic injury is mild and easily reversible, but in rare
occasions, celiac disease may lead even to liver failure [45]. The severity of hypertransaminasemia
seems to be associated with the presence of malabsorption, high values of celiac autoantibodies,
and advanced duodenal lesion [8,46], and the suggested mechanisms include altered gut permeability
leading to an increased exposure to hepatotoxins in the portal circulation [47]. Interestingly,
TG2 autoantibody deposits have been found in liver biopsies from affected patients and could
contribute to the hepatocellular damage [21]. It is also important to keep in mind that celiac patients
have overrepresentation of coexisting liver diseases such as autoimmune hepatitis, primary biliary
cholangitis, and primary sclerosing cholangitis [48].
4.6. Joint Manifestations
Variable joint symptoms are quite often, although again inconsistently, reported in celiac disease
(Table 1). The observed symptoms are usually described vaguely as arthralgia rather than objective
synovitis [20,49]. However, subclinical synovial effusion and sacroiliitis have also been reported [50–52].
Differential diagnosis is challenging and includes, for example, growing pains in children and variable
musculoskeletal complaints and arthrosis in adults. Once again, it should be remembered that
celiac disease is associated with many autoimmune conditions, including rheumatologic diseases
such as Sjögren’s syndrome [53], juvenile rheumatoid/idiopathic arthritis [54], and systemic lupus
erythematosus [55]. At present, the pathogenesis of the joint symptoms in celiac disease remains
entirely speculative.
4.7. Dermatitis Herpetiformis
Dermatitis herpetiformis is a dermatological manifestation of celiac disease that usually appears
in adulthood (Table 1). The characteristic itching and blistering rash appears mostly on elbows, knees,
and buttocks. In contrast to intestinal celiac disease, dermatitis herpetiformis is more common in males
than females [7]. The diagnosis is based on skin biopsy showing characteristic IgA deposits in the
papillary dermis next to the lesion [56]. Interestingly, besides TG2, dermatitis herpetiformis patients
can also develop autoantibodies targeted against epidermal transglutaminase 3 [24]. Even though the
characteristic rash is the primary manifestation, up to 72% of the patients also have enteropathy [57].
Interestingly, the incidence of dermatitis herpetiformis seems to be decreasing in contrast to other
forms of celiac disease [7]. Furthermore, ‘classical’ celiac disease patients with poor dietary adherence
can change their phenotype to dermatitis herpetiformis over time [58].
4.8. Bone Disease
Rickets is a classical finding in children with celiac disease, but it is nowadays rarely seen in
developed countries. On the contrary, osteoporosis is common in adult celiac disease patients (Table 1),
particularly in elderly patients and in postmenopausal women. The malabsorption of calcium and
vitamin D may lead to secondary hyperparathyroidism and subsequently a high bone turnover and
osteoporosis [59]. Increasing the circulating cytokines and an altered balance of bone turnover have also
been suggested to play a role [60,61]. Neutralizing autoantibodies against osteoprotegerin have been
detected in celiac disease patients [25], but their true role in the development of osteoporosis remains
contradictory [62]. Decreased bone mineral density can also be seen in screen-detected patients [63],
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even before the development of enteropathy [64]. These observations emphasize the importance of
early diagnosis of celiac disease to prevent advanced bone disease and subsequent fractures.
4.9. Problems in Reproductive and Endocrine Systems
Delayed puberty can be observed in children with untreated celiac disease [15,32], and various
problems in reproductive health, such as infertility, recurrent miscarriages, and intrauterine growth
restriction, have been reported in adult female patients [9,15]. The pathogenesis of delayed puberty in
celiac disease is unknown, although it is a common finding also in many other chronic diseases during
adolescence. However, there are several hypotheses for the pathogenesis of reproductive system’s
maladies. Untreated celiac disease may lead to deficiencies of micronutrients such as zinc, selenium,
and folic acid which are important during pregnancy and fetal development, anemia may also have
a role [9]. Celiac disease may affect other hormonal systems, for example, TG2 autoantibodies are
able to bind to TG2 in thyroid tissue and the celiac autoantibody titers have been shown to correlate
with the antithyroperoxidase antibody titers [65]. However, this should not be confused with the
overrepresentation of celiac disease among children with autoimmune thyroid disease due to a shared
genetic background [66].
4.10. Other Extraintestinal Manifestations
Besides the above-mentioned, several other extraintestinal manifestations have been suggested
to be associated with celiac disease. Aphtous ulcers, headache, and fatigue are frequently reported
but unspecific clinical findings [15,31,35]. Several neuropsychiatric conditions including learning
disorders, developmental delay, and attention deficit hyperactivity disorder have also been associated
with celiac disease [31], as well as are psychiatric disorders including depression, anxiety, and even
schizophrenia [15,67]. In addition, there are reports about possible associations between celiac disease
and uveitis, eczema, psoriasis, asthma, and various cardiovascular symptoms [68–71]. However,
because of the common and non-specific nature of these conditions, a true pathogenic relationship to
celiac disease requires further evidence [15,72].
5. Effects of Dietary Treatment to the Extraintestinal Manifestations
In general, a gluten-free diet is an effective treatment for celiac disease. However, the dietary
response might be faster and more complete in children than in adults [73,74]. Extraintestinal
manifestations also have a good prognosis in children if appropriately treated with a gluten-free
diet (Table 2) [8,73,75], but in adults and in a subgroup of children, the dietary response might be
incomplete [12]. In such cases, the possibility of coexisting conditions should be remembered. Dapsone
medication is often needed as an additional therapy in dermatitis herpetiformis for some time [75].
A gluten-free diet has also been shown to be beneficial for more advanced extraintestinal
manifestations, such as a low bone mineral density, liver failure, and infertility [9,13,46,76–78], but here,
the timing of the diagnosis is crucial (Table 2). Early developing complications such as dental enamel
defects should actually be treated even before their appearance [44]. In children with poor growth,
a significant catch-up growth is usually achieved after the beginning of dietary treatment and thus
reduced adult height is uncommon [78,79]. However, growth problems should likely be treated at
latest in puberty, in order to avoid suboptimal height development [80–82]. With regards to bone
health, patients diagnosed in childhood seem to have no increased risk for osteoporotic fractures [83],
but again, in order to achieve optimal bone accrual, an early diagnosis is beneficial [84].
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Table 2. Response of extraintestinal manifestations in celiac disease to a gluten-free diet (GFD).
Manifestation Response Comments References
Anemia Yes Sometimes slow or incomplete response [12,15]
Dermatitis herpetiformis Yes Dietary response may be slow andrequire additional Dapsone medication [15,75]
Transaminasemia Usually Often mild and reversible; in rare casesmay lead to liver failure [8,45]
Poor growth Variable May lead to reduced adulthood heightif not treated before puberty [15,82]
Neurological symptoms Variable In children, usually good response, butin adults, possibly irreversible [6,43]
Decreased bone mineral density Variable Initiation of GFD before school age maybe needed for optimal bone accrual [13,76,84]
Joint problems Variable Coexisting musculoskeletal diseaseshould be excluded if poor response [15]
Enamel defects Infrequently Early appearance and irreversible inpermanent teeth [44]
Infertility Unclear Conflicting results [9,77,85]
Non-adherence is the most common reason for an unsatisfactory treatment response [15,73].
Nevertheless, some extraintestinal manifestations may not improve entirely despite an apparently
strict diet, which may reflect their more complex etiology [15,72,73], but it is also possible that at least
a part of them are in fact related to disorders other than celiac disease. Accordingly, Jericho et al. found
that almost 30% of the children with a failure of catch-up growth on a gluten-free diet to have some
co-existing condition [15]. Therefore, additional reasons for poor response should be sought in cases
with proven adherence. True pediatric refractory celiac disease is almost non-existent and one should
be very cautious before making such a diagnosis [86].
6. Importance of Early Diagnosis
As discussed, it seems that most of the advanced extraintestinal manifestations might be
preventable by the early diagnosis of celiac disease. One way to increase the diagnostic yield would
be screening of at-risk groups. Counterweighting this approach is the burden of a gluten-free diet,
which is challenging to maintain, socially restrictive, and expensive. This may lead to reduced quality
of life particularly in patients with negligible symptoms. There is, however, some evidence that
even apparently asymptomatic adults may already have advanced histological disease and benefit
from the diet [63,87]. Furthermore, a long diagnostic delay may increase the risk of poor clinical
response [73,88,89]. This issue is less well defined in screen-detected children, but there is data showing
that they may also experience unrecognized symptoms, including extraintestinal manifestations [90,91],
and benefit from an early diagnosis [91–94].
An unsolved question is that a part of screened individuals may have a so-called potential celiac
disease with positive celiac autoantibodies but normal villi, and thus do not fulfil the current diagnostic
criteria [95]. This might be an early stage of developing celiac disease, but at present, more evidence
about the natural history of this condition is warranted [96].
Population-based mass screening would be a very effective approach to finding unrecognized
celiac patients, but is currently not recommended because of the lack of scientific evidence [95,97,98].
Major open questions concerning such a wide-scale screening are the above-mentioned challenges in
the diagnostics of patients with early or potential celiac disease, and the balance of the benefits and
harms of the treatment for asymptomatic patients. Furthermore, the cost-effectiveness of screening
is particularly important in these circumstances, but, unfortunately, this issue is currently very
scarcely studied.
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All in all, the current recommendations about screening for celiac disease have been varying
between countries and between children and adults [95,98,99]. However, most organizations
recommend a targeted at-risk group screening, this usually including first-degree relatives of celiac
disease patients and those suffering from type 1 diabetes [95,99]. Meanwhile, before further evidence
about screening is provided, active case finding is especially important. By carrying this out efficiently,
at least part a of the patients with extraintestinal manifestations could be diagnosed before appearance
of permanent complications.
7. Conclusions
In recent years, we have witnessed an upsurge of interest towards different gluten-related
conditions, demonstrated, for example, by the rapid increase of the popularity of self-adopted
gluten-free lifestyle. This notwithstanding, the clinical prevalence of officially diagnosed celiac disease,
is all but satisfactory. This is worrisome, as the condition is proven to be associated with an increased
risk of long-term complications that could very likely be prevented by timely diagnosis and initiation
of a gluten-free diet.
As wide-scale serological screening is currently not recommended, we should aim to improve
the physicians’ and other allied health professionals’ knowledge of the diverse presentations of celiac
disease. For pediatricians, this especially means the identification of the manifestations that can present
already at early childhood and may lead to permanent problems if undetected. Then again, many
extraintestinal symptoms may appear later in life and should thus be known by physicians of relevant
adult subspecialties. It is important to acknowledge the critical role of primary healthcare in these
circumstances, as only effective first-line case finding can lessen the ill-health caused by untreated
celiac disease at the population level. Therefore, we should educate particularly the primary care
providers, in order to understand the value of the early detection of this multifaceted condition.
In the future, we need more information on the prevalence, age of appearance, dietary response,
and long-term prognosis of the variable extraintestinal features of celiac disease. Moreover, at present,
the details of the pathogenesis and reasons for the substantial phenotype heterogeneity in celiac disease
remain mostly obscure. This information could, besides improving the diagnostics of celiac disease,
also provide novel insight of the development of autoimmune diseases in general.
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Abstract: Gluten related disorders (GRD) represent a wide spectrum of clinical manifestations that
are triggered by the ingestion of gluten. Coeliac disease (CD) or gluten sensitive enteropathy is the
most widely recognised, but extra-intestinal manifestations have also been increasingly identified
and reported. Such manifestations may exist in the absence of enteropathy. Gluten sensitivity (GS)
is another term that has been used to include all GRD, including those where there is serological
positivity for GS related antibodies in the absence of an enteropathy. Gluten ataxia (GA) is the
commonest extraintestinal neurological manifestation and it has been the subject of many publications.
Other movement disorders (MDs) have also been reported in the context of GS. The aim of this review
was to assess the current available medical literature concerning MDs and GS with and without
enteropathy. A systematic search was performed while using PubMed database. A total of 48 articles
met the inclusion criteria and were included in the present review. This review highlights that the
phenomenology of gluten related MDs is broader than GA and demonstrates that gluten-free diet
(GFD) is beneficial in a great percentage of such cases.
Keywords: movement disorders; coeliac disease; gluten; gluten free diet
1. Introduction
The term Gluten related disorders (GRD) covers a broad spectrum of immune-mediated clinical
manifestations that are triggered by the same environmental insult; dietary gluten. Coeliac disease (CD)
or gluten-sensitive enteropathy is the best-characterized disease within this wide clinical spectrum.
Moreover, CD is the most common immune-mediated gastrointestinal (GI) disorder diagnosed both in
childhood and adulthood, with an increasing global prevalence [1].
The classical presentation of CD includes GI symptoms (i.e. diarrhoea, abdominal pain, abdominal
bloating), malnutrition, anaemia, and weight loss. The treatment is strict adherence to a gluten-free
diet (GFD). Rarely patients with CD may no longer respond to GFD and are diagnosed with refractory
CD a condition that may require immunosuppressive treatment [2].
Often, patients with gluten sensitivity (GS) can present with subtle or even no GI symptoms and a
wide range of extra-intestinal manifestations affecting different organs. Gluten ataxia (GA), defined as
sporadic cerebellar ataxia in the presence of circulating antigliadin antibodies and no alternative etiology
for the ataxia, is by far the commonest neurological presentation. Nonetheless, several other neurological
manifestations have been reported, such as epilepsy [3,4], gluten encephalopathy [5,6], myopathy [7],
peripheral neuropathy [8–11], and other movement disorders (MDs). On some occasions, MDs have
been recognized as a complication of or co-existing with systemic autoimmune diseases [12,13].
In this paper, we performed a systematically review of the current medical literature on MDs
in CD and GS. We have excluded GA as this has been extensively studied and reviewed previously,
and as such, it is a well-recognised entity [14,15].
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2. Materials and Methods
2.1. Literature and Search Strategy
A systematic computer-based literature search on the topic was conducted on February 12th, 2018
using the Pubmed database. For the search we used two Medical Subject Headings (MeSH) terms
in all fields. Term A was “celiac” or “coeliac” or “gluten” and term B was “chorea” or “choreiform”
or “choreic” or “choreoathetosis” or “athetosis” or “tremor” or “dystonia” or “hemidystonia” or
“torticollis” or “antecollis” or “anterocollis” or “retrocollis” or “laterocollis” or “blepharospasm” or
“ballism” or “hemiballism” or “ballismus” or “hemiballismus” or “stiff” or “Parkinson” or “Parkinson’s”
or “parkinsonism” or “myoclonus” or “myoclonic” or “tic” or “myokymia” or “myorhythmia” or
“Huntington” or “Huntington’s” or “dyskinesia”, and “RLS”. Limitations included English language,
human species, and full text available. We also perused the reference lists of the papers since the
drafting of this paper in order to identify papers not identified through the search strategy.
2.2. Inclusion and Exclusion Criteria
To be included in this review, the articles had to meet the following inclusion criteria:
1. To be original clinical papers.
2. To study human subjects.
3. To involve single cases, case series, or retrospective observational studies with the combination
of CD or GS and MDs.
Exclusion criteria included:
1. Reviews, book chapters, letters to editors, and editorials that are not providing new data.
2. Papers referring only to GA.
3. Results
3.1. Search Results
The search strategy that is described above resulted in the identification of 215 articles. After the
eligibility assessment, 173 articles were further excluded, as they did not meet our inclusion criteria.
Scanning the reference list, six more papers were identified. In total, 48 papers were used for this
review. Table 1 summarizes the characteristics of these papers and Figure 1 illustrates the study
selection process. Table 2 summarizes the characteristics of the patients and the response to GFD in
each movement disorder type.
3.2. Chorea
Chorea is defined as irregular, brief, purposeless movements that flit from one body part to another,
and it can be inherited or acquired [16,17]. Vascular, drug-induced, AIDS-related, and metabolic
were the most common causes of acquired chorea in the case series published by Piccolo et al. [18]
Investigation of chorea should be directed to the most likely causes [19].
The first report suggesting the link between CD and chorea was by Willis and colleagues,
who conducted a retrospective observational study to investigate patients with dermatitis herpetiformis
(DH), which is another extraintestinal manifestation of CD affecting the skin, for evidence of
neurological manifestations [20]. One out of 35 patients with DH suffered chorea. However, of note
is that this patient had been on phenytoin over the last 14 years after a single seizure that may have
played a role in the development of chorea [21,22]. However, subsequently, case reports and small
cases series of patients with chorea and CD or GS, and no other risk factors for developing chorea,
have been published [23–26].
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Figure 1. PRISMA chart. To be included in this review, the articles had to meet the following inclusion
criteria: (1) To be original clinical papers, (2) to study human subjects, (3) to involve single cases,
case series or retrospective observational studies with the combination of Coeliac disease (CD) or
gluten sensitivity (GS) and movement disorders (MDs).
Table 1. Characteristics of the papers included in the review.
Number of Papers Related to Each Movement Disorder (%)
Chorea 5 (11%)
Restless leg syndrome 4 (8%)
Myoclonus 15 (31%)
Palatal tremor 3 (6%)
Dystonia 3 (6%)
Tremor 5 (11%)
Stiff Person Syndrome 2 (5%)
Parkinsonism 3 (6%)
Tics 3 (6%)
Other less commonly reported movement disorders
Opsoclonus-myoclonus 1 (2%)
Propiospinal myoclonus 1 (2%)




Female to male ratio 7:2




Retrospective observational studies 9
Prospective pilot study 1
Year of Publication
Range 1966–2018
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Table 2. Characteristics of the papers included in the review.
Movement
Disorder









E, S, N, L
HLA DQ2/DQ8 CD:GS













Myoclonus 28 15:13 47.7 (17.3) S 1 (3%)N 28 (97%) NA 28:0
Palatal tremor 3 1:2 51.3 (8.1) E 1 (33%)N 2 (67%)
DQ2(+) 1 (33%)
NA: 2 (67%) 1:2
Dystonia 2 1:1 49.50 (2.1) N 2 (100%) NA 2:0
Tremor 9 3:6 54.6 (14.9) E 6 (67%)N 3 (33%)
DQ2(+) 6 (67%)
NA: 3 (33%) 9:0
Parkinsonism 3 0:3 54.0 (18.7) E 1 (33%)N 2 (67%) NA 3:0
Tics 1 0:1 13 E (100%) DQ8(+) 1 (100%) 0:1
OM 1 1:0 2 E (100%) NA 1:0
PSM 1 0:1 23 E (100%) NA 1:0
Paroxysmal
dyskinesia 1 0:1 0.5 E (100%) NA 1:0
Myorhythmia 1 0:1 68 N (100%) DQ2 (+) 1(100%) 1:0
Myokymia 1 0:1 72 N (100%) NA 1:0
RLS, restless legs syndrome; OM, opsoclonus-myoclonus; PSM, propiospinal myoclonus; NA, not available;
GFD, gluten-free diet; E, evident; S, slight; N, none; L, lack of data; CD, coeliac disease; GS, gluten sensitivity.
Demographic data of patients with gluten related chorea were available in seven of the cases.
The choreiform movements were described as generalized affecting predominantly the upper limbs.
The majority was female (86%) and their mean age of onset was 57.4 ± 12.9 years. Five patients had
biopsy proven CD, whereas two patients had only serological evidence of GS. HLA DQ2 was tested in
four of the patients, and positive just in two of the cases tested. There was a significant improvement
in the choreiform movements after embarking on a GFD in five of the patients and no response in two.
3.3. Restless Legs Syndrome
Restless leg syndrome (RLS) is a circadian disorder appearing typically at the end of the day,
being characterised by an intense and irresistible urge to move the lower extremities, either by itself
or in response to unpleasant leg sensations. Symptoms typically improve while walking, stretching,
or moving the lower limbs [27]. There are five essential diagnostic criteria and all must be met: (1) An
urge to move the legs usually but not always accompanied by or felt to be caused by uncomfortable and
unpleasant sensations in the legs, (2) Symptoms begin or worsen during periods of rest or inactivity
such as lying down or sitting, (3) Symptoms are partially or totally relieved by movement, such as
walking or stretching, at least as long as the activity continues, (4) Symptoms only occur or are
worse in the evening or night than during the night, and (5) The occurrences of the above features
are not solely accounted for as symptoms primary to another medical or behavioral condition [28].
The prevalence of RLS varies among different population surveyed. The data from REST (RLS
Epidemiology, Symptoms, and Treatment), which is the largest trial till date with 23.052 patients,
revealed that any degree of RLS symptoms was present in 11.9% [29]. The pathogenesis of RLS
continues to be only partially understood, but there is substantial evidence for abnormalities in brain
iron metabolism and dopaminergic dysfunction probably plays a key role [30]. RLS severity increases
with decreased peripheral iron [31]. In fact, its prevalence is significantly greater in individuals with
iron-deficiency anaemia [32].
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Whether there is a link between RLS and CD or GS remains controversial. The first report
suggesting an association between CD and RLS was by Manchanda et al. who presented a consecutive
case series of four patients with RLS, low serum ferritin, and biopsy proven CD [33], which was
considered to be the underlying cause for low serum ferritin. Subsequently, in two studies RLS was
found to be more frequent in patients with CD than in controls [34,35]. On the other hand, however,
Cikrikcioglu et al. studied the presence of antibodies relating to GS (tissue transglutaminase antibody
IgA and IgG, antiendomyisium antibody IgA and IgG, and/or antigliadin antibody IgA and IgG)
in 96 patients with RLS and age, sex, and BMI matching 97 subjects without RLS and could not
demonstrate a significant difference between the two groups [36]. Furthermore, contradictory data
have hitherto been published related to iron metabolism parameters in coeliac patients with active
RLS and coeliac patients without RLS. Weinstock et al., found that concomitant iron deficiency was
significantly more common in coeliac patients with RLS than in coeliac patients without RLS, but
there were no statistically significant differences in haemoglobin levels between both groups [34].
In contrast, Moccia et al. could not find statistically significant differences in blood levels of iron,
ferritin, and MCV between coeliac patients with RLS and coeliac patients without RLS in their study.
However, haemoglobin levels were significantly lower in coeliac patients with RLS than in coeliac
patients without RLS [35].
There are no data available regarding the age of onset of RLS in patients with CD or GS.
The majority of described patients are female (91%). All of the patients had biopsy proven CD.
The information about response to GFS is limited; three out of four CD patients with RLS improved on
GFD and iron supplementation, whereas one patient improved after being on a GFD without receiving
iron supplementation and still having low ferritin levels [33]. Weinstock and colleagues reported
that 50% of the CD patients found relief in their RLS symptoms being on GFD, and similarly not all
were receiving iron supplementation [34], suggesting that GFD can independently improve the RLS
symptoms in people with RLS and CD or GS.
3.4. Myoclonus
Myoclonus is defined as a sudden, brief, shock like involuntary movement caused by active muscle
contraction (positive myoclonus), or inhibition of on-going muscle activity (negative myoclonus) [37].
All of the studies that attempt to evaluate the general occurrence of myoclonus have various biases.
There is an epidemiological study on myoclonus due to any cause in a defined population where the
average annual incidence of pathological and persistent myoclonus for 1976 to 1990 was 13 cases per
100,000 person-years [38]. Progressive myoclonic ataxia (PMA) is a rare syndrome where progressive
myoclonus and cerebellar ataxia coexist [39].
The first report suggesting the comorbidity of CD and PMA was by Cook and colleagues in
1966 [40]. Subsequently, several case reports were published [41–47]. Lu and colleagues published
a case series of patients with ataxia and myoclonus providing for the first time electrophysiological
evidence for the cortical origin of the myoclonus [48]. These findings were further confirmed later
in many cases and case series [49–53]. The largest case series was published by Sarrigiannis et al.,
and included nine patients with CD, myoclonus of cortical origin and ataxia. All of the patients were
compliant with a strict GFD, as evident by the elimination of gluten-related antibodies. Nonetheless,
there was still evidence of enteropathy in all, and in some it was suggestive of refractory CD type 2.
Aggressive immunosuppression improved ataxia and enteropathy in contrast to myoclonus that
remained unchanged [54].
The mean age of onset of gluten related PMA is 47.7 ± 17.3 years. The majority of patients are
males (55%). All of the patients reported to date had biopsy proven CD. Myoclonus phenomenology
was described as often stimulus sensitive, asymmetrical, and irregular, generally focal at onset
involving one or more limbs and sometimes the face, with a tendency to become gradually more
generalized. However, it tends to still remain asymmetrical. In general, GFD, even in combination
169
Nutrients 2018, 10, 1034
with aggressive immunosuppression, shows minimal effect on the myoclonus, but it may improve the
enteropathy and the ataxia.
3.5. Palatal Tremor
Palatal tremor is defined as brief, rhythmic involuntary movements of the soft palate. It can be
divided into symptomatic palatal tremor (SPT) and essential palatal tremor (EPT). SPT results from
an insult in the Mollaret triangle being composed of the inferior olive, red nucleus, and contralateral
dentate nucleus. In contrast, in EPT, no lesion is demonstrable. Data regarding the prevalence of SPT
or EPT are scarce. SPT rarely can be associated with ataxia and is referred as progressive ataxia palatal
tremor syndrome (PAPT) [55].
To date, three case reports of PAPT (one male and two females) in the context of CD have been
reported [41,50,56]. The mean age of onset was 51.3 ± 8.1 years. HLA DQ2 was tested just in one
of the cases and was positive. Two of the patients had biopsy proven CD, whereas another refused
biopsy but it was diagnosed with GS based on the high titer of antigliadin antibodies. In the latter,
palatal tremor improved after GFD, whereas no response to GFD was evident on the other two cases.
3.6. Dystonia
Dystonia is defined as a hyperkinetic movement disorder characterized by sustained or
intermittent muscle contractions that cause abnormal involuntary repetitive movements, postures, or
both [57]. There is significant variability in the reported prevalence of dystonia because to date the
epidemiological studies published have adopted different methodologies for case ascertainment.
A systematic review and meta-analysis that was published in 2012 reported a prevalence of
16.43 per 100,000, but it is likely to be underestimated, with many cases remaining undiagnosed [58].
The pathophysiology of dystonia is still poorly understood [59].
Two isolated cases of patients (one male and one female) with previous biopsy proven CD
diagnosis that presented with dystonia have been reported to date [51,60]. The mean age of onset was
49.5 ± 2.1 years. In both cases, dystonia was focal affecting one limb. There was no response to GFD.
In a large study where Bürk et al. screened patients with biopsy proven CD for neurological symptoms
or signs, 3 out of 72 patients presented with dystonia [61]. Wittstock and colleagues reported a case of
secondary dystonia due to cerebral vasculitis in a patient with biopsy proven CD [62]. This case may
only illustrate coincidence of isolated vasculitis and CD. However, dystonia due to vascular lesion in
the context of vasculitis and CD were diagnosed simultaneously and the dystonic symptoms improved
after being combined with GFD and immunosuppressive therapy. This led the authors to postulate a
causative relationship between the dystonia and CD.
3.7. Postural Tremor
Tremor is a rhythmic oscillation of a body part, which is produced by either alternating or
synchronous contractions of reciprocally innervated antagonist muscles [63]. Several cases of patients
with CD presenting with tremor often in association with or without later development of ataxia have
been reported [64–67]. Tremor is focal and generally postural, affecting mainly the limbs, but also
head, jaw, and tongue.
The mean age of onset of tremor is 54.6 ± 14.9 years and the male:female ratio was 1:2. All of the
patients had biopsy proven CD and 67% had HLA DQ2 positive. There was a significant response to
GFD in two-thirds of patients. Of interest is that postural tremor of abrupt onset has also been reported
even in childhood in a case of a four year old boy with CD who suffered central pontine myelinolysis
without electrolyte abnormalities [68]. The lack of neurophysiological characterisation of the tremor in
such reports means that it is not possible to distinguish from myoclonus.
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3.8. Stiff-Person Syndrome
Stiff person syndrome (SPS) is characterised by the increased tone of axial and limb muscles, with
superimposed muscle spasms leading to lumbar hyperlordosis, impaired gait, falls, and autonomic
dysfunction associated with anti-GAD and/or other autoantibodies [69]. This syndrome has a strong
concurrence with other autoimmune entities [70–72]. SPS has an estimated prevalence of 1–2 cases
per million with an incidence of one case per million per year [73]. In their study, Hadjivassiliou
et al. screened patients with neurological disorders of unknown aetiology for GS and showed that
such patients had a higher prevalence of circulating antigliadin antibodies [74]. In particular, out of
131 patients with GS and neurological disorders of unknown aetiology, four had the diagnosis of
SPS [75]. A higher prevalence of GS in patients with SPS was found than what would be expected in the
context of coexistence of two autoimmune diseases [76]. As SPS symptoms follow a relapsing-remitting
pattern, the assessment of responsiveness to GFD is challenging. Nevertheless, there is evidence of
reduction of the anti-GAD antibody titer after the implementation of GFD suggesting that GFD may
be beneficial in treating the condition [77].
3.9. Parkinsonism
Parkinsonism is defined as a hypokinetic syndrome and it is characterised by the presence of
resting tremor, rigidity, bradykinesia, and postural instability. The most common primary cause
of parkinsonism is idiopathic Parkinson’s disease (IPD), with a prevalence of 130 per 100,000 [78],
but many secondary or acquired causes of parkinsonism exist [79]. Recently, Di Lazzaro and colleagues
reported a case of improvement of parkinsonian symptoms after GFD implementation in a patient
with biopsy proven CD [80]. Gonzalez Aleman and colleagues presented the case of a patient with
parkinsonism and increased echogenicity in substantia nigra that is associated with biopsy proven CD
and clozapine treatment. They postulated that the patient may have had subclinical IPD, which was
unveiled after clozapine exposure or that she had a neuroleptic-induced akinetic rigid syndrome.
However, they also speculated that CD might have played a role in the pathogenesis, taking into
account the young age of the patient [81].
In the study of neurological disorders in a group of unselected patients with biopsy-proven CD
conducted by Bürk and colleagues, 2 out of 72 patients fulfilled the diagnostic criteria for PD [61].
However, as these patients had previously followed a GFD and they were considered to be in
remission, this finding may have just merely been coincidental. One out of the 10 CD cases reported
by Luostarinen and colleagues, which were initially referred to the neurological department because
of neurological symptoms and were finally found to have CD, presented with a four-month history of
an asymmetrical left sided parkinsonian syndrome. Four years later diagnosis of CD was established,
but the patient was never compliant with GFD [65]. In all cases, parkinsonism was described as
affecting one side of the body more than the other. The mean age of onset was 54.0 ± 18.7, all the
patients were females and had a biopsy proven CD. Only one patient out of three showed a response
to GFD. Given that Parakinsonism is a relatively common neurological condition, the co-occurence of
CD and Parkinsonism may well be co-incidental.
3.10. Tics
Tics are sudden, rapid, non-rhythmic, intermittent muscle movements (motor tics), or sounds
(phonic tics), which can be classified as simple or complex [82,83]. What characterizes tics is an
inner urge to make the movement or a local premonitory sensation experienced and temporarily
relieved by its performance. Several studies have examined the prevalence of tic disorders. However,
wide variation was evident across these studies in terms of specific diagnoses examined and the age
of the population under study [84]. Zelnik and colleagues conducted a study to look for a broader
spectrum of neurologic disorders in CD. However, an association between CD and Tic disorders was
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not demonstrated [85]. In the previously mentioned study that was conducted by Bürk and colleagues,
two out of 72 suffered with Tics [61].
Gilles de la Tourette syndrome (GTS) is characterised by the presence of multiple motor tics and
one vocal or phonic tic persisting for more than a year, from the appearance of the first tic [86]. A case
report of a patient with CD, HLA DQ8 positive, and GTS has been reported and it was shown that GFD
could be beneficial in managing the tics [87]. Rodrigo et al. carried out a prospective interventional
study to analyse and evaluate the efficacy of GFD in a series of childhood and adult patients with GTS.
Gluten removal was useful for reducing the intensity and frequency of motor and vocal/phonic tics
and OCD symptoms [88].
3.11. Other Movement Disorders
3.11.1. Opsoclonus-Myoclonus
Opsoclonus-myoclonus syndrome is characterised by opsoclonus, myoclonus, and ataxia,
associated with behavioural changes [89]. Opsoclonus is encompassed in the group of eye movement
abnormalities known as saccadic intrusions, defined as involuntary multidirectional saccades that
interrupt steady fixation. [90,91]. Deconinck and colleagues reported the case of a two-year-old male
with CD, cerebellar ataxia, palpebral flutter, action myoclonus and opsoclonus. Both GI symptoms,
as well as the neurological symptoms, improved after GFD implementation and treatment with steroids
and immunoglobulins [92].
3.11.2. Propiospinal Myoclonus
Propiospinal myoclonus (PSM) is an uncommon movement disorder involving axial muscles
characterized by painless, usually flexor arrhythmic jerks affecting the trunk, hips, and knees. It is
often stimulus sensitive and typically worsens while adopting supine position [93]. The etiology of
PSM is most commonly idiopathic [94]. Zhang and colleagues reported a case of a 23-year-old lady
who developed PSM in the setting of CD [95]. On examination there were continual relatively rhythmic
flexor muscle jerks affecting the neck, shoulders, trunk and hips. The jerks were elicited by patellar
tendon tap in the supine position but not while sitting. The myoclonus began minutes to hours after
gluten intake. There was complete resolution of the symptoms on GFD.
3.11.3. Paroxysmal Dyskinesia
Paroxysmal dyskinesia is defined as a group of episodic abnormal involuntary movements
manifested by recurrent attacks of dystonia, chorea, athetosis, or a combination of these disorders [96].
Most cases are familial and usually autosomal dominant, but some are idiopathic [97]. Hall and
colleagues reported the case of a female patient with abnormal movements from the age of six
months [98]. The episodes were described as twisting of her upper body to one side, with an
outstretched arm as well as a flexed position of the left leg lasting from 5 to 30 min and appearing
several times in a day. At the age of eight, she presented with GI and after extensive workup,
the diagnosis of biopsy proven CD was established. She was commenced on GFD and the symptoms
resolved completely after six months.
3.11.4. Myorhythmia
Myorhythmia is characterised by slow rhythmic movements, usually involving the limb or cranial
muscles, and it has been linked with a variety of identifiable etiologies [99]. Dimberg and colleagues
reported the case of a 68-year-old lady with refractory CD who presented with myorhythmia [100] of
the tongue, cheek, and fingers. Movements were described as continuous, synchronous, semirhythmic
contractions occurring at rest as well as with movement. Two months after the onset of myorhythmia,
the patient developed an encephalopathy that was confirmed by neuroimaging and neuropathology,
that appeared to be inflammatory. An infectious aetiology was excluded by CSF analysis. Screening
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for autoimmune encephalitis and paraneoplastic syndromes was negative. The patient was HLA-DQ2
and -DQ8 positive.
3.11.5. Myokymia
Myokymia is characterised by spontaneous, fine fascicular contractions of muscle that usually can
be seen on the skin as vermicular or continuous rippling movements [101]. A case of a 72-year-old lady
with biopsy-confirmed CD, who initially presented with progressive generalized myokymia has been
reported [102]. On examination, prominent vermicular, undulating slow movements of her orbicularis
oris, mentalis, and right intrinsic hand muscle were noticed. EMG revealed myokymic potentials in
several muscles. Subsequently, she developed both, action and stimulus-sensitive myoclonus, as well
as ataxia. There was histologic improvement on jejunal biopsy on GFD. In contrast, there was no
clinical progression of neurologic symptoms.
4. Conclusions
This paper aimed to systematically review the current literature regarding MDs in CD and GS.
To our knowledge, this is the first review on the topic highlighting that the phenomenology of the
gluten related movement disorders is broad and that GFD is apparently beneficial in many cases.
Our review also indicates the following key points:
1. GS and CD should be considered in the diagnostic workup of MDs of unknown etiology in
patients of all ages and both genders, even in the absence of GI symptoms.
2. Neurologic manifestations, including MDs, may precede the diagnosis of GS and CD.
3. Some of the MDs may improve or resolve after dietary gluten removal, so early diagnosis should
rapidly lead to the implementation of GFD.
4. Once GFD is implemented, it should generally continue lifelong like in CD. In fact, in some cases,
sporadic accidental gluten ingestion continues to trigger the MD.
5. In contrast, other types of MDs, such as ataxia with myoclonus, appear to be linked to refractory
CD and when observed, there is prompt need for repeat biopsy of the small intestine and often
aggressive immunosuppression.
6. The fact that the majority of the included papers refer to CD rather than the broader spectrum of
GS may mean that the relationship of MDs to GS without enteropathy is under-studied.
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Abstract: Increased antibody reactivity towards self-antigens is often indicative of a disruption of
homeostatic immune pathways in the body. In celiac disease, an autoimmune enteropathy triggered
by the ingestion of gluten from wheat and related cereals in genetically predisposed individuals,
autoantibody reactivity to transglutaminase 2 is reflective of the pathogenic role of the enzyme in
driving the associated inflammatory immune response. Autoantibody reactivity to transglutaminase
2 closely corresponds with the gluten intake and clinical presentation in affected patients, serving as
a highly useful biomarker in the diagnosis of celiac disease. In addition to gastrointestinal symptoms,
celiac disease is associated with a number of extraintestinal manifestations, including those affecting
skin, bones, and the nervous system. Investigations of these manifestations in celiac disease have
identified a number of associated immune abnormalities, including B cell reactivity towards various
autoantigens, such as transglutaminase 3, transglutaminase 6, synapsin I, gangliosides, and collagen.
Clinical relevance, pathogenic potential, mechanism of development, and diagnostic and prognostic
value of the various identified autoantibody reactivities continue to be subjects of investigation and
will be reviewed here.
Keywords: celiac disease; gluten; gliadin; autoantibody; B cell; T cell; transglutaminase; synapsin;
ganglioside; gluten sensitivity; gastrointestinal symptoms; molecular mimicry; intermolecular
help; biomarker
1. Introduction
Celiac disease is a T cell-mediated systemic autoimmune disease triggered by the ingestion
of wheat gluten and related proteins in rye and barley in genetically susceptible individuals [1–3].
Gluten is comprised of approximately 70 different proteins (including various gliadins and glutenins),
which share a number of immunogenic amino acid sequences found to be pathogenic in the context
of celiac disease [4]. Celiac disease has a strong genetic component, with approximately 95% of
patients expressing the human leukocyte antigens (HLA)-DQ2 and HLA-DQ8 [5]. The frequency
of HLA-DQ2 and -DQ8 and the per capita consumption of wheat are important determinants of
celiac disease prevalence [6]. Although formerly considered as a rare condition mainly affecting
children, celiac disease is now recognized as one of the most common autoimmune disorders and
estimated to affect approximately 1% of the population worldwide [7]. In North America and Europe,
celiac disease prevalence has been found to be increasing in recent decades [2,8,9]. The frequency of
celiac is also rising in Asia-Pacific regions, where traditional rice-based diets are increasingly replaced
by Western-style diets with a larger content of wheat-containing products [10].
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The increasing prevalence of celiac disease is also partly attributed to the recent development of
highly specific and sensitive serologic tests, which allow for safe and effective screening in individuals
suspected of having celiac disease [11]. The gold standard for the diagnosis of celiac disease is based
on endoscopic biopsy of the small intestine demonstrating the characteristic histologic features of
duodenal lymphocyte infiltration, crypt hyperplasia, and villous atrophy, further supported by positive
serologic tests, and the confirmation of remission of symptoms upon the removal of gluten-containing
foods from diet [11,12]. Complete elimination of gluten-containing food from diet is currently the only
effective and safe treatment for celiac disease [13,14].
The classic gastrointestinal symptoms of celiac disease includes diarrhea, abdominal pain,
and malabsorption. However, celiac disease is often also associated with a number of extraintestinal
manifestations such as osteoporosis, anemia, and dermatitis herpetiformis, among others [3,14,15].
The clinical picture in some patients can also include other autoimmune diseases, including type 1
diabetes, autoimmune thyroiditis, and autoimmune hepatitis, likely due in part to shared genetic
factors [5,16,17].
The production of autoantibodies is an important feature of many autoimmune diseases,
indicating a loss of immune tolerance to self-antigens. In celiac disease, a significantly enhanced
autoantibody response to the transglutaminase 2 (TG2) enzyme, also known as tissue transglutaminase
(tTG), is a hallmark of the pathogenic process and signifies a loss of tolerance to wheat gluten [11,18].
In addition to antibodies against TG2, other autoantibodies have also been reported in patients with
celiac disease, particularly in the context of extraintestinal manifestations. In this review, the origin,
development, and the potential pathogenic role of autoantibodies associated with extraintestinal
manifestations of celiac disease are discussed.
2. Transglutaminases
2.1. Transglutaminase 2
By the 1960s, it was clear that, in addition to antibodies against the immunostimulatory gluten
proteins of wheat and related cereals, patients with celiac disease express elevated autoantibody
responses to the connective tissue surrounding smooth muscle fibers [19,20]. These antibodies became
known as anti-endomysial and anti-reticulin antibodies [21–23]. It was not until 1997, when Dieterich
et al. identified TG2 as the major endomysial target autoantigen [24]. Later research has shown that
the target of the so-called anti-reticulin antibodies was also TG2 [25].
TG2 is a member of the structurally and functionally related group of transglutaminase proteins
that catalyze the modification of proteins by introducing covalent bonds between amine groups (such as
a lysine) and γ-carboxamide groups of peptide-bound glutamines [26]. TG2, the first transglutaminase
discovered, is unique in some aspects, including that it is a ubiquitously expressed enzyme expressed
in various tissues and cell types, and in various locations inside the cell and at the cell surface [26].
Under certain conditions, TG2 may react with H2O in preference over an amine, converting a specific
glutamine to glutamate via deamidation [27]. Intracellular TG2 is involved in signaling events that
support cell survival in response to wounding, hypoxia, and oxidative stress [27]. Extracellular TG2
has a role in the regulation of the cytoskeleton by crosslinking extracellular matrix proteins such
as fibronectin and integrins, and is believed to function in cell adhesion, matrix assembly, and cell
motility [28].
TG2 plays a central role in the initiation of immune reactivity towards dietary gluten in the context
of celiac disease [29,30], which also involves the celiac disease susceptibility genes, HLA-DQ2 and
-DQ8 [31]. TG2 can effectively deamidate specific glutamine residues of gluten sequences that may
have crossed the epithelial barrier and found access to the lamina propria. Antigen presenting cells
expressing the HLA-DQ2 and HLA-DQ8 molecules have an increased affinity for these deamidated
peptides [32]. Subsequent binding of the generated immunogenic peptides to the HLA molecules
results in peptide complexes that can activate host gluten specific CD4+ T cells in the lamina propria.
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Activation of these T cells is accompanied by the production of a number of cytokines that can
in turn promote inflammation and villous damage in the small intestine through the release of
metalloproteinases by fibroblasts and inflammatory cells, as well as providing help to activate
gluten-specific B cell responses [30,33].
Gluten-specific CD4+ T cells are speculated to stimulate B cell production of not only anti-gluten
antibody, but also anti-TG2 antibody. In the absence of any TG2-specific T cells being identified,
the anti-TG2 antibody response is believed to be driven by a process referred to as intermolecular help,
similar to the hapten-carrier system. Accordingly, gluten-specific CD4+ T cells are thought to provide
help to TG2-specific B cells when TG2–gluten complexes are formed [34]. Such a gluten-specific T
cell-driven mechanism would lead to an anti-TG2 immune response without the requirement for
TG2-specific T cells. With repeated exposure to TG2–gluten complexes, affinity maturation towards the
TG2 antigen can potentially generate specific high-affinity autoantibody reactivity [35–37]. Anti-TG2
autoantibodies are thus gluten-dependent, and the antibody titer decreases rapidly after the elimination
of gluten from diet [18,38]. IgA anti-TG2 autoantibodies have high specificity (>90%) and sensitivity
(>95%) in celiac disease, currently serving as a particularly useful aid in diagnosis [18,39].
Whether antibodies to TG2 can play a clear role in disease pathogenesis in humans has not been
definitively proven. Anti-TG2 antibodies bind to several epitopes of TG2, including the enzymatic core
of the protein, and can thus interfere with TG2 bioactivity [40]. As TG2 is involved in epithelial cell
differentiation through activation of transforming growth factor β [41], anti-TG2 autoantibodies have
been shown to reduce epithelial cell differentiation, increase epithelial cell permeability in an intestinal
cell line, and induce monocyte activation upon binding to Toll-like receptor 4 [42–44]. Data from in vitro
studies indicate that anti-TG2 antibodies detected along the villous and crypt basement membranes
in the jejunum from celiac disease patients may take part in the intestinal damage, particularly the
remodeling of the small bowel mucosal architecture and the development of villous atrophy as well as
crypt hyperplasia [43,45–47].
Because TG2 is the most widely expressed member of the transglutaminase family of proteins
in the body, being present in almost all cell types, and participates in various biological reactions,
the autoantibodies have the potential to negatively affect the activity of the enzyme and its biological
role in tissues outside of the gastrointestinal tract as well [48]. The presence of IgA deposits colocalizing
with TG2 in the liver, lymph nodes, muscle, thyroid, bone, and brain indicates that the circulating
autoantibodies originating from the small intestine can access the autoantigen throughout the body
and may potentially exert certain pathogenic effects [42,49–51]. Although the significance of anti-TG2
antibody binding to thyroid tissue or bone is not clear, both thyroid dysfunction and reduced bone
density are common in celiac disease, raising the possibility that the antibodies may affect target organ
function [49,50,52]. Anti-TG2 autoantibodies found within the muscular layer of brain vessels have
also been speculated to cause disruption of the blood–brain barrier, which may further expose the
central nervous system to other autoantibodies and potential toxins [51]. In mice, the injection of
anti-TG2 antibodies in the lateral ventricle of the brain has been shown to cause deficits in motor
coordination [53]. The data suggest that once exposed to the central nervous system, anti-TG2
antibodies may play a role in inducing neurologic deficits. Anti-TG2 antibodies isolated from celiac
disease patients also have the potential to cross-react with other members of the transglutaminase
family of enzymes due to some level of sequence homology, suggesting that such autoantibodies may
additionally affect the activity of other transglutaminases [53]. Taken together, the data are suggestive
of a pathogenic role for anti-TG2 autoantibodies in some of the extraintestinal manifestations of
celiac disease.
2.2. Transglutaminase 3
The skin manifestation of celiac disease, known as dermatitis herpetiformis, was first described
by Louis Adolphus Duhring in 1884 as an itchy, blistering, skin disease [54]. Dermatitis herpetiformis
is characterized by the deposition of pathognomonic granular IgA in the dermal papillae, sometimes
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without significant gastrointestinal symptoms, and shares the same HLA associations with celiac
disease [5]. In 2002, epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3),
was identified as the main autoantigen target in skin IgA deposits in dermatitis herpetiformis [55].
In addition to increased anti-TG2 antibodies, dermatitis herpetiformis patients also present with
elevated levels of antibody directed at TG3 [55,56].
TG3 is mainly expressed in the cornified layer of the epidermis and has been shown to play
an important role in epidermal keratinization and in the formation of cornified envelope, which is
essential for the maintenance for skin homeostasis [57]. Serum levels of anti-TG2 and anti-TG3
antibodies appear to correlate in celiac disease patients without skin manifestation, but not in patients
with dermatitis herpetiformis, suggesting there is antibody reactivity to specific non-cross-reactive
epitopes of TG3 in dermatitis herpetiformis [55,58]. IgA autoantibodies against TG3 have been reported
to be detected in as much as 95% of dermatitis herpetiformis patients, substantially more than those
against TG2 (79% of patients) [59]. In addition, detection of IgA antibody to TG3 has been found to
efficiently distinguish untreated dermatitis herpetiformis from other dermatological itchy diseases and
to be highly sensitive to a gluten-free diet [60]. IgA anti-TG3 antibody has been proposed as a useful
diagnostic marker for dermatitis herpetiformis in both pediatric and adult patients [59–61].
The production of anti-TG3 antibodies may begin as a result of cross-reactivity of anti-TG2 IgA
antibodies with TG3, which is released from epidermal keratinocytes and can diffuse through the
basement membrane in regions of trauma [62]. Prolonged gluten immune stimulation may allow for
epitope spreading and further maturation of these antibodies, resulting in the development of high
affinity anti-TG3 antibodies [55,62,63]. Disappearance of anti-TG3 IgA antibody in response to dietary
exclusion of gluten is slow and may take longer than for antibody response to TG2, suggesting that
mechanisms other than homology between TG2 and TG3 might trigger the production of anti-TG3
antibodies [64–66].
Deposition of IgA antibodies in dermatitis herpetiformis is believed to play a role in the infiltration
of neutrophils into the papillary dermis and in the formation of basement membrane zone vesicles in
the lamina lucida [55]. TG3 in the papillary dermis has been found to overlap with the deposits
of IgA antibodies in dermatitis herpetiformis patients, implying that TG3 is bound by the IgA
autoantibodies [55,63]. It is hypothesized that active TG3 may cross-link anti-TG3 antibodies to
certain dermal structural elements, leading to the dermal deposition of anti-TG3 IgA, which can in
turn invoke skin pathology such as the associated blisters and papules [55]. However, anti-TG3 IgA
deposits have also been found in uninvolved skin in affected patients, in areas away from lesions,
suggesting that factors beyond these immune complexes may be necessary for lesion formation [62,63].
2.3. Transglutaminase 6
In addition to the well-characterized gastrointestinal and skin manifestations, a number of
studies have reported on various other symptoms associated with celiac disease. Neurologic deficits,
including peripheral neuropathy and cerebellar ataxia, are among the most common extraintestinal
symptoms reported in conjunction with celiac disease [67,68]. Furthermore, elevated levels of
anti-gliadin antibody have been associated with idiopathic neuropathy and idiopathic ataxia, even in
the apparent absence of the characteristic mucosal pathology [69–72]. The terms “gluten ataxia” and
“gluten neuropathy” have been used to describe these conditions, although the significance of the
anti-gliadin antibodies in the absence of biopsy-proven intestinal damage has been debated [70,72,73].
Among these, idiopathic or sporadic ataxia associated with anti-gliadin antibodies has been the
best studied in terms of understanding its frequency in different populations of ataxia patients and
its potential etiology and pathogenic mechanism. A recent meta-analysis of several studies further
validates the presence of significantly increased levels of antibody to gliadin among patients with
non-hereditary ataxia [74]. There have been suggestions that gluten ataxia would fit better within the
spectrum of non-celiac wheat/gluten sensitivity (NCWS) rather than celiac disease, based on serologic,
histologic, and genetic markers [75,76]. In 2008, a novel neuronal transglutaminase, TG6, was reported
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as a target autoantigen in patients with gluten ataxia [77]. Antibodies to TG6 were later also detected
in patients with gluten neuropathy [78]. However, the specificity of anti-TG6 antibodies in gluten
ataxia and gluten neuropathy needs further investigation, as other studies have found such antibodies
in patients with other conditions and in those without neurologic symptoms as well [77–81].
TG6 is predominantly expressed in a subset of neurons and plays a role in neurogenesis,
particularly in the context of nervous system development and motor function [82]. TG6 is encoded on
the same chromosome (20q11–12) as TG2 in humans [83]. Similarly to TG2, when TG6 is incubated
with gluten peptides, it can both deamidate and transamidate glutamine residues, and there is a large
degree of overlap in glutamine donor substrates of TG6 and TG2 [82]. TG6 can also form the previously
mentioned hapten-carrier complexes with gluten, but to a lesser extent when compared with TG2 [84].
Therefore, it is conceivable that, in the event of blood–brain or blood–nerve barrier disruption, TG6 may
become exposed to gluten-derived antigens. As such, gluten-specific CD4+ T cells may be able to
provide help to TG6-specific B cells, leading to the production of anti-TG6 autoantibodies in a similar
fashion to anti-TG2 antibodies.
The relationship between gluten intake and the development of anti-TG6 antibodies has been
examined. Lindfors et al. did not observe a decrease in anti-TG6 IgA antibodies in celiac disease
patients on a gluten-free diet, suggesting a lack of gluten-dependency of TG6 autoantibodies [81].
However, a more recent study on a pediatric cohort of celiac disease patients found anti-TG6
antibody reactivity to correlate with the duration of gluten exposure, and to decline in response
to the introduction of a gluten-free diet [79].
Similar to what has been described for anti-TG2 autoantibodies, anti-TG6 antibodies have the
potential to disrupt TG6’s biological functions. In mice, the injection of celiac disease patient-derived
TG2 antibody that can cross-react with TG6 into mouse brain has been shown to cause deficits in
motor coordination [53]. Recently, missense mutations in the of transglutaminase 6 gene have been
identified in families of Chinese patients with spinocerebellar ataxia type 35 (SCA35) [85]. However,
a causative link between neurological manifestations and autoantibodies to TG6 remains unclear [86].
Future studies on anti-TG6 antibodies can help in further clarifying their diagnostic and pathogenic
potential in the context of neurologic and other manifestations in celiac disease and gluten sensitivity.
3. Gangliosides
Gangliosides are sialic acid-containing glycosphingolipids present in high concentrations
in the nervous system, as well as on gut epithelial cells [87,88]. Antibodies to gangliosides,
especially GM1, GD1a, GD1b, and GQ1b, are associated with and serve as diagnostic markers
for a number of immune-mediated peripheral neuropathies, such as multifocal motor neuropathy
and Guillain-Barré syndrome [89–91]. The antibodies are directed at carbohydrate epitopes of the
ganglioside molecule [89]. The presence of anti-ganglioside antibodies in celiac disease patients with
peripheral neuropathy was first reported by our team in 2002 [92]. A number of subsequent studies
have confirmed the presence of various anti-ganglioside antibodies in conjunction with neurologic
symptoms in celiac disease patients and those with immune reactivity to gluten [93–99]. At least one
study has found that anti-ganglioside antibody reactivity responds to the exclusion of gluten from diet
in a significant subset of patients with celiac disease [96].
Generation of anti-ganglioside antibodies is speculated to be linked to the intestinal immune
response to ingested gluten. In acute immune-mediated neuropathies, the presence of anti-ganglioside
antibodies has been demonstrated to result from molecular mimicry between gangliosides and bacterial
or viral oligosaccharides [100,101]. While some gliadins may be glycosylated, epitopes that resemble
gangliosides have not been found [102], making molecular mimicry less likely. However, it should be
noted that while most gluten proteins appear to bear few or no carbohydrates, glycosylation of gluten
can take place during or after the processing of flour and especially in food preparation under elevated
temperatures [103]. A role for such Maillard reaction modifications of gluten in triggering an immune
response that may target other autoantigens cannot be ruled out.
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An alternative mechanism by which the antibody response to GM1 and other gangliosides could
be generated may be through intermolecular help in a way similar to anti-TG2 autoantibodies in
celiac disease [30]. In fact, it has been shown that gliadin can bind to the ganglioside-rich intestinal
brush border membrane in an enzyme-independent way and can form stable complexes with GM1
ganglioside that are resistant to denaturing conditions [102]. The binding appears to take place at
least partially through the ganglioside’s pentasaccharide chain [102]. The reported dependence of
anti-ganglioside antibodies on gluten intake would support such a mechanism of intermolecular
help [96].
4. Synapsin I
The development of IgG and IgA antibody reactivity to gluten is a hallmark of celiac
disease [11,14]. Whether anti-gluten antibodies can cross-react with autoantigens has been the subject
of speculation and investigation for some time, especially in the context of extraintestinal manifestation
of celiac disease. In a study by our group, we demonstrated that affinity-purified anti-gliadin antibodies
from both immunized animals and celiac disease patients, particularly those with neurologic symptoms,
can cross-react strongly with synapsin I (SYN1), a neuron-specific cytosolic phosphoprotein present
in most nerve terminals [104]. The anti-gliadin antibodies bound to both isomers of SYN1, a and b,
which have similar amino acid sequences.
SYN1 is primarily associated with synaptic vesicle membranes at the cytoplasmic surface [105].
It is a major substrate for protein kinases and its state of phosphorylation can affect synaptic
function [105]. The similarity in certain repeat amino acid sequences found in both gliadin proteins
and SYN1, with high frequencies of proline and glutamine residues and the presence of PQP and
PQQP motifs, is believed to contribute to the cross-reactivity between anti-gliadin antibodies and
SYN1 [104]. While SYN1 is known to carry O-linked N-acetylglucosamine and fucosyl groups [106,107],
the removal of these carbohydrates do not inhibit the binding of anti-gliadin antibodies to the protein,
ruling out a major role for them as target epitopes.
Whether SYN1-cross-reactive anti-gliadin antibodies can exert a pathogenic effect in humans
is unknown. Synapsins are multifunctional proteins, containing different domains with distinct
activities [108]. In addition to binding synaptic vesicles and various cytoskeletal proteins [109–111],
synapsins may have enzymatic functions as well [112,113]. Disruption of SYN1 activity via the use
of anti-SYN1 antibodies to the aplysia sea slug homologue of synapsin has been shown to reduce
post-tetanic potentiation, and to increase the rate and extent of synaptic depression [114]. However,
sufficient data to clearly link anti-SYN1 antibodies to neurologic manifestations in the context of
autoimmunity does not exist yet. The data from celiac disease patients demonstrate that only certain
subsets of anti-gliadin antibodies cross-react with SYN1 [104]. Because of the large number and
heterogeneous nature of gluten proteins and associated epitopes [115], the anti-gliadin immune
response involves a diverse repertoire of antigenic determinants. Therefore, varying degrees of
cross-reactivity to SYN1 would be expected in different individuals with an elevated immune response
to gluten. Such differences in the degree of cross-reactivity may explain and reveal clues about
the association of such antibodies with specific extraintestinal complications, including neurologic
manifestations. Ultimately, the type and specificity of the immune response, local integrity of the
blood–nerve and blood–brain barriers, and other pro-inflammatory factors are likely contribute to
and influence the potential pathogenic role of SYN1-cross-reactive anti-gliadin antibodies [116]. It is
worth noting that the pathogenic effect of anti-synapsin immune reactivity might not be limited to the
nervous system, as the presence of low levels of SYN1 has been demonstrated in non-neuronal cells as
well, including liver epithelial cells [117] and pancreatic β cells [118]. It is expected that these tissues
would be more accessible to antibodies and T cells than the nervous system.
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5. Other Autoantigens in Celiac Disease
A number of studies have reported on antibodies to cytoskeletal actin in the context of celiac
disease [119–121]. Although these antibodies are not specific to celiac disease and have also been
associated with chronic hepatitis [122,123], IgA anti-actin antibodies do appear to correlate with the
degree of villous atrophy [121,124]. These findings suggest that anti-actin antibodies are linked with
mucosal injury and may result from the release of actin from injured or dying cells, thus triggering
an autoantibody response. In addition, their appearance in celiac disease is dependent on gluten
intake [125]. It is not clear whether they are associated with or play any role in the extraintestinal
manifestations of celiac disease. IgA autoantibodies to collagen types I, III, V, and VI have also been
found in association with celiac disease. No specific clinical manifestation is reported to be associated
with these antibodies yet, but the prevalence of connective tissue diseases in patients with celiac
disease may be related to an anti-collagen immune reactivity. Antibody reactivity to single- and
double-stranded DNA, ATP synthase β chain, cardiolipin, and enolase α has also been found in some
celiac disease patients [120,126], but their clinical relevance remains to be assessed.
As celiac disease is associated with several other autoimmune disorders, including type 1
diabetes and autoimmune thyroiditis, autoantibodies specifically linked to these disorders can be
found in patients with celiac disease [127]. A list of such antibodies and associated conditions
is included in Table 1. The link between celiac disease and associated autoimmune disorders is
believed to be primarily due to common genetic background, particularly in the HLA region
of chromosome 6 [127–130]. Whether gluten intake can contribute to the development of these
organ-specific autoantibodies is not entirely clear yet. However, there are reports showing that
diabetes- and thyroid disease-related antibodies in children with celiac disease may disappear in
response to the exclusion of gluten-containing foods from diet [131].
6. Autoantibodies in Non-Celiac Wheat Sensitivity
Some individuals experience a range of symptoms in response to the ingestion of
gluten-containing foods, i.e., wheat, rye, and barley, without the characteristic serologic or histologic
markers of celiac disease and wheat allergy [132–135]. The condition is variably referred to as non-celiac
gluten sensitivity or non-celiac wheat sensitivity (NCWS). NCWS is associated with gastrointestinal
symptoms, commonly including bloating, abdominal pain, and diarrhea, as well as extra-intestinal
symptoms, among which fatigue, headache, anxiety, and cognitive difficulties are predominant [133].
Accurate figures for the prevalence of NCWS are not known, but current estimates put the number
at similar to or greater than for celiac disease [136,137]. The identity of the exact component(s) of
wheat and related cereals responsible for triggering the associated symptoms remains uncertain. While
recent controlled trials have indicated a prominent role for gluten [134,138], non-gluten proteins and
fermentable short chain carbohydrates have also been suggested by some studies to drive aberrant
immune responses or to be associated with symptoms [139,140].
Recent research indicates that NCWS is associated with increased innate and adaptive systemic
immune activation in response to microbial translocation [141]. Affected individuals also have elevated
levels of intestinal fatty acid-binding protein that correlates with the markers of immune activation,
suggesting a compromised intestinal epithelial barrier integrity [141]. By definition, NCWS patients
do not have elevated levels of antibody to TG2, the celiac disease-specific autoantibody. Whether there
is any autoimmune component to NCWS is not clear. However, one study has found that compared
with irritable bowel syndrome (IBS) patients, an increased proportion of individuals with NCWS
develops an autoimmune disease [142]. In addition, the study reported an increased frequency
of anti-nuclear antibodies (ANA) in NCWS patients, as detected by indirect immunofluorescence
using HEp-2 cells [142]. Anti-nuclear antibodies bind to proteins in the cell nucleus and are found
to be elevated in some systemic autoimmune disorders, including systemic lupus erythematosus.
The specific target antigen(s) and pathogenic relevance of these antibodies, or their association with
specific extraintestinal manifestations, in the context of NCWS remains to be determined.
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Table 1. Autoantibody reactivities associated with other autoimmune diseases found in patients with
celiac disease.
Autoantibody Target Associated Autoimmune Disease Reference
Islet cells; Glutamic acid decarboxylase Type 1 diabetes mellitus [16,131,143]
Thyroperoxidase; Thyroglobulin, Thyroid stimulating
hormone receptor; Thyroid microsomal antigen Autoimmune thyroid disease [16,131,144,145]
Liver-kidney microsomal antigen Autoimmune liver disease [16,146,147]
Double-stranded DNA; Nuclear antigen Systemic lupus Erythematosus [16,37,148]
Sjögren syndrome-related antigen A (Ro), Sjögren
syndrome-related antigen B (La); Nuclear antigen Sjögren syndrome [16,149]
Cardiolipin; Phophatidylserine/prothrombin Anti-phospholipid syndrome [126,150–153]
7. Conclusions
Celiac disease is a systemic autoimmune condition with intestinal and extraintestinal
manifestations. Autoantibody reactivity against a number of autoantigens has been described in the
context of the various manifestations of the disease. The clinical relevance and pathogenic role of such
antibodies continue to be the subject of investigation and debate. Questions regarding the mechanisms
by which such autoantibodies are generated and how they may access target tissues, such as the
nervous system, also remain incompletely resolved. Identification of autoantibody biomarkers closely
associated with specific extraintestinal manifestations of celiac disease can be particularly useful for
the development of predictive and diagnostic tests, in addition to providing novel clues regarding
disease mechanism and therapeutic approaches. Although a number of advances in the identification
and understanding of autoantibody reactivity in celiac disease have been made in the past 20 years,
further research and confirmatory studies with larger cohorts of patients and controls, as well as more
in-depth preclinical mechanistic studies will be needed to clarify remaining questions.
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Abstract: Autoimmune pancreatitis (AIP) is a rare disorder whose association with coeliac disease
(CD) has never been investigated, although CD patients display a high prevalence of both endocrine
and exocrine pancreatic affections. Therefore, we sought to evaluate the frequency of CD in
patients with AIP and in further medical pancreatic disorders. The screening for CD was carried
out through the detection of tissue transglutaminase (tTG) autoantibodies in sera of patients
retrospectively enrolled and divided in four groups: AIP, chronic pancreatitis, chronic asymptomatic
pancreatic hyperenzymemia (CAPH), and control subjects with functional dyspepsia. The search for
anti-endomysium autoantibodies was performed in those cases with borderline or positive anti-tTG
values. Duodenal biopsy was offered to all cases showing positive results. One patient out of 72 (1.4%)
with AIP had already been diagnosed with CD and was following a gluten-free diet, while one case
out of 71 (1.4%) with chronic pancreatitis and one out of 92 (1.1%) control subjects were diagnosed
with de novo CD. No cases of CD were detected in the CAPH group. By contrast, a high prevalence of
cases with ulcerative colitis was found in the AIP group (13.8%). Despite a mutual association between
CD and several autoimmune disorders, our data do not support the serologic screening for CD in AIP.
Further studies will clarify the usefulness of CD serologic screening in other pancreatic disorders.
Keywords: autoimmune pancreatitis; coeliac disease; pancreatic disorders; screening
1. Introduction
Coeliac disease (CD) is an autoimmune condition affecting the small bowel mucosa of a proportion
of subjects carrying the human leukocyte antigen (HLA)-DQ2 or -DQ8 haplotypes upon gluten
ingestion [1]. Its prevalence, as assessed by serologic tests, is 0.4% in South America, 0.5% in Africa
and North America, 0.6% in Asia, and 0.8% in Europe and Oceania, with higher values in female
versus male individuals (0.6% vs. 0.4%; p < 0.001) [2]. The intestinal lesions encompass a variable
degree of villous atrophy and crypt hyperplasia, with a heavy lymphocytic infiltrate of both the
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epithelial and lamina propria layers (Figure 1) [3]. The clinical picture is multifaceted, ranging from
an overt malabsorption syndrome to apparently asymptomatic forms, with anaemia, isolated fatigue,
cryptic hypertransaminasaemia, infertility, peripheral and central neurologic disorders, osteopenia,
short stature, and dental enamel defects, being the main findings [1,4]. A gluten-free diet leads to an
almost complete recovery of both mucosal lesions and clinical features in the vast majority of cases [1].
Remarkably, owing the same genetic and/or environmental predisposing factors, CD patients are
at risk of developing further systemic or organ-specific immune-mediated disorders, with type 1
diabetes being the most prevalent and widely studied association, thus justifying the mutual serologic
screening [5]. By contrast, no information about the possible association between CD and autoimmune
pancreatitis (AIP), the immune-mediated condition affecting the exocrine component of the pancreas,
is available so far.
Figure 1. Histological features of duodenal mucosa of active coeliac disease showing subtotal
villous atrophy with crypt hyperplasia and heavy lymphocytic inflammatory infiltrate in both the
epithelial (arrows) and lamina propria (head arrows) compartments (hematoxylin-eosin, original
magnification × 100).
AIP is a rare (estimated prevalence of 0.82:100,000 [6]), chronic fibro-inflammatory condition
affecting the whole or a part of the gland, characterized by specific histological, radiological
and serological aspects that disappear following a course of steroid therapy [7]. Two different
types of AIP (type 1 and type 2) can be distinguished histologically. The first is the so called
lymphoplasmacytic sclerosing pancreatitis displaying a dense periductal infiltration of plasma cells,
mainly immunoglobulin (Ig)G4 positive, and lymphocytes, peculiar storiform fibrosis, and oblitering
venulitis (Figure 2). The second, also called idiopathic duct-centric pancreatitis, is characterized by
the presence of intraluminal and intraepithelial neutrophils in medium-sized and small ducts as well
as in acini, often leading to destruction and obliteration of the duct lumen. However, the diagnosis
of type 1 or type 2 AIP can be made even in the absence of histology by applying a combination
of two or more of the following International Consensus Diagnostic Criteria [8]: (1) characteristic
imaging features of both the parenchyma and main duct, i.e., a diffuse enlargement with delayed
enhancement of the parenchyma with a long or multiple duct strictures without marked upstream
dilatation in the typical form, while a segmental/focal enlargement with delayed enhancement of
the parenchyma with segmental short duct narrowing in the atypical one; (2) increased level of IgG4;
(3) other organ involvement, i.e., biliary duct, retroperitoneum, kidneys, salivary/lachrymal gland,
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as assessed histologically or radiologically; (4) response to steroid therapy. In those cases where
distinctive criteria cannot be identified, the diagnosis of AIP not otherwise specified is given.
Figure 2. Histological features of autoimmune pancreatitis showing a dense periductal infiltration
of plasma cells and lymphocytes leading to obliteration of the affected veins (arrows), and peculiar
storiform fibrosis (head arrows) (hematoxylin-eosin, original magnification × 100).
At variance with AIP, some evidence is available in the literature about the association between CD
and non-immune-mediated disorders of the exocrine pancreas. Indeed, CD patients have been found
to be at increased risk of developing both acute and chronic pancreatitis in comparison to the general
population [9,10]. In addition, patients with villous atrophy, including CD, may carry an exocrine
pancreatic insufficiency [11]. Finally, asymptomatic pancreatic hyperamylasemia, which usually
precedes the diagnosis of CD and often disappears following a gluten-free diet, has been also
described [12]. Similarly, macroamylasemia, a benign condition caused by circulating complexes
of pancreatic or salivary amylases bound to plasma proteins that cannot be cleared by the renal
glomeruli, has also been described in adulthood CD, but it possibly decreases or resolves after a strict
gluten-free diet [13].
The aim of this study, therefore, was to establish the prevalence of CD in patients suffering from
AIP by using the sera collected in the Biobank of a Tertiary Italian referral centre for pancreatic diseases.
This gave us the unique opportunity to include also patients with non-immune-mediated pancreatic
disorders, i.e., chronic pancreatitis and chronic asymptomatic pancreatic hyperenzymemia (CAPH),
as control diseased groups, other than control subjects.
2. Patients and Methods
2.1. Study Population
Four groups of adult patients not taking steroids or immunosuppressive therapy at the time of
blood sample harvest were enrolled in this study, as detailed below:
Group 1 (AIP). The sera of 72 out of 259 patients diagnosed with AIP (type 1 n = 43, type 2
n = 16, not otherwise specified n = 13) according to the International Consensus Diagnostic Criteria [8]
were collected at the Pancreas Institute of the Policlinico G.B. Rossi (AOUI and University of Verona,
Italy), from January 2003 through December 2017. Specifically, 40 out of 43 with type 1 AIP (93%),
2 out of 16 with type 2 AIP (12.5%), and 0 out of 13 with not otherwise specified AIP (0%) displayed
IgG4 positivity.
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Group 2 (chronic pancreatitis). A cohort of 71 out of 492 patients diagnosed with chronic
pancreatitis from January 2012 to December 2017 was included in the study. The diagnostic criteria,
as adapted following our experience, included at least one of the following criteria: (1) presence
of pancreatic-type pain, history of acute/recurrent pancreatitis, presence of steatorrhea or diabetes,
weight loss; (2) imaging findings of pancreatic parenchyma atrophy, main pancreatic duct dilation
>6 mm and/or presence of irregularities, secondary ducts dilation, presence of pancreatic calcifications;
(3) laboratory findings of decreased level of faecal elastase-1 (<100 μg/g of stool), glycated haemoglobin
>6.5%; (4) histological features of chronic pancreatitis (loss of acinar cells, presence of interlobular
fibrosis, infiltration of inflammatory cells and relative conservation of intralobular ducts and islets) in
surgical specimens [14].
Group 3 (CAPH). This group comprised 32 out of 160 patients who were found with CAPH from
January 2012 to December 2017. The diagnosis was made when the serum levels of lipases and/or
pancreatic amylases were found above the upper normal limits (>10%) for at least three consecutive
times lasting for more than six months in the absence of pancreatic-type pain [15]. Moreover, in all cases
no lesions of the parenchyma and/or the ductal system were evident at the magnetic resonance of the
abdomen with cholangiopancreatography sequences.
Group 4 (control subjects). The serum samples of a cohort of 92 patients suffering from
functional dyspepsia, as assessed following the Rome III criteria [16], were collected from June 2012 to
December 2016. The presence of relevant co-morbidities, such as primary immunodeficiencies, cancer,
active infections or organ failure, was considered an exclusion criterion.
The demographic and clinical features of the study groups are listed in Table 1.









Number of cases 72 71 32 92
Male/female ratio 55/17 57/14 18/14 48/44
Mean age in years (SD) 56.5 (16.9) 55.1 (13.2) 52.7 (14.6) 45.7 (18.3)
Body mass index: kg/m2
(mean ± SD) 25.1 ± 4.1 23.2 ± 5.7 24.9 ± 4.4 22.7 ± 5.2
Time from diagnosis in months
(mean ± SD) 25.4 ± 29.3 81 ± 37.5 n.a. n.a.
Concomitant autoimmune
disorders: IBD 13 (10 UC) 1 (Crohn) 0 1 (UC)
Thyroiditis 5 1 1 2
Psoriasis 3 0 0 1
Asthma 1 2 0 2
Coeliac disease 1 * 0 0 0
Rheumatic diseases 2 1 0 3
Thrombocytopenia 1 0 0 0
Abbreviation: SD: Standard Deviation; IBD: inflammatory bowel disease; n.a.: not applicable; UC: ulcerative colitis.
* case already diagnosed with coeliac disease.
The Biobank of the Pancreas Institute, Policlinico G.B. Rossi, AOUI and University of Verona, Italy
had been previously approved by the local Ethics Committee (Protocol number 5604, 2 February 2012).
This study was approved by the local Ethics Committee (Protocol number 49061, 7 July 2018) and each
enrolled patient gave written informed consent.
2.2. Screening for Coeliac Disease
Detection of tissue transglutaminase (tTG) IgA antibody was performed by using a commercial
Elisa test (Eu-tTG®IgA kit, Eurospital, Trieste, Italy; cut-off levels: negative < 9 U/mL, borderline
9–15 U/mL, positive > 15 U/mL). Patients with borderline or positive tTG IgA results underwent
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investigation for IgA anti-endomysium antibodies (EMA-IgA), which was performed by indirect
immunofluorescent technique (Eurospital), according to the manufacturer’s instructions. Sera with
low tTG IgA levels (<1 U/mL) were also evaluated by tTG IgG antibody determination (Eu-tTG®IgG
kit, Eurospital, Trieste, Italy; cut-off levels: negative < 20 U/mL, positive ≥ 20 U/mL).
Duodenal mucosal sampling was offered to all cases with positive tTG-IgA and/or EMA-IgA.
Four biopsies from the second part of the duodenum and two from the bulb were taken during upper
endoscopy for the histological examination according to the Corazza–Villanacci classification [3].
2.3. Statistical Analysis
Continuous variables were expressed as the mean and standard deviation (SD). Discrete data
were tabulated as numbers and percentages. The prevalence of CD was computed, together with its
95% exact binomial confidence intervals (95% CI) overall, for pancreatic disorders as a whole and by
diagnostic group. Stata 15 (StataCorp, College Station, TX, USA) was used for computation.
3. Results
A total of 267 serum samples harvested from 178 males and 89 females (mean age: 51.8 years,
range: 18–85) were included in this study, with 175 being from patients with pancreatic disorders and 92
from control subjects with functional dyspepsia. Worth of note, a large prevalence of males was found
in both AIP and chronic pancreatitis groups, accordingly with literature data [7,17], whereas a similar
proportion of both genders was observed in the other two groups. As shown in Table 1, one case
out of 72 patients of group 1 (1.4%), who was diagnosed with type 1 AIP, had already received the
diagnosis of CD two years earlier because of unexplained hypertransaminasemia and weight loss.
Since then, he was following a strict gluten-free diet with full recovery of laboratory and clinical
features. Therefore, his CD serology resulted negative, and a normal mucosal architecture was found at
histology (see Table 2). The radiological findings that led to the diagnosis of AIP type 1, together with
a high level of IgG4, are shown in Figure 3. The serologic screening did not detect any further case of
CD among patients affected by AIP. However, in two cases a search for tTG-IgG was carried out because
of a very low level of tTG-IgA (less than 1.0 U/mL), giving negative results (4.34 and 6.25 U/mL).
Remarkably, a consistent number of patients with AIP (13 out 72, 20.8%, of whom three had type 1 and
10 had type 2 AIP) was also affected by inflammatory bowel disease, mostly ulcerative colitis (10 out
of 13 cases, while two had indeterminate colitis and one had Crohn’s disease). Specifically, one case
was diagnosed with ulcerative colitis and AIP simultaneously, whereas the diagnosis of ulcerative
colitis preceded that of AIP by a median interval of 28 months (range, 3 to 67 months) in the remaining
patients. The vast majority of ulcerative colitis patients (eight out of 10) were not taking systemic
corticosteroids at the time of diagnosis of AIP, although they had previously undergone this therapy;
only a small proportion of them (three out of 10) was under biological agents (anti-tumour necrosis
factor monoclonal antibody). Also, one patient amongst the 71 with chronic pancreatitis (1.4%) showed
a positive value of both tTG-IgA antibodies, although at low titre (15,875 U/mL), and EMA-IgA at
1:5 dilution. The histologic examination of the duodenal biopsies showed the characteristic lesions,
thus confirming the diagnosis of CD (see Table 2), and the patient was willing to start a gluten-free
diet. When collecting his clinical history, aphthous stomatitis appeared evident. One further case was
found within the group of patients with functional dyspepsia (1.1%), displaying positivity for both
tTG-IgA (value 123 U/mL) and EMA-IgA at 1:16 dilution, thus leading to a definitive diagnosis of
CD upon the demonstration of the characteristic lesions at histologic examination of the duodenal
biopsies (see Table 2). Interestingly, she complained of infertility. An additional two cases in this
group showed borderline values of tTG-IgA (12.44 and 13.47 U/mL) but was negative for the EMA
test; hence, they did not undergo endoscopy, whereas in four cases a search for tTG-IgG was carried
out because of a very low level of tTG-IgA (less than 1.0 U/mL), giving negative results (5.42, 5.73,
5.8, 8.15 U/mL). By contrast, no cases of positive CD serology were detected among the 32 patients
with CAPH (mean value of tTG-IgA: 2.93 U/mL, range 1.276–7.537 U/mL). Therefore, as shown in
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Table 2, a total of three cases were identified to suffer from CD (two active and one treated) in the study
population; that prevalence was similar in patients with pancreatic disorders and control subjects
(overall prevalence 1.1%). Confidence intervals were consistent and ranged from 0% to about 10% in
the single diagnostic groups and up to 4% in aggregated diagnoses.
 
Figure 3. Abdominal magnetic resonance scan showing a diffuse enlargement of the body of the
pancreas, with a “sausage-like” aspect (A), and multiple long stenosis of the main pancreatic duct at
the cholangiopancreatography sequences (B).
Table 2. Cases with positive results at the serological screening with their histological findings.
N tTG IgA tTg IgG EMA Histology § Prevalence (95% CI)
Group 1 72 0 0 0 Grade A lesions * 1.4% (0.0–7.5)
Group 2 71 1 0 1 Grade B1 lesions 2.4% (0.0–7.6)
Group 3 32 0 0 0 Not performed 0% (0.0–10.9)
Group 4 92 1 + 2borderline 0 1 Grade B2 lesions 1.1% (0.0–5.9)
Pancreatic
disorders 175 1 0 1 − 1.1% (0.1–4.1)
Total 267 2 0 2 3 1.1% (0.2–3.2)
Abbreviations. EMA: anti-endomysium autoantibody; IgA: class A immunoglobulin; IgG: class G immunoglobulin;
N: number of cases; tTG: tissue transglutaminase. § Following the Corazza–Villanacci classification [3]. * case already
diagnosed with coeliac disease.
4. Discussion
Limited information is available about the occurrence of exocrine pancreatic disorders during
the course of CD [18], while strong evidence demonstrates an association between CD and type 1
diabetes [5,19]. In fact, approximately 90% of patients with type 1 diabetes carry either HLA-DQ2
or -DQ8 haplotypes as compared to 30% of the general population [20], with those diabetic cases
homozygous for DR3-DQ2 having a 33% risk for the presence of tTG autoantibodies [21]. This is
why the heterodimers encoded by these HLA haplotypes efficiently bind negatively charged
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peptides derived from gliadin upon tTG deamidation, thus eliciting a T- and B-cell mediated
immune response [22]. This, in turn, leads to an upregulation of key pro-inflammatory molecules,
such as interferon-γ [23] and interleukin (IL)-21 [24], responsible for tissue damage. It has also been
suggested that dietary gluten could be involved in the pathogenesis of type 1 diabetes [25]. Conversely,
a gluten-free diet largely prevented diabetes onset in non-obese diabetic mice, possibly through
a modification of the gut microbiota [26].
However, autoimmune attack against the pancreas may involve not only the endocrine component,
but also the exocrine one, giving rise to AIP. This is the pancreatic manifestation of the IgG4-related
disease, whose genetic susceptibility and pathogenic mechanisms are still poorly understood [7].
Nonetheless, almost all of the candidate genes are directly or indirectly implicated in the regulation
of the immune response [7]. A further aspect supporting an autoimmune background is the large
proportion of AIP patients displaying autoantibodies, mostly against enzymes, such as lactoferrin,
carbonic anhydrases, pancreatic secretory trypsin inhibitor, and trypsinogens [27,28]. Even CD is
characterized by the presence of autoantibodies against a ubiquitous enzyme, tTG2, which, besides
being the main autoantigen and target of the anti-endomysium autoantibodies [29], catalyses
a specific and ordered deamidation of gliadin peptides, giving rise to immunodominant epitopes [22].
In addition, tTG2 seems to play a crucial role in the development of secondary autoimmunity through
a post-translational modification of additional proteins, leading to the generation of neoantigens [30].
Also of note, transgenic HLA-DQ8 mice, grown in germ-free conditions and fed a gluten-free diet,
developed acute pancreatitis after intra-peritoneal injection of cerulein, a cholecystokinin analogue that
causes hyperstimulation of the exocrine component [31]. Whether or not gliadin was then introduced
in the diet of these mice, an increased level of IgG1 (homologous of human IgG4) was observed,
together with a histological pattern resembling that of human AIP [31]. Moreover, an increased
level of serum IgG4 was documented in patients suffering from both CD and pancreatic exocrine
insufficiency [32], while an increased number of IgG4+ cells was occasionally found at the mucosal
levels of CD patients [33]. Finally, it is conceivable that the mucosal dysbiosis found in CD patients [34]
might also contribute to an autoimmune attack in close organs, like the pancreas.
Despite these hypotheses, only one case suffering from both CD and AIP has been reported so
far [35], thus we sought to investigate a putative association between these two immune-mediated
conditions, taking advantage of the sera collected at the Biobank of a Tertiary Referral centre for
pancreatic diseases. We found one patient among the 72 AIP patients who had already received the
diagnosis of CD two years earlier. Therefore, the same prevalence of CD in AIP as that of the general
population [2] was evident (1.4%). This also suggests that a gluten-free diet does not protect against
the development of AIP. One possible explanation may lie in the different genetic predisposition
since, at least in the Japanese population, an association of the DRB1*0405-DQB1*0401 haplotype with
AIP was found [36], whereas CD is associated with the HLA-DQ2 and -DQ8 ones [1,5]. Moreover,
unlike classic autoimmune diseases in which T-cells with regulatory effect are defective in number
and/or function, they are likely activated in AIP. Indeed, an increased rate of transcription factor
Forkhead box P3+CD4+CD25+ T-cells in both pancreatic tissue [37] and peripheral blood [38] was found
in AIP patients, together with upregulation of two cytokines with modulatory functions, i.e., IL-10 and
transforming growth factor-β [7]. These seem to be key molecules since the former contributes to IgG4
class switching [39], while the latter is involved in the development of fibrosis [40].
At variance with CD, a strong association between AIP and IBD (18.0% of cases), mostly
ulcerative colitis (13.9%), has been found in our cohort of Caucasian patients, thus confirming previous
reports [41,42]. However, the prevalence was higher than that found in either an American [41]
or an Asiatic [42] study, where a frequency of 5.6% and 5.8%, respectively, was found. Likewise,
both have a retrospective design and a similar sample size (71 and 104 AIP cases, respectively) [41,42].
However, the tools applied for the diagnosis of AIP were different, since the HISORt criteria for
AIP [43] were used in the former, whereas the Asian Diagnostic Criteria for AIP [44] were used in
the latter, thus possibly affecting the final results. The discrepancy may also be partly related to
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ethnic differences and to the relatively small number of patients recruited. Interestingly, the course of
ulcerative colitis was worst in those suffering from both diseases since, during the follow-up period of
10 years, 33.3% of patients underwent a colectomy versus none of those suffering from ulcerative colitis
alone [42]. Finally, although Berkson’s bias (patients with two uncommon diseases are more likely
to be referred to a tertiary medical centre than patients with just one such disease) [45] could have
inflated the magnitude of this association, our data strongly suggest that the AIP and ulcerative colitis
are related to some degree whose extent deserves further investigation.
As far as the non-immune-mediated pancreatic disorders are concerned, it is widely acknowledged
that both functional and anatomical changes of the gland may be caused by or coexist with CD [18].
A Swedish register study, indeed, found an increased risk of both acute and chronic pancreatitis
in patients with adulthood CD during the observational period of 1964 to 2003 [9]. Furthermore,
it was estimated that over 20% of patients with CD have defective exocrine pancreatic function [10].
This seems to be related to an impaired secretion of cholecystokinin pancreozymin secondary to
enteropathy and/or malnutrition, since normalization of both intestinal mucosa and nutritional status
restores the secretion of digestive hormones and enzymes [46]. Nevertheless, no information on the
prevalence of CD in non-immune-mediated pancreatic disorders is available so far. We found one case
in the chronic pancreatitis group (1.4%) and one in the control subject group (1.1%), again overlapping
with the prevalence in the general population [2]. Thus, despite a relationship between CD and
pancreatic disorders having been demonstrated, the opposite does not seem true. Accordingly, we did
not find any positivity at the serologic screening for CD in the CAPH group, even though an abnormal
elevation of serum amylase and/or lipase was found in CD patients but disappeared upon a course of
gluten-free diet [12].
Obviously, our study has strengths and weaknesses. A point of strength is that this is the first study
investigating the prevalence of CD in patients suffering from pancreatic disorders, whereas the studies
published so far did the opposite. Moreover, if we consider that AIP is a rare and difficult-to-diagnose
condition, the large sample size available, together with the appropriateness of the diagnosis, put us in
a privileged situation where the putative higher prevalence of CD in this clinical setting might have
been demonstrated, if there was any. The limitations include the retrospective design and the small
sample size (and thus the relatively large confidence intervals) of the CAPH and chronic pancreatitis
groups in comparison with the overall institutional cohorts due to the low level of willingness to give
serum samples for future unknown studies, whereas the lack of sex and age matching among AIP and
chronic pancreatitis patients with CAPH and control cases was largely expected [7,47]. In addition,
serum IgG or IgG4 levels were not available in non-AIP groups because they are not routinely measured.
Despite these limitations, our cohort of 72 patients with AIP represents one of the largest single-centre
experiments to date.
5. Conclusions
In summary, our findings suggest that there is a low probability of there being an association
of CD with AIP, thus serological screening for CD is not recommended in patients with AIP.
By contrast, a strong association between AIP and ulcerative colitis appears evident. AIP is a relatively
“new” diagnostic entity, thus further prospective and multicentre studies are needed to confirm the
conclusions of this study.
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Abstract: Background: Patients with gluten ataxia (GA) without enteropathy have lower levels of
antigliadin antibodies (AGA) compared to patients with coeliac disease (CD). Magnetic Resonance
Spectroscopy (NAA/Cr area ratio) of the cerebellum improves in patients with GA following a strict
gluten-free diet (GFD). This is associated with clinical improvement. We present our experience of the
effect of a GFD in patients with ataxia and low levels of AGA antibodies measured by a commercial
assay. Methods: Consecutive patients with ataxia and serum AGA levels below the positive cut-off
for CD but above a re-defined cut-off in the context of GA underwent MR spectroscopy at baseline
and after a GFD. Results: Twenty-one consecutive patients with GA were included. Ten were on a
strict GFD with elimination of AGA, 5 were on a GFD but continued to have AGA, and 6 patients
did not go on a GFD. The NAA/Cr area ratio from the cerebellar vermis increased in all patients on
a strict GFD, increased in only 1 out of 5 (20%) patients on a GFD with persisting circulating AGA,
and decreased in all patients not on a GFD. Conclusion: Patients with ataxia and low titres of AGA
benefit from a strict GFD. The results suggest an urgent need to redefine the serological cut-off for
circulating AGA in diagnosing GA.
Keywords: Gluten ataxia; antigliadin antibodies; coeliac disease; MR spectroscopy; gluten sensitive
enteropathy; antigliadin antibody titre
1. Introduction
Gluten ataxia (GA) is defined as otherwise idiopathic sporadic ataxia with serological evidence of
gluten sensitivity in the absence of an alternative cause [1]. The presence or absence of an enteropathy
is not a prerequisite for its diagnosis [2]. Indeed, up to 50% of patients with GA do not have an
enteropathy, yet they still benefit from a gluten-free diet (GFD) [2]. For this reason, IgG and IgA
native antigliadin antibodies (AGA) are currently the most sensitive marker for GA when compared
to endomysium (EMA) and transglutaminase 2 antibodies (TG2), both of which are specific for the
presence of enteropathy (Coeliac Disease-CD) [2]. Despite this, the majority of immunology laboratories
in the UK and other countries have abandoned the use of native AGA assays in the diagnosis of CD
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because of poor specificity. Estimation of specificity, however, is based on the presence of a gold
standard, in this case the presence of enteropathy (CD). It is now widely accepted that sensitivity
to gluten can be present without enteropathy [3]. The only current serological biomarker helpful in
diagnosing gluten sensitivity without enteropathy is AGA [4].
Patients with CD often have high titres of circulating AGA, whereas patients with GA and
no enteropathy tend to have low titres. The serological cut-off for significant titre in commercially
available AGA assays is calculated to maximize diagnostic specificity using data from patients with
CD. This would not necessarily be applicable to those patients with gluten sensitivity who do not have
enteropathy and those patients with extraintestinal manifestations.
Having previously demonstrated the beneficial effect of a GFD in patients with GA using MR
spectroscopy of the cerebellum, in this report we present our experience of the effect of a GFD in
patients with ataxia and AGA levels that are below what is considered positive, as defined by the
manufacturer, but above a newly defined cut-off AGA level based on our extensive experience in
managing patients with GA and the re-evaluation of over 500 patients with GA.
2. Methods
This report is based on prospective observational case series of patients regularly attending the
gluten sensitivity/neurology clinic run by one of the authors (M.H.). The South Yorkshire Research
Ethics Committee has confirmed that no ethical approval is indicated given that a gluten-free diet is
a recognized treatment for suspected patients with GA and that all investigations/interventions were
clinically indicated and did not form part of a research study.
2.1. AGA Serological Testing
In January 2015, the immunology lab at Sheffield Teaching Hospitals NHS Trust changed the ELISA
AGA (IgG and IgA) assay to Phadia 2500 [5]. The decision was based on the benefits of an automated
high throughput process. After consultation with the clinicians using the AGA assay, a decision was
made to provide numerical values for the AGA results instead of just positive/negative results.
The manufacturers provided the following information regarding positivity (for both IgA and IgG)
of their assay: 0–7 U/mL negative, 7–10 U/mL borderline, >10 U/mL positive.
2.2. Patient Selection and Follow-up
The Sheffield Ataxia Centre cares for over 1800 patients with progressive ataxia, including over
500 patients with GA. All patients with ataxia undergo extensive investigations to try and identify
a cause [6]. Such investigations include serological testing for AGA, EMA and TG2. Our previous
report on the effect of a GFD on MR spectroscopy in 117 patients with GA was based on those
patients with AGA serological positivity (with or without serological positivity for TG2 and EMA
antibodies and/or enteropathy) using previous commercial AGA assays by our immunology lab,
or those patients who had a value of over 7 U/mL using the new assay [7]. Fifty percent of our cohort
of patients with GA have an enteropathy (CD). As expected in patients with enteropathy, EMA and
TTG antibodies are also positive. All patients diagnosed with GA at our centre are routinely advised
to adopt a strict GFD and are referred to an experienced dietitian for GFD advice. Strict adherence
to a GFD is assumed when there is elimination of all gluten related antibodies. If patients have
persistently positive antibodies, they are reviewed by an experienced dietitian (NT) for further advice.
Patients who still have persistently positive AGA are assumed not to be strict with a GFD.
In the current report we have included only those consecutive patients with serological results
for IgG and/or IgA AGA over 3 U/mL but less than 7 U/mL. The lower cut-off value of 3 U/mL
was derived based on our experience in the diagnosis and management of over 500 patients with GA
who regularly attend the Sheffield Ataxia Centre and either did not adopt a GFD or were on a partial
(non-strict) GFD. All of these patients were repeatedly tested using the new assay, irrespective of their
GFD status. The new serological cut-off was also based on AGA estimation in those GA patients
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already on a strict GFD who had persistently absent circulating AGA, using previous assays and with
evidence of improvement of their ataxia clinically and on MR spectroscopy. All of these patients with
GA who remained neurologically stable had values below 3 U/mL on the new assay. Patients on
partial or no GFD had levels above 3 U/mL but often less than 7 U/mL. We therefore used the cut-off
of 3 U/mL, below which we assumed strict adherence to a GFD.
Consecutive patients included in this report attend the Sheffield Ataxia Centre on a 6 monthly
basis. All patients had undergone more than one clinical MR spectroscopy scan for the purpose of
diagnosis and monitoring of their ataxia since 2015, the year of the introduction of the new AGA assay.
Only a third of the patients reported here underwent gastroscopy and duodenal biopsy to establish
the presence of enteropathy (triad of villus atrophy, crypt hyperplasia and increased intraepithelial
lymphocytes). This was based on patient choice after informing them of their serological results,
including the negative serology for TG2 and EMA antibodies. None of these patients had enteropathy
as predicted by the negative EMA and TG2 antibodies, but presence or not of enteropathy was not an
exclusion criterion. Patients were reviewed by an experienced dietitian (NT) who provided detailed
advice on a GFD with further monitoring by telephone or face-to-face consultations. The patients
underwent repeat clinical evaluation and further serological testing at approximately 6 monthly
intervals. Strict adherence to a GFD was indicated by serological elimination of circulating AGA
(<3 U/mL). For the purpose of this report, the patients were divided into 3 groups: those with strict
adherence to GFD with AGA levels of <3 U/mL, those with partial adherence to a GFD as evident
from the presence of AGA (above 3 U/mL but less that 7 U/mL), and a third group consisting of
patients that declined GFD (AGA level above 3 U/mL and less than 7 U/mL).
We also reviewed the AGA results in patients with classical CD presenting to gastroenterology
clinics and patients with idiopathic sporadic ataxia. Data on the prevalence of AGA (range between
3–7 U/mL) was also available from healthy volunteers as part of another ongoing study.
2.3. MR Spectroscopy
In addition to volumetric 3T MR imaging, all patients underwent single-voxel H1 MR spectroscopy
of the cerebellum. This imaging protocol is in clinical use as part of the investigation of all patients
with cerebellar ataxia attending the Sheffield Ataxia Centre. The brain imaging protocol for structural,
volumetric, and spectroscopy studies has been previously described [7]. The main measurement is
the NAA/Cr area ratio within the cerebellar vermis. N-acetyl aspartate (NAA) reflects the health
of neurons and is a reliable marker of monitoring neuronal energy impairment and dysfunction.
Creatine (Cr) is a stable metabolite with little variation between different pathologies. As such,
it is typically used as an internal standard in MR spectroscopy from which metabolite ratios can
be calculated.
A baseline MR spectroscopy scan was done on all patients and a repeat scan was done after the
introduction of the GFD. In common with other immune-mediated ataxias, the cerebellar vermis is
primarily involved in GA; therefore, MR spectroscopy results reported here are measurements from
the cerebellar vermis.
2.4. Statistical Analysis
Change in mean values between the groups was compared with Student’s two-tailed t-test for
unpaired samples. A value of p < 0.05 was considered significant.
3. Results
A total of 21 consecutive patients with GA were included at the time of writing this report.
Detailed clinical characteristics of patients with GA have been described previously. The patients
included in this report did not differ in any way from those patients with GA described previously [1,8].
All patients had two MR spectroscopy scans at baseline and the second after a mean interval
of 19 months (range 5 months to 36 months). Of the 21 patients, 10 were on a strict GFD with
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elimination of all antibodies (IgG and/or IgA AGA <3 U/mL), 5 were on a GFD but still had serological
evidence of circulating AGA, indicating ongoing exposure to gluten (IgG and/or IgA >3 U/mL),
and 6 patients were not on the diet (IgG and/or IgA AGA >3 U/ml and <7 U/mL). There were no
significant differences in the duration of ataxia between the 3 groups. The patients on partial GFD
were significantly younger that the other 2 groups. There were, however, no significant differences in
age between the strict GFD and no GFD groups. Those patients that declined a GFD also had a repeat
scan for monitoring purposes. The NAA/Cr area ratio taken from the cerebellar vermis increased in
all 10 patients on a strict diet, but in only 1 out of 5 (20%) patients on a partial GFD with persistent
circulating AGA. In the remaining 4, the NAA/Cr area ratio decreased. In all of the 6 patients not on
a diet, there was a decrease in NAA/Cr area ratio on repeat scanning. These results are illustrated in
Figures 1 and 2. A Chi squared contingency table looking at numbers improved on MR spectroscopy
on a strict diet compared with no diet was significant p < 0.0001. A comparison of the change in
MR spectroscopy values from baseline between the 3 groups showed the following: no diet mean
change −0.098, Standard error of the Mean (SEM) 0.06, partial diet mean change −0.028, SEM 0.087
and strict diet mean change +0.092, SEM 0.06. Comparison between the strict diet and no diet groups
was significant (p < 0.0001), as was the comparison between partial diet and no diet (p = 0.0028).
Figure 1. NAA/Cr area ratio in patients with gluten ataxia without enteropathy following the
introduction of a gluten-free diet (GFD) in the 2 sub-groups (number of patients on gluten free diet
10, partial diet 5). The third subgroup consisted of 6 patients who declined a GFD. All patients had
antigliadin antibodies (AGA) IgG and/or IgA of >3 U/mL and <7 U/mL at baseline. Both the partial
diet and no diet groups still had AGA values >3 U/mL at the time of the second scan. All 10 patients
on a strict GFD showed improvement of the NAA/Cr area ratio (vertical axis) of the vermis 4 of the
5 patients on partial GFD and all 6 patients not on GFD showed deterioration of the NAA/Cr ratio.
A Chi squared contingency table looking at numbers improved on magnetic resonance spectroscopy
on a strict diet compared with no diet was significant p < 0.0001.
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Figure 2. Mean change of the area ratio of NAA/Cr from baseline in the 3 groups.
Using the same serological cut-off for AGA titres of >3 U/mL, the prevalence of AGA positivity
amongst 68 patients with classical CD presenting to the gastroenterologists was 100%. The mean
baseline value for AGA titre in this classical CD group was 46.5 U/mL. This compares to a mean
AGA titre of 4.1 U/mL in the 21 patients reported here. The prevalence amongst 28 healthy controls
was 7%, and the prevalence amongst 197 patients with otherwise idiopathic sporadic ataxia was 39%.
This group of 197 did not include patients with ataxia who had AGA levels over 7 U/mL or those who
also had enteropathy. Table 1 summarises the clinical and serological characteristics of the GA groups.
Table 1. Summary of clinical characteristics and the change in magnetic resonance spectroscopy and
antigliadin antibody titre at baseline and at the time of the second scan in the 3 groups. The differences
in numbers improved and in the changes in MR spectroscopy between the strict GFD and the not
on GFD groups were significant p < 0.0001. There were no significant clinical differences between
the strict GFD and the partial or not on diet groups. The patients on partial GFD were significantly
younger than the other 2 groups. GA = gluten ataxia; NAA/Cr = N Acetyl Aspartate to Creatine ratio;



























strict GFD 10 65 6.4 +0.092 10 3.6 (0.46) 1.8 (0.74)
partial GFD 5 50 6.6 −0.028 1 4.5 (1.3) 3.8 (1)
not on diet 6 77 7.3 −0.098 0 4.2 (1.3) 4.2 (1.8)
4. Discussion
We have previously demonstrated clinical and MR spectroscopic improvement in patients with
GA after a year of strict adherence to a gluten-free diet [7,9]. The current study demonstrates that in
patients with GA with low titres of AGA, NAA/Cr area ratio within the cerebellar vermis improves
with strict adherence to a gluten-free diet, worsens with on-going exposure to gluten, and also largely
worsens with partial adherence to a gluten-free diet, as indicated by persistently positive circulating
AGA. The improvement in MR spectroscopy was accompanied by clinical improvement or stabilisation
of the ataxia in the strict GFD group.
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The advantage of MR spectroscopy as a monitoring tool is that it can be easily performed as part of
routine MR imaging, it is reproducible in an individual on a particular scanner, and relies on objective
measurements such as the NAA/Cr area ratio [7,10]. It therefore overcomes the disadvantages of the
clinical scales (interrater variability, fluctuation of ataxia symptoms and signs due to fatigue, insensitive
scales in disabled patients and ceiling effect). Other groups have also demonstrated good correlation
between MR spectroscopy and the clinical status as assessed by ataxia rating scales [11]. This report
also demonstrates the importance of strict adherence to the GFD. Amongst those patients on the diet,
but not strict, only 20% improved on MR spectroscopy as opposed to 100% in those on a strict GFD.
Strict diet with serological evidence of elimination of all antibodies appears to have the potential to
stabilise and partially reverse immune mediated damage to the cerebellum.
This report also demonstrates that for extraintestinal manifestations of gluten sensitivity, and in
particular for those patients without enteropathy, the level of circulating AGA that is still significant
is lower than that seen in the context of enteropathy. This means that the serological cut-off titre for
diagnosing GA requires adjustment. This has major implications for the diagnosis of GA. Our data
from 197 patients with idiopathic sporadic ataxia collected since 2015 (the year of the introduction of
the new assay), excluding those with positive AGA (using the manufacturer’s serum cut-off level for
positivity) and those with CD, showed that 39% had AGA levels between 3 and 7 U/mL. As we have
shown here, these patients also benefited from a strict GFD. Up until now, such patients would have
remained undiagnosed and therefore followed a progressive course as a result of ongoing exposure to
gluten. Indeed, some of these patients had been under regular follow-up in our ataxia clinic but were
negative for AGA on previous assays used by our immunology lab.
We have found MR spectroscopy a reliable and useful tool in the monitoring of patients with GA
and other ataxias. Improvement of NAA/Cr in patients adherent to a GFD bolsters the diagnosis of
GA and, in our experience, is accompanied by clinical improvement [9]. Such improvement also acts as
a motivation for patients to continue with the GFD. The commonest cause for the lack of improvement
tends to be poor adherence to the GFD.
Both this report and previous publications from our group have highlighted the importance
of using the correct serological markers for the diagnosis of GA. The presence of enteropathy
(associated with the presence of positive TG2 and endomysium antibodies) does not influence the
response to the GFD, and thus any patient with positive antigliadin antibodies and no other cause of
ataxia should be offered a strict gluten-free diet, even in the absence of enteropathy.
In conclusion, using MR spectroscopy data we have demonstrated that patients with ataxia and
low titre of AGA improve on a strict GFD. We are therefore proposing a new AGA titre cut-off level
that should be used in the diagnosis of GA.
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Abstract: Objective: The aim of this systematic review was to explore the relationship between coeliac
disease (CD) and headache. The objectives were to establish the prevalence of each entity amongst
the other, to explore the role of gluten free diet (GFD), and to describe the imaging findings in those
affected by headaches associated with CD. Methodology: A systematic computer-based literature
search was conducted on the PubMed database. Information regarding study type, population size,
the age group included, prevalence of CD amongst those with headache and vice versa, imaging
results, the nature of headache, and response to GFD. Results: In total, 40 articles published between
1987 and 2017 qualified for inclusion in this review. The mean pooled prevalence of headache
amongst those with CD was 26% (95% CI 19.5–33.9%) in adult populations and 18.3% (95% CI
10.4–30.2%) in paediatric populations. The headaches are most often migraine-like. In children
with idiopathic headache, the prevalence of CD is 2.4% (95% CI 1.5–3.7%), whereas data for adult
populations is presently unavailable. Brain imaging can be normal, although, cerebral calcifications
on CT, white matter abnormalities on MRI and deranged regional cerebral blood flow on SPECT can
be present. GFD appears to be an effective management for headache in the context of CD, leading to
total resolution of headaches in up to 75% of patients. Conclusions: There is an increased prevalence
of CD amongst idiopathic headache and vice versa. Therefore, patients with headache of unknown
origin should be screened for CD, as such patients may symptomatically benefit from a GFD.
Keywords: gluten sensitivity; coeliac disease; gluten free diet; migraine; headache
1. Introduction
Gluten-related disorders (GRDs) represent a diverse spectrum of clinical entities for which the
ingestion of gluten is a common trigger.
Coeliac disease (CD) is the best-recognised GRD and it is characterized by a small bowel
enteropathy occurring in genetically susceptible individuals whilst exposed to the protein gliadin [1].
Non-coeliac gluten sensitivity (NCGS) is a term that is used by gastroenterologists to describe patients
with primarily gastrointestinal (GI) symptoms that are related to the ingestion of wheat, barley,
and rye, who do not have enteropathy, but do symptomatically benefit from a gluten free diet (GFD) [2]
However, in the context of neurological manifestations, patients might have serological evidence of
gluten sensitivity (GS); usually anti-gliadin IgG and/or IgA (AGA), with or without transglutaminase
(TG) or endomysial antibodies (EMA), but no histological changes on biopsy of the bowel to suggest
CD [3]. Such patients might still benefit neurologically from a strict GFD.
Although the gastrointestinal manifestations of GRDs are the most prevalent, a range of debilitating
neurological manifestations are increasingly being recognised in clinical practice, often preceding or in
the absence of GI symptoms. The most well-known neurological GRDs are cerebellar ataxia [4] and
Nutrients 2018, 10, 1445; doi:10.3390/nu10101445 www.mdpi.com/journal/nutrients213
Nutrients 2018, 10, 1445
peripheral neuropathy [5], however clear links between GS/CD and epilepsy [3], various movement
disorders [6], and headaches [7] have also been described.
The aim of this paper is to systematically review the current literature in order to establish the
relationship between headache and CD.
2. Methods
2.1. Literature Search Strategy
This study is reported in accordance with the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) guidelines [8]. A systematic search was performed on the 29 August
2018 using the PubMed database. For the search, two medical subject headings (MeSH terms) were
used and they were restricted to title/abstract fields. Term A was “coeliac” or “celiac” or “gluten”.
Term B was “headache” or “migraine”. English language was applied as a filter. The reference lists of
included articles were examined in order to identify further relevant articles.
2.2. Inclusion and Exclusion Criteria
Articles to be included in the review were required to meet the following criteria:
1. The study subjects were diagnosed with idiopathic headache and gluten sensitivity or
coeliac disease.
2. The study subjects were human.
3. The study contained original data.
4. The study was available as a full-text, English language article, or contained utilisable information
in an English language abstract.
5. For randomised control trials, a JADAD score [9] of above 3 to ensure good quality and to reduce
any potential bias.
Details of the inclusion process are detailed in the PRISMA chart, Figure 1.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) chart.
2.3. Statistical Analyses
A database was developed using IBM SPSS Statistics (version 23.0 for Mac, IBM. New York,
United States). Data were extracted from each study and included: study type; population size; the age
group included; prevalence of GRD/headache; imaging results; the nature of headache; and, response
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to GFD. Frequencies and descriptive statistics were examined for each variable. The outcomes of
interest were the proportion of patients with CD or GS suffering from headache and the proportion of
patients suffering from idiopathic headache that had CD or GS.
Meta-analysis of the pooled proportions was conducted in R language [10] while using the default
settings of the “meta” package using the “metaprop” function. The meta-analysis of odds ratios
was conducted using the RevMan program [11], as suggested by the Cochrane Collaboration Group.
Heterogeneity between studies was assessed using the I2 statistic. Data were analysed using a random
effects model.
A value of p < 0.05 was considered to be statistically significant.
2.4. Compliance with Ethical Guidelines




The search strategy identified 96 articles. A total of 57 articles were excluded during the eligibility
assessment. After perusing the reference lists of included studies, one additional article meeting our
inclusion criteria was identified, which had not already been discovered in the aforementioned search
strategy. Therefore, in total 40 articles published between 1987 and 2017 qualified for inclusion in this
review, studying a total of 42,388 individuals with either headache or GRD (mean number of patients
per citation 1059.7 ± 4626.5). The characteristics of the included papers are summarised in Table 1.
Figure 1 illustrates the study selection process.
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Table 1. Descriptive of studies included in the review.
Parameter Value






Case report 9 (22.5)
Cohort/Case series 16 (40.0)




Coeliac disease 36 (90.0)
Mixed group: CD/GS 1 (2.5)
Mixed group: NCGS/GS 3 (7.5)
Type of headache reported
Migraine 16 (40.0)
All types 6 (15.0)
Not specified 14 (35.0)
Idiopathic intracranial hypertension–related 2 (5.0)





No imaging data 24 (60.0)
Table 1. Cont.
Parameter Value
Year of publication (%)
Until 2000 5 (12.5)
2000–2009 15 (37.5)
2010–2018 20 (50.0)
* Some citations had data on more than one imaging types.
3.2. Prevalence of Headache in Patients with CD
Only one population based epidemiological study, inclusive of all ages, has been conducted
to date [12]. In this population-based retrospective cohort study that was conducted in Sweden,
Lebwohl et al. reported that among 28,638 patients with CD and 143,126 controls, headache-related
visits occurred in 4.7% and 2.9% of each group, respectively, suggesting a hazard ratio of 1.7 (95% CI
1.6–1.8; p < 0.0001). However, in this study, there was no information provided regarding the criteria
for headache diagnosis used and if diagnosed, its exact type.
Information about prevalence of headache in adults was available through five cohort [13–17] and
four case-controlled studies [18–21]. As shown in Figure 2, the pooled mean prevalence of headache in
adults with CD was 26% (95% CI 19.5–33.9%). The meta-analysis of the four case-controlled studies is
summarized in Figure 3; the odds of having a headache were significantly higher in the CD groups
when compared to controls (OR 2.7, 95% CI 1.7–4.3, p < 0.0001).
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Figure 2. Pooled mean prevalence of headache in adults with coeliac disease.
Figure 3. Meta-analysis results as illustrated in the forest plot regarding the odds of having headache
in adults with coeliac disease compared to controls.
Information about prevalence of headache in children and adolescents, was available through
five cohort [17,22–25], one case-controlled [26], and one population-based study [27]. As shown in
Figure 4, the pooled mean prevalence of headache in children and adolescents with CD was 18.3%
(95% CI 10.4–30.2%). A cross-sectional, population-based study that was conducted by Assa et al. [27]
investigated the association between CD and various comorbidities, demonstrating that the odds
of suffering from headache were significantly higher in children and adolescents with CD when
compared to controls (OR 2.3, 95% CI 2.1–2.5, p < 0.0001).
Figure 4. Pooled mean prevalence of headache in children with coeliac disease.
3.3. Prevalence of CD in Patients with Idiopathic Headache
Headache, usually migraine, has been reported as the first manifestation of CD in several case
reports [28–36].
In a case-controlled study, Gabrielli et al. [37] investigated the prevalence of CD amongst 90 adults
with idiopathic migraine when compared to blood donor controls. Of them, 4.4% were found to have
CD against 0.4% of controls (p < 0.05).
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Information about prevalence of CD in children with headache was available through two
case-control [38,39] and two cohort studies [26,40]. As demonstrated in Figure 5, the pooled mean
prevalence of CD in children with idiopathic headache is 2.4% (95% CI 1.5–3.7%), which is significantly
higher as compared to the prevalence of CD in the general population in the same age group. Although
in one of these studies the authors conclude that that the prevalence of CD was not higher in patients
with migraine relative to the control group [38], the other three studies concluded that the odds of a
child with headache having CD is significantly higher than in children without headaches, with OR
ranging from 1.7 to 8.3 [26,39,40].
Figure 5. Pooled mean prevalence of coeliac disease in children with idiopathic headache.
3.4. Imaging Findings
Sixteen papers provided information regarding imaging findings [7,14,22,26,28–31,33–37,41–43].
3.4.1. Computed Tomography (CT)
Although brain CT scans in patients with CD and headache are usually normal, there have
been cases described of migraine-like headaches with occipital [29,30] or parieto-occipital [33,35]
calcifications in both adult and children patients. The two patients with headache and parieto-occipital
calcifications being described in the literature were adults, with no evidence of epilepsy or epileptiform
activity on EEG. By contrast, all three patients with headache and occipital calcifications were children,
of which two also had epilepsy. Cerebral calcifications in the context of CD have been associated
with epilepsy [3], which is most commonly known as “epilepsy and cerebral calcification (CEC)
syndrome”. However, although the available evidence is limited, there are cases with calcifications and
migraine-like headaches in the absence of epilepsy. Therefore, patients who present with idiopathic
headache in the presence of calcifications in the occipital or parieto-occipital areas of the brain should
be screened for CD.
3.4.2. Magnetic Resonance Imaging (MRI)
MRI findings have been reported in isolated case reports and small case series. In a consecutive
cohort of 33 adult patients with CD who were referred for a neurological opinion, Currie et al. reported
that 12 patients (36%) had white matter abnormalities (WMA) on MRI [14]. When looking specifically
into patients with headache, four out of six (67%) had WMA on MRI. In children, one out of six patients
with headaches and CD that have been reported to date [22,42,43] was found to have WMA on MRI.
Hadjivassiliou et al. has presented the largest series of patients with CD or GS and WMA on MRI
to date [7]. Among 40 adult patients with symptoms and signs of central nervous system dysfunction,
most of which had cerebellar ataxia, ten patients (four with CD and six with GS) were found to
have WMA. All patients had episodic migraine-like headache. In children with GS the available
evidence is limited, however Alehan et al. reported that WMA were present in one out of four TG
positive patients [41]. Therefore, patients of all ages who present with idiopathic headache and have
non-specific WMA on MRI should be screened for CD and GS.
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3.4.3. Single Photon Emission Computed Tomography (SPECT)
Gabrielli et al. conducted a case-controlled study of four adult patients with migraine and newly
diagnosed CD and five control patients with migraine, but no CD who underwent a brain SPECT study,
which was performed by the administration of 740 MBq of 99mTc hexemethyl-propylene-amineoxime
using a brain-dedicated tomograph [37]. All SPECT studies were performed in the headache free
period. All four patients that were affected by both migraine and CD showed evident abnormalities
in regional cerebral blood flow. In all cases, a circumscribed area of cortical hypoperfusion was
present, whereas there were no interhemispheric asymmetries of cortical regional blood flow in the
five migraine patients without evidence of CD.
3.4.4. Positron Emission Tomography (PET)
Lionetti et al. studied the cerebral perfusion in four children headaches and CD with an
eight-ring whole-body PET scanner using 2-[18F]-fluoro-2-deoxy-D-glucose, without identifying any
abnormalities [26]. This could be because of a selection bias, as the patients that underwent PET had
normal standard cerebral imaging, or it might suggest that cerebral hypoperfusion is not present in
children with headaches and CD.
3.5. Effect of Gluten-Free Diet
The effect of a gluten-free diet (GFD) has been reported in numerous cohort studies [7,15,17,20,24–
26,28,37,40]. In adults, a positive response, defined as a significant reduction in headache frequency,
varies from 51.6% [20] to 100% [7,37] of the patients who embarked on a GFD. In up to 75% of adult
patients [15] with CD, GFD led to the total resolution of headache. In children, the response rates
range between 69.2% [24] and 100% [25,28,40]. In up to 71.3% of paediatric patients [25] with CD,
GFD resulted in headache resolution.
As well as direct clinical improvement, it has been demonstrated that a GFD can normalize
the cortical hypoperfusion abnormalities that are seen in SPECT [37]. Although, WMA and brain
calcifications are not reversible when present, patients on a strict GFD have a lower incidence of
WMA [14].
In a survey of pediatric patients with CD that was conducted by Rashid et al., it was reported
that up to 13% of patients experience headache after accidental gluten ingestion [44]. In a similar
survey of predominantly adults (patients > 16 years old) with CD, Zarkadas et al. found that 23%
of patients experienced a headache when they knowingly consumed gluten [45]. In their study,
Faulkner-Hogg et al. reported that dietary analysis of patients with persistent symptoms, including
headaches, showed that up to 56% of patient still consume traces of gluten. When such patients
switched to a strict GFD their symptoms improved [46]. Therefore, specialist dietician advice should
always be offered to patients with CD and headaches, and their compliance with the diet should be
routinely checked (i.e., AGA titre monitoring).
3.6. Gluten-Related Intracranial Hypertension
Some case reports describe patients who presented with headache secondary to increased
intracranial pressure and CD. Dotan et al. reported two cases of boys (three and four years old)
who presented with idiopathic intracranial hypertension (IIH). Diagnostic work-up revealed low
serum vitamin A titres and further diagnostic work-up led to a diagnosis of CD [43]. A therapeutic
regimen of vitamin A supplements, GFD, and acetazolamide proved very effective. Rani et al. reported
a single case of a 14-year-old girl with IIH, whose diagnostic work-up revealed CD [42]. Despite
the fact that the patient was overweight (BMI 30) a GFD proved to be beneficial, even before the
patient started to lose weight and without requiring administration of acetazolamide. Although these
data are limited and the evidence is currently weak, the potential link between CD and intracranial
hypertension should be investigated further.
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3.7. Gluten–Encephalopathy
Gluten encephalopathy is a term that is used to describe a combination of frequent, often
intractable, headaches, and cognitive complaints (which patients sometimes describe as a “foggy
brain”). Crosato et al. were the first to describe a case of a nine-year-old boy with a history of seizures,
headaches, episodes of drowsiness and cerebral calcification on CT who, because of his very low folate
levels, was eventually diagnosed with CD [29]. Kakoraç et al. reported a case of a 48-year old man
who presented with two episodes of headache, confusion, and seizures and normal MRI, and because
of carnitine deficiency, was eventually diagnosed with CD [34].
3.8. NCGS/GS and Headache
A link between headache and NCGS or GS has been also demonstrated in a smaller number
of studies.
Information about prevalence of GS in children with headache (all reporting migraine), was
available through three case-controlled studies [41,47,48]. As shown in Figure 6, the pooled mean
prevalence of GS in children with idiopathic migraine is 6.2% (95% CI 2.6–14.1%). Figure 7 demonstrates
that the odds of having migraine are higher (trend for statistical significance) in children with CD as
compared to controls (OR 2.8, 95% CI 0.9–8.6, p = 0.06).
Figure 6. Pooled mean prevalence of serologically confirmed gluten sensitivity in children with
idiopathic migraine.
Information about the prevalence of headache in patients with NCGS was available through two
studies [49,50]. In a cohort of 486 patients (children and adults), 54% presented with headaches [50].
In a cohort of 78 children with NCGS, 32% presented with headaches, when not on a GFD [49]. It is of
interest that 56% of patients with NCGS, when not on a GFD, have positive AGA. This highlights the
need to test patients for AGA, the only currently available biomarker of GS.
Figure 7. Meta-analysis results as illustrated in the forest plot regarding the odds of having migraine
in children with coeliac disease compared to controls.
4. Conclusions and Future Directions
This systematic review, highlights the following key points:
1. There is an increased prevalence of headache amongst patients with CD and an increased
prevalence of CD amongst those with idiopathic headache. Such an increased prevalence is
evident in both child and adult populations; however, the figures are higher in the latter.
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2. Headaches that are associated with CD are predominantly migraines. However, many studies
that were used in this report tended to report headaches without specifying the exact type
(i.e., tension, cluster, migraine, etc.) making the interpretation of the findings more difficult.
3. CT calcifications and WMA are frequent in patients with headaches that are related to CD,
and therefore patients with such imaging findings in in the context of idiopathic headache require
further testing for CD.
4. GFD is a very effective treatment for headaches associated with CD and should therefore be
offered as soon as possible. This is highly consistent with other neurological GRD, such as the
observation that GFD is associated with a significant reduction of pain in patients with gluten
neuropathy and an improvement of their quality of life [51,52]. Specialist dietary advise should
always be offered, as often patients consume gluten, whilst believe that they are on a strict GFD.
Serological testing (i.e., AGA titre) can help in monitoring compliance with diet.
5. Further studies of the prevalence of GS in patients with idiopathic headache are needed. Currently,
to our knowledge, no such studies in adults exist.
6. Although there is some evidence that brain hypoperfusion and perivascular inflammation might
play a role in the pathogenesis of GS-related headaches more studies on the likely pathogenetic
mechanisms are needed.
7. Serum positivity for TG6 antibodies has been identified as a sensitive measure of neurological
involvement in GS [53,54] Therefore, a study of the prevalence of TG6 antibodies in patients with
headaches that are related to CD and GS should be conducted.
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Abstract: Celiac disease may present with a range of different symptoms, including abdominal
problems in a broader sense, iron deficiency and “constant tiredness”. All of these symptoms should
consequently lead the clinicians to consider celiac disease as a potential etiopathogenetic cause.
Although the pathophysiology of celiac disease is well documented, the actual mechanisms for
disease presentation(s) are less well understood. We here address the topic of fatigue in celiac disease.
A systematic literature search identified 298 papers of which five met the criteria for full evaluation.
None of the reviewed papers were of high quality and had several methodological weaknesses.
We conclude that there is an unmet need to study the contributing factors and management of fatigue
in celiac disease.
Keywords: fatigue; energy; celiac disease; extra-intestinal manifestations
1. Introduction
Celiac disease is by definition an inflammatory disorder in the small intestine that is driven by
dietary gluten from wheat, rye and barley [1]. The disease is often also termed an autoimmune disease
due to a hallmark of the disease; autoantibodies to the endogenous enzyme tissue transglutaminase
TG2. The crucial importance of intestinal inflammation and the most frequent presentation of the
disease as a severe malabsorption syndrome led most clinicians to think of the disease as mainly an
intestinal disorder. However, we now know that a very large proportion of the patients do not primarily
display intestinal complaints, but that their disease presentation is more coloured by extra-intestinal
manifestations [2,3]. In a recent review by Leffler et al. [3] this is well described, including anaemia,
musculoskeletal, skin, neurological and organ-specific manifestations. Some of these manifestations
are caused by the intestinal disorder, others may be caused by systemic inflammation and/or genetic
overlap to other immune disorders [4]. Today we consider that symptoms like abdominal problems in
the wider sense, unexplained iron deficiency and “constant tiredness” should all prompt the clinicians
to consider celiac disease [5,6].
From our own clinical practice, we experience many patients with untreated celiac disease that
suffer from fatigue. In most cases fatigue improves with diet, but far from always. In addition,
these patients also present with a significant reduction in their health-related quality of life [2]. Fatigue
is described as a “persistent, overwhelming sense of tiredness, weakness or exhaustion resulting in a
decreased capacity for physical and/or mental work”. While fatigue may be a natural and transient
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part of life, a typical feature in chronic disease is that these symptoms are unrelieved by adequate
sleep or rest [7]. The aetiopathogenesis of fatigue in chronic disease appears to result from a complex
inter-relationship of biological, psychosocial and behavioural processes [8].
The aim of this review was consequently to address the aspect of fatigue in celiac disease and to
systematically summarise the existing literature on this topic.
2. Materials and Methods
Multiple searches were undertaken using MEDLINE, CINAHL, EMBASE, Psychinfo, Academic
Search Premiere, and Cochrane. Both medical subject heading (MeSH) searching and free-text searching
were used to maximize citation retrieval (Table 1). The searches were performed independently by a
university librarian, and one of the co-authors (L.-P.J.-J.).
Table 1. Search terms used for literature search.
Fatigue Coeliac Disease









Due to the limited number of publications on fatigue in coeliac disease, no time limit was set for
the papers. The searches were performed between April and June 2018, and the most recent search
was performed on August 5th, 2018. The searches were limited to “humans”, “adult” and English
language since there was no scope for translation.
Studies with all types of designs were included if they had measured and reported data on fatigue
in patients with celiac disease. Reviews, commentaries, abstracts/posters, case reports, protocols and
letters to editors were excluded. The review was conducted in line with the PRISMA guidelines [9].
3. Results
The search yielded 298 references in total, of which 248 were excluded on title (Figure 1).
After removing duplicates and screening the remaining 42 papers, a total of 16 papers were examined
in full. Of these 16 papers, 11 did not report any specific methodology for fatigue measurement and
were consequently excluded. Hence, a total of five papers were included in full review. Figure 1
describes the citation retrieval and the handling process in detail.
3.1. Quality Assessment
The quality of the included papers was assessed using the Joanna Briggs Institute Critical
Appraisal Checklist, specific to the methodological design of each paper. The studies were classified
as being of high, medium or low quality. A quality score was reduced if the paper did not define
fatigue, report the sample size, if the sample size was judged inadequate according to study design,
if the response rate was low or not reported, if the questionnaires used were not validated, if the
methods and statistical analysis was insufficiently described or if there were indications of selective
reporting. Two researchers (T.B./L.-P.J.-J.) performed quality assessment independently to ensure
optimal assessment of the included papers. Based on these criteria, all of the reviewed papers had
several methodological weaknesses, and none were judged to be of high quality. However, due to
the low number of publications on fatigue and celiac disease, none of the papers were excluded from
full-review based on quality.
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Figure 1. Citation retrieval and handling process.
3.2. Outline of the Included Papers
In total, three papers assessed fatigue as the primary endpoint, one study investigated
extra-intestinal symptoms and health-related quality of life (HRQoL), while one study assessed
quality of sleep. An overview of the included papers is presented in Table 2.














A subgroup of members
(1000/18,355) from the German
Coeliac Society (GZG) ≥18 years was
invited to participate
Every 18th person on the membership
list was invited in order to ensure a
geographically representative sample
Normative data were collected from
the handbooks of the SF-36, GBB-24
and HADS-D










L: Fatigue not specified as aim,
merely reported as parts of the
questionnaire results
L: No definition of fatigue
L: Sample consisting of members of a
patient society only
L: Low response rate
S: Normative data for comparison
L: Self-reported information on
comorbidity
L: Single centre study
S: Validated instruments used
L: Coeliac disease diagnosis
self-reported only
Siniscalchi
et al., 2005 [11]
Caucation adults ≥18 years of age
from Campania, Italy, were
consecutively recruited from an
outpatient clinic
Participants divided into two groups
(Group 1: Patients on gluten
containing diet, Group 2: Patients on
gluten-free diet)
Control group consisted of volunteers
recruited from medical an
non-medical hospital staff
Exclusion criteria: <18 years of age,
lack of informed consent, major











S: Definition of fatigue.
L: Inadequate language
L: Groups not comparable due to
differences in BMI, Ferritin,
Haemoglobin
L: No evidence of appropriate
matching of groups
L: Inadequate statistical control for
differences between groups
L: Methods used to collect
socio-demographic and clinical data
is lacking
L: Unclear presentation of results
L: Procedure for questionnaire
handling insufficiently described
L: Lack of information about validity
and reliability on the study
questionnaires, both in Italian and in
the target group
L: No clear identification and control
of potential confounding factors
L: Data not presented in line with
study aims
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Patients with celiac disease seen
between March 2008 and April 2009
were prospectively invited to
participate in the study
Included patients stratified in two
groups (Group 1: Following




Group 1: n = 38
Group 2: n = 13
D-FIS
L: No definition of fatigue.
S: Validated fatigue questionnaire used
L: Small sample and small subgroups
L: Lack of information on
recruitment procedure
L: Lack of information concerning the
collection of socio-demographic and
clinical data
L: No information on ethical approval
L: No information about response rate or
number of patients approached
for inclusion
L: Characteristics differ between groups
Ciacci et al.,
2007 [13]
Patients with CD screened for
inclusion at the Department of
Clinical and Experimental Medicine,
Federico II University—Naples, Italy6







group n = 30,






S: Definition of fatigue
S: Randomized groups
S: Allocation concealment
S: Clear definition of coeliac disease
L: Large number of participants did not
complete study (n = 13 (22%))
L: Single centre
L: Lack of calculation of effect size





Adult coeliac disease patients
consecutively recruited from
September 2009 to March 2010 from
Frederico II University (Naples, Italy)
Participants divided into two groups
(Group 1: Coeliac patients at
diagnosis on gluten containing diet.




Inclusion criteria: Informed consent,
19–60 years
Exclusion criteria: Major psychiatric
disease, cancer, pregnancy or children
blow 3 years of age
Case Control
study
Group 1: n = 30




L: Fatigue not specified as aim, merely
reported as parts of the
questionnaire results.
L: No definition of fatigue
L: No information about response rate or
number of patients approached
for inclusion
L: Large numeric differences in
characteristics between coeliac groups
L: No control for confounding variables
S: Gender- and age-matched controls
Table legends and abbreviations: L; Limitation., S; Strength., SF-36; Short Form-36 Health Survey., D-FIS;
Daily Fatigue Impact Scale., FSS; Fatigue Severity Scale., CFS; Chronic Fatigue Syndrome Questionnaire., GBB-24.,
Geißener Symptom Check List., VSA; Verbal Scale for Asthenia, VSA. CD; Coeliac disease, HADS-D; Hospital
anxiety and depression scale – depression.
3.3. Definition and Measurement of Fatigue
In two out of five papers, a definition or a more detailed description of fatigue was provided.
Both Siniscalchi et al. [11] and Ciacci et al. [13] defined fatigue as ”difficulty in initiating or sustaining
regular activities”. However, in none of these studies a reference to the definition were provided.
In total, six different ways of measuring fatigue have been used in the five studies reviewed.
Five of these instruments have only been used once. In addition, one study has used the sub-scale
vitality from the health-related quality of life questionnaire SF-36.
In a majority of the papers, there is lack of information about the validity and reliability of the
instruments used to measure fatigue. While Häuser et al. [10] and Jordá et al. [12] provide references
to adequate psychometrical testing of the SF-36, Giessener Symptom Checklist (GBB-24) and Daily
Fatigue Impact Scale (D-FIS), none of the Italian studies provide clear reference to adequate testing.
In fact, in two of the latter studies one of the instruments seem to have been labeled differently
while referring to the same reference by Wessely et al. [15]. While Siniscalchi et al. [11] use the label
Chronic Fatigue Syndrome (CFS) questionnaire, Ciacci et al. [13] use the label Verbal Scale for Asthenia.
Moreover, when investigating the original study by Wessely et al. [15] in depth, it seems like this
instrument was developed for this particular study and that the necessary tests for validity and
reliability were not performed, and at least not published.
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3.4. Prevalence of Fatigue and Its Associations
None of the reviewed studies present prevalence data, even though one of the aims in the study
by Siniscalchi et al. [11] were to evaluate the prevalence of fatigue in celiac disease. When looking at
fatigue in patients on normal versus gluten-free diet, results also differ. While Zingone et al. [14] and
Siniscalchi et al. [11] found no significant differences, Jordá et al. [12] found that untreated patients
reported significantly worse fatigue. In addition, when comparing celiac disease patients and healthy
controls, both Häuser et al. [10] and Zingone et al. [14] found impaired scores in celiac disease.
While Zingone et al. [14] found impaired sleep to be associated with increased fatigue,
Jordá et al. [12] found that increased fatigue was associated with impaired HRQoL. Merely two
studies [11,12] investigated potential socio-demographic and clinical factors associated with fatigue,
finding that there is no association between fatigue and factors such as gender, age, or GI symptoms
in celiac disease. While Jordá et al. [12] reported that lower haemoglobin levels were correlated with
worse scores of the D-FIS fatigue scale, Siniscalchi et al. [11] were not able to identify any association.
3.5. Interventions to Alleviate Fatigue
Only one of the studies were designed as an intervention. The study by Ciacci et al. [13] aimed
to investigate the effect on fatigue of a long L-Carnitine treatment in adult celiac disease patients.
While there were no reports of serious adverse events, abdominal and skin problems were registered
in a total of six patients (10%). Moreover, a large number of patients did not complete the study
(n = 13), of which three were dropouts. The main finding is that fatigue scores were significantly
more improved in the intervention versus placebo group. However, even though fatigue scores in the
intervention group displayed a larger decrease than in the placebo group, patients in the intervention
group had a higher fatigue scores than the placebo group at baseline (T0). Moreover, the mean fatigue
VAS at the end of study (T2) was 2.40 (SD 1.80) versus 2.93 (SD 1.85) in the intervention versus placebo
group, respectively. While Ciacci et al. does not report any measures of effect size, calculation of
Cohens d [16] on the differences between the intervention and placebo group at T2 reveal a small effect
size (0.29).
4. Discussion
In this review we were only able to identify 16 papers that, to some extent, had investigated
fatigue in celiac disease. Of these, 11 papers [6,17–26] did not report any specific methodology
concerning fatigue assessment. Of the remaining five papers [10–14], in which fatigue assessment had
been described methodologically, merely three investigated fatigue as the primary endpoint [11–13].
In addition, critical assessment revealed that none of the included studies held high scientific quality.
A basic problem in fatigue research is the lack of a common accepted definition [27]. Indeed,
lack of definition and conceptual clarification was also observed in this review, where only two studies
provided a definition of fatigue [11,13]. On the other hand, the fatigue definitions presented in those
two papers both lacked a clear reference to existing literature.
Fatigue is frequently reported by patients as well as observed by clinicians in celiac
disease [23,25,26]. However, a vast majority of the published literature base their reports merely on
clinical consultation rather than rigorous methodological research (i.e., using validated measurement
tools). Thus, the actual prevalence of fatigue in celiac disease remains unclear. However, there are
indications that the level of fatigue is higher in these patients than in control groups and the background
population [10,14]
We were only able to identify one single study that reported on potential socio-demographic
and clinical factors associated with fatigue symptoms in celiac disease [11]. Of the factors studied,
none were significantly associated with fatigue. However, since data is not shown, it is unclear whether
this finding was true for all of the different fatigue measures used in the study. Furthermore, two of the
included studies found that fatigue was associated with reduced HRQoL and increased sleep problems,
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respectively [12,14]. Although there is currently very limited documentation on these associations,
this appears to coincide with findings in other patient populations [28–32]. In addition, our review
only found one study that was designed as an intervention with fatigue as the primary endpoint.
Even though Ciacci et al. [13] conclude that L-Carnitine therapy is safe and effective in ameliorating
fatigue in celiac disease, these results should be interpreted with extreme caution. Firstly, the study is
hampered by the fact that it does not reach its own power estimates due to a large number of patients
not completing the study (21.6%). Secondly, the study does not use fatigue measurement tools that has
been adequately tested for validity and reliability. In addition, the absolute difference in mean fatigue
VAS between the groups at end of study revealed a small effect size according to Cohen’s d [16,33].
Several studies in other populations have shown that anaemia is associated with increased fatigue
symptoms [7,34]. The pathogenesis of anaemia-related fatigue remains unclear, but some suggest that
abnormalities in energy metabolism play a role in inducing fatigue [35]. Moreover, while some
studies have shown that haemoglobin response is associated with meaningful improvements
in fatigue, others have not been able to reveal any significant association between the use of
erythropoiesis-stimulating agents and fatigue symptom [36,37]. In the current review we were unable
to identify studies that specifically looked at anaemia as predictor of fatigue in celiac disease. However,
Siniscalchi et al. [11] noted that the included celiac patients in their study had significantly lower
haemoglobin levels. A similar observation was reported in Jordá et al. [12]. In the latter study,
a significant correlation between worse fatigue scores and lower haemoglobin levels was reported.
However, even though Jordá et al. [12] report that their regression analysis show that haemoglobin
levels may be involved in the perception of fatigue, the data presented in the paper does not justify
such a conclusion. In fact, the dependent variable used in their study was not fatigue, but HRQoL
(EQ-5D-VAS). Consequently, the current observation on the potential association between fatigue and
anaemia was based on a univariate analysis only.
This review is not without limitations. The fact that we chose to limit our focus to adults and
English publications only may have influenced our identification of relevant publications. On the other
hand, a strength is the rigorous literature search in several databases, as well as the blinded quality
assessment of each of the papers by two of the authors.
5. Conclusions
Although frequently reported in clinical practice, fatigue has been scarcely studied in celiac
disease. In addition, existing literature is characterized by significant methodological weaknesses.
Consequently, there is an unmet need to understand contributing factors for fatigue as well as the
impact of fatigue in celiac disease.
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Abstract: Celiac disease patients may suffer from a number of extra-intestinal diseases related to
long-term gluten ingestion. The diagnosis of celiac disease is based on the presence of a manifest
small intestinal mucosal lesion. Individuals with a normal biopsy but an increased risk of developing
celiac disease are referred to as potential celiac disease patients. However, these patients are not
treated. This review highlights that patients with normal biopsies may suffer from the same
extra-intestinal gluten-induced complications before the disease manifests at the intestinal level.
We discuss diagnostic markers revealing true potential celiac disease. The evidence-based medical
literature shows that these potential patients, who are “excluded” for celiac disease would in fact
benefit from gluten-free diets. The question is why wait for an end-stage disease to occur when
it can be prevented? We utilize research on dermatitis herpetiformis, which is a model disease
in which a gluten-induced entity erupts in the skin irrespective of the state of the small intestinal
mucosal morphology. Furthermore, gluten ataxia can be categorized as its own entity. The other
extra-intestinal manifestations occurring in celiac disease are also found at the latent disease stage.
Consequently, patients with celiac traits should be identified and treated.
Keywords: gluten; latent celiac disease; potential celiac disease; extra-intestinal manifestations; mild
enteropathy; early developing celiac disease; genetic gluten intolerance; natural history; celiac trait
1. Introduction
Celiac disease is an autoimmune systemic disorder in genetically susceptible persons perpetuated
by the daily ingestion of gluten cereals (wheat, rye, and barley) with manifestations in the small
intestine and organs outside the gut. Patients diagnosed with celiac disease show gluten-induced and
gluten-dependent duodenal mucosal lesions (i.e., the typical crypt hyperplastic lesion with villous
atrophy). Clinically these newly diagnosed patients may or may not be suffering from gastrointestinal
symptoms. A gluten-driven extra-intestinal manifestation is often the only clue for the disease. In the
primary care and within different medical disciplines, physicians should suspect celiac disease and
perform case finding by serum autoantibody screening. Positive serology is often the only way to
identify potential patients for a diagnostic upper intestinal endoscopy [1–3]. In fact, less than half of
all adult patients diagnosed with celiac disease complain of gastrointestinal symptoms at an initial
diagnosis [4]. This knowledge comes from Finland, where adult celiac disease diagnoses have increased
20 times in recent decades and 0.8% of the total population has a biopsy-confirmed diagnosis [5–7].
Patients diagnosed with celiac disease including a duodenal mucosal lesion may suffer from
a number of extra-intestinal diseases [2,3]. Dermatitis herpetiformis manifests outside the gut, is
gluten driven and dependent [8,9], has the same genetic background, and occurs within the same
families as celiac disease [9,10]. In fact, one identical twin may have celiac disease while the other
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suffers from dermatitis herpetiformis [11]. Other gluten-driven extra-intestinal manifestations in celiac
disease include osteopenia, osteoporosis, fractures [12–14], permanent tooth enamel defects [6,15],
arthritis, and arthralgia [16–18] as well as further central and peripheral nervous system [19–22],
liver [23–25], and reproductive system involvements [26,27]. Even autoimmune diseases may be gluten
driven [28,29], and there is a risk for malignant complications, especially non-Hodgkin lymphoma, in
untreated celiac disease [30,31].
By definition, celiac disease is excluded in patients who have normal small intestinal mucosal
morphology at their first diagnostic endoscopy if they have been following a normal gluten-containing
diet. However, it seems evident that this is not accurate. In a review in 2001, we wrote that
gluten-induced extra-intestinal manifestations may develop at the latent disease stage when the
mucosa is still morphologically normal [32], citing several observations [19,33–36]. Today such patients
are often referred to as having “potential celiac disease” because they are found to be “normal” on
biopsy [37]. Meanwhile, dermatitis herpetiformis is our model disease, in which an extra-intestinal
manifestation is treated with a gluten-free diet irrespective of the mucosal finding (diseased or not).
We reviewed the literature for evidence for extra-intestinal gluten-dependent manifestations in patients
“excluded” for celiac disease. In this paper, we also discuss tools for identifying these “potential”
treatable patients.
2. Latent or Potential Celiac Disease
The “pre-celiac” state has been described in patients with dermatitis herpetiformis, in whom
small intestinal mucosal deterioration was shown to occur after adding extra gluten to the diet [38–40].
An extra gluten load also induced mucosal lesions in healthy individuals [39,41]. The concept of latent
celiac disease, without having an extra load of gluten, was shown to be part of the gluten sensitivity
spectrum and natural history of celiac disease [42–45]. Specifically, this was shown in Finland in celiac
patients who, by chance, had previously undergone a small intestinal biopsy that was reported as
normal or who were followed up because of positive serum autoantibody results.
We chose to use the term “latent celiac disease”, which is similar to Weinstein [38], when referring
to patients with a normal biopsy who later exhibited mucosal deterioration and were diagnosed as
celiac disease patients. For us, “latent” means existing but not manifest (i.e., the disease exists but is
not manifest at the mucosal level). Based on our early descriptions, Ferguson et al. (1993) defined
latent celiac disease as follows: “This term should only be applied to patients who fulfill the following
conditions: (i) have a normal jejunal biopsy while taking a normal diet, (ii) at some other time, before
or since, have had a flat jejunal biopsy which recovers on a gluten free diet” [46]. Following the first
reports on existing celiac disease latency, a numbers of other results have been published, with early
papers by Troncone [47] and Corazza et al. [48]. It is now clear that oral tolerance towards gluten can
be kept for longer periods, even for decades and into older age [49].
The term “potential celiac disease” has been used interchangeably with latent celiac disease,
and this has led to confusion in the celiac disease literature. Thus, the Oslo task force discouraged the
use of the term “latent celiac disease”, and individuals with a normal outcome from a small intestinal
biopsy but who are at increased risk of developing celiac disease based on positive celiac disease
serology should be referred to as having potential celiac disease [37]. These “potential patients” are
not treated as celiac. The question is, what should a gluten-triggered and gluten-dependent treatable
disease outside the gut be called, when the extra-intestinal manifestation occurs at the latent stage of
the disease and when conventional diagnostic biopsy criteria have excluded celiac disease? We infer
that such patients should not be categorized as having potential celiac disease. Rather, they require
proper treatment [50,51].
In Figure 1, we summarize the lifespan natural history of celiac gluten sensitivity, where each
line represents a single individual. The term celiac gluten sensitivity encompasses celiac traits, latent
celiac disease, genetic gluten intolerance, mild enteropathy celiac disease, early developing celiac
disease, and celiac disease itself [1,32,50–53]. The gluten-induced mucosal damage develops rapidly
234
Nutrients 2019, 11, 320
or gradually from normal mucosal morphology to a manifest mucosal lesion. The tolerance towards
gluten is individual, and it may be broken after only months or years (childhood celiac disease) but
also at adolescence, adulthood, and even after decades of gluten ingestion in old age. The latent celiac
disease patients, the “true potential” patients in Figure 1 (i.e., normal on biopsy showing villus height
crypt depth ratio >2), are classified as having celiac disease only when the disease has deteriorated to
the degree of a manifest mucosal lesion (i.e., villus height crypt depth ratio <2).
Figure 1. Natural history of developing celiac disease (CD) at the small intestinal mucosal level. Each
line represents one individual. We are born with a normal mucosal morphology, a villus height (VH),
and a crypt depth (CrD) ratio of approximately three and villi three times taller than crypts are deep.
Upon gluten ingestion, mucosal injury proceeds rapidly or gradually at different ages, in childhood or
only at an older age. Before developing a manifest mucosal lesion (diseased mucosa on biopsy, VH:CrD
<2) every CD patient belongs to the category latent “true potential” CD (normal on biopsy, VH:CrD >2).
3. Markers of Existing Early Disease
An existing gluten-dependent disease without evidence of enteropathy until a later age - latent
celiac disease - includes in its definition the susceptibility genes for celiac disease and the genes
encoding the human leukocyte antigen (HLA) DQ2 or DQ8 molecules [1,32,54]. This is a check that
clinicians may perform when there are symptoms and signs suggestive of celiac disease, but the biopsy
is normal or does not show clear crypt hyperplasia. It shows only inflammation and descriptive mild
villus atrophy. Positivity for DQ2 or DQ8 does not mean very much, since 30% to 40% of the citizens
in the country are positive, but double negative means that no celiac disease will develop.
Patients positive for celiac disease serology with normal biopsies should be considered to have
potential celiac disease [37]. However, gliadin antibody positivity, which is a frequent finding
in celiac disease control patients and even in healthy individuals, does not correlate with celiac
disease susceptibility genes [55]. Currently, tissue transglutaminase autoantibody (TG2-ab) testing
is used to screen for celiac disease. It should be noted, however, that not all serum TG2-abs
predict celiac disease [56]. TG2-abs have been described in other autoimmune diseases as well
as in infections, tumors, myocardial damage, liver disorders, and psoriasis [54]. These antibodies
are not associated with endomysial autoantibodies and may occur in persons negative both for HLA
DQ2 and DQ8. The serum endomysial antibody test is the gold standard, and the presence of these
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autoantibodies predicts impending celiac disease [1,45,50,53,55]. In celiac disease in patients with
extra-intestinal manifestations, other autoantibodies play a role in diagnosis and potentially in disease
mechanisms [57].
At the mucosal level, inflammation, as measured as the density of intraepithelial T cells
(IELs), is a very unspecific finding, but is also gluten-dependent in cases of celiac disease [58].
Marsh 1 lesions with increased IELs were shown to have a sensitivity of 59% and specificity of
57% in predicting forthcoming celiac disease [59]. However, when searched for, an autoimmune
insult to the morphologically normal intestinal mucosa is, in fact, present. A high density of γδ
T-cell-receptor-bearing IELs in patients with morphologically normal mucosa who also carry the
susceptibility genes for celiac disease seems to be a prerequisite for developing celiac disease [43,60,61].
Yet, even if an increased density of γδ T cells is found in latent celiac disease, such a finding is not
pathognomonic for the disease [59,61]. In the small intestine, the gluten-dependent autoantibodies
target extracellular TG2 and may be detected as IgA deposits in biopsy tissues at the latent disease
stage [62–64] (Figure 2). In fact, the IgA deposits in the duodenal biopsies accurately predicted
forthcoming celiac disease better than IELs, γδ+ IELs, or serum autoantibodies [59]. The detection
of intestinal TG2-abs by phage-antibody libraries is another possibility for diagnosis [52]. However,
intestinal TG2-ab production is not only found in celiac disease [65]. Again, when finding an increased
density of γδ+ IELs or IgA deposits in a patient with normal small intestinal mucosal morphology, it is
recommended to check whether the patient belongs to the “celiac family” (i.e., are carrying either the
HLA DQ2 or DQ8 molecules).
 
Figure 2. Small intestinal mucosal immunoglobulin (Ig) A deposits are shown in a villus tip from
a dermatitis herpetiformis patient with normal mucosal morphology. IgA is stained with green (A),




In dermatitis herpetiformis, a gluten-induced and gluten-dependent manifestation occurs outside
the gut even in the absence of intestinal mucosal villous atrophy [8,66]. Today, up to 30% of patients
with dermatitis herpetiformis have a normal small intestinal mucosal lining [67]. Typically, the disease
manifests with itchy papules and vesicles on the elbows, knees and buttocks, and overt gastrointestinal
symptoms are rare [67,68]. When patients without enteropathy are challenged with extra gluten, their
small intestinal mucosae deteriorate in a way typical of celiac disease [38–40]. When no enteropathy is
present, patients only test positively for serum TG2-abs and endomysial antibodies in 40% of cases [67].
However, the patients could be serum endomysial autoantibody positive already while having normal
small intestinal mucosa prior to any evidence of skin eruptions [44]. If searched for, the autoimmune
effect to the morphologically normal intestinal mucosa caused by an environmental trigger—the daily
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ingestion of gluten—is, in fact, present. Mucosal inflammatory markers (i.e., the high density of
γδ+ IELs) shows this [35]. Furthermore, in patients who are negative for serum autoantibodies, the
antibodies are found at the mucosal level targeting extracellular TG2 [62,69,70], which is a finding
typical for an existing disease that is not manifest at the mucosal architectural level (Figure 2).
We infer that patients with gluten-triggered extra-intestinal manifestations, who are now classified
as having dermatitis herpetiformis but show a normal small intestinal mucosa, do not belong to the
category of potential celiac disease. These patients may even be suffering from osteoporosis and
experience bone fractures. Clearly, it is a treatable disease [67,68,71]. In the following, we use parallel
reasoning for patients having other gluten-dependent extra-intestinal manifestations occurring at the
latent stage of celiac disease.
4.2. Central and Peripheral Nervous System
Gluten-induced neurological manifestations including gluten ataxia are common in adult celiac
disease [19–22] and occur in children [2]. Hadjivassiliou et al. noticed that gluten sensitivity was found
in patients with neurological disease, and they screened the patients with gliadin antibodies [72]. They
also showed that neurological complications occurred during the latent stage of celiac disease. Their use
of gliadin antibodies created some skepticism toward the findings, but today gluten ataxia has become
a gluten-induced entity in itself, similar to dermatitis herpetiformis [20,73]. In fact, it was shown that
gluten ataxia might respond to a strict gluten-free diet even in the absence of an enteropathy [74,75].
Serum transglutaminase 6 antibodies are used for detecting gluten ataxia in patients with and without
small intestinal mucosal lesions. Negative seroconversion results from a gluten-free diet [75]. Further
evidence that gluten ataxia without enteropathy belongs to the celiac spectrum comes from the finding
that TG2-specific autoantibody deposits were detected in the intestinal mucosa [74]. The patients were
HLA DQ2-positive or DQ8-positive. All of the control ataxia patients were negative for celiac-type HLA,
and they had no IgA deposits in the mucosa [74]. In one gluten ataxia patient, similar TG2-targeted
IgA deposits were found in the small vessels of the brain [74]. In a different cohort of idiopathic
ataxia patients, the TG2-targeted IgA deposits were again detected, even in the absence of circulating
TG2-abs [76].
Gluten-induced peripheral nervous system involvement often expresses as a symmetrical
sensorimotor axonal peripheral neuropathy [77]. In patients with or without enteropathy, neuropathies
cannot be differentiated based on clinical, genetic, or immunological grounds [78,79].
4.3. Bone Disease
Bone diseases, osteopenia, osteoporosis, and even fractures are highly prevalent in untreated
celiac disease [14,80,81]. Strict gluten-free diets improve bone health in celiac disease and are an
effective therapy for long-term bone mineral recovery [13,82].
Latent celiac disease patients, before manifesting an overt disease, might suffer from
gluten-dependent symptoms as well as osteopenia and osteoporosis [62,83–86]. Kaukinen et al. showed
that eight of 10 patients without villous atrophy had a bone disease, and they all were DQ2 positive [83].
On biopsy, it was shown that they belonged to the celiac spectrum since they had increased densities
of γδ+ IELs. Furthermore, their initial TG2 and endomysial antibodies normalized with a gluten-free
diet. Dickey et al. again measured bone mineral density in 31 endomysial antibody-positive patients
who were excluded for celiac disease (i.e., classified as having Marsh 0 or Marsh 1 lesions). They
found osteopenia to be present in 30% and osteoporosis in 10% of these patients, and the degree of
bone disease did not differ from that found in patients diagnosed with overt celiac disease. Negative
seroconversion followed upon implementation of a gluten-free diet in the 26 of the 27 patients with
normal biopsies. On the contrary, eight patients continued their gluten-containing diet, and seven
of them evolved toward villous atrophy compatible with celiac disease within one to two years [84].
Kurppa et al. proved that the gluten-free diet had a positive effect on the bone mineral density in
endomysial antibody-positive patients with normal villous morphology, which is similar to those with
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celiac-type enteropathy [85]. Zanini et al. concluded that celiac disease patients with mild enteropathy
have various markers of existing malabsorption including bone disease, and, thus, require treatment
with a gluten-free diet [86].
Patients with true potential celiac disease are also a risk of fractures. Pasternack et al. showed
that dermatitis herpetiformis patients reported earlier fractures in 45 out of 222 cases at diagnosis.
Altogether, 16% of the fractures had occurred in patients with normal small intestinal histology, 35%
occurred in patients with partial villous atrophy, and 49% occurred in patients with subtotal villous
atrophy in Reference [71].
4.4. Liver Diseases
Celiac disease may initially present as a monosymptomatic liver disease, such as cryptogenic
hypertransaminasaemia or autoimmunue-type of liver damage [23–25,87]. There are few reports of
liver injury in potential or latent celiac disease. Zanini et al. observed that celiac disease with mild
enteropathy and positive celiac disease-related serology is not a mild disease. Moreover, they showed
alanine aminotransferase serum values to be elevated in 9/121 (8%), γ-glutamyltransferase in 5/102
(5%), and alkaline phosphatase in 6/101 (6%) of patients. The authors concluded that these patients
should also be treated [86].
4.5. Other Extraintestinal Manifestations
4.5.1. Permanent Tooth Dental Enamel Defects
Adult patients with celiac disease and dermatitis herpetiformis, as well as children with dermatitis
herpetiformis, show celiac-type dental enamel defects in their permanent dentition [15,88–90]. Typical
enamel defects were found in all healthy family members of celiac disease patients found to have
manifest mucosal lesions. Furthermore, these celiac-type enamel defects occurred without small
intestinal changes and were strongly associated with the HLA DR3 [34]. Importantly, these permanent
tooth enamel defects are induced by gluten ingestion in early childhood, when the enamel is developing
(i.e., at the latent stage of celiac disease and dermatitis herpetiformis).
4.5.2. Malignancies
In 1986, Freeman and Chiu reported that intestinal lymphoma might appear at the latent stage of
celiac disease when the mucosa is morphologically normal [33]. However, it is not known whether
untreated patients without a manifest mucosal lesion carry an increased risk of malignancy. However,
there are many complications, including malignancies, that may occur in adulthood when the patient
is undiagnosed by ingesting gluten. Celiac disease patients diagnosed at an adult and elderly age have
not had manifest mucosal lesions from early childhood (Figure 1) [42–45,48,49].
Figure 3 indicates that all the extra-intestinal manifestations induced by gluten in untreated celiac
disease can be detected in the latent stage of the disease.
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Figure 3. Celiac trait. Gluten-induced extra-intestinal manifestations exist in both patients with normal
(latent celiac disease, CD) and diseased small intestinal mucosa (overt CD). Drawing adapted from the
“cooking pot” of splashing extra-intestinal manifestations, which is first presented at the International
Celiac Disease Symposium in Dublin 1992, and from drawings in references No. 34, 53, and 54.
5. Celiac Trait
Celiac disease diagnosis requires a gluten-induced small intestinal mucosal lesion. As indicated
in Figure 3, the so-called “flat” lesion is the end stage of the mucosal injury. Figure 3 also summarizes
our review and shows that, when there is a gluten-induced and gluten-dependent extra-intestinal
manifestation in celiac disease, the manifestation can be found in patients before the mucosa is
diseased or when it shows only minor non-specific changes. For susceptible persons, upon gluten
ingestion, celiac disease develops gradually from normal mucosal morphology through mucosal
inflammation, crypt hyperplasia, and villous atrophy to the “flat” mucosal lesions [91]. When the
mucosa is morphologically normal and, for example, bones are already fracturing due to gluten
ingestion, we should not call this condition potential celiac disease [38]. Moreover, we should not wait
for the manifest mucosal lesion to develop (i.e., celiac disease). The patient deserves accurate treatment
early. The benefit of treating these patients may be due to correction of micronutrient deficiencies
having an impact on extra-intestinal manifestations [58]. We suggest that the term celiac trait be used
in these cases [1,32,51].
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Abstract: Celiac disease (CD) is an immune-mediated gastrointestinal disorder driven by innate
and adaptive immune responses to gluten. Patients with CD are at an increased risk of several
neurological manifestations, frequently peripheral neuropathy and gluten ataxia. A systematic
literature review of the most commonly reported neurological manifestations (neuropathy and ataxia)
associated with CD was performed. MEDLINE, Embase, the Cochrane Library, and conference
proceedings were systematically searched from January 2007 through September 2018. Included
studies evaluated patients with CD with at least one neurological manifestation of interest and
reported prevalence, and/or incidence, and/or clinical outcomes. Sixteen studies were included
describing the risk of gluten neuropathy and/or gluten ataxia in patients with CD. Gluten neuropathy
was a neurological manifestation in CD (up to 39%) in 13 studies. Nine studies reported a lower
risk and/or prevalence of gluten ataxia with a range of 0%–6%. Adherence to a gluten-free diet
appeared to improve symptoms of both neuropathy and ataxia. The prevalence of gluten neuropathy
and gluten ataxia in patients with CD varied in reported studies, but the increased risk supports
the need for physicians to consider CD in patients with ataxia and neurological manifestations of
unknown etiology.
Keywords: celiac disease; gluten neuropathy; gluten ataxia; prevalence; incidence; gluten-free diet
1. Introduction
Celiac disease (CD) is a chronic, immune-mediated enteropathy in which dietary gluten triggers an
inflammatory reaction of the small intestine in genetically predisposed individuals [1–3]. The clinical
presentation of the disease varies broadly and may include an array of intestinal symptoms and
extra-intestinal manifestations, such as iron-deficiency anemia, osteoporosis, dermatitis herpetiformis,
and neurologic disorders [4].
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Over the last several decades, the clinical presentation of CD has changed [5] with the proportion
of patients presenting with classical CD symptoms decreasing and a corresponding increase in the
frequency of extra-intestinal symptoms in children and adults [5–7]. This increasing proportion
of extra-intestinal symptoms at presentation can result in lengthened diagnostic delay [8]. Active
case-finding to facilitate prompt detection of CD and life-long adherence to a strict gluten-free diet
(GFD) among patients with confirmed CD is recommended to reduce symptoms and the likelihood of
disease of potentially serious manifestations [1].
Manifestations of CD can include a broad spectrum of musculoskeletal, neurological,
cardiovascular, and autoimmune disorders. Most notably, peripheral neuropathies and gluten ataxia
are frequent neurological manifestations of CD [9,10]. Many patients who present with neurological
manifestations of CD have no gastrointestinal symptoms [11]. Peripheral neuropathy in patients with
CD presents with tingling, pain, and numbness from nerve damage, initially in the hands and feet.
Otherwise known as gluten neuropathy, it is defined as apparently sporadic idiopathic neuropathy in
the absence of an alternative etiology and in the presence of serological evidence of gluten sensitivity.
It is a slowly progressive disease with a mean age at onset of 55 years. Only one-third of patients have
evidence of enteropathy on biopsy, but the presence or absence of enteropathy does not predetermine
the effect of a GFD [12].
CD patients with ataxia often present with difficulty with arm and leg control, gait instability,
poor coordination, loss of fine motor skills such as writing, problems with talking, and visual issues.
Gluten ataxia usually has an insidious onset with a mean age at onset of 53 years [11]. Patients with
gluten ataxia can show signs of cerebellar atrophy which can be irreversible and difficult to treat.
Other neurological symptoms include encephalopathy, myopathy, myelopathy, ataxia with myoclonus,
and chorea [9,10]. Gluten ataxia was first defined in 1996 as apparently idiopathic sporadic ataxia in
patients with positive anti-gliadin antibodies (AGA). CD patients with gluten ataxia also often have
oligoclonal bands in their cerebrospinal fluid, evidence of perivascular inflammation in the cerebellum,
and anti-Purkinje cell antibodies [13].
Although these neurological manifestations of CD have been described over the last 30 years in
the literature, there are still diagnostic delays often resulting in permanent neurological disability. Such
delays are attributed to “controversies” arising from some variation in reported prevalence and poor
understanding of the use of appropriate serological testing [14–16]. To examine the recent evidence,
a systematic literature review was conducted to evaluate the prevalence and outcomes of the two most
commonly reported neurological manifestations of CD: gluten neuropathy and gluten ataxia.
2. Materials and Methods
A systematic review of literature indexed in MEDLINE (via PubMed), Embase, and the Cochrane
Library from January 2007 to August 2018 was performed in accordance with Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17]. The search strategy
conducted in MEDLINE (via PubMed) is provided in Table 1. Manual backwards citation tracking of
references from included studies and systematic review articles was performed to identify additional
relevant studies. Searches were also performed in proceedings of the past three meetings (2015–2018)
of the following conferences: Digestive Disease Week, American College of Gastroenterology, and
United European Gastroenterology Week.
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Table 1. MEDLINE (via PubMed.com) Search Strategy.
Search No. Search Terms
Search Results
(28 August 2018)
1 celiac*[tiab] OR coeliac*[tiab] OR celiac disease[MeSH] 31,137
2 ((coeliac OR celiac) AND (trunk* OR axis OR node*)) OR“coeliac artery” OR “celiac artery” 7348
3 #1 NOT #2 25,521
4
(cerebellar ataxia[MeSH] OR “cerebellar ataxia”[tiab] OR
((cerebellum* OR cerebellar) AND ataxi*) OR “gluten ataxia”
OR “gluten-sensitive ataxia”)
17,238
5 neuropathy[tiab] OR neuropathies[tiab] OR neuropathic[tiab] 88,749
6 #3 AND #4 141
7 #3 AND #5 213
8 #6 OR #7 309
9 case reports[pt] 1,893,340
10 #8 NOT #9 238
11 mice OR mouse OR murine OR rodent* 1,754,334
12 #10 NOT #11 227
13 review[pt] NOT (systematic OR Cochrane OR meta-analy*) 2,162,485
14 #12 NOT #13 160
15 #14; Filter: published 2007 or later 99
16 #15; Filter: abstract 96
Footnotes: *, wildcard search term; #, search number. Abbreviations: tiab, title/abstract; pt, publication type.
To be included, studies (primary studies or systematic reviews with or without meta-analyses) had
to be conducted in patients with CD, published from 2007 or later (or last three meetings for conference
abstracts) in English, and report the incidence, prevalence, and/or clinical outcomes of ataxia and/or
neuropathy. Neuropathy, which is often used synonymously with peripheral neuropathy, is classified
according to the type of damage to the nerve. In this systematic review, the terms “neuropathy” and
“peripheral neuropathy” are stated as the authors have used them in their studies, recognizing that
“neuropathy” may include a wider range of symptoms than peripheral neuropathy, which would
represent a large proportion of neuropathy cases overall.
A single investigator screened titles and abstracts to determine if the citation met inclusion
criteria, with validation by a second reviewer required for exclusion. Two investigators independently
reviewed all potentially relevant full-text citations, with discrepancies resolved by a third reviewer.
Screening, data extraction, and validation were performed using DistillerSR (Evidence Partners Inc.,
Kanata, Ottawa, Canada). One investigator abstracted all data using a standardized tool, and a second
reviewer verified entries.
Two independent investigators assessed the quality of included studies using the Oxford Levels
of Evidence Instrument [18]. Reviewers used the “Differential diagnosis/symptom prevalence study”
section to assess the overall grade of the evidence. Details regarding the categorization of the study
designs are available in Table 2.
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Table 2. Oxford Levels of Evidence & Grades of Recommendation.
Level Differential Diagnosis/Symptom Prevalence Study
1a Systematic review (with homogeneity) of prospective cohort studies
1b Prospective cohort study with good follow-up
1c All or none case-series
2a Systematic review (with homogeneity) of 2b and better studies
2b Retrospective cohort study, or poor follow-up
2c Ecological studies
3a Systematic review (with homogeneity) of 3b and better studies
3b Non-consecutive cohort study, or very limited population
4 Case-series or superseded reference standards
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first
principles”
Grade Levels of Individual Studies
A Consistent level 1 studies
B Consistent level 2 or 3 studies or extrapolations from level 1 studies
C Level 4 studies or extrapolations from level 2 or 3 studies
D Level 5 evidence or troublingly inconsistent or inconclusive studies of any level
Table adapted from the Oxford Centre for Evidence-Based Medicine [18].
3. Results
The searches identified 441 citations, 299 conference abstracts, and 1 additional citation
identified through backwards citation tracking. After removal of duplicates and screening of
titles and abstracts screening, 45 were eligible for full-text review. A total of 16 studies met
all eligibility criteria and were included in the systematic review (Figure 1, Table 3) [10,19–33].
Nine studies on gluten ataxia [10,20–23,26,28,31,32] and 13 articles on gluten neuropathy were
included [10,19,20,22,24–30,32,33].
Figure 1. Flow Diagram Showing the Results of the Literature Search.
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The PRISMA flow diagram depicts the flow of information through the different phases of this
systematic review. It maps out the number of records identified, included and excluded, and the
reasons for exclusions.
Of the studies included, 50% (eight out of 16) were full-text, prospective analyses that reported
global prevalence or incidence rates of gluten neuropathy and gluten ataxia [19–24,28,29]. See Box 1 for
the definitions of CD, gluten ataxia, and gluten neuropathy. Most studies were performed in Europe
(9; Germany, Italy, Romania, Sweden, and United Kingdom (UK)), while four were from the United
States (US), two from Turkey, and one multinational study. Findings reported on adults (5), children
(5), and both children and adults (6). Clinical outcomes of CD manifestations were reported in 50%
(8 out of 16) of the included studies, while the remainder only addressed epidemiology.
Box 1. Definitions of gluten-sensitivity spectrum disorders used in this study.
celiac disease – autoimmune disorder whereby gluten ingestion damages the portion of the small intestine
responsible for nutrient absorption; also referred to as gluten-sensitive enteropathy.
gluten ataxia – autoimmune disorder whereby gluten ingestion damages the cerebellum, which controls gait
and muscle coordination, and fine control of voluntary movements is compromised.
gluten neuropathy – autoimmune disorder whereby gluten ingestion damages the nerves of the peripheral
nervous system, which disrupts communication from the brain and spinal cord to the rest of the body.
3.1. Gluten Neuropathy
Thirteen articles reported gluten neuropathy as a manifestation of CD [10,19,20,22,24–30,32,33].
Estimates of the prevalence of neuropathy in these patients ranged from 0% to 39%, with an increased
prevalence/risk in older and female patients. In retrospective and prospective studies of patients with CD
in the US and Europe, prevalence of neuropathy ranged from 4% to 23% of adults [20,25,27], 0% to 7% of
children [22,24,25,28,32], and 0.7% to 39% of combined/unspecified populations [20,29,30,32]. While these
ranges appear to overlap, a few studies directly compared the prevalence and risk of neuropathy by age
and indicated that neuropathy occurs more frequently in older populations [27]. In a retrospective US study
of adults (n = 171) and children (n = 157) with CD, gluten neuropathy was reported in 23% of adults with a
follow-up period of >24 months between 2002 and 2014; however, no cases were reported in children [25].
Another retrospective US study found that significantly more elderly patients aged ≥65 years (11%) had
gluten neuropathy compared with younger patients aged 18–30 years (4%; p = 0.023) [27]. Similar to
young adults, gluten neuropathy was identified in 3 to 4.5% of children with CD in two studies [28,32].
Another questionnaire-based US study found that the risk of gluten neuropathy rose significantly with
every ten-year increase in age (OR, 1.13; 95% CI, 1.04–1.23; p = 0.006). This study also reported a higher
risk of gluten neuropathy in females (OR, 1.71; 95% CI, 1.25–2.33; p = 0.001) [29].
Gluten neuropathy may account for approximately one-quarter of neurological manifestations in
those with CD. In two studies (one retrospective (n = 228) and one prospective (n = 72)) examining
patients with CD and neurological conditions, gluten neuropathy accounted for 19% to 30% of
neurological manifestations [10,20]. Patients with CD have a higher risk of gluten neuropathy and
experience more severe neuropathic symptoms compared with non-CD controls (p < 0.01) [29]. In three
studies (two retrospective and one questionnaire-based) from the US and Sweden, patients with
CD had a significantly higher (2.3–5.6 times) risk of peripheral neuropathy compared with control
populations [26,29,30]. The risk of polyneuropathy appears highest (4.4–5.6 times) during the first year
of follow-up after CD diagnosis [26,30], compared with overall risk, or risk excluding the first year of
follow-up (2.3–3.4 times) [26,30]. The risk estimate for neuropathy was only marginally affected after
adjustment for education, socioeconomic status, type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus
(T2DM), thyroid disease, rheumatologic diseases, pernicious anemia, vitamin deficiencies, and alcoholic
disorders (Hazard Ratio (HR), 2.3; 95% Confidence Interval (CI), 1.9–2.7) [30]. Notably, two of these
studies adjusted their design to control for the rate of T1DM, as peripheral neuropathy is a long-term
manifestation of T1DM [26,30]. However, Thawani et al. (2017) observed there was no significant
250
Nutrients 2019, 11, 380
increased risk of neuropathy for biopsy-confirmed CD patients with T1DM after examining neuropathy
incidence in the first five years of CD diagnosis when compared to patients with T1DM only [33].
Symptoms from gluten neuropathy improve when patients with CD follow a GFD, although the
diet may not prevent its development, and longer adherence to a GFD may not completely reverse
neuropathy. One retrospective US study found that among patients who developed gluten neuropathy
(n = 39), there was a significant improvement on a GFD (p < 0.05) [25]. Two prospective Italian
studies also reported that in patients with gluten neuropathy, dietary adherence led to improvement
in neuropathy and non-adherence led to worsening [20,28]. However, it should be noted that only
one to two patients developed neuropathy in each of these Italian studies. While a GFD may improve
symptoms of gluten neuropathy, one questionnaire-based US study found that duration of the diet
(<5 vs. 5–9 vs. ≥10 years) did not significantly change the proportion of patients who developed
the manifestation [29]. Similar proportions of patients developed neuropathy regardless of whether
patients were reported to be following a GFD [10,22,25]. In the studies that did document GFD
status, the extent of GFD adherence was not reported, limiting assessment of the relationship between
neuropathy and degree of gluten exposure.
The severity of gluten neuropathy is variable. With a follow-up period of >20 years, one
retrospective British study found that patients with CD on a GFD who developed gluten neuropathy,
severity was mild (confined to the legs) in 27%, moderate (involvement of arms but sparing radial
nerve) in 40%, and severe (involvement of radial nerve) in 33% [10]. A questionnaire-based US study
suggested that the severity of neuropathy is not associated with duration on the GFD [29].
3.2. Gluten Ataxia
Upon physical examination for neurological deficits in patients with CD, estimates of the
prevalence of gluten ataxia varied from 0% to 6% [20–23,28,32]. However, in studies among CD
patients with neurological manifestations, gluten ataxia was reported in 19% to 41% of patients [10,23].
While studies tended to use similar definitions of ataxia, prevalence estimates varied. Six of the ten
included studies used standard neurological exams with combinations of either magnetic resonance
imaging (MRI) or magnetic resonance spectroscopy (MRS), or computed tomography (CT) to confirm
the diagnosis of ataxia by examination of the vermis, eliminating other potential common causes
of ataxia such as thyroid dysfunction, vitamin E deficiency, toxicity, and genetic forms of ataxia
(spinocerebellar and Friedrich’s) [20–23,28,31].
Of the prospective European studies that used diagnostic CT or MRI/MRS, gluten ataxia was
diagnosed in two studies [21,23]. One study of adults (n = 72) [21] and one of children (n = 48) [23] each
reported a prevalence of 6% in patients with CD. The study of 48 children attributed the prevalence of
gluten ataxia and the presence of the comorbidities of mental retardation and developmental delays to
nutritional deficiencies and toxic effects of severe malnutrition [23]. The other three studies utilizing
CT or MRI to define ataxia, one in adults (n = 71) [20] and two in children (n = 27 and n = 835) [22,28],
reported that no patients (0%) developed ataxia.
Two included retrospective studies did not report a prevalence of gluten ataxia [10,26]. One
study used International Classification of Diseases (ICD, 7–10) codes to identify the symptom of ataxia
(excluding trauma or toxicity as main diagnoses) or hereditary ataxia to determine the risk of ataxia
in patients with CD [26]. The remaining study had less transparency in the diagnosis of ataxia as the
diagnostic criteria were not described, where authors reported that a standard neurological assessment
was performed and only reported on the severity of ataxia [10].
One British study suggested that most cases (69%) of gluten ataxia in patients with CD are mild,
and patients could walk without assistance [10]. Of the remaining ataxia cases, 17% were moderate
(requiring walking aids/support), and 14% were severe (needing a wheelchair). All patients were
reported to be following a GFD [10].
In the nine included studies [10,20–23,26,28,31,32], gluten ataxia accounted for up to half of all
neurological manifestations observed in people with CD. Definitive conclusions cannot be made
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regarding age-related differences in CD-associated ataxia from included studies, but available data
suggest that gluten ataxia accounts for a smaller proportion of neurological manifestations in children
with CD compared with adults.
The risk of gluten ataxia appears to vary over time after CD diagnosis. A retrospective
population-based registry study from Sweden evaluated the risk of gluten ataxia in patients with a
hospital-based diagnosis of CD (n = 14,371), and found a greater risk of ataxia compared with controls
without CD when patients were followed during the first year after discharge (HR, 2.6; 95% CI, 1.0–6.5;
p = 0.042) [26]. However, if the first year of follow-up was excluded, the higher risk of ataxia was no
longer statistically significant (HR, 1.9; 95% CI, 0.6–6.2; p > 0.05) based upon 14,371 patients with CD
and 70,155 reference individuals [26].
The observed effect of GFD on ataxia may be dependent upon the methodological tests to monitor
adherence to a GFD and the metrics utilized to assess neurological improvement. A quantitative
assessment of the effect of GFD on gluten ataxia was provided by cerebellar MRS in Hadjivassiliou et al.
(2017) [31]. In this study, CD patients with gluten ataxia (n = 117) were reviewed for response to
GFD: 63 were on strict GFD with the elimination of AGAs, 35 were on GFD but still positive for
AGAs, and 19 patients were not on a GFD. GFD adherence was monitored by serological assessments.
On MRS, there was a significant improvement in the cerebellum in 62 out of 63 (98%) patients on
a strict GFD, in nine of 35 (26%) patients on GFD with positive AGAs, but in only one of 19 (5%)
patients not on GFD. Notably, the presence of enteropathy (CD), usually required for the diagnosis
of CD, in addition to positive serology, was not found to be a prerequisite for improvement in the
cerebellum. The authors concluded that patients with positive serology results and negative duodenal
biopsy should still be treated with strict GFD and noted that improved cerebellar function with GFD
adherence was associated with clinical improvement [31]. In contrast, a prospective Romanian study
in 48 children reported that none of the patients with gluten ataxia had improved symptoms while
on a GFD [23]. However, Diaconu et al. (2014) did not state how GFD adherence was monitored and
ataxia assessments were self-reported by the parents of the children affected [23].
3.3. Quality Assessment
Based on Oxford Levels of Evidence, the evidence in this review has an overall grade of B. Only
one study provided Level 1b evidence [19]. Seven studies [10,25–27,30,32,33] were retrospective cohort
studies, which represented Level 2b evidence. One study was a prospective case series, representing
level 4 evidence [31]. The remaining seven studies [20–24,28,29] were cross-sectional studies, which
we have categorized as Level 2c. The levels of evidence for individual studies are shown in Table 4.
Table 4. Quality Assessment of Included Studies.
Study Identifier Oxford Level of Evidence
Briani and Doria et al. (2008) [19] 2c. Ecological study *
Briani and Zara et al. (2008) [20] 1b. Prospective cohort study
Burk et al. (2013) [21] 2c. Ecological study *
Cakir et al. (2007) [22] 2c. Ecological study *
Diaconu et al. (2013) [23] 2c. Ecological study *
Hadjivassiliou et al. (2016) [10] 2b. Retrospective cohort study
Hadjivassiliou et al. (2017) [31] 4. Case-series or superseded reference standards
Isikay et al. (2015) [24] 2c. Ecological study *
Jericho et al. (2017) [25] 2b. Retrospective cohort study
Ludvigsson et al. (2007) [26] 2b. Retrospective cohort study
Mukherjee et al. (2010) [27] 2b. Retrospective cohort study
Ruggieri et al. (2008) [28] 2c. Ecological study *
Sangal et al. (2017) [32] 2b. Retrospective cohort study
Shen et al. (2012) [29] 2c. Ecological study *
Thawani et al. (2015) [30] 2b. Retrospective cohort study
Thawani et al. (2017) [33] 2b. Retrospective cohort study
*, Note that this was a cross-sectional study, not an ecological study; there is no Oxford Level of Evidence for
cross-sectional studies [18].
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4. Discussion
This systematic review demonstrates that gluten neuropathy was reported more often than
gluten ataxia (81.25% of included studies reported neuropathy), although the prevalence of gluten
neuropathy varied widely (0%–39%). Both ataxia and neuropathy were more prevalent in patients
with CD compared with controls. Symptoms of neuropathy were most commonly categorized as
moderate, affecting extremities. Prevalence of gluten ataxia in patients with diagnosed CD varied from
0–6%; symptoms were often described as mild, in which patients were still able to walk, although
in some cases could be very severe and persistent. The variations in prevalence rates across studies
of both gluten ataxia and gluten neuropathy may be related to study design and inclusion criteria,
retrospective nature of data collection, quality of assessment of adherence to a GFD, clinical assessment
of neurological symptoms, and the age of the populations included.
The prevalence of idiopathic neuropathy in the general population is low but the risk is increased
in CD. A literature review of 28 studies reported the prevalence of neuropathy in the general
middle-aged and elderly population between 0.1% and 3.3% [34]. Increased neuropathy prevalence
was reported in a US study published in 2003 using retrospective data from 400 patients with
neuropathy, whereby neuropathy rates for CD were between 2.5% and 8% (compared to 1% in
the healthy population) [35]. In a large Swedish population-based study that examined the risk of
neurological disease, polyneuropathy was found to be significantly associated with CD (odds ratio
5.4; 95% CI 3.6–8.2) [36]. In further support of this, an age- and sex-matched control study, identified
in this review, comparing patients with CD to controls found that CD was associated with a 2.5-fold
increased risk of later neuropathy [30]. The highest risk for gluten neuropathy was just after diagnosis
of CD, but there was also a consistent excess risk of neuropathy beyond five years after a diagnosis
of CD. Two other included studies compared patients with CD of different ages and found that
younger patients were less likely to experience neuropathy [25,27]. However, these studies examined
established patients with CD and their findings may be an underestimation of risk of neuropathy in
young patients. The presentation of atypical symptoms, such as neurological complications, at time of
CD diagnosis in children, reported neuropathy prevalence of 10.5% in this small study population [32].
Similar to trends for neuropathy, the prevalence of ataxia in the general population is very low, but
this risk is increased in patients with CD. A UK based population-based study estimated the prevalence
of late-onset cerebellar ataxia as 0.01% in the general population [37]. Three studies identified in this
review reported no cases (0%) of ataxia in both adults and children [20,22,28]; however, estimates
of ataxia prevalence ranged from 0-6% across all ages [21,23,32]. In studies that determined ataxia
prevalence in children, neurological manifestations were the initial symptoms of CD in 25%–33.33% of
patients, and ataxia accounted for 5.26%–18.8% of those cases. [23,32]. The risk of ataxia in those with
CD was estimated to be 1.9- to 2.6-fold compared with controls during the first year after diagnosis [26].
Although the prevalence of ataxia in CD is thought to be low, it may be underestimated. A recent
UK study of 500 patients diagnosed with progressive ataxia and evaluated over a period of 13 years,
found that 101 of 215 (47%) patients with idiopathic sporadic ataxia had serological evidence of gluten
reactivity [38]. A study of 1500 patients with cerebellar ataxia referred to the Sheffield Ataxia Centre,
UK assessed over 20 years found that 20% had a family history of ataxia, and the remaining 80%
had sporadic ataxia. Of sporadic ataxias, gluten ataxia was the most common cause (25%); followed
by genetic causes (13%), alcohol excess (12%), and a cerebellar variant of multiple system atrophy
(11%) [39]. In a review of gluten sensitivity by Hadjivassiliou et al. (2010) [11], many studies reported
that a high proportion of patients with sporadic ataxias (12%–47%) tested positive for AGA compared
with 2%–12% of healthy controls [11,38–48]. These studies suggest that even though ataxia is rare,
gluten ataxia is a common subtype of sporadic ataxia.
Adherence to a strict GFD can result in clinical improvement in both gluten neuropathy and gluten
ataxia. Publications which met criteria for inclusion in this review unanimously support a beneficial
effect of the GFD on neuropathy, however, a benefit in ataxia is less clear. Some studies report that
ataxia persists in patients on a GFD, while others demonstrated improvement on GFD [10,21,23,31].
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This heterogeneity is most likely due to differences in study design, including the assessment of GFD
adherence and ataxia symptoms. Severity of ataxia can be assessed with a variety of instruments
including self-report and clinician determination using scales for the assessment and rating of ataxia
(e.g., Brief Ataxia Rating Scale (BARS), Scale for the Assessment and Rating of Ataxia (SARA),
International Cooperative Ataxia Rating Scale (ICARS), modified ICARS (MICARS)), and imaging
studies (e.g., MRS, MRI, EEG). Objective quantitation of motor deficits in ataxia is fundamental for
measurement of clinical severity but was not commonly reported in studies examining the association
between improvements of ataxia and GFD adherence. One study by Hadjivassiliou et al. (2017) utilized
a quantitative methodology via MRS to monitor ataxia severity by cerebellar atrophy and assessed
GFD adherence with AGA testing [31]. This study demonstrated a beneficial effect of strict GFD
adherence on ataxia and benefits were seen in all AGA positive individuals, regardless of baseline
enteropathy [31].
It is important to clarify the differences between CD and gluten sensitivity in the context of gluten
ataxia and gluten neuropathy. This systematic review primarily concentrated on patients with CD
and these two common neurological manifestations. These manifestations, however, may exist in the
presence of AGA alone (gluten sensitivity) without evidence of enteropathy (CD), and such patients
benefit equally from GFD. Indeed Hadjivassiliou et al. (2016) demonstrated there are no distinguishing
features (e.g., type of neurological manifestation, severity, and response to GFD) between those patients
with neurological manifestations and CD and those with just positive AGA (no enteropathy) [10].
Despite this, the majority of immunological laboratories have abandoned the use of native AGA assays
due to poor specificity in diagnosing CD. Estimation of specificity, however, is based on the presence
of a gold standard, in this case, the presence of enteropathy. Given that sensitivity to gluten exists in
the absence of enteropathy, then AGA remains probably the only serological marker in diagnosing the
whole spectrum of extraintestinal manifestations. Another important consideration when using AGA
is the serological cut-off for positive AGA. Such assays are calibrated using serology from patients
with CD as the gold standard, and consequently, the serological cut-off tends to be high. It has recently
been shown that by recalibrating the serological cut-off of a commercially available AGA assay based
on the ability to diagnose GA, the sensitivity of AGA in diagnosing CD became 100% [49].
There were a small number of studies identified that did not meet our inclusion criteria but
described the association between gluten neuropathy and enteropathy, and the effects of strict GFD
on gluten neuropathy. Of note, a study published by Hadjivassiliou et al. (2006) reported that of
100 patients with clinical immunological characteristics of gluten neuropathy, 29% of patients had
evidence of enteropathy [50]. A prospective study published in 2006, followed 35 patients with gluten
neuropathy, 25 of which were assigned to strict adherence to a GFD with the remaining ten patients as
controls. Strict GFD adherence was defined by the elimination of AGA after one year. When asked,
16/25 patients on the GFD said their neuropathy was better compared to 0/10 in the control group.
Eight out of ten patients in the control group stated that their neuropathy was worse [12]. Gluten
neuropathy can be associated with significant chronic pain and negatively impact mental health.
A recent study assessed neuropathic pain in 60 patients with gluten neuropathy. Neuropathic pain was
present in 33 patients and painless neuropathy was more common in patients on a strict GFD (55.6%
versus 21.2%, p = 0.006). Patients with painful gluten neuropathy presented with significantly worse
mental health status [12]. Multivariate analysis showed that, after adjusting for age, gender and mental
health index-5, strict GFD was associated with an 89% reduction in risk of peripheral neuropathic pain
(p = 0.006) [51].
Gluten ataxia and neuropathy were selected for this review because they are the most common
neurological manifestations in CD. However, there are other neurological manifestations not assessed
(a systematic review of movement disorders related to gluten sensitivity by Vinagre-Aragon et al.
(2017) is available [52] for reference). A prospective study reported that up to 22% of patients with
CD (n = 71) developed some form of neurologic or psychiatric dysfunction (headache, depression,
entrapment syndromes, peripheral neuropathy, and epilepsy) [20]. In a British study published in 1998,
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57% of patients with neurological dysfunction of unknown cause had serological evidence of gluten
sensitivity, compared with 12% of healthy blood donors [53]. Neurological manifestations can have
a significant impact on patients’ quality of life, and a greater understanding of these complications
is needed.
There are several limitations to this systematic review. Both clinical and methodological
heterogeneity among reviewed studies limited comparisons of the data. Across all studies included,
it is not possible to determine whether factors such as the timing of diagnosis, presentation of CD,
or differences diagnostic techniques, affect rates of ataxia and peripheral neuropathy. Lastly, there is
potential for publication bias and missed eligible articles in any literature review. However, this risk is
assumed to be minimal due to strict adherence to standards for systematic search methodology.
5. Conclusions
In conclusion, this systematic review provides important evidence on the substantially increased
risk of gluten ataxia and gluten neuropathy in patients with CD, although estimates across studies vary.
These results indicate that adherence to a GFD appears to improve symptoms of both neuropathy and
ataxia. The scarcity of data from this global search highlights the need for additional well-designed
studies to improve the understanding of neurological manifestations in patients with CD. Given that
these results suggest an increased risk of ataxia and neuropathy among patients with CD, clinicians
should evaluate for gluten sensitivity in patients with ataxia and neuropathy of unknown origin.
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